Filter by species, tissue, cell type, disease, or experiment to explore our curated enhancer collection
| Enhancer ID | Genome Location | Tissue | Cell Source | Disease | Experiment Type |
|---|---|---|---|---|---|
| E_00001 | chr3:148898000~148901500 | Kidney | 769p | Clear cell renal cell carcinoma | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_00002 | chr3:148898000~148901500 | Kidney | 786o | Clear cell renal cell carcinoma | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_00003 | chr3:148898000~148901500 | Kidney | VMRC-RCW | Clear cell renal cell carcinoma | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_00004 | chr3:148898000~148901500 | Kidney | CAKI-1 | Clear cell renal cell carcinoma | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_00005 | chr1:47680000~47681000 | Blood | Jurkat T-ALL Cells | T-cell acute lymphoblastic leukemia | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_00006 | chr1:47680000~47681000 | Blood | MOLT4 Cells | T-cell acute lymphoblastic leukemia | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_00007 | chr1:47680000~47681000 | Blood | Jurkat T-ALL | T-cell acute lymphoblastic leukemia | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_00008 | chr2:116230440~116232740 | Mammary gland | MCF-7 | Breast invasive carcinoma | Luciferase reporter assay, loss-of-function ASO/shRNA knockdown, ChIP-qPCR, Pol II ChIA-PET chromatin interaction |
| E_00009 | chr2:116230440~116232740 | Mammary gland | BT474 | Breast invasive carcinoma | Luciferase reporter assay, loss-of-function ASO/shRNA knockdown, ChIP-qPCR, Pol II ChIA-PET chromatin interaction |
| E_00010 | chr2:116230440~116232740 | Mammary gland | MCF-7 | Breast invasive carcinoma | Luciferase reporter assay, loss-of-function ASO/shRNA knockdown, ChIP-qPCR, Pol II ChIA-PET chromatin interaction |
| E_00011 | chr2:116230440~116232740 | Mammary gland | BT474 | Breast invasive carcinoma | Luciferase reporter assay, loss-of-function ASO/shRNA knockdown, ChIP-qPCR, Pol II ChIA-PET chromatin interaction |
| E_00012 | chr2:116230440~116232740 | Mammary gland | MCF-7 | Breast invasive carcinoma | Luciferase reporter assay, loss-of-function ASO/shRNA knockdown, ChIP-qPCR, Pol II ChIA-PET chromatin interaction |
| E_00013 | chr2:116230440~116232740 | Mammary gland | BT474 | Breast invasive carcinoma | Luciferase reporter assay, loss-of-function ASO/shRNA knockdown, ChIP-qPCR, Pol II ChIA-PET chromatin interaction |
| E_00014 | chr2:127082600~127082962 | Brain microglia | hPSC-derived microglia | Alzheimer's disease | CRISPR-Cas9 loss-of-function deletion, PLAC-seq chromatin interaction, ChIP-qPCR |
| E_00015 | chr2:127082600~127082962 | Brain microglia | hPSC-derived neuron | Alzheimer's disease | CRISPR-Cas9 loss-of-function deletion, PLAC-seq chromatin interaction, ChIP-qPCR |
| E_00016 | chr2:127082600~127082962 | Brain microglia | hPSC-derived astrocyte | Alzheimer's disease | CRISPR-Cas9 loss-of-function deletion, PLAC-seq chromatin interaction, ChIP-qPCR |
| E_00017 | chr3:46186503~46187707 | Bone | MG-63 | Osteoporosis | Dual-luciferase reporter assay, CRISPR-Cas9 deletion loss-of-function, 3C chromatin capture, ChIP-qPCR |
| E_00018 | chr3:46186503~46187707 | Bone | primary human osteoblasts | Osteoporosis | Dual-luciferase reporter assay, CRISPR-Cas9 deletion loss-of-function, 3C chromatin capture, ChIP-qPCR |
| E_00019 | chr3:46186503~46187707 | Bone | MG-63 | Osteoporosis | Dual-luciferase reporter assay, ChIP-qPCR |
| E_00020 | chr3:46186503~46187707 | Bone | primary human osteoblasts | Osteoporosis | Dual-luciferase reporter assay, ChIP-qPCR |
| E_00021 | chr9:130812462~130813421 | Bone marrow | SEM | B-cell acute lymphoblastic leukemia | CRISPR-Cas9 deletion loss-of-function, Capture-C chromatin interaction, ChIP-qPCR |
| E_00022 | chr9:130812462~130813421 | Bone marrow | SEM | B-cell acute lymphoblastic leukemia | CRISPR-Cas9 deletion loss-of-function, Capture-C chromatin interaction, ChIP-qPCR |
| E_00023 | chr12:4900187~4901013 | Bone marrow | RS4;11 | B-cell acute lymphoblastic leukemia | CRISPR-Cas9 deletion loss-of-function, Capture-C chromatin interaction, ChIP-qPCR |
| E_00024 | chr12:4900187~4901013 | Bone marrow | RS4;11 | B-cell acute lymphoblastic leukemia | CRISPR-Cas9 deletion loss-of-function, Capture-C chromatin interaction, ChIP-qPCR |
| E_00025 | chr6:101482232~101483107 | Bone marrow | Primary human KMT2A::AFF1 ALL blasts | B-cell acute lymphoblastic leukemia | Micro-Capture-C chromatin interaction + patient gene expression validation, ChIP-qPCR |
| E_00026 | chr6:101482232~101483107 | Bone marrow | Primary human KMT2A::AFF1 ALL blasts | B-cell acute lymphoblastic leukemia | Micro-Capture-C chromatin interaction + patient gene expression validation, ChIP-qPCR |
| E_00027 | chr6:9087104~9087962 | Bone marrow | Primary human KMT2A::AFF1 ALL blasts | B-cell acute lymphoblastic leukemia | Micro-Capture-C chromatin interaction + patient gene expression validation, ChIP-qPCR |
| E_00028 | chr6:9087104~9087962 | Bone marrow | Primary human KMT2A::AFF1 ALL blasts | B-cell acute lymphoblastic leukemia | Micro-Capture-C chromatin interaction + patient gene expression validation, ChIP-qPCR |
| E_00029 | chr6:174249537~174250490 | Bone marrow | WS hMPC | Cellular senescence | Luciferase reporter assay, ChIP-qPCR, Hi-C chromatin interaction validation |
| E_00030 | chr6:174249537~174250490 | Bone marrow | WT hMPC | Cellular senescence | Luciferase reporter assay, ChIP-qPCR, Hi-C chromatin interaction validation |
| E_00031 | chr6:174249537~174250490 | Bone marrow | WS hMPC | Osteoarthritis | Luciferase reporter assay, ChIP-qPCR, Hi-C chromatin interaction validation |
| E_00032 | chr6:174249537~174250490 | Bone marrow | WT hMPC | Osteoarthritis | Luciferase reporter assay, ChIP-qPCR, Hi-C chromatin interaction validation |
| E_00033 | chr8:209981000~209990000 | Bone marrow | K562 | Acute myeloid leukemia | CRISPRi interference, clonal genomic deletion, Hi-C chromatin contact validation |
| E_00034 | chr8:209981000~209990000 | Bone marrow | K562 | Erythroleukemia | CRISPRi interference, clonal genomic deletion, Hi-C chromatin contact validation |
| E_00035 | chr8:210003000~210012000 | Bone marrow | K562 | Acute myeloid leukemia | CRISPRi interference, clonal genomic deletion, Hi-C chromatin contact validation |
| E_00036 | chr8:210003000~210012000 | Bone marrow | K562 | Erythroleukemia | CRISPRi interference, clonal genomic deletion, Hi-C chromatin contact validation |
| E_00037 | chr8:210011000~210018000 | Bone marrow | K562 | Acute myeloid leukemia | CRISPRi interference, Hi-C chromatin contact validation |
| E_00038 | chr8:210011000~210018000 | Bone marrow | K562 | Erythroleukemia | CRISPRi interference, Hi-C chromatin contact validation |
| E_00039 | chr8:210024000~210032000 | Bone marrow | K562 | Acute myeloid leukemia | CRISPRi interference, Hi-C chromatin contact validation |
| E_00040 | chr8:210024000~210032000 | Bone marrow | K562 | Erythroleukemia | CRISPRi interference, Hi-C chromatin contact validation |
| E_00041 | chr8:210041000~210048000 | Bone marrow | K562 | Acute myeloid leukemia | CRISPRi interference, Hi-C chromatin contact validation |
| E_00042 | chr8:210041000~210048000 | Bone marrow | K562 | Erythroleukemia | CRISPRi interference, Hi-C chromatin contact validation |
| E_00043 | chr8:210055000~210063000 | Bone marrow | K562 | Acute myeloid leukemia | CRISPRi interference, Hi-C chromatin contact validation |
| E_00044 | chr8:210055000~210063000 | Bone marrow | K562 | Erythroleukemia | CRISPRi interference, Hi-C chromatin contact validation |
| E_00045 | chr8:210071000~210079000 | Bone marrow | K562 | Acute myeloid leukemia | CRISPRi interference, clonal genomic deletion, Hi-C chromatin contact validation |
| E_00046 | chr8:210071000~210079000 | Bone marrow | K562 | Erythroleukemia | CRISPRi interference, clonal genomic deletion, Hi-C chromatin contact validation |
| E_00047 | chr10:90723100~90723900 | Hypothalamus | Neuro-2a | CRISPRa gain-of-function, ChIP-qPCR, in vivo transgenic reporter validation | |
| E_00048 | chr10:90723100~90723900 | Hypothalamus | Neuro-2a | Obesity due to Sim1 haploinsufficiency | CRISPRa gain-of-function, ChIP-qPCR, in vivo transgenic reporter validation |
| E_00049 | chr10:90723100~90723900 | Hypothalamus | mouse primary hypothalamic neuron | CRISPRa gain-of-function, ChIP-qPCR, in vivo transgenic reporter validation | |
| E_00050 | chr10:90723100~90723900 | Hypothalamus | mouse primary hypothalamic neuron | Obesity due to Sim1 haploinsufficiency | CRISPRa gain-of-function, ChIP-qPCR, in vivo transgenic reporter validation |
| E_00051 | chr7:131323622~131334609 | Mammary gland | MDA-MB-436 | Triple-negative breast cancer | CRISPR-Cas9 knockout loss-of-function, dCas9-KRAB CRISPRi repression, Hi-C chromatin looping validation, CasRx eRNA knockdown |
| E_00052 | chr7:131323622~131334609 | Mammary gland | MDA-MB-231 | Triple-negative breast cancer | CRISPR-Cas9 knockout loss-of-function, dCas9-KRAB CRISPRi repression, Hi-C chromatin looping validation, CasRx eRNA knockdown |
| E_00053 | chr7:131323622~131334609 | Mammary gland | MDA-MB-468 | Triple-negative breast cancer | CRISPR-Cas9 knockout loss-of-function, dCas9-KRAB CRISPRi repression, Hi-C chromatin looping validation, CasRx eRNA knockdown |
| E_00054 | chr2:106412871~106423516 | Mammary gland | MDA-MB-436 | Triple-negative breast cancer | CRISPR-Cas9 knockout loss-of-function, dCas9-KRAB CRISPRi repression, Hi-C chromatin looping validation, CasRx eRNA knockdown |
| E_00055 | chr2:106412871~106423516 | Mammary gland | MDA-MB-436 | Triple-negative breast cancer | CRISPR-Cas9 knockout loss-of-function, dCas9-KRAB CRISPRi repression, Hi-C chromatin looping validation, CasRx eRNA knockdown |
| E_00056 | chr20:63680793~63682109 | Brain | U251 | Glioblastoma multiforme | CRISPR-Cas9 full locus knockout, dCas9-KRAB CRISPRi, dual-luciferase reporter assay, 3C-qPCR, ChIP-qPCR, SNP base editing |
| E_00057 | chr20:63680793~63682109 | Brain | LN229 | Glioblastoma multiforme | CRISPR-Cas9 full locus knockout, dCas9-KRAB CRISPRi, dual-luciferase reporter assay, 3C-qPCR, ChIP-qPCR, SNP base editing |
| E_00058 | chr20:63680793~63682109 | Brain | U87 | Glioblastoma multiforme | CRISPR-Cas9 full locus knockout, dCas9-KRAB CRISPRi, dual-luciferase reporter assay, 3C-qPCR, ChIP-qPCR, SNP base editing |
| E_00059 | chr8:12738300~12744200 | Brain | U251 | Glioblastoma multiforme | dCas9-KRAB CRISPRi, HiChIP chromatin looping validation, 3C-qPCR |
| E_00060 | chr17:5958900~5960100 | Brain | U251 | Glioblastoma multiforme | dCas9-KRAB CRISPRi, HiChIP chromatin looping validation, 3C-qPCR |
| E_00061 | chr2:18910338~18911438 | Brain | U251 | Glioblastoma multiforme | dCas9-KRAB CRISPRi, HiChIP chromatin looping validation |
| E_00062 | chr2:18910338~18911438 | Brain | U251 | Glioblastoma multiforme | dCas9-KRAB CRISPRi, HiChIP chromatin looping validation |
| E_00063 | chr2:18910338~18911438 | Brain | U251 | Glioblastoma multiforme | dCas9-KRAB CRISPRi, HiChIP chromatin looping validation |
| E_00064 | chr2:18910338~18911438 | Brain | U251 | Glioblastoma multiforme | dCas9-KRAB CRISPRi, HiChIP chromatin looping validation |
| E_00065 | chr2:121923152~121923710 | Peripheral blood | Jurkat E6-1 | CRISPRi loss-of-function, CRISPRa gain-of-function, ATAC-qPCR chromatin accessibility validation | |
| E_00066 | chr2:121926020~121926640 | Peripheral blood | Jurkat E6-1 | CRISPRi loss-of-function, CRISPRa gain-of-function, ATAC-qPCR chromatin accessibility validation | |
| E_00067 | chr2:121926020~121926640 | Peripheral blood | primary human memory CD4 T cell | CRISPRi loss-of-function, CRISPRa gain-of-function, ATAC-qPCR chromatin accessibility validation | |
| E_00068 | chr2:121928130~121928780 | Peripheral blood | Jurkat E6-1 | CRISPRi loss-of-function, CRISPRa gain-of-function | |
| E_00069 | chr12:68541220~68541790 | Peripheral blood | Jurkat E6-1 | CRISPRi loss-of-function, CRISPRa gain-of-function | |
| E_00070 | chr13:73958961~73960160 | Colon | HCT116 | Colorectal adenocarcinoma | Dual-luciferase reporter assay, CRISPR-Cas9 base editing, CRISPRi silencing, 3C chromatin capture, ChIP-qPCR |
| E_00071 | chr13:73958961~73960160 | Colon | SW480 | Colorectal adenocarcinoma | Dual-luciferase reporter assay, CRISPR-Cas9 base editing, CRISPRi silencing, 3C chromatin capture, ChIP-qPCR |
| E_00072 | chr13:73958961~73960160 | Colon | HCT116 | Colorectal adenocarcinoma | Dual-luciferase reporter assay, CRISPR-Cas9 base editing, CRISPRi silencing, 3C chromatin capture, ChIP-qPCR |
| E_00073 | chr13:73958961~73960160 | Colon | SW480 | Colorectal adenocarcinoma | Dual-luciferase reporter assay, CRISPR-Cas9 base editing, CRISPRi silencing, 3C chromatin capture, ChIP-qPCR |
| E_00074 | chr13:73958961~73960160 | Colon | HCT116 | Colorectal adenocarcinoma | Dual-luciferase reporter assay, CRISPR-Cas9 base editing, CRISPRi silencing, 3C chromatin capture, ChIP-qPCR |
| E_00075 | chr13:73958961~73960160 | Colon | SW480 | Colorectal adenocarcinoma | Dual-luciferase reporter assay, CRISPR-Cas9 base editing, CRISPRi silencing, 3C chromatin capture, ChIP-qPCR |
| E_00076 | chr13:73958961~73960160 | Colon | HCT116 | Colorectal adenocarcinoma | Dual-luciferase reporter assay, CRISPR-Cas9 base editing, CRISPRi silencing, 3C chromatin capture, ChIP-qPCR |
| E_00077 | chr13:73958961~73960160 | Colon | SW480 | Colorectal adenocarcinoma | Dual-luciferase reporter assay, CRISPR-Cas9 base editing, CRISPRi silencing, 3C chromatin capture, ChIP-qPCR |
| E_00078 | chr3:70961242~70974816 | Umbilical vein | HUVEC | dCas9-KRAB CRISPRi loss-of-function, dual-luciferase reporter assay | |
| E_00079 | chr3:70961242~70974816 | Embryonic kidney | HEK293T | dCas9-KRAB CRISPRi loss-of-function, dual-luciferase reporter assay | |
| E_00080 | chr3:70961242~70974816 | Umbilical vein | HUVEC | Vascular aging | dCas9-KRAB CRISPRi loss-of-function, dual-luciferase reporter assay |
| E_00081 | chr3:70961242~70974816 | Embryonic kidney | HEK293T | Vascular aging | dCas9-KRAB CRISPRi loss-of-function, dual-luciferase reporter assay |
| E_00082 | chr3:70961242~70974816 | Umbilical vein | HUVEC | Atherosclerosis | dCas9-KRAB CRISPRi loss-of-function, dual-luciferase reporter assay |
| E_00083 | chr3:70961242~70974816 | Embryonic kidney | HEK293T | Atherosclerosis | dCas9-KRAB CRISPRi loss-of-function, dual-luciferase reporter assay |
| E_00084 | chr20:63680793~63682109 | Brain | U251 | Glioblastoma multiforme | Dual-luciferase reporter assay, CRISPR-Cas9 full locus knockout, CRISPR base editing, 3C-qPCR, ChIP-qPCR, dCas9-KRAB CRISPRi |
| E_00085 | chr20:63680793~63682109 | Brain | LN229 | Glioblastoma multiforme | Dual-luciferase reporter assay, CRISPR-Cas9 full locus knockout, CRISPR base editing, 3C-qPCR, ChIP-qPCR, dCas9-KRAB CRISPRi |
| E_00086 | chr20:63680793~63682109 | Brain | U251 | Glioblastoma multiforme | Dual-luciferase reporter assay, CRISPR-Cas9 full locus knockout, 3C-qPCR, ChIP-qPCR, dCas9-KRAB CRISPRi |
| E_00087 | chr20:63680793~63682109 | Brain | LN229 | Glioblastoma multiforme | Dual-luciferase reporter assay, CRISPR-Cas9 full locus knockout, 3C-qPCR, ChIP-qPCR, dCas9-KRAB CRISPRi |
| E_00088 | chr8:12738300~12744200 | Brain | U251 | Glioblastoma multiforme | dCas9-KRAB CRISPRi, HiChIP chromatin looping validation, 3C-qPCR |
| E_00089 | chr17:5958900~5960100 | Brain | U251 | Glioblastoma multiforme | dCas9-KRAB CRISPRi, HiChIP chromatin looping validation, 3C-qPCR |
| E_00090 | chr2:18910338~18911438 | Brain | U251 | Glioblastoma multiforme | dCas9-KRAB CRISPRi, HiChIP chromatin looping validation |
| E_00091 | chr2:18910338~18911438 | Brain | U251 | Glioblastoma multiforme | dCas9-KRAB CRISPRi, HiChIP chromatin looping validation |
| E_00092 | chr2:18910338~18911438 | Brain | U251 | Glioblastoma multiforme | dCas9-KRAB CRISPRi, HiChIP chromatin looping validation |
| E_00093 | chr2:18910338~18911438 | Brain | U251 | Glioblastoma multiforme | dCas9-KRAB CRISPRi, HiChIP chromatin looping validation |
| E_00094 | chr3:111274001~111275000 | Colon | COLO320DM | Colorectal adenocarcinoma | Dual-luciferase reporter assay, dCas9-KRAB CRISPRi loss-of-function, Hi-C chromatin contact mapping, ORCA single-cell chromatin imaging |
| E_00095 | chr3:111274001~111275000 | Colon | COLO320HSR | Colorectal adenocarcinoma | Dual-luciferase reporter assay, dCas9-KRAB CRISPRi loss-of-function, Hi-C chromatin contact mapping, ORCA single-cell chromatin imaging |
| E_00096 | chr3:27713393~27715978 | Definitive endoderm | HUES8 | dCas9-KRAB CRISPRi loss-of-function, Hi-C chromatin contact validation | |
| E_00097 | chr1:226210519~226211619 | Definitive endoderm | HUES8 | dCas9-KRAB CRISPRi loss-of-function, Hi-C chromatin contact validation | |
| E_00098 | chr18:22026135~22027396 | Definitive endoderm | HUES8 | dCas9-KRAB CRISPRi loss-of-function, CRISPR-Cas9 clonal deletion, Hi-C chromatin contact validation | |
| E_00099 | chr18:22061243~22062444 | Definitive endoderm | HUES8 | dCas9-KRAB CRISPRi loss-of-function, CRISPR-Cas9 clonal deletion, Hi-C chromatin contact validation | |
| E_00100 | chr8:54268120~54269407 | Definitive endoderm | HUES8 | dCas9-KRAB CRISPRi loss-of-function, Hi-C chromatin contact validation | |
| E_00101 | chr21:43361800~43362620 | Mammary gland | MCF-7 | CRISPR-Cas9 locus deletion, 4C-seq chromatin interaction, ChIP-qPCR, siRNA cohesin knockdown | |
| E_00102 | chr21:43361800~43362620 | Mammary gland | MCF-7 | CRISPR-Cas9 locus deletion, 4C-seq chromatin interaction, ChIP-qPCR, siRNA cohesin knockdown | |
| E_00103 | chr11:72968100~72968850 | Mammary gland | MCF-7 | CRISPR-Cas9 promoter knockout, 4C-seq chromatin looping, ChIP-qPCR | |
| E_00104 | chr11:72968100~72968850 | Mammary gland | MCF-7 | CRISPR-Cas9 promoter knockout, 4C-seq chromatin looping, ChIP-qPCR | |
| E_00105 | chr6:38991200~38991920 | Mammary gland | MCF-7 | CRISPR-Cas9 promoter deletion, 4C-seq chromatin contact validation, ChIP-qPCR | |
| E_00106 | chr6:38991200~38991920 | Mammary gland | MCF-7 | CRISPR-Cas9 promoter deletion, 4C-seq chromatin contact validation, ChIP-qPCR | |
| E_00107 | chr11:100842300~100843050 | Mammary gland | MCF-7 | CRISPR promoter knockout, 4C-seq, ChIP-qPCR | |
| E_00108 | chr11:100842300~100843050 | Mammary gland | MCF-7 | CRISPR promoter knockout, 4C-seq, ChIP-qPCR | |
| E_00109 | chr13:73096200~73097010 | Skin | HEK293T | Melanoma | CRISPRi promoter inhibition, CRISPR-Cas9 SNP knock-in, 4C-seq chromatin looping |
| E_00110 | chr13:73096200~73097010 | Lung | HEK293T | Lung adenocarcinoma | CRISPRi promoter inhibition, CRISPR-Cas9 SNP knock-in, 4C-seq chromatin looping |
| E_00111 | chr19:19942100~19942880 | Bone marrow | MCF-7 | B-cell non-Hodgkin lymphoma | CRISPRi ZCCHC7 promoter silencing, Hi-C chromatin contact validation |
| E_00112 | chr8:128745000~128752600 | Epithelium | MCF-7 | Cancer | CRISPRi PVT promoter repression, Hi-C chromatin mapping |
| E_00113 | chr1:205814100~205814900 | Brain | iPSC-derived NPC | Parkinson's disease | dCas9-KRAB enhancer silencing, allele-specific 4C-seq, ChIP-qPCR CTCF binding |
| E_00114 | chr12:88624101~88624740 | Bone marrow | K562 | Chronic myelogenous leukemia | CRISPRa gain-of-function perturbation, single-cell RNA-seq functional validation |
| E_00115 | chr12:43108222~43108860 | Bone marrow | K562 | Chronic myelogenous leukemia | CRISPRa gain-of-function perturbation, single-cell RNA-seq functional validation |
| E_00116 | chr12:64791312~64791930 | Brain | WTC11 iPSC-neuron | CRISPRa gain-of-function perturbation, single-cell RNA-seq validation | |
| E_00117 | chr12:64791312~64791930 | Brain | WTC11 iPSC-neuron | Neurodevelopmental disorder | CRISPRa gain-of-function perturbation, single-cell RNA-seq validation |
| E_00118 | chr12:64791312~64791930 | Bone marrow | K562 | Chronic myelogenous leukemia | CRISPRa gain-of-function perturbation, single-cell RNA-seq validation |
| E_00119 | chr20:63680793~63682109 | Brain | U251 | Glioblastoma multiforme | CRISPR-Cas9 full locus knockout, CRISPR base editing, dual-luciferase reporter assay, 3C-qPCR, HiChIP, ChIP-qPCR |
| E_00120 | chr20:63680793~63682109 | Brain | LN229 | Glioblastoma multiforme | CRISPR-Cas9 full locus knockout, CRISPR base editing, dual-luciferase reporter assay, 3C-qPCR, HiChIP, ChIP-qPCR |
| E_00121 | chr20:63680793~63682109 | Brain | U251 | Glioblastoma multiforme | CRISPR-Cas9 full locus knockout, 3C-qPCR, HiChIP, ChIP-qPCR |
| E_00122 | chr20:63680793~63682109 | Brain | LN229 | Glioblastoma multiforme | CRISPR-Cas9 full locus knockout, 3C-qPCR, HiChIP, ChIP-qPCR |
| E_00123 | chr8:12738300~12744200 | Brain | U251 | Glioblastoma multiforme | dCas9-KRAB CRISPRi, HiChIP chromatin looping validation, 3C-qPCR |
| E_00124 | chr17:5958900~5960100 | Brain | U251 | Glioblastoma multiforme | dCas9-KRAB CRISPRi, HiChIP chromatin looping validation, 3C-qPCR |
| E_00125 | chr2:18910338~18911438 | Brain | U251 | Glioblastoma multiforme | dCas9-KRAB CRISPRi, HiChIP chromatin looping validation |
| E_00126 | chr2:18910338~18911438 | Brain | U251 | Glioblastoma multiforme | dCas9-KRAB CRISPRi, HiChIP chromatin looping validation |
| E_00127 | chr2:18910338~18911438 | Brain | U251 | Glioblastoma multiforme | dCas9-KRAB CRISPRi, HiChIP chromatin looping validation |
| E_00128 | chr2:18910338~18911438 | Brain | U251 | Glioblastoma multiforme | dCas9-KRAB CRISPRi, HiChIP chromatin looping validation |
| E_00129 | chr3:70961242~70974816 | Umbilical vein | HUVEC | Vascular aging | dCas9-KRAB CRISPRi loss-of-function, dual-luciferase reporter assay |
| E_00130 | chr3:70961242~70974816 | Embryonic kidney | HEK293T | Vascular aging | dCas9-KRAB CRISPRi loss-of-function, dual-luciferase reporter assay |
| E_00131 | chr3:70961242~70974816 | Umbilical vein | HUVEC | dCas9-KRAB CRISPRi loss-of-function, dual-luciferase reporter assay, CUT&Tag-qPCR | |
| E_00132 | chr3:70961242~70974816 | Embryonic kidney | HEK293T | dCas9-KRAB CRISPRi loss-of-function, dual-luciferase reporter assay, CUT&Tag-qPCR | |
| E_00133 | chr3:70961242~70974816 | Umbilical vein | HUVEC | Vascular aging | dCas9-KRAB CRISPRi loss-of-function, dual-luciferase reporter assay, CUT&Tag-qPCR |
| E_00134 | chr3:70961242~70974816 | Embryonic kidney | HEK293T | Vascular aging | dCas9-KRAB CRISPRi loss-of-function, dual-luciferase reporter assay, CUT&Tag-qPCR |
| E_00135 | chr3:70961242~70974816 | Umbilical vein | HUVEC | Atherosclerosis | dCas9-KRAB CRISPRi loss-of-function, dual-luciferase reporter assay, CUT&Tag-qPCR |
| E_00136 | chr3:70961242~70974816 | Embryonic kidney | HEK293T | Atherosclerosis | dCas9-KRAB CRISPRi loss-of-function, dual-luciferase reporter assay, CUT&Tag-qPCR |
| E_00137 | chr8:128900000~128900620 | Bone marrow | ANBL6 | Multiple myeloma | dCas9-KRAB CRISPRi, CRISPR-Cas9 binding site knockout, dual-luciferase reporter assay, Micro-C chromatin contact validation |
| E_00138 | chr8:128900000~128900620 | Bone marrow | ANBL6 | Multiple myeloma | dCas9-KRAB CRISPRi, CRISPR-Cas9 binding site knockout, dual-luciferase reporter assay, Micro-C chromatin contact validation |
| E_00139 | chr8:12890650~12891240 | Bone marrow | ANBL6 | Multiple myeloma | dCas9-KRAB CRISPRi, Micro-C chromatin contact validation |
| E_00140 | chr8:12891280~12891910 | Bone marrow | ANBL6 | Multiple myeloma | dCas9-KRAB CRISPRi, Micro-C chromatin contact validation |
| E_00141 | chr8:12891950~12892610 | Bone marrow | ANBL6 | Multiple myeloma | dCas9-KRAB CRISPRi, CRISPR-Cas9 binding site knockout, dual-luciferase reporter assay, Micro-C chromatin contact validation |
| E_00142 | chr8:12891950~12892610 | Bone marrow | ANBL6 | Multiple myeloma | dCas9-KRAB CRISPRi, CRISPR-Cas9 binding site knockout, dual-luciferase reporter assay, Micro-C chromatin contact validation |
| E_00143 | chr8:12891950~12892610 | Bone marrow | ANBL6 | Multiple myeloma | dCas9-KRAB CRISPRi, CRISPR-Cas9 binding site knockout, dual-luciferase reporter assay, Micro-C chromatin contact validation |
| E_00144 | chr12:25538405~25539356 | Bone Marrow | AML cell line | acute myeloid leukemia | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_00145 | chr12:25538405~25539356 | Bone Marrow | CD34+ HSPCs | acute myeloid leukemia | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_00146 | chr12:25538405~25539356 | Bone Marrow | Primary AML cells | acute myeloid leukemia | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_00147 | chr2:23820300~23821251 | Bone Marrow | AML cell line | acute myeloid leukemia | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_00148 | chr2:23820300~23821251 | Bone Marrow | CD34+ HSPCs | acute myeloid leukemia | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_00149 | chr2:23820300~23821251 | Bone Marrow | Primary AML cells | acute myeloid leukemia | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_00150 | chr13:20993543~20994585 | Airway epithelium | SAEC | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay | |
| E_00151 | chr13:20993543~20994585 | Nasal epithelium | HNECs | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay | |
| E_00152 | chr13:20993543~20994585 | Embryonic Kidney | HEK293T | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay | |
| E_00153 | chr10:105668100~105669000 | Skin | A375 | skin melanoma | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay, TF binding assay |
| E_00154 | chr10:105668100~105669000 | Skin | CJM | skin melanoma | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay, TF binding assay |
| E_00155 | chr10:105668100~105669000 | Skin | UACC1816 | skin melanoma | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay, TF binding assay |
| E_00156 | chr10:105668100~105669000 | Neural Crest | Human Neural Crest Cells | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay, TF binding assay | |
| E_00157 | chr10:105668100~105669000 | Esophagus | KYSE140 | esophageal squamous cell carcinoma | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay, TF binding assay |
| E_00158 | chr3:181624870~181626200 | Breast | MDA-MB-231 | breast carcinoma | Enhancer activity assay, Functional perturbation assay |
| E_00159 | chr20:50027744~50030383 | Brain | U-87 MG | glioblastoma | Enhancer activity assay, Functional perturbation assay |
| E_00160 | chr9:22102683~22103683 | Brain | U-118 MG | glioblastoma | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay |
| E_00161 | chr9:22102683~22103683 | Brain | Neural progenitor cells | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay | |
| E_00162 | chr9:22102683~22103683 | Cervical Epithelium | HeLa | cervical cancer | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay |
| E_00163 | chr12:105800000~105801000 | Cranial neural crest | hCNCC cells | Chromatin interaction assay, Functional perturbation assay | |
| E_00164 | chr17:68663972~68675613 | Cranial neural crest | hCNCC | Enhancer activity assay, Functional perturbation assay | |
| E_00165 | chr4:8698911~8707711 | Peripheral Blood | SC monocyte-derived cells | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay | |
| E_00166 | chr7:128573036~128573717 | Prostate | Human prostate carcinoma cell | prostate cancer | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay, TF binding assay |
| E_00167 | chr8:128750000~129000000 | Breast | MCF7 | breast carcinoma | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_00168 | chr9:94700500~94701500 | Skin | MALME-3M | skin melanoma | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_00169 | chr9:94700500~94701500 | Breast | ZR-75-1 | breast carcinoma | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_00170 | chr9:94700500~94701500 | Breast | T-47D | breast carcinoma | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_00171 | chr9:94700500~94701500 | Skin | BJ fibroblasts | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay | |
| E_00172 | chr9:94700500~94701500 | Tongue | Cal27 | tongue squamous cell carcinoma | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_00173 | chr3:98678906~98697335 | Liver | HepG2 | hepatocellular carcinoma | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_00174 | chr16:68362000~68362400 | Peripheral Blood | K562 | chronic myeloid leukemia | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_00175 | chr8:128747000~128750000 | Cervical Epithelium | HeLa | cervical cancer | Functional perturbation assay, Chromatin interaction assay, TF binding assay |
| E_00176 | chr1:16479332~16499332 | Colon | HCT116 | colorectal cancer | Enhancer activity assay, Functional perturbation assay |
| E_00177 | chr1:16479332~16499332 | Breast | MCF7 | breast carcinoma | Enhancer activity assay, Functional perturbation assay |
| E_00178 | chr1:16479332~16499332 | Cervical Epithelium | HeLa | cervical cancer | Enhancer activity assay, Functional perturbation assay |
| E_00179 | chr1:16499333~16519333 | Colon | HCT116 | colorectal cancer | Enhancer activity assay, Functional perturbation assay |
| E_00180 | chr1:16499333~16519333 | Breast | MCF7 | breast carcinoma | Enhancer activity assay, Functional perturbation assay |
| E_00181 | chr1:16499333~16519333 | Cervical Epithelium | HeLa | cervical cancer | Enhancer activity assay, Functional perturbation assay |
| E_00182 | chr1:16519334~16539780 | Colon | HCT116 | colorectal cancer | Enhancer activity assay, Functional perturbation assay |
| E_00183 | chr1:16519334~16539780 | Breast | MCF7 | breast carcinoma | Enhancer activity assay, Functional perturbation assay |
| E_00184 | chr1:42614062~42616745 | Colon | HCT116 | colorectal cancer | Enhancer activity assay, Functional perturbation assay |
| E_00185 | chr1:42614062~42616745 | Bone Marrow | Primary AML blasts | acute myeloid leukemia | Enhancer activity assay, Functional perturbation assay |
| E_00186 | chr3:46453226~46459225 | prostate | NA | prostate cancer | integrated epigenomic analysis |
| E_00187 | chr3:168855000~168870000 | Peripheral Blood | K562 | chronic myeloid leukemia | Chromatin interaction assay, Functional perturbation assay |
| E_00188 | chr3:168855000~168870000 | Bone Marrow | AML cell line | acute myeloid leukemia | Chromatin interaction assay, Functional perturbation assay |
| E_00189 | chr3:168866500~168868000 | Bone Marrow | Primary AML blasts | acute myeloid leukemia | Chromatin interaction assay, Functional perturbation assay, TF binding assay |
| E_00190 | chr3:168866500~168868000 | Peripheral Blood | K562 | chronic myeloid leukemia | Chromatin interaction assay, Functional perturbation assay, TF binding assay |
| E_00191 | chr3:168866500~168868000 | Bone Marrow | MUTZ-3 | acute myeloid leukemia | Chromatin interaction assay, Functional perturbation assay, TF binding assay |
| E_00192 | chr3:168915400~168918000 | Peripheral Blood | Human B lymphoblastoid cell | Functional perturbation assay, Chromatin interaction assay, TF binding assay | |
| E_00193 | chr3:168915400~168918000 | Blood | Jurkat | T-cell acute lymphoblastic leukemia | Functional perturbation assay, Chromatin interaction assay, TF binding assay |
| E_00194 | chr8:130475000~130775000 | Peripheral Blood | THP-1 | acute monocytic leukemia | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay |
| E_00195 | chr8:130475000~130775000 | Prostate | 22Rv1 | prostate cancer | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay |
| E_00196 | chr19:16439455~16439541 | Prostate | LNCaP | prostate cancer | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_00197 | chr19:16439455~16439541 | Kidney | 786-O | renal cell carcinoma | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_00198 | chr19:16439455~16439541 | Lung | A549 | lung adenocarcinoma | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_00199 | chr8:128531465~128532665 | Embryonic Kidney | HEK293 | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay | |
| E_00200 | chr8:128531465~128532665 | Skin | SKmel147 | skin melanoma | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_00201 | chr8:128531465~128532665 | Skin | 501MEL | skin melanoma | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_00202 | chr8:128531465~128532665 | Umbilical vein | HUVEC | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay | |
| E_00203 | chr8:128889122~128889450 | Colon | Colorectal carcinoma cells | colorectal cancer | Enhancer activity assay, Functional perturbation assay, Chromatin interaction assay |
| E_00204 | chr11:31240000~31241000 | Liver | Mouse hepatoma cell | hepatocellular carcinoma | Enhancer activity assay, Chromatin interaction assay |
| E_00205 | chr11:31240000~31241000 | Liver | Human hepatoblastoma cell | hepatoblastoma | Enhancer activity assay, Chromatin interaction assay |
| E_00206 | chr12:47732000~47733500 | Cervical Epithelium | HeLa | cervical cancer | Enhancer activity assay, Functional perturbation assay |
| E_00207 | chr12:47732000~47733500 | Colon | Human colorectal carcinoma cell | colorectal cancer | Enhancer activity assay, Functional perturbation assay |
| E_00208 | chr2:46573123~46594333 | Prostate | Human prostate cancer cell | prostate cancer | Enhancer activity assay, Functional perturbation assay |
| E_00209 | chr4:76192040~76237727 | Inner cell mass | H1 hESCs | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay | |
| E_00210 | chr14:101283029~101284356 | Peripheral Blood | THP-6 | acute monocytic leukemia | Functional perturbation assay, Chromatin interaction assay, TF binding assay |
| E_00211 | chr14:101283029~101284356 | Prostate | LNCaP | prostate cancer | Functional perturbation assay, Chromatin interaction assay, TF binding assay |
| E_00212 | chr8:29256000~29256500 | Breast | MCF7 | breast carcinoma | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay |
| E_00213 | chr4:76192040~76237727 | Brain | G361 glioblastoma | glioblastoma | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay |
| E_00214 | chr8:128531465~128532665 | Brain | GBM3565 glioblastoma | glioblastoma | Functional perturbation assay, Chromatin interaction assay, TF binding assay |
| E_00215 | chr6:30754822~30755196 | Ovary | OVCAR3 | ovarian carcinoma | Functional perturbation assay, Enhancer activity assay |
| E_00216 | chr6:135640000~135645000 | Prostate | PDX cells | prostate cancer | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_00217 | chr14:36973254~36996211 | Prostate | Prostate carcinoma cell line (C4-2B) | prostate cancer | Chromatin interaction assay, Functional perturbation assay |
| E_00218 | chr11:114058000~114058850 | Prostate | LNCaP | prostate cancer | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_00219 | chr7:54932020~54934020 | Brain | GBM3565 glioblastoma | glioblastoma | Functional perturbation assay |
| E_00220 | chr7:54888020~54890020 | Brain | G361 glioblastoma | glioblastoma | Functional perturbation assay |
| E_00221 | chr7:54888020~54890020 | Brain | GBM3565 glioblastoma | glioblastoma | Functional perturbation assay |
| E_00222 | chr20:53730511~53757381 | Ovary | OVCAR3 | ovarian carcinoma | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_00223 | chr1:16162175~16195191 | Ovary | OVCAR3 | ovarian carcinoma | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_00224 | chr12:122510495~122510896 | Prostate | PDX cells | prostate cancer | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay |
| E_00225 | chr12:122510495~122510896 | Prostate | Prostate carcinoma cell line (C4-2B) | prostate cancer | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay |
| E_00226 | chr8:130548000~130549050 | Bone Marrow | Primary AML blasts | acute myeloid leukemia | Chromatin interaction assay, Functional perturbation assay |
| E_00227 | chr8:130548000~130549050 | Peripheral Blood | K562 | chronic myeloid leukemia | Chromatin interaction assay, Functional perturbation assay |
| E_00228 | chr12:6448000~6450000 | Blood | CD4+ T cells | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay | |
| E_00229 | chr12:6448000~6450000 | Blood | CD8+ T cells | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay | |
| E_00230 | chr2:217994794~217995294 | Breast | MCF7 | breast carcinoma | Enhancer activity assay, Functional perturbation assay |
| E_00231 | chr2:217994794~217995294 | Breast | T47D | breast carcinoma | Enhancer activity assay, Functional perturbation assay |
| E_00232 | chr8:128320000~128322000 | Colon | HCT116 | colorectal cancer | Chromatin interaction assay, Functional perturbation assay |
| E_00233 | chr1:47679000~47722000 | Blood | Human chronic myeloid leukemia cell | chronic myeloid leukemia | Enhancer activity assay, Functional perturbation assay |
| E_00234 | chr11:5301549~5302549 | Liver | HepG2 | hepatocellular carcinoma | Enhancer activity assay, Functional perturbation assay |
| E_00235 | chr2:27740600~27741238 | Liver | mouse primary hepatocytes | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_00236 | chr2:27740600~27741238 | Liver | human liver biopsies | hepatocellular carcinoma | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_00237 | chr2:27740600~27741238 | Lung | A549 | lung adenocarcinoma | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_00238 | chr3:181465000~181468600 | Lung | H1299 | non-small cell lung carcinoma | Functional perturbation assay |
| E_00239 | chr3:181465000~181468600 | Vascular tissue | iPSC-ECs | Functional perturbation assay | |
| E_00240 | chr6:12852000~12853000 | Lung | Beas-2B | Enhancer perturbation assay | |
| E_00241 | chr13:24149800~24150800 | Colon | HCT116 | colorectal cancer | Enhancer activity assay, Functional perturbation assay, Chromatin interaction assay |
| E_00242 | chr17:46682000~46685000 | Colon | HCT116 | colorectal cancer | Functional perturbation assay |
| E_00243 | chr17:46692000~46695000 | Colon | HCT116 | colorectal cancer | Functional perturbation assay, TF binding assay |
| E_00244 | chr17:46670277~46684332 | Breast | MCF7 | breast carcinoma | Enhancer activity assay, Functional perturbation assay |
| E_00245 | chr21:34600000~34610000 | Bone Marrow | SEM cells | B-cell acute lymphoblastic leukemia | Enhancer activity assay, Chromatin interaction assay |
| E_00246 | chr8:128533830~128534830 | Bone Marrow | Primary T-ALL cells | T-cell acute lymphoblastic leukemia | Enhancer activity assay, Functional perturbation assay |
| E_00247 | chr1:47677466~47678021 | Blood | Jurkat | T-cell acute lymphoblastic leukemia | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_00248 | chr1:47677466~47678021 | Blood | Peer | T-cell acute lymphoblastic leukemia | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_00249 | chr1:47677466~47678021 | Blood | PDX cells | T-cell acute lymphoblastic leukemia | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_00250 | chr1:47677466~47678021 | Bone Marrow | GDM-1 | acute myeloid leukemia | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_00251 | chr6:135644579~135645062 | Bone Marrow | DND-41 | T-cell acute lymphoblastic leukemia | Enhancer activity assay, Chromatin interaction assay |
| E_00252 | chr14:98602411~98675204 | Bone Marrow | UT242 | T-cell acute lymphoblastic leukemia | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay |
| E_00253 | chr14:98602411~98675204 | Bone Marrow | UT308 | T-cell acute lymphoblastic leukemia | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay |
| E_00254 | chr14:98602411~98675204 | Lymph node | Karpas-422 | diffuse large B-cell lymphoma | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay |
| E_00255 | chr8:129180000~129190000 | Lymph node | SUDHL-5 | diffuse large B-cell lymphoma | Enhancer activity assay, Functional perturbation assay |
| E_00256 | chr8:129180000~129190000 | Lymph node | HT | diffuse large B-cell lymphoma | Enhancer activity assay, Functional perturbation assay |
| E_00257 | chr8:129180000~129190000 | Lymph node | BJAB | Burkitt lymphoma | Enhancer activity assay, Functional perturbation assay |
| E_00258 | chr8:129180000~129190000 | Lymph node | Karpas-422 | diffuse large B-cell lymphoma | Enhancer activity assay, Functional perturbation assay |
| E_00259 | chr8:129190000~129195000 | Lymph node | SUDHL-5 | diffuse large B-cell lymphoma | Enhancer activity assay, Functional perturbation assay |
| E_00260 | chr8:129190000~129195000 | Lymph node | HT | diffuse large B-cell lymphoma | Enhancer activity assay, Functional perturbation assay |
| E_00261 | chr8:129190000~129195000 | Lymph node | BJAB | Burkitt lymphoma | Enhancer activity assay, Functional perturbation assay |
| E_00262 | chr8:129190000~129195000 | Blood | Leukemia cell lines | leukemia | Enhancer activity assay, Functional perturbation assay |
| E_00263 | chr21:39854000~39855000 | Breast | MDA-MB-231 | breast carcinoma | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_00264 | chr12:2880430~3018116 | Breast | MCF-7 | breast carcinoma | Functional perturbation assay, Chromatin interaction assay, Enhancer activity assay |
| E_00265 | chr12:2880430~3018116 | Bone | U2OS | osteosarcoma | Functional perturbation assay, Chromatin interaction assay, Enhancer activity assay |
| E_00266 | chr12:2880430~3018116 | Cervix | HeLa | cervical cancer | Functional perturbation assay, Chromatin interaction assay, Enhancer activity assay |
| E_00267 | chr12:2880430~3018116 | Embryonic Kidney | HEK-293T | Functional perturbation assay, Chromatin interaction assay, Enhancer activity assay | |
| E_00268 | chr12:2880430~3018116 | Pancreatic islet | EndoC-??H1 | Functional perturbation assay, Chromatin interaction assay, Enhancer activity assay | |
| E_00269 | chr11:1713879~1716230 | Pancreatic islet | primary human pancreatic islets | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay | |
| E_00270 | chr11:1713879~1716230 | Cranial neural crest | hCNCC | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay | |
| E_00271 | chr17:68720009~68721009 | Colon | COLO 320DM cells | colorectal cancer | Functional perturbation assay |
| E_00272 | chr3:111274086~111275786 | Blood | K562 | chronic myeloid leukemia | Enhancer activity assay, Functional perturbation assay |
| E_00273 | chr16:23819225~23820225 | Brain | U87MG | glioblastoma | Functional perturbation assay |
| E_00274 | chr2:177480000~177490000 | Brain | Normal human astrocytes | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay | |
| E_00275 | chr2:177480000~177490000 | Aorta | HAEC | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay | |
| E_00276 | chr2:188184262~188184791 | Cervix | Human cervical adenocarcinoma cell | cervical cancer | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_00277 | chr12:61890000~61895000 | Cervix | Human cervical adenocarcinoma cell | cervical cancer | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay |
| E_00278 | chr12:61890000~61895000 | Cervix | Human cervical adenocarcinoma cell | cervical cancer | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay |
| E_00279 | chr12:61890000~61895000 | Cervix | Human cervical adenocarcinoma cell | cervical cancer | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay |
| E_00280 | chr19:50913170~50987888 | Cervix | Human cervical adenocarcinoma cell | cervical cancer | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay |
| E_00281 | chr19:50913170~50987888 | Cervix | Human cervical adenocarcinoma cell | cervical cancer | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay |
| E_00282 | chr19:50913170~50987888 | Cervix | Human cervical adenocarcinoma cell | cervical cancer | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay |
| E_00283 | chr19:50913170~50987888 | Blood | Human T-ALL cell | T-cell acute lymphoblastic leukemia | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay |
| E_00284 | chr8:129400000~130035000 | Bone Marrow | U266B1 | multiple myeloma | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay |
| E_00285 | chr19:50913170~50987888 | Lung | H1299 | non-small cell lung carcinoma | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay |
| E_00286 | chr11:68155000~68173900 | Embryonic Kidney | HEK293T | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_00287 | chr15:67150000~67600000 | Skin | Melanoma cell line | skin melanoma | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_00288 | chr11:5248250~5249100 | Breast | MDA-MB-231 | breast carcinoma | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_00289 | chr10:89912175~89913031 | Pancreas | PANC-1 | pancreatic ductal adenocarcinoma | Functional perturbation assay, Enhancer activity assay |
| E_00290 | chr5:74678000~74688000 | Skin | Melanoma cell line | skin melanoma | Functional perturbation assay, Enhancer activity assay |
| E_00291 | chr16:53500000~53510000 | Colon | SW480 | colorectal cancer | Super enhancer activity assay, Functional perturbation assay |
| E_00292 | chr12:85074000~85075186 | Colon | HCT116 | colorectal cancer | Functional perturbation assay, Chromatin interaction assay, Enhancer activity assay |
| E_00293 | chr13:74003796~74004073 | Colon | SW480 | colorectal cancer | Functional perturbation assay, Chromatin interaction assay, TF binding assay |
| E_00294 | chr13:74003796~74004073 | Colon | HCT116 | colorectal cancer | Functional perturbation assay, Chromatin interaction assay, TF binding assay |
| E_00295 | chr8:128231146~128231713 | Breast | MCF-7 | breast carcinoma | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_00296 | chr8:128231146~128231713 | Pancreatic islet | Beta cell | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay | |
| E_00297 | chr11:69329684~69330954 | Colon | HCT116 | colorectal cancer | Enhancer activity assay |
| E_00298 | chr3:123065517~123065936 | Colon | HT29 | colorectal cancer | Enhancer activity assay, Functional perturbation assay |
| E_00299 | chr3:183286632~183287223 | Breast | MDA-MB-231 | breast carcinoma | Enhancer activity assay, Functional perturbation assay |
| E_00300 | chr3:183286632~183287223 | Breast | MCF-7 | breast carcinoma | Enhancer activity assay, Functional perturbation assay |
| E_00301 | chr8:128821500~128822500 | Breast | MDA-MB-231 | breast carcinoma | Enhancer activity assay, Functional perturbation assay, Chromatin interaction assay, TF binding assay |
| E_00302 | chr8:128821500~128822500 | Breast | MCF-7 | breast carcinoma | Enhancer activity assay, Functional perturbation assay, Chromatin interaction assay, TF binding assay |
| E_00303 | chr8:128866000~128867000 | Breast | MDA-MB-231 | breast carcinoma | Enhancer activity assay, Functional perturbation assay, Chromatin interaction assay, TF binding assay |
| E_00304 | chr8:128866000~128867000 | Breast | MCF-7 | breast carcinoma | Enhancer activity assay, Functional perturbation assay, Chromatin interaction assay, TF binding assay |
| E_00305 | chr8:128912000~128913000 | Breast | MDA-MB-231 | breast carcinoma | Enhancer activity assay, Chromatin interaction assay, TF binding assay |
| E_00306 | chr8:128912000~128913000 | Breast | MCF-7 | breast carcinoma | Enhancer activity assay, Chromatin interaction assay, TF binding assay |
| E_00307 | chr8:128919000~128920000 | Colon | HCT116 | colorectal cancer | Enhancer activity assay, Functional perturbation assay, Chromatin interaction assay, TF binding assay |
| E_00308 | chr17:46656000~46658000 | Colon | HCT116 | colorectal cancer | Enhancer activity assay, Functional perturbation assay |
| E_00309 | chr17:46658000~46660000 | Colon | HCT116 | colorectal cancer | Enhancer activity assay, Functional perturbation assay, TF binding assay |
| E_00310 | chr17:46658000~46660000 | Pulmonary artery | hPAEC | Enhancer activity assay, Functional perturbation assay, TF binding assay | |
| E_00311 | chr17:46658000~46660000 | Pancreas | L3.6pl | pancreatic ductal adenocarcinoma | Enhancer activity assay, Functional perturbation assay, TF binding assay |
| E_00312 | chr8:41184163~41184463 | Pancreas | PacR | pancreatic ductal adenocarcinoma | Enhancer activity assay, Functional perturbation assay |
| E_00313 | chr22:39666991~39667170 | Pancreas | L3.6pl | pancreatic ductal adenocarcinoma | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay |
| E_00314 | chr22:39666991~39667170 | Pancreas | PacR | pancreatic ductal adenocarcinoma | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay |
| E_00315 | chr19:1109765~1110214 | Bone | A673 | Ewing sarcoma | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay |
| E_00316 | chr19:1109765~1110214 | Adrenal gland | CHLA10 | neuroblastoma | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay |
| E_00317 | chr2:176265000~176270000 | Heart | Primary cardiomyocytes | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay | |
| E_00318 | chr2:176265000~176270000 | Blood | K562 erythroleukemia cells | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay | |
| E_00319 | chr3:158194000~158195200 | Prostate | 22Rv1 cells | prostate cancer | Enhancer activity assay, Functional perturbation assay |
| E_00320 | chr11:5225000~5225500 | Embryonic Kidney | Human embryonic kidney cell | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay | |
| E_00321 | chr11:5301549~5302549 | Blood | K562 | chronic myeloid leukemia | Enhancer activity assay, Functional perturbation assay, TF binding assay |
| E_00322 | chr12:115092472~115096258 | Blood | Jurkat | T-cell acute lymphoblastic leukemia | Chromatin interaction assay |
| E_00323 | chr11:5301549~5302549 | Peripheral Blood | Primary ATL cells | adult T-cell leukemia/lymphoma | Enhancer activity assay,Functional perturbation assay,TF binding assay |
| E_00324 | chr18:9876906~9877723 | Peripheral Blood | T cell leukemia cell | adult T-cell leukemia/lymphoma | Functional validation |
| E_00325 | chr8:130180217~130180629 | Peripheral Blood | Primary ATL cells | adult T-cell leukemia/lymphoma | Enhancer activity assay, Chromatin interaction assay, TF binding assay, Functional perturbation assay |
| E_00326 | chr1:3560600~3600000 | Peripheral Blood | T cell leukemia cell | adult T-cell leukemia/lymphoma | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_00327 | chr1:3560600~3600000 | Peripheral Blood | Primary ATL cells | adult T-cell leukemia/lymphoma | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_00328 | chr1:3572730~3574116 | Peripheral Blood | T cell leukemia cell | adult T-cell leukemia/lymphoma | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_00329 | chr1:3572730~3574116 | Blood | K562 erythroleukemia | chronic myeloid leukemia | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_00330 | chr1:3592595~3594569 | Blood | iPSC-derived macrophages | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_00331 | chr1:3592595~3594569 | Peripheral Blood | T cell leukemia cell | adult T-cell leukemia/lymphoma | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_00332 | chr11:5301549~5302549 | Blood | K562 erythroleukemia | chronic myeloid leukemia | Enhancer activity assay, Functional perturbation assay, TF binding assay |
| E_00333 | chr12:6444399~6447744 | Blood | iPSC-derived macrophages | Enhancer activity assay | |
| E_00334 | chr5:149631000~149636000 | Breast | Human breast cancer cell | breast carcinoma | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_00335 | chr11:72482883~72512882 | Breast | MDA-MB-231 | breast carcinoma | Enhancer activity assay, Functional perturbation assay |
| E_00336 | chr14:77808992~77809573 | Brain | SH-SY5Y | neuroblastoma | Chromatin interaction assay, Enhancer activity assay, Functional perturbation assay |
| E_00337 | chr7:23467757~23468022 | Liver | HepG2 | hepatocellular carcinoma | Enhancer activity assay, Functional perturbation assay, Chromatin interaction assay |
| E_00338 | chr6:43740121~43741621 | Blood | K562 | chronic myeloid leukemia | Functional perturbation assay |
| E_00339 | chr2:60722300~60722700 | Hematopoietic system | HUDEP-2 | Functional perturbation assay, Enhancer activity assay | |
| E_00340 | chr11:5301862~5302715 | Hematopoietic system | K562 | chronic myeloid leukemia | Functional perturbation assay |
| E_00341 | chr1:53893000~53895000 | Liver | HepG2 | hepatocellular carcinoma | Enhancer activity assay, Functional perturbation assay |
| E_00342 | chr2:126521490~126522490 | Brain | H1-derived microglia | Regulatory element functional validation, 3D chromatin interaction mapping | |
| E_00343 | chr6:132270000~132270500 | Colon | HCT116 colorectal cancer | colorectal carcinoma | Functional perturbation assay, TF binding assay, Enhancer activity assay |
| E_00344 | chr17:69107686~69108045 | Prostate | LNCaP | prostate cancer | Enhancer activity assay, TF binding assay, Chromatin interaction assay |
| E_00345 | chr17:69107686~69108045 | Prostate | VCaP cells | prostate cancer | Enhancer activity assay, TF binding assay, Chromatin interaction assay |
| E_00346 | chr8:124417000~124427000 | Prostate | LNCaP cells | prostate cancer | Enhancer activity assay, Chromatin interaction assay |
| E_00347 | chr6:132272417~132273191 | Breast | MDA-MB-231 | breast carcinoma | Enhancer activity assay |
| E_00348 | chr8:127744001~127744701 | Colon | HCT116 | colorectal carcinoma | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_00349 | chr8:127744001~127744701 | Embryonic Kidney | HEK293 | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay | |
| E_00350 | chr6:44500000~45600000 | Hematopoietic tissue | CAL-1 | blastic plasmacytoid dendritic cell neoplasm | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_00351 | chr6:44500000~45600000 | Hematopoietic tissue | CAL-1 | blastic plasmacytoid dendritic cell neoplasm | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_00352 | chr13:28840000~28850000 | Bone Marrow | SEM | B-cell acute lymphoblastic leukemia | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_00353 | chr12:52304911~53120196 | Breast | MCF7 | breast carcinoma | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_00354 | chr2:74404247~74404647 | Blood | GM12878 | Enhancer activity assay, TF binding assay | |
| E_00355 | chr10:102880001~102881789 | Pancreas | MIA PaCa-2 | pancreatic ductal adenocarcinoma | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_00356 | chr4:74500000~74575000 | Liver | Liver sinusoidal endothelial cells (LSEC) | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay | |
| E_00357 | chr17:48110000~48150000 | Skin | A375 | skin melanoma | TF binding assay, Enhancer activity assay, Functional perturbation assay |
| E_00358 | chr12:122510495~122510896 | Prostate | P-90 PDX primary | prostate cancer | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay |
| E_00359 | chr12:122510495~122510896 | Prostate | P-90 PDX primary | prostate cancer | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay |
| E_00360 | chr17:79780000~79828000 | Lung | A549 | lung adenocarcinoma | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_00361 | chr17:79780000~79828000 | Lung | PC-9 | lung adenocarcinoma | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_00362 | chr17:79780000~79828000 | Lung | LUAD primary tumor | lung adenocarcinoma | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_00363 | chr20:48900221~48901229 | Liver | Hepatocellular carcinoma cell line (HepG2) | hepatocellular carcinoma | Functional perturbation assay, Enhancer activity assay |
| E_00364 | chr12:12874700~12875275 | Embryonic Kidney | HEK293 | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay | |
| E_00365 | chr12:12874700~12875275 | Blood | Jurkat | T-cell acute lymphoblastic leukemia | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay |
| E_00366 | chr12:12874700~12875275 | Blood | Primary B cells | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay | |
| E_00367 | chr12:12874700~12875275 | Blood | Primary T cells | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay | |
| E_00368 | chr6:139766548~139767000 | Blood | K562 | chronic myeloid leukemia | Functional validation |
| E_00369 | chr4:8708912~8710911 | Craniofacial Tissue | hCNCC | Enhancer activity assay, Chromatin interaction assay | |
| E_00370 | chr4:8708912~8712911 | Craniofacial Tissue | hCNCC | Enhancer activity assay, Chromatin interaction assay | |
| E_00371 | chr7:128573817~128574098 | Peripheral Blood | SC monocyte-derived cells | Enhancer activity assay, TF binding assay, Chromatin interaction assay | |
| E_00372 | chr7:128573817~128574098 | Peripheral Blood | Primary CD14+ monocytes | Enhancer activity assay, TF binding assay, Chromatin interaction assay | |
| E_00373 | chr7:128573817~128574098 | Embryonic Kidney | HEK293 | Enhancer activity assay, TF binding assay, Chromatin interaction assay | |
| E_00374 | chr8:128132902~128133724 | Kidney | Human renal cell carcinoma cell | renal cell carcinoma | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_00375 | chr8:128132902~128133724 | Kidney | Kidney proximal tubule epithelial cell | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_00376 | chr8:128526339~128526710 | Kidney | Human renal cell carcinoma cell | renal cell carcinoma | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_00377 | chr8:128526339~128526710 | Kidney | Kidney proximal tubule epithelial cell | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_00378 | chr8:128230503~128380503 | Colon | HCT116 | colorectal carcinoma | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_00379 | chr8:128230503~128380503 | Colon | SW480 | colorectal carcinoma | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_00380 | chr8:128662857~128663857 | Colon | HCT116 | colorectal carcinoma | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_00381 | chr8:128662857~128663857 | Colon | SW480 | colorectal carcinoma | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_00382 | chr12:85074370~85074815 | Skin | skin melanoma | Enhancer activity assay, TF binding assay, Chromatin interaction assay | |
| E_00383 | chr1:22101842~22103407 | Umbilical vein | HUVEC | Enhancer functional assay | |
| E_00384 | chr2:46345000~46347000 | Breast | MCF7L | breast carcinoma | Enhancer activity assay, Functional perturbation assay, TF binding assay |
| E_00385 | chr2:46345000~46347000 | Breast | TamR | breast carcinoma | Enhancer activity assay, Functional perturbation assay, TF binding assay |
| E_00386 | chr2:46348000~46350000 | Breast | MCF7L | breast carcinoma | Enhancer activity assay, Functional perturbation assay, TF binding assay |
| E_00387 | chr2:46348000~46350000 | Breast | TamR | breast carcinoma | Enhancer activity assay, Functional perturbation assay, TF binding assay |
| E_00388 | chr2:46530000~46535000 | Breast | MCF7L-TamR | breast carcinoma | Functional perturbation assay |
| E_00389 | chr13:28710000~28715000 | Bone Marrow | Primary BCP ALL cells | B-cell acute lymphoblastic leukemia | Enhancer activity assay, Chromatin interaction assay |
| E_00390 | chr13:28710000~28715000 | Blood | GM12878 | Enhancer activity assay, Chromatin interaction assay | |
| E_00391 | chr13:28710000~28715000 | Bone Marrow | NALM-6 | B-cell acute lymphoblastic leukemia | Enhancer activity assay, Chromatin interaction assay |
| E_00392 | chr13:28843000~28843500 | Bone Marrow | Primary BCP ALL cells | B-cell acute lymphoblastic leukemia | Enhancer activity assay, Chromatin interaction assay |
| E_00393 | chr13:28843000~28843500 | Blood | GM12878 | Enhancer activity assay, Chromatin interaction assay | |
| E_00394 | chr13:28843000~28843500 | Bone Marrow | NALM-6 | B-cell acute lymphoblastic leukemia | Enhancer activity assay, Chromatin interaction assay |
| E_00395 | chr4:70849125~70849971 | Embryonic Kidney | 293FT cells | Enhancer activity assay | |
| E_00396 | chr4:70849125~70849971 | Salivary Gland | AciCC primary tumor cells | salivary gland acinic cell carcinoma | Enhancer activity assay |
| E_00397 | chr4:70849125~70849971 | Salivary Gland | normal parotid gland cells | Enhancer activity assay | |
| E_00398 | chr1:218299740~218299908 | Skin | Primary human dermal fibroblasts | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_00399 | chr11:5246600~5247600 | Bone Marrow | K562 | chronic myeloid leukemia | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay |
| E_00400 | chr11:5246600~5247600 | Embryonic Kidney | HEK-293T | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay | |
| E_00401 | chr7:92384001~92385000 | Blood | ChiPSC22 cells | Functional perturbation assay, Chromatin interaction assay | |
| E_00402 | chr7:92384001~92385000 | Blood | HSPCs | Functional perturbation assay, Chromatin interaction assay | |
| E_00403 | chr8:129165000~129166500 | Lung | Human non-small cell lung carcinoma cell | non-small cell lung carcinoma | Enhancer functional validation, Transcription factor binding analysis, Genome editing |
| E_00404 | chr8:129166547~129190290 | Lung | Human non-small cell lung carcinoma cell | non-small cell lung carcinoma | Epigenomic mapping, Enhancer functional validation, Genome editing |
| E_00405 | chr3:41172000~41174000 | Bone | SaOS-2 | osteosarcoma | Enhancer activity assay, Chromatin interaction assay |
| E_00406 | chr3:41172000~41174000 | Embryonic Kidney | HEK293 | Enhancer activity assay, Chromatin interaction assay | |
| E_00407 | chr3:41174000~41176000 | Bone | SaOS-2 | osteosarcoma | Enhancer activity assay, Chromatin interaction assay |
| E_00408 | chr3:41174000~41176000 | Embryonic Kidney | HEK293 | Enhancer activity assay, Chromatin interaction assay | |
| E_00409 | chr3:41177000~41179000 | Bone | SaOS-2 | osteosarcoma | Enhancer activity assay, Chromatin interaction assay |
| E_00410 | chr3:41177000~41179000 | Embryonic Kidney | HEK293 | Enhancer activity assay, Chromatin interaction assay | |
| E_00411 | chr17:48100000~48130000 | Skin | WM1552C | skin melanoma | Enhancer activity assay, Functional perturbation assay |
| E_00412 | chr17:48100000~48130000 | Skin | YUCHIME | skin melanoma | Enhancer activity assay, Functional perturbation assay |
| E_00413 | chr17:48100000~48130000 | Skin | SKmel147 | skin melanoma | Enhancer activity assay, Functional perturbation assay |
| E_00414 | chr2:202204000~202204758 | Breast | MCF-10A | Enhancer activity assay, TF binding assay, eQTL analysis, Genetic association study | |
| E_00415 | chr2:202204000~202204758 | Breast | T-47D | breast carcinoma | Enhancer activity assay, TF binding assay, eQTL analysis, Genetic association study |
| E_00416 | chr2:202204000~202204758 | Breast | MCF-7 | breast carcinoma | Enhancer activity assay, TF binding assay, eQTL analysis, Genetic association study |
| E_00417 | chr9:136402000~136406000 | Bone Marrow | K562 | chronic myeloid leukemia | Enhancer activity assay |
| E_00418 | chr6:135515000~135515800 | Salivary gland | ACC patient-derived xenograft cell lines (ACCX2, ACCX9, ACCX12, ACCX19, ACCX22) | salivary gland adenoid cystic carcinoma | Enhancer activity assay, Chromatin interaction assay |
| E_00419 | chr8:128740000~128790000 | Colon | HCT-116 | colorectal carcinoma | Enhancer activity assay, TF binding assay |
| E_00420 | chr6:152400000~152450000 | Breast | MCF-7 | breast carcinoma | Enhancer activity assay, TF binding assay |
| E_00421 | chr8:128322000~128323000 | Colon | HCT116 | colorectal carcinoma | Chromatin interaction assay |
| E_00422 | chr11:63800000~63802500 | Connective Tissue | Human Mesenchymal Progenitor | Enhancer activity assay, Functional perturbation assay | |
| E_00423 | chr17:38065500~38067500 | Blood | Primary CD4+ T cells | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay | |
| E_00424 | chr17:38065500~38067500 | Blood | HUT-78 | cutaneous T-cell lymphoma | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_00425 | chr8:140900000~140930000 | Brain | Adult brain tissue | Chromatin interaction assay, Enhancer activity assay | |
| E_00426 | chr9:131300000~131320000 | Cerebellum | Cerebellar granule neuron progenitors (CGNPs) | Enhancer activity assay, Functional perturbation assay | |
| E_00427 | chr20:32580000~32595000 | Cerebellum | Cerebellar granule neuron progenitors (CGNPs) | Enhancer activity assay, Functional perturbation assay | |
| E_00428 | chr19:44905642~44906512 | Prostate | LNCaP | prostate cancer | Enhancer activity assay, TF binding assay |
| E_00429 | chr1:207450000~207452000 | Blood | K562 | chronic myeloid leukemia | Functional perturbation assay |
| E_00430 | chr1:207455000~207457000 | Blood | K562 | chronic myeloid leukemia | Functional perturbation assay |
| E_00431 | chr1:207460000~207462000 | Blood | K562 | chronic myeloid leukemia | Functional perturbation assay |
| E_00432 | chr1:207465000~207467000 | Blood | K562 | chronic myeloid leukemia | Functional perturbation assay |
| E_00433 | chr6:44500000~45600000 | Hematopoietic tissue | CAL-1 BPDCN | blastic plasmacytoid dendritic cell neoplasm | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_00434 | chr9:72895815~73001135 | Prostate | 22RV1 | prostate cancer | Enhancer activity assay, Functional perturbation assay |
| E_00435 | chr12:120975000~121005271 | Prostate | 22RV1 | prostate cancer | Enhancer activity assay, Functional perturbation assay |
| E_00436 | chr3:128322357~128323157 | Bone Marrow | HNT-34 | acute myeloid leukemia | TF binding assay, Enhancer activity assay, Functional perturbation assay |
| E_00437 | chr10:23508400~23508721 | Pancreas | Pancreatic Multipotent Progenitor Cells (MPCs) | Functional perturbation assay, Enhancer activity assay | |
| E_00438 | chr2:213700000~214600000 | Blood | DND41 | T-cell acute lymphoblastic leukemia | Chromatin interaction assay, Functional perturbation assay |
| E_00439 | chr7:54925000~54927000 | Brain | GBM3565 glioblastoma | glioblastoma | Functional perturbation assay |
| E_00440 | chr7:54915000~54917000 | Brain | GBM3565 glioblastoma | glioblastoma | Functional perturbation assay |
| E_00441 | chr2:217955458~217957767 | Breast | MDA-MB-231 | breast carcinoma | Enhancer activity assay, Functional perturbation assay |
| E_00442 | chr5:74680400~74682399 | Breast | MDA-MB-231 | breast carcinoma | Enhancer activity assay |
| E_00443 | chr5:74682400~74683933 | Breast | MDA-MB-231 | breast carcinoma | Enhancer activity assay |
| E_00444 | chr5:74686000~74687899 | Breast | MDA-MB-231 | breast carcinoma | Enhancer activity assay |
| E_00445 | chr3:128250000~128350000 | Peripheral Blood | K562 | chronic myeloid leukemia | TF binding assay, Functional perturbation assay |
| E_00446 | chr3:128250000~128350000 | Bone Marrow | MUTZ-3 | acute myeloid leukemia | TF binding assay, Functional perturbation assay |
| E_00447 | chr6:156425000~156525000 | Peripheral Blood | K562 | chronic myeloid leukemia | TF binding assay, Functional perturbation assay |
| E_00448 | chr7:92350000~92450000 | Peripheral Blood | K562 | chronic myeloid leukemia | TF binding assay, Functional perturbation assay |
| E_00449 | chr7:128579302~128580416 | Peripheral Blood | SC monocyte-derived cells | Enhancer activity assay, TF binding assay, Chromatin interaction assay | |
| E_00450 | chr7:128579302~128580416 | Peripheral Blood | Primary CD14+ monocytes | Enhancer activity assay, TF binding assay, Chromatin interaction assay | |
| E_00451 | chr7:128579302~128580416 | Embryonic Kidney | HEK293 | Enhancer activity assay, TF binding assay, Chromatin interaction assay | |
| E_00452 | chr8:130180065~130180972 | Blood | Human T-ALL cell | T-cell acute lymphoblastic leukemia | Enhancer activity assay, Chromatin interaction assay, TF binding assay |
| E_00453 | chr19:33790834~33791348 | Bone Marrow | MUTZ-3 | acute myeloid leukemia | Enhancer activity assay, TF binding assay |
| E_00454 | chr8:128835000~128837000 | Colon | HCT116 | colorectal carcinoma | Enhancer activity assay |
| E_00455 | chr22:39370500~39372500 | Blood | Primary CLL B cells | chronic lymphocytic leukemia | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_00456 | chr22:39378500~39380500 | Blood | Primary CLL B cells | chronic lymphocytic leukemia | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_00457 | chr22:39385500~39387500 | Blood | Normal B cells | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_00458 | chr7:117074000~117077000 | Nasal epithelium | HNECs | Chromatin interaction assay | |
| E_00459 | chr8:27456150~27456350 | Embryonic Kidney | HEK293 | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_00460 | chr8:27456150~27456350 | Embryonic Kidney | HEK293 | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_00461 | chr8:27456150~27456350 | Embryonic Kidney | HEK293 | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_00462 | chr6:8120004~8120873 | Skin | SK-MEL28 | skin melanoma | Enhancer activity assay, Functional perturbation assay |
| E_00463 | chr7:150360481~150366493 | Blood | Jurkat | T-cell acute lymphoblastic leukemia | Functional perturbation assay |
| E_00464 | chr4:77558000~77558500 | Prostate gland | LNCaP | prostate cancer | Enhancer activity assay |
| E_00465 | chr13:42939000~42967000 | Blood | GM12878 | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay | |
| E_00466 | chr13:42939000~42967000 | Bone Marrow | CD34+ hematopoietic stem cells | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay | |
| E_00467 | chr13:42939000~42967000 | Bone | U2-OS osteosarcoma osteoblastic cells | osteosarcoma | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay |
| E_00468 | chr13:42940000~42940969 | Bone | U2-OS osteosarcoma osteoblastic cells | osteosarcoma | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_00469 | chr13:42940000~42940969 | Blood | GM12878 | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay | |
| E_00470 | chr13:42955000~42955967 | Bone | U2-OS osteosarcoma osteoblastic cells | osteosarcoma | Enhancer activity assay, Chromatin interaction assay |
| E_00471 | chr13:42955000~42955967 | Blood | GM12878 | Enhancer activity assay, Chromatin interaction assay | |
| E_00472 | chr13:42955000~42955967 | Bone Marrow | CD34+ hematopoietic stem cells | Enhancer activity assay, Chromatin interaction assay | |
| E_00473 | chr13:42956000~42956832 | Bone | U2-OS osteosarcoma osteoblastic cells | osteosarcoma | Enhancer activity assay, Chromatin interaction assay |
| E_00474 | chr13:42956000~42956832 | Blood | GM12878 | Enhancer activity assay, Chromatin interaction assay | |
| E_00475 | chr13:42956000~42956832 | Bone Marrow | CD34+ hematopoietic stem cells | Enhancer activity assay, Chromatin interaction assay | |
| E_00476 | chr13:42965000~42965891 | Bone | U2-OS osteosarcoma osteoblastic cells | osteosarcoma | Enhancer activity assay, Chromatin interaction assay |
| E_00477 | chr13:42965000~42965891 | Blood | GM12878 | Enhancer activity assay, Chromatin interaction assay | |
| E_00478 | chr13:42965000~42965891 | Bone Marrow | CD34+ hematopoietic stem cells | Enhancer activity assay, Chromatin interaction assay | |
| E_00479 | chr18:57075464~57076425 | Stomach | AGS | gastric adenocarcinoma | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_00480 | chr18:57075464~57076425 | Colon | HT29 | colorectal adenocarcinoma | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_00481 | chr18:57075464~57076425 | Uvea | MUM2B | uveal melanoma | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_00482 | chr16:47658623~47659423 | Blood | K562 | chronic myeloid leukemia | Enhancer activity assay |
| E_00483 | chr16:47657923~47659423 | Blood | K562 | chronic myeloid leukemia | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay |
| E_00484 | chr21:36200000~36210000 | Breast | MCF7 | breast carcinoma | Enhancer activity assay |
| E_00485 | chr15:38846389~38846967 | Blood | Jurkat | T-cell acute lymphoblastic leukemia | Enhancer activity assay |
| E_00486 | chr15:38846389~38846967 | Embryonic Kidney | HEK293 | Enhancer activity assay | |
| E_00487 | chr15:38850022~38850502 | Blood | Jurkat | T-cell acute lymphoblastic leukemia | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_00488 | chr15:38850022~38850502 | Embryonic Kidney | HEK293 | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_00489 | chr15:38850022~38850502 | Blood | primary human T-cells | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_00490 | chr15:45650000~45651000 | Pancreas | PANC-1-IN | pancreatic ductal adenocarcinoma | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay |
| E_00491 | chr15:45650000~45651000 | Pancreas | Capan-1 | pancreatic ductal adenocarcinoma | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay |
| E_00492 | chr15:45650000~45651000 | Pancreas | CFPAC-1 | pancreatic ductal adenocarcinoma | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay |
| E_00493 | chr15:45675000~45676000 | Pancreas | PANC-1-IN | pancreatic ductal adenocarcinoma | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay |
| E_00494 | chr15:45675000~45676000 | Pancreas | Capan-1 | pancreatic ductal adenocarcinoma | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay |
| E_00495 | chr15:45675000~45676000 | Pancreas | CFPAC-1 | pancreatic ductal adenocarcinoma | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay |
| E_00496 | chr15:45700000~45701000 | Pancreas | PANC-1-IN | pancreatic ductal adenocarcinoma | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay |
| E_00497 | chr15:45700000~45701000 | Pancreas | Capan-1 | pancreatic ductal adenocarcinoma | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay |
| E_00498 | chr15:45700000~45701000 | Pancreas | CFPAC-1 | pancreatic ductal adenocarcinoma | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay |
| E_00499 | chr19:13110271~13175850 | Bone Marrow | NB4 | acute promyelocytic leukemia | Super enhancer activity assay, Functional perturbation assay |
| E_00500 | chr15:56550000~56550573 | Colon | LS180 | colorectal carcinoma | Enhancer activity assay, TF binding assay |
| E_00501 | chr17:32562334~32563183 | Liver | Liver sinusoidal endothelial cell | Functional perturbation assay, Enhancer activity assay | |
| E_00502 | chr8:128744932~128746104 | Prostate gland | MDA PCa 2B cells | prostate cancer | Enhancer activity assay |
| E_00503 | chr22:39370500~39372500 | Blood | Normal B cells | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_00504 | chr22:39378500~39380500 | Blood | Normal B cells | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_00505 | chr6:396143~396593 | Skin | Human melanoma cell | skin melanoma | Enhancer activity assay, TF binding assay |
| E_00506 | chr10:92680870~92681128 | Breast | MDA-MB-231 | breast carcinoma | Enhancer activity assay |
| E_00507 | chr6:132272417~132273191 | Breast | MDA-MB-231 | breast carcinoma | Enhancer activity assay |
| E_00508 | chr7:117038917~117040917 | Intestine | Human colorectal adenocarcinoma cell | Functional perturbation assay | |
| E_00509 | chr16:1480850~1482378 | Stomach | Gastrointestinal epithelial cells | Enhancer activity assay, Functional perturbation assay | |
| E_00510 | chr22:39385500~39387500 | Blood | Primary CLL B cells | chronic lymphocytic leukemia | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_00511 | chr13:37428439~37429439 | Brain | HD-MB03 | medulloblastoma | Chromatin interaction assay, Enhancer-target gene assignment assay |
| E_00512 | chr2:202122995~202124526 | Breast | HMEC | Enhancer activity assay, TF binding assay, eQTL analysis, Genetic association study | |
| E_00513 | chr2:202122995~202124526 | Breast | MCF-10A | Enhancer activity assay, TF binding assay, eQTL analysis, Genetic association study | |
| E_00514 | chr2:202122995~202124526 | Breast | T-47D | breast carcinoma | Enhancer activity assay, TF binding assay, eQTL analysis, Genetic association study |
| E_00515 | chr2:202122995~202124526 | Breast | MCF-7 | breast carcinoma | Enhancer activity assay, TF binding assay, eQTL analysis, Genetic association study |
| E_00516 | chr7:107615000~107635000 | Bone marrow | bone marrow mesenchymal stem | Enhancer activity assay, Chromatin interaction assay, eQTL validation | |
| E_00517 | chr3:186560000~186562000 | Bone marrow | bone marrow mesenchymal stem | Enhancer activity assay, Chromatin interaction assay, TF binding assay | |
| E_00518 | chr3:12335000~12337000 | Bone marrow | bone marrow mesenchymal stem | Enhancer activity assay, Chromatin interaction assay, TF binding assay | |
| E_00519 | chr6:45300000~45302000 | Bone marrow | bone marrow mesenchymal stem | Enhancer activity assay, Chromatin interaction assay, TF binding assay | |
| E_00520 | chr6:132200000~132202000 | Bone marrow | bone marrow mesenchymal stem | Enhancer activity assay, Chromatin interaction assay, TF binding assay | |
| E_00521 | chr4:54950000~54952000 | Bone marrow | bone marrow mesenchymal stem | Enhancer activity assay, Chromatin interaction assay, TF binding assay | |
| E_00522 | chr19:33790000~33792000 | Bone marrow | bone marrow mesenchymal stem | Enhancer activity assay, Chromatin interaction assay, TF binding assay | |
| E_00523 | chr1:92948000~92952000 | Bone marrow | Jurkat T-ALL | T-cell acute lymphoblastic leukemia | Enhancer activity assay |
| E_00524 | chr1:92952000~92956000 | Bone marrow | Jurkat T-ALL | T-cell acute lymphoblastic leukemia | Enhancer activity assay |
| E_00525 | chr22:43012000~43013000 | Umbilical vein | HUVEC | Enhancer activity assay | |
| E_00526 | chr6:132272417~132273191 | Breast | MDA-MB-231 | breast carcinoma | Enhancer activity assay |
| E_00527 | chr21:42770000~42770700 | Breast | MCF7 | breast carcinoma | Enhancer activity assay |
| E_00528 | chr1:191100000~191150000 | Nasopharyngeal epithelium | C666-1 | nasopharyngeal carcinoma | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay |
| E_00529 | chr1:185660000~185710000 | Nasopharyngeal epithelium | C666-1 | nasopharyngeal carcinoma | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay |
| E_00530 | chr6:134350000~134400000 | Nasopharyngeal epithelium | C666-1 | nasopharyngeal carcinoma | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay |
| E_00531 | chr8:127580017~127580036 | Lymph node | SMZ-1 | blastic plasmacytoid dendritic cell neoplasm | Regulatory element functional validation, 3D chromatin interaction mapping |
| E_00532 | chr11:85780828~85780847 | Lymph node | SMZ-1 | blastic plasmacytoid dendritic cell neoplasm | Regulatory element functional validation, 3D chromatin interaction mapping |
| E_00533 | chr11:85773039~85773058 | Lymph node | SMZ-1 | blastic plasmacytoid dendritic cell neoplasm | Regulatory element functional validation, 3D chromatin interaction mapping |
| E_00534 | chr2:202122200~202123730 | Breast | MCF10A | Enhancer activity assay | |
| E_00535 | chr2:202204360~202205118 | Breast | T-47D | breast carcinoma | Enhancer activity assay |
| E_00536 | chr17:69108466~69108765 | Breast | MCF10A | Enhancer activity assay, TF binding assay | |
| E_00537 | chr17:69108466~69108765 | Prostate | LNCaP | prostate cancer | Enhancer activity assay, TF binding assay |
| E_00538 | chr10:92680870~92681128 | Prostate | VCaP cells | prostate cancer | Enhancer activity assay |
| E_00539 | chr16:19866900~19867895 | Breast | MDA-MB-231 | breast carcinoma | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_00540 | chr22:44315438~44315637 | Blood | Jurkat | T-cell acute lymphoblastic leukemia | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_00541 | chr2:74399364~74399764 | Liver | HepG2 | hepatocellular carcinoma | Enhancer activity assay, TF binding assay |
| E_00542 | chr10:17275000~17276500 | Blood | GM12878 | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_00543 | chr16:120000~121400 | Pancreas | CAPAN1 | pancreatic ductal adenocarcinoma | Enhancer activity assay, Chromatin interaction assay |
| E_00544 | chr16:144000~145400 | Blood | iPSC-derived erythroblasts | Enhancer activity assay, Chromatin interaction assay | |
| E_00545 | chr16:183000~184400 | Blood | iPSC-derived erythroblasts | Enhancer activity assay, Chromatin interaction assay | |
| E_00546 | chr16:194000~195400 | Blood | iPSC-derived erythroblasts | Enhancer activity assay, Chromatin interaction assay | |
| E_00547 | chr3:30300000~31100000 | Blood | iPSC-derived erythroblasts | Chromatin interaction assay, Functional perturbation assay | |
| E_00548 | chr20:61300000~61600000 | Blood | Rec-1 | mantle cell lymphoma | Chromatin interaction assay, Functional perturbation assay |
| E_00549 | chr2:202122500~202124030 | Blood | Rec-1 | mantle cell lymphoma | Enhancer activity assay, TF binding assay |
| E_00550 | chr2:202122500~202124030 | Breast | MCF10A | Enhancer activity assay, TF binding assay | |
| E_00551 | chr2:202204362~202205119 | Breast | T-47D | breast carcinoma | Enhancer activity assay, TF binding assay |
| E_00552 | chr2:202204362~202205119 | Breast | MCF10A | Enhancer activity assay, TF binding assay | |
| E_00553 | chr1:165355703~165356702 | Breast | T-47D | breast carcinoma | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_00554 | chr1:165355703~165356702 | Brain | Primary Medulloblastoma Tissue (Group4 subgroup) | medulloblastoma | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_00555 | chr1:182307087~182307634 | Cerebellum | Mouse Embryonic Cerebellum | Functional validation | |
| E_00556 | chr1:182308166~182308458 | Blood | K562 | chronic myeloid leukemia | Functional validation |
| E_00557 | chr1:71140581~71141097 | Blood | K562 | chronic myeloid leukemia | Functional validation |
| E_00558 | chr16:23833191~23833694 | Blood | K562 | chronic myeloid leukemia | Functional validation |
| E_00559 | chr2:127402697~127403360 | Blood | K562 | chronic myeloid leukemia | Functional validation |
| E_00560 | chr4:56595855~56596581 | Blood | K562 | chronic myeloid leukemia | Functional validation |
| E_00561 | chr4:56596632~56597095 | Blood | K562 | chronic myeloid leukemia | Functional validation |
| E_00562 | chr4:56600029~56600394 | Blood | K562 | chronic myeloid leukemia | Functional validation |
| E_00563 | chr4:8712912~8728565 | Blood | K562 | chronic myeloid leukemia | Enhancer activity assay, Chromatin interaction assay |
| E_00564 | chr2:69343058~70165537 | Craniofacial Tissue | hCNCC | Chromatin interaction assay, Functional perturbation assay | |
| E_00565 | chr1:109714926~109989926 | Connective Tissue | Primary human fibroblasts | Enhancer-target gene connection validation | |
| E_00566 | chr9:5455064~5456191 | Liver | Primary human hepatocytes | Enhancer activity assay | |
| E_00567 | chr9:5455064~5456191 | Brain | Human meningioma cell | meningioma | Enhancer activity assay |
| E_00568 | chr9:5455064~5456191 | Brain | KALS1 | meningioma | Enhancer activity assay |
| E_00569 | chr9:5459072~5460776 | Brain | Brain tumor initiating cells | meningioma | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_00570 | chr9:5459072~5460776 | Brain | Human meningioma cell | meningioma | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_00571 | chr9:5459072~5460776 | Brain | KALS1 | meningioma | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_00572 | chr9:5459072~5459797 | Brain | Brain tumor initiating cells | meningioma | Enhancer activity assay |
| E_00573 | chr9:5459072~5459797 | Brain | Human meningioma cell | meningioma | Enhancer activity assay |
| E_00574 | chr9:5459072~5459797 | Brain | KALS1 | meningioma | Enhancer activity assay |
| E_00575 | chr9:5504029~5504679 | Brain | Brain tumor initiating cells | meningioma | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_00576 | chr9:5504029~5504679 | Brain | Human meningioma cell | meningioma | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_00577 | chr9:5504029~5504679 | Brain | KALS1 | meningioma | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_00578 | chr7:117130000~117131000 | Brain | Brain tumor initiating cells | meningioma | Enhancer activity assay |
| E_00579 | chr11:69448000~69452000 | Colon | Caco-2 | colorectal adenocarcinoma | Genetic perturbation screen |
| E_00580 | chr2:11679389~11680097 | Breast | MCF-7 | breast carcinoma | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_00581 | chr2:11679389~11680097 | Prostate gland | LNCaP | prostate cancer | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_00582 | chr2:234861935~234862442 | Prostate gland | VCaP | prostate cancer | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_00583 | chr2:234861935~234862442 | Prostate gland | LNCaP | prostate cancer | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_00584 | chr3:189630000~189680000 | Prostate gland | VCaP | prostate cancer | Enhancer activity assay |
| E_00585 | chr1:24520000~24525000 | Breast | MCF10A | Enhancer activity assay | |
| E_00586 | chr11:8289480~8289520 | Breast | MCF10A | Enhancer activity assay | |
| E_00587 | chr3:107705500~107706800 | Blood | Jurkat | T-cell acute lymphoblastic leukemia | Enhancer activity assay |
| E_00588 | chr9:75595800~75602900 | Breast | MCF7 | breast carcinoma | Enhancer activity assay |
| E_00589 | chr16:68779512~68779800 | Lung | A549 | lung adenocarcinoma | Enhancer activity assay, TF binding assay |
| E_00590 | chr16:68779512~68779800 | Colon | HCT116 | colorectal carcinoma | Enhancer activity assay, TF binding assay |
| E_00591 | chr14:56265000~56275000 | Colon | HT29 | colorectal carcinoma | Enhancer activity assay, chromatin interaction assay |
| E_00592 | chr6:163826086~163833600 | Umbilical vein | HUVEC | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_00593 | chr6:163826086~163833600 | Liver | PLC-PRF-5 | hepatocellular carcinoma | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_00594 | chr8:41090000~41090300 | Liver | Hep3B | hepatocellular carcinoma | Enhancer activity assay |
| E_00595 | chr8:128748351~128800823 | Pulmonary artery | hPAEC | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_00596 | chr8:128748351~128800823 | Prostate | CWR22RV1 | prostate cancer | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_00597 | chr5:159927785~159928129 | Prostate | LNCaP95 | prostate cancer | Functional perturbation assay |
| E_00598 | chr2:16200000~16205000 | Blood | Monocyte | Super enhancer activity assay | |
| E_00599 | chr13:27950000~27980000 | Lung | H128 | small cell lung carcinoma | Histone modification ChIP-seq, Chromosome conformation capture sequencing, CRISPR interference |
| E_00600 | chr13:27950000~27980000 | Bone Marrow | NALM16 | B-cell acute lymphoblastic leukemia | Histone modification ChIP-seq, Chromosome conformation capture sequencing, CRISPR interference |
| E_00601 | chr13:27950000~27980000 | Bone Marrow | primary human B-ALL blasts | B-cell acute lymphoblastic leukemia | Histone modification ChIP-seq, Chromosome conformation capture sequencing, CRISPR interference |
| E_00602 | chr13:28268000~28270000 | Bone Marrow | PDX B-ALL cells | B-cell acute lymphoblastic leukemia | Histone modification ChIP-seq, Chromosome conformation capture sequencing, RNA-DNA FISH |
| E_00603 | chr13:28268000~28270000 | Bone Marrow | NALM16 | B-cell acute lymphoblastic leukemia | Histone modification ChIP-seq, Chromosome conformation capture sequencing, RNA-DNA FISH |
| E_00604 | chr13:28268000~28270000 | Bone Marrow | primary human B-ALL blasts | B-cell acute lymphoblastic leukemia | Histone modification ChIP-seq, Chromosome conformation capture sequencing, RNA-DNA FISH |
| E_00605 | chr4:75746565~75746914 | Bone Marrow | PDX B-ALL cells | B-cell acute lymphoblastic leukemia | Chromatin interaction assay, Functional perturbation assay |
| E_00606 | chr8:128751884~128753219 | Colon | Normal colon epithelial cells | Enhancer activity assay | |
| E_00607 | chr4:76213678~76224314 | Prostate gland | LNCaP cells | prostate cancer | Enhancer activity assay |
| E_00608 | chr4:76213678~76224314 | Colon | FHC mutant cells | Enhancer activity assay | |
| E_00609 | chr2:69342699~69343679 | Colon | FHC mutant cells | Chromatin interaction assay, Enhancer activity assay, Functional perturbation assay | |
| E_00610 | chr2:69342699~69343679 | Connective Tissue | Primary fibroblasts | Chromatin interaction assay, Enhancer activity assay, Functional perturbation assay | |
| E_00611 | chr2:69342699~69343679 | Bone Marrow | Mesenchymal stromal cells | Chromatin interaction assay, Enhancer activity assay, Functional perturbation assay | |
| E_00612 | chr4:75746565~75746914 | Cartilage | Chondrocytes | Chromatin interaction assay, Functional perturbation assay | |
| E_00613 | chr9:27519599~27519750 | Colon | Human normal colon epithelial cell | Enhancer activity assay | |
| E_00614 | chr9:27519749~27519900 | Skin | Normal human keratinocytes | Enhancer activity assay | |
| E_00615 | chr9:27520189~27520340 | Skin | Normal human keratinocytes | Enhancer activity assay | |
| E_00616 | chr15:89411868~89412019 | Skin | Normal human keratinocytes | TF binding assay, Functional perturbation assay | |
| E_00617 | chr1:207411000~207424000 | Blood | Human monocytic leukemia cell | acute monocytic leukemia | Functional perturbation assay |
| E_00618 | chr1:207411000~207424000 | Blood | Reh | Functional perturbation assay | |
| E_00619 | chr4:75700000~76000000 | Blood | Reh | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay | |
| E_00620 | chr4:76191350~76202240 | Colon | Human normal colon epithelial cell | Enhancer activity assay | |
| E_00621 | chr4:76192040~76237727 | Colon | FHC mutant cells | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay | |
| E_00622 | chr1:183149939~183150336 | Colon | Human normal colon epithelial cell | Enhancer activity assay, TF binding assay | |
| E_00623 | chr22:42412900~42413141 | Colon | Caco-2 | colorectal adenocarcinoma | Enhancer activity assay |
| E_00624 | chr20:43210000~43212000 | Liver | HepG2 hepatocellular carcinoma | hepatocellular carcinoma | Enhancer activity assay |
| E_00625 | chr5:149432000~149433000 | Liver | HepG2 | hepatocellular carcinoma | Enhancer activity assay |
| E_00626 | chr5:149432000~149433000 | Heart | Cardiac precursor | Enhancer activity assay | |
| E_00627 | chr5:149432000~149433000 | Heart | Cardiac precursor | Enhancer activity assay | |
| E_00628 | chr5:149433000~149434000 | Heart | Cardiac precursor | Enhancer activity assay | |
| E_00629 | chr5:149433000~149434000 | Heart | Cardiac precursor | Enhancer activity assay | |
| E_00630 | chr5:149434000~149435000 | Heart | Cardiac precursor | Enhancer activity assay | |
| E_00631 | chr5:149434000~149435000 | Heart | Cardiac precursor | Enhancer activity assay | |
| E_00632 | chr10:131264200~131265727 | Heart | Cardiac precursor | Enhancer activity assay, Functional perturbation assay | |
| E_00633 | chr6:170855462~170856787 | Lung | Human Bronchial Epithelial Cells (HBEC1) | Enhancer activity assay | |
| E_00634 | chr17:73746447~73746564 | Pancreatic islet | Islet | Enhancer activity assay | |
| E_00635 | chr13:94663320~94664200 | Adrenal gland | H295R | adrenocortical carcinoma | Enhancer activity assay, CNV functional assay |
| E_00636 | chr8:128749000~128750000 | Esophagus | KYSE-30 | esophageal squamous cell carcinoma | Enhancer activity assay, Functional perturbation assay |
| E_00637 | chr11:63800000~63802500 | Endometrium | MFE-296 | endometrial adenocarcinoma | Functional perturbation assay, Enhancer activity assay |
| E_00638 | chr22:29145000~29155000 | Connective Tissue | Human Mesenchymal Progenitor | Regulatory element functional validation, 3D chromatin interaction mapping | |
| E_00639 | chr22:29165000~29175000 | Pancreas | AsPC1 | pancreatic ductal adenocarcinoma | Regulatory element functional validation, 3D chromatin interaction mapping |
| E_00640 | chr22:29185000~29195000 | Pancreas | AsPC1 | pancreatic ductal adenocarcinoma | Regulatory element functional validation, 3D chromatin interaction mapping |
| E_00641 | chr5:149433000~149434000 | Pancreas | AsPC1 | pancreatic ductal adenocarcinoma | Enhancer activity assay |
| E_00642 | chr3:85552000~85554000 | Heart | Cardiac precursor | Functional perturbation assay | |
| E_00643 | chr7:84508000~84510000 | Bone marrow | K562 | chronic myeloid leukemia | Functional perturbation assay |
| E_00644 | chr6:138229810~138230149 | Bone marrow | K562 | chronic myeloid leukemia | Enhancer activity assay, Chromatin interaction assay, TF binding assay |
| E_00645 | chr11:8264000~8265500 | Blood | Jurkat cells | T-cell acute lymphoblastic leukemia | Enhancer activity assay |
| E_00646 | chr8:128747000~128753000 | Blood | Jurkat cells | T-cell acute lymphoblastic leukemia | Enhancer activity assay, Oncogenic dependency assay |
| E_00647 | chr11:69470000~69470500 | Lymphoid tissue | DLBCL cells | diffuse large B-cell lymphoma | Chromatin interaction assay |
| E_00648 | chr8:128817000~128818000 | Breast | MCF-7 cells | breast carcinoma | Enhancer activity assay |
| E_00649 | chr6:35574362~35576362 | Embryonic Kidney | HEK293FT | Enhancer activity assay | |
| E_00650 | chr8:128745000~128745100 | Colon | HCT116 cells | colorectal cancer | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay |
| E_00651 | chr8:128750000~128750100 | Colon | HCT116 cells | colorectal cancer | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay |
| E_00652 | chr12:68482000~68483000 | Peripheral Blood | CD4+ Th1 T Cells | Enhancer activity assay, Chromatin interaction assay, TF binding assay, Functional perturbation assay | |
| E_00653 | chr12:68546500~68547500 | Peripheral Blood | CD4+ Th1 T Cells | Enhancer activity assay, Chromatin interaction assay, TF binding assay, Functional perturbation assay | |
| E_00654 | chr12:68664000~68665000 | Peripheral Blood | CD4+ Th1 T Cells | Enhancer activity assay, Chromatin interaction assay, TF binding assay, Functional perturbation assay | |
| E_00655 | chr7:155595558~155596658 | Kidney | COS-1 | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_00656 | chr8:128910869~128911521 | Blood | K562 | chronic myeloid leukemia | Functional perturbation assay |
| E_00657 | chr8:128972341~128973219 | Blood | K562 | chronic myeloid leukemia | Functional perturbation assay |
| E_00658 | chr8:129057272~129057795 | Blood | K562 | chronic myeloid leukemia | Functional perturbation assay |
| E_00659 | chr11:5270500~5271500 | Blood | K562 | chronic myeloid leukemia | Functional perturbation assay |
| E_00660 | chr2:172949712~172954378 | Prostate | VCaP | prostate cancer | Enhancer activity assay, TF binding assay |
| E_00661 | chr4:108226000~108228000 | Larynx | TU177 | laryngeal squamous cell carcinoma | Enhancer activity assay, TF binding assay |
| E_00662 | chr17:31254200~31255700 | Pancreas | PANC1 | pancreatic ductal adenocarcinoma | TF binding assay, Functional perturbation assay |
| E_00663 | chr1:230294600~230294900 | Liver | HepG2 | hepatocellular carcinoma | Enhancer activity assay, TF binding assay |
| E_00664 | chr9:101828429~101928429 | Brain | HD-MB03 | medulloblastoma | Enhancer activity assay, Chromatin interaction assay |
| E_00665 | chr9:101828429~101928429 | Cerebellum | Primary Medulloblastoma Tissue | medulloblastoma | Enhancer activity assay, Chromatin interaction assay |
| E_00666 | chr13:37378439~37578439 | Brain | HD-MB03 | medulloblastoma | Enhancer activity assay, Chromatin interaction assay |
| E_00667 | chr13:37378439~37578439 | Cerebellum | Primary Medulloblastoma Tissue | medulloblastoma | Enhancer activity assay, Chromatin interaction assay |
| E_00668 | chr1:230294900~230294900 | Liver | HepG2 cells | hepatocellular carcinoma | Enhancer activity assay, TF binding assay |
| E_00669 | chr13:75142500~75142700 | Pancreatic Islet | Mouse pancreatic beta cell | Enhancer activity assay, TF binding assay | |
| E_00670 | chr15:71106519~71106719 | Pancreatic Islet | Mouse pancreatic beta cell | Enhancer activity assay, TF binding assay | |
| E_00671 | chr15:71136738~71136938 | Pancreatic Islet | Mouse pancreatic beta cell | Enhancer activity assay, TF binding assay | |
| E_00672 | chr3:179641018~179641218 | Pancreatic Islet | Mouse pancreatic beta cell | Enhancer activity assay, TF binding assay | |
| E_00673 | chr1:207411000~207424000 | Blood | B lymphoblastoid cell line (GM12878) | Enhancer activity assay | |
| E_00674 | chr1:207411000~207424000 | Lymph node | Raji | Burkitt lymphoma | Enhancer activity assay |
| E_00675 | chr19:151500000~152500000 | Nasopharynx | CNE-2 | nasopharyngeal carcinoma | Enhancer activity assay, Functional perturbation assay |
| E_00676 | chr2:202030000~202040000 | Nasopharynx | CNE-2 | nasopharyngeal carcinoma | Enhancer activity assay, Functional perturbation assay |
| E_00677 | chr2:20628003~20667995 | Liver | Huh7 | hepatocellular carcinoma | Enhancer activity assay, Functional perturbation assay |
| E_00678 | chr2:43550000~43551000 | Bone Marrow | Primary AML blasts | acute myeloid leukemia | Enhancer activity assay |
| E_00679 | chr2:43550000~43551000 | Bone Marrow | CD34+ HSPCs | Enhancer activity assay | |
| E_00680 | chr3:128300000~128301000 | Bone Marrow | Primary AML blasts | acute myeloid leukemia | Enhancer activity assay, Chromatin interaction assay |
| E_00681 | chr3:128300000~128301000 | Bone Marrow | CD34+ HSPCs | Enhancer activity assay, Chromatin interaction assay | |
| E_00682 | chr6:156475000~156476000 | Bone Marrow | Primary AML blasts | acute myeloid leukemia | Enhancer activity assay |
| E_00683 | chr6:156475000~156476000 | Bone Marrow | CD34+ HSPCs | Enhancer activity assay | |
| E_00684 | chr7:92400000~92401000 | Bone Marrow | Primary AML blasts | acute myeloid leukemia | Enhancer activity assay |
| E_00685 | chr7:92400000~92401000 | Bone Marrow | CD34+ HSPCs | Enhancer activity assay | |
| E_00686 | chr14:106152156~106153203 | Blood | Human Burkitt lymphoma cell | Burkitt lymphoma | Functional perturbation assay, Enhancer activity assay |
| E_00687 | chr14:106152156~106153203 | Blood | Human DLBCL cell | diffuse large B-cell lymphoma | Functional perturbation assay, Enhancer activity assay |
| E_00688 | chr14:106162681~106163347 | Blood | Human Burkitt lymphoma cell | Burkitt lymphoma | Functional perturbation assay, Enhancer activity assay |
| E_00689 | chr14:106162681~106163347 | Blood | Human DLBCL cell | diffuse large B-cell lymphoma | Functional perturbation assay, Enhancer activity assay |
| E_00690 | chr14:106328838~106329184 | Blood | Human Burkitt lymphoma cell | Burkitt lymphoma | Functional perturbation assay, Enhancer activity assay |
| E_00691 | chr14:106328838~106329184 | Blood | Human DLBCL cell | diffuse large B-cell lymphoma | Functional perturbation assay, Enhancer activity assay |
| E_00692 | chr14:106328838~106329184 | Blood | Human B-cell lymphoma cell | B-cell lymphoma | Functional perturbation assay, Enhancer activity assay |
| E_00693 | chr14:57419008~57421445 | Retina | Enhancer activity assay, TF binding assay, Chromatin interaction assay | ||
| E_00694 | chr22:38686443~38686999 | Peripheral Blood | B cells | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_00695 | chr22:38687301~38687766 | Peripheral Blood | B cells | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_00696 | chr10:43447346~43448347 | Fetal gut | Neuroblastoma cell | neuroblastoma | Enhancer activity assay, TF binding assay |
| E_00697 | chr6:31132200~31132800 | Gonadal Tissue | hESC | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_00698 | chr6:31132200~31132800 | Gonadal Tissue | hPGCLC | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_00699 | chr6:31132200~31132800 | Gonadal Tissue | hPGC | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_00700 | chrX:66118920~66127943 | Prostate | LNCaP | prostate cancer | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay |
| E_00701 | chrX:66118920~66127943 | Prostate | 22RV1 | prostate cancer | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay |
| E_00702 | chr11:33396000~33396331 | Prostate | LNCaP | prostate cancer | Enhancer activity assay, TF binding assay |
| E_00703 | chr9:21980404~21981404 | Brain | Neural Stem Cells | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_00704 | chr9:21980404~21981404 | Cervix | HeLa | cervical cancer | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_00705 | chr9:21980404~21981404 | Lung | IMR90 | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_00706 | chr9:21980404~21981404 | Breast | MCF7 | breast carcinoma | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_00707 | chr9:21980404~21981404 | Embryonic Kidney | HEK293 | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_00708 | chr8:102449260~102449687 | Pluripotent embryonic tissue | Human embryonic stem cells | Functional perturbation assay, TF binding assay, Chromatin interaction assay | |
| E_00709 | chr8:102467180~102467504 | Pluripotent embryonic tissue | Human embryonic stem cells | Functional perturbation assay, TF binding assay, Chromatin interaction assay | |
| E_00710 | chr8:102486442~102486801 | Pluripotent embryonic tissue | Human embryonic stem cells | Functional perturbation assay, TF binding assay, Chromatin interaction assay | |
| E_00711 | chr12:117827344~117845711 | Umbilical vein | HUVECs | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_00712 | chr20:21566572~21586800 | Bone | A673 cells | Ewing sarcoma | Enhancer activity assay, Functional perturbation assay |
| E_00713 | chr20:21566572~21586800 | Bone | SKNMC cells | Ewing sarcoma | Enhancer activity assay, Functional perturbation assay |
| E_00714 | chr20:21566572~21586800 | Bone | EWS-502 cells | Ewing sarcoma | Enhancer activity assay, Functional perturbation assay |
| E_00715 | chr11:69616543~69628302 | Bone | A673 cells | Ewing sarcoma | Enhancer activity assay, Functional perturbation assay |
| E_00716 | chr11:69616543~69628302 | Bone | SKNMC cells | Ewing sarcoma | Enhancer activity assay, Functional perturbation assay |
| E_00717 | chr11:69616543~69628302 | Bone | EWS-502 cells | Ewing sarcoma | Enhancer activity assay, Functional perturbation assay |
| E_00718 | chr4:15450000~15579703 | Bone Marrow | ALL cell line | acute lymphoblastic leukemia | Enhancer activity assay, Chromatin interaction assay, TF binding assay, Functional perturbation assay |
| E_00719 | chr4:15450000~15579703 | Colon | HCT116 | colorectal carcinoma | Enhancer activity assay, Chromatin interaction assay, TF binding assay, Functional perturbation assay |
| E_00720 | chr4:15450000~15579703 | Bone Marrow | Primary MLL-AF4 ALL blasts | B-cell acute lymphoblastic leukemia | Enhancer activity assay, Chromatin interaction assay, TF binding assay, Functional perturbation assay |
| E_00721 | chr4:15581130~15619993 | Bone Marrow | ALL cell line | acute lymphoblastic leukemia | Enhancer activity assay, Chromatin interaction assay, TF binding assay, Functional perturbation assay |
| E_00722 | chr4:15581130~15619993 | Colon | HCT116 | colorectal carcinoma | Enhancer activity assay, Chromatin interaction assay, TF binding assay, Functional perturbation assay |
| E_00723 | chr4:15581130~15619993 | Bone Marrow | Primary MLL-AF4 ALL blasts | B-cell acute lymphoblastic leukemia | Enhancer activity assay, Chromatin interaction assay, TF binding assay, Functional perturbation assay |
| E_00724 | chr6:12826550~12826620 | Umbilical vein | HUVEC | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_00725 | chr6:12826550~12826620 | Aorta | hESC-derived endothelial cells | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_00726 | chr8:48025841~48796048 | Liver | Huh7 | hepatocellular carcinoma | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_00727 | chr8:48025841~48796048 | Liver | Normal liver cell | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_00728 | chr7:155594277~155595077 | Embryonic Limb Bud | Embryonic limb bud mesenchymal cells | Functional perturbation assay, Enhancer activity assay | |
| E_00729 | chr21:40000000~40800000 | Heart | Cardiomyocytes | Enhancer activity assay, Chromatin interaction assay | |
| E_00730 | chr1:144983210~144983310 | Breast | Human breast adenocarcinoma cell | breast carcinoma | Enhancer activity assay, TF binding assay |
| E_00731 | chr2:10504857~10504957 | Breast | Human breast adenocarcinoma cell | breast carcinoma | Enhancer activity assay, TF binding assay |
| E_00732 | chr2:11562351~11562451 | Breast | Human breast adenocarcinoma cell | breast carcinoma | Enhancer activity assay, TF binding assay |
| E_00733 | chr21:42872877~42872977 | Breast | Human breast adenocarcinoma cell | breast carcinoma | Enhancer activity assay, TF binding assay |
| E_00734 | chr21:42880677~42880777 | Breast | Human breast adenocarcinoma cell | breast carcinoma | Enhancer activity assay, TF binding assay |
| E_00735 | chr4:75746565~75746914 | Colon | Human normal colon epithelial cell | Functional perturbation assay, Chromatin interaction assay | |
| E_00736 | chr4:75700000~76000000 | Colon | Human normal colon epithelial cell | Chromatin interaction assay, Functional perturbation assay, Enhancer activity assay | |
| E_00737 | chr4:75700000~76000000 | Colon | Human normal colon epithelial cell | Chromatin interaction assay, Functional perturbation assay, Enhancer activity assay | |
| E_00738 | chr22:38688102~38688577 | Peripheral Blood | B cells | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_00739 | chr5:140657200~140658500 | Peripheral Blood | Classical monocytes | Enhancer activity assay | |
| E_00740 | chr5:140659800~140661200 | Peripheral Blood | Classical monocytes | Enhancer activity assay | |
| E_00741 | chr5:140662500~140663800 | Peripheral Blood | Classical monocytes | Enhancer activity assay | |
| E_00742 | chr14:22758000~22759600 | Liver | HepG2 | hepatocellular carcinoma | Enhancer activity assay, Chromatin interaction assay, TF binding assay, eRNA functional assay |
| E_00743 | chr17:70397161~70432161 | Breast | MDA-MB-157 | breast carcinoma | Regulatory element functional validation, 3D chromatin interaction mapping |
| E_00744 | chr17:70447161~70494161 | Breast | MDA-MB-157 | breast carcinoma | Regulatory element functional validation, 3D chromatin interaction mapping |
| E_00745 | chr17:70530161~70632161 | Breast | MDA-MB-157 | breast carcinoma | Regulatory element functional validation, 3D chromatin interaction mapping |
| E_00746 | chr11:5278952~5279402 | Bone marrow | K-562 | chronic myeloid leukemia | CRISPRi-based single-cell enhancer perturbation |
| E_00747 | chr1:67739940~67741075 | Blood | Primary CD4+ T | Enhancer activity assay | |
| E_00748 | chr6:135502600~135502750 | Bone marrow | Primary human hematopoietic progenitor cells | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_00749 | chr6:135502600~135502750 | Bone marrow | KG1a AML cell line | acute myeloid leukemia | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_00750 | chr6:135502600~135502750 | Embryonic Kidney | HEK293 | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_00751 | chr21:36180372~36181392 | Bone marrow | K562 | chronic myeloid leukemia | Enhancer activity assay |
| E_00752 | chr16:86543000~86544500 | Dermis | Primary Dermal Lymphatic Endothelial Cells (hLECs) | Enhancer activity assay | |
| E_00753 | chr22:20224442~20228467 | Brain | Neuronal | Enhancer activity assay | |
| E_00754 | chr5:50400000~50401200 | Pancreatic islet | Human pancreatic islet | Enhancer activity assay | |
| E_00755 | chr22:18795000~18797200 | Hippocampus | Primary neuron | Enhancer activity assay | |
| E_00756 | chr9:131200000~131400000 | Cerebellum | Cerebellar granule neuron progenitors (CGNPs) | Enhancer activity assay | |
| E_00757 | chr20:32500000~32650000 | Cerebellum | Cerebellar granule neuron progenitors (CGNPs) | Enhancer activity assay | |
| E_00758 | chr12:79345000~79347000 | Embryonic stem cell tissue | Human embryonic stem cells (hESC) | Enhancer activity assay, Signal switching assay | |
| E_00759 | chr9:133238853~133239354 | Blood | K562 cells | chronic myeloid leukemia | Enhancer activity assay, TF binding assay |
| E_00760 | chr19:51347500~51349700 | Prostate | Primary epithelial | Enhancer activity assay | |
| E_00761 | chr16:1600000~1600110 | Blood | K562 Erythroleukemia Cells | chronic myeloid leukemia | Enhancer activity assay |
| E_00762 | chr11:5196000~5197000 | Blood | K562 erythroleukemia cells | chronic myeloid leukemia | Enhancer activity assay |
| E_00763 | chr18:28988494~35919423 | Lung | NCI-H1963 | small cell lung carcinoma | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_00764 | chr21:36179867~36180107 | Breast | Human Mammary Epithelial Cells (HMEC) | Enhancer activity assay, TF binding assay | |
| E_00765 | chr16:68770000~68771500 | Pancreas | CAPAN1 | TF binding assay | |
| E_00766 | chr16:30669227~30670310 | Neural tissue | hESC-derived NPCs | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_00767 | chr19:17438298~17439337 | Neural tissue | hESC-derived NPCs | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_00768 | chr11:65200000~66000000 | Blood | DND41 | T-cell acute lymphoblastic leukemia | Chromatin interaction assay |
| E_00769 | chr11:65200000~66000000 | Blood | Rec-1 | mantle cell lymphoma | Chromatin interaction assay |
| E_00770 | chr21:36282225~36337655 | Bone Marrow | hiPSC-derived iMSCs | Functional perturbation assay, Chromatin interaction assay | |
| E_00771 | chr21:36282225~36337655 | Bone | hiPSC-derived osteoblasts | Functional perturbation assay, Chromatin interaction assay | |
| E_00772 | chr21:36282225~36337655 | Bone Marrow | hiPSC-derived iMSCs | Functional perturbation assay, Chromatin interaction assay | |
| E_00773 | chr21:36282225~36337655 | Bone | hiPSC-derived osteoblasts | Functional perturbation assay, Chromatin interaction assay | |
| E_00774 | chr21:36759535~36828803 | Bone Marrow | hiPSC-derived iMSCs | Functional perturbation assay, Chromatin interaction assay, In vivo functional assay | |
| E_00775 | chr21:36759535~36828803 | Bone | hiPSC-derived osteoblasts | Functional perturbation assay, Chromatin interaction assay, In vivo functional assay | |
| E_00776 | chr21:36759535~36828803 | Bone | NOD-SCID mouse calvarial cells | Functional perturbation assay, Chromatin interaction assay, In vivo functional assay | |
| E_00777 | chr21:36759535~36828803 | Bone Marrow | hiPSC-derived iMSCs | Functional perturbation assay, Chromatin interaction assay, In vivo functional assay | |
| E_00778 | chr21:36759535~36828803 | Bone | hiPSC-derived osteoblasts | Functional perturbation assay, Chromatin interaction assay, In vivo functional assay | |
| E_00779 | chr21:36759535~36828803 | Bone | NOD-SCID mouse calvarial cells | Functional perturbation assay, Chromatin interaction assay, In vivo functional assay | |
| E_00780 | chr18:48951365~48952877 | Skin | Human Hypertrophic Scar Fibroblasts (HSFs) | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_00781 | chrX:135577559~135581959 | Peripheral Blood | PBMCs | Chromatin interaction assay | |
| E_00782 | chrX:135625877~135641072 | Peripheral Blood | PBMCs | Chromatin interaction assay | |
| E_00783 | chrX:135656769~135660247 | Peripheral Blood | PBMCs | Chromatin interaction assay | |
| E_00784 | chrX:135846959~135851769 | Peripheral Blood | PBMCs | Chromatin interaction assay | |
| E_00785 | chrX:135959959~135963959 | Peripheral Blood | PBMCs | Chromatin interaction assay, Enhancer activity assay | |
| E_00786 | chrX:135959959~135963959 | Embryonic Kidney | HEK293 | Chromatin interaction assay, Enhancer activity assay | |
| E_00787 | chrX:135990759~135994160 | Peripheral Blood | PBMCs | Chromatin interaction assay | |
| E_00788 | chr3:185511500~185511700 | Pancreatic Islet | Mouse pancreatic beta cell | Enhancer activity assay | |
| E_00789 | chr6:170843500~170843700 | Pancreatic Islet | Mouse pancreatic beta cell | Enhancer activity assay | |
| E_00790 | chr6:170848100~170848300 | Pancreatic Islet | Mouse pancreatic beta cell | Enhancer activity assay | |
| E_00791 | chr1:51429600~51450093 | Brain | Glioma stem cell | glioblastoma | Enhancer activity assay |
| E_00792 | chr19:33794100~33794613 | Bone Marrow | MUTZ-3 | acute myeloid leukemia | Enhancer activity assay |
| E_00793 | chr8:128320500~128321500 | Colon | HCT116 | colorectal carcinoma | Chromatin interaction assay |
| E_00794 | chr21:36189300~36189537 | Bone Marrow | CD34+ hematopoietic stem/progenitor cells | Enhancer prediction, SNP association, Functional validation | |
| E_00795 | chr21:36189300~36189537 | Bone Marrow | K562 cell line | chronic myeloid leukemia | Enhancer prediction, SNP association, Functional validation |
| E_00796 | chr16:1480850~1482378 | Gastrointestinal Tract | Enteroendocrine cells | Functional perturbation assay | |
| E_00797 | chr1:47220000~47260000 | Blood | Jurkat | T-cell acute lymphoblastic leukemia | Enhancer activity assay, Functional perturbation assay |
| E_00798 | chr1:47220000~47260000 | Bone Marrow | MOLT-3 | T-cell acute lymphoblastic leukemia | Enhancer activity assay, Functional perturbation assay |
| E_00799 | chr20:5921142~6004055 | Brain | Glioma stem cell | glioblastoma | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_00800 | chr20:5921142~6004055 | Brain | Neural stem cells | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_00801 | chr8:128210000~128260000 | Breast | MDA-MB-231 | breast carcinoma | Chromatin interaction assay |
| E_00802 | chr2:239884251~239900294 | Lung | NCI-H460 | non-small cell lung carcinoma | Functional perturbation assay |
| E_00803 | chr13:43058344~43062075 | Bone | Periodontal ligament cells | TF binding assay, Enhancer activity assay | |
| E_00804 | chr7:117175700~117176900 | Intestine | Human colorectal adenocarcinoma cell | Enhancer activity assay, Functional perturbation assay | |
| E_00805 | chr8:128667652~128669252 | Brain | Primary medulloblastoma tissue | medulloblastoma | Super-enhancer mapping, TF binding assay, Enhancer activity assay, Chromatin interaction assay |
| E_00806 | chr8:128667652~128669252 | Brain | HD-MB03 | medulloblastoma | Super-enhancer mapping, TF binding assay, Enhancer activity assay, Chromatin interaction assay |
| E_00807 | chr14:57220000~57221600 | Brain | Primary medulloblastoma tissue | medulloblastoma | Super-enhancer mapping, Enhancer activity assay, Gene expression assay |
| E_00808 | chr14:57220000~57221600 | Brain | HD-MB03 | medulloblastoma | Super-enhancer mapping, Enhancer activity assay, Gene expression assay |
| E_00809 | chr14:57220000~57221600 | Brain | MED8A | medulloblastoma | Super-enhancer mapping, Enhancer activity assay, Gene expression assay |
| E_00810 | chr14:57220000~57221600 | Brain | D425 | medulloblastoma | Super-enhancer mapping, Enhancer activity assay, Gene expression assay |
| E_00811 | chr3:147033502~147035102 | Brain | Primary medulloblastoma tissue | medulloblastoma | Super-enhancer mapping, Enhancer activity assay, Gene expression assay |
| E_00812 | chr3:147033502~147035102 | Brain | HD-MB03 | medulloblastoma | Super-enhancer mapping, Enhancer activity assay, Gene expression assay |
| E_00813 | chr3:147033502~147035102 | Brain | MED8A | medulloblastoma | Super-enhancer mapping, Enhancer activity assay, Gene expression assay |
| E_00814 | chr3:147033502~147035102 | Brain | D425 | medulloblastoma | Super-enhancer mapping, Enhancer activity assay, Gene expression assay |
| E_00815 | chr2:223164458~223164688 | Skin | A375 | skin melanoma | Enhancer activity assay |
| E_00816 | chr2:223164846~223165065 | Skin | SK-MEL28 | skin melanoma | Enhancer activity assay |
| E_00817 | chr7:48230000~48231500 | Liver | HepG2 | hepatocellular carcinoma | Enhancer activity assay |
| E_00818 | chr18:60983148~60983597 | Blood | Jurkat | T-cell acute lymphoblastic leukemia | Chromatin interaction, expression validation |
| E_00819 | chr8:128210000~128260000 | Breast | MDA-MB-231 | breast carcinoma | Chromatin interaction assay |
| E_00820 | chr7:22760000~22761000 | Heart | AC16 | Enhancer activity assay, Functional perturbation assay | |
| E_00821 | chr17:38065000~38068000 | Peripheral blood | Primary CD4+ T cells | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay | |
| E_00822 | chr11:5225000~5227000 | Bone Marrow | CD34+ cell | Chromatin interaction assay | |
| E_00823 | chr3:189520000~189522000 | Testis | Spermatogonia | Functional perturbation assay | |
| E_00824 | chr19:51353600~51354200 | Prostate | LNCaP cells | prostate cancer | Enhancer activity assay, TF binding assay |
| E_00825 | chr19:51350000~51351000 | Prostate | LNCaP cells | prostate cancer | Enhancer activity assay |
| E_00826 | chr22:35772741~35773741 | Cervix | HeLa cells | cervical cancer | Enhancer activity assay, TF binding assay |
| E_00827 | chr22:35767741~35768741 | Cervix | HeLa cells | cervical cancer | Enhancer activity assay, TF binding assay |
| E_00828 | chr8:128320000~128321000 | Colon | HCT116 | colorectal carcinoma | Chromatin interaction assay |
| E_00829 | chr3:128124000~128125500 | Bone Marrow | AML blasts | acute myeloid leukemia | Functional perturbation assay |
| E_00830 | chr8:128589642~128590670 | Prostate | LNCaP | prostate cancer | Enhancer activity assay, Chromatin interaction assay, TF binding assay |
| E_00831 | chr8:128588859~128589357 | Prostate | LNCaP | prostate cancer | Enhancer activity assay, TF binding assay |
| E_00832 | chr11:5198400~5198625 | Blood | K562 erythroleukemia cells | chronic myeloid leukemia | TF binding assay, Enhancer activity assay |
| E_00833 | chr9:21206044~21206127 | Blood | U937 | histiocytic lymphoma | Enhancer activity assay, TF binding assay |
| E_00834 | chr10:131265950~131266000 | Brain | LN18 glioma cells | glioblastoma | Functional perturbation assay, Enhancer activity assay |
| E_00835 | chr2:172661000~172662500 | Prostate | VCaP | prostate cancer | Enhancer activity assay, TF binding assay, Chromatin interaction assay |
| E_00836 | chr20:48400000~49200000 | Breast | MB157 | breast carcinoma | Chromatin interaction assay |
| E_00837 | chr20:48400000~49200000 | Breast | HCC1599 | breast carcinoma | Chromatin interaction assay |
| E_00838 | chr3:181708088~181708477 | Breast | MCF7 breast carcinoma | breast carcinoma | Enhancer activity assay, Functional perturbation assay |
| E_00839 | chr3:181708088~181708477 | Breast | T47D breast carcinoma | breast carcinoma | Enhancer activity assay, Functional perturbation assay |
| E_00840 | chr3:181708088~181708477 | Pluripotent embryonic tissue | human embryonic stem | Enhancer activity assay, Functional perturbation assay | |
| E_00841 | chr14:61101000~61102000 | Kidney | Nephron Progenitor | Enhancer activity assay, TF binding assay | |
| E_00842 | chr14:61116934~61117934 | Kidney | Nephron Progenitor | Enhancer activity assay, TF binding assay | |
| E_00843 | chr14:23500000~23501600 | Liver | HepG2 | hepatocellular carcinoma | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay |
| E_00844 | chr14:23500000~23501600 | Liver | HL7702 | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay | |
| E_00845 | chr8:128647663~128667652 | Brain | MED8A | medulloblastoma | Enhancer activity assay, TF binding assay, Chromatin interaction assay |
| E_00846 | chr8:128647663~128667652 | Brain | D425 | medulloblastoma | Enhancer activity assay, TF binding assay, Chromatin interaction assay |
| E_00847 | chr8:128647663~128667652 | Brain | HD-MB03 | medulloblastoma | Enhancer activity assay, TF binding assay, Chromatin interaction assay |
| E_00848 | chr8:128647663~128667652 | Brain | Primary Medulloblastoma Tissue | medulloblastoma | Enhancer activity assay, TF binding assay, Chromatin interaction assay |
| E_00849 | chr14:57182300~57183900 | Brain | Primary Medulloblastoma Tissue | medulloblastoma | Enhancer activity assay |
| E_00850 | chr3:147013502~147063501 | Brain | Primary Medulloblastoma Tissue | medulloblastoma | Enhancer activity assay, TF binding assay |
| E_00851 | chr21:47738157~47748156 | Brain | Primary Medulloblastoma Tissue (WNT subgroup) | medulloblastoma | Enhancer activity assay |
| E_00852 | chr1:221037098~221047097 | Brain | Primary Medulloblastoma Tissue (SHH subgroup) | medulloblastoma | Enhancer activity assay |
| E_00853 | chr5:121620525~121630524 | Brain | Primary Medulloblastoma Tissue (Group3 subgroup) | medulloblastoma | Enhancer activity assay |
| E_00854 | chr5:925833~926832 | Brain | Primary Medulloblastoma Tissue (Group4 subgroup) | medulloblastoma | Enhancer activity assay, TF binding assay |
| E_00855 | chr2:73956813~73957241 | Peripheral Blood | B cell | Enhancer activity assay, TF binding assay, Chromatin interaction assay | |
| E_00856 | chr2:73956813~73957241 | Peripheral Blood | LCL | Enhancer activity assay, TF binding assay, Chromatin interaction assay | |
| E_00857 | chr2:73956813~73957241 | Peripheral Blood | GM12878 | Enhancer activity assay, TF binding assay, Chromatin interaction assay | |
| E_00858 | chr6:33548076~33548616 | Embryonic Kidney | 293T | Enhancer activity assay, TF binding assay | |
| E_00859 | chr6:33548076~33548616 | Inner cell mass | H1-hESC | Enhancer activity assay, TF binding assay | |
| E_00860 | chr17:37648901~37649206 | Kidney | Kidney Tubule Primary Cells | Enhancer activity assay, TF binding assay | |
| E_00861 | chr11:75928700~75928930 | Lung | SCLC cell line H889 | small cell lung carcinoma | TF binding assay, Functional perturbation assay |
| E_00862 | chr14:106032312~106033352 | Blood | Diffuse large B-cell lymphoma cell line | diffuse large B-cell lymphoma | Functional perturbation assay |
| E_00863 | chr14:106041116~106041795 | Blood | Burkitt lymphoma cell line | Burkitt lymphoma | Functional perturbation assay |
| E_00864 | chr14:106041116~106041795 | Blood | Diffuse large B-cell lymphoma cell line | diffuse large B-cell lymphoma | Functional perturbation assay |
| E_00865 | chr14:106152156~106153203 | Blood | Burkitt lymphoma cell line | Burkitt lymphoma | Functional perturbation assay |
| E_00866 | chr14:106152156~106153203 | Blood | Diffuse large B-cell lymphoma cell line | diffuse large B-cell lymphoma | Functional perturbation assay |
| E_00867 | chr14:106162681~106163347 | Blood | Burkitt lymphoma cell line | Burkitt lymphoma | Functional perturbation assay |
| E_00868 | chr14:106162681~106163347 | Blood | Diffuse large B-cell lymphoma cell line | diffuse large B-cell lymphoma | Functional perturbation assay |
| E_00869 | chr14:106328838~106329184 | Blood | Burkitt lymphoma cell line | Burkitt lymphoma | Functional perturbation assay |
| E_00870 | chr14:106328838~106329184 | Blood | Diffuse large B-cell lymphoma cell line | diffuse large B-cell lymphoma | Functional perturbation assay |
| E_00871 | chr17:38050770~38051866 | Blood | Jurkat | T-cell acute lymphoblastic leukemia | Enhancer activity assay |
| E_00872 | chr4:156635141~156635310 | Whole Blood | Endothelial cells | Reporter assay, TF binding, Functional validation | |
| E_00873 | chr7:117323000~117324600 | Colon | Caco-2 | colorectal adenocarcinoma | Enhancer activity assay |
| E_00874 | chr6:31784438~31784648 | Lung | H1299 | non-small cell lung carcinoma | Enhancer activity assay |
| E_00875 | chr1:161559500~161559700 | Lung | H1299 | non-small cell lung carcinoma | Enhancer activity assay |
| E_00876 | chr6:36642000~36645000 | Breast | MCF-7 | breast carcinoma | Genetic perturbation screen |
| E_00877 | chr11:118813865~118815965 | Breast | MCF-7 | breast carcinoma | Enhancer activity assay |
| E_00878 | chr7:9470000~9472826 | Endometrium | Endometrial stromal cells | Enhancer activity assay, functional perturbation assay | |
| E_00879 | chr4:84255915~84256935 | Stomach | AGS | gastric adenocarcinoma | Chromatin interaction assay, TF binding assay |
| E_00880 | chr4:84255915~84256935 | Stomach | SGC-7901 | gastric adenocarcinoma | Chromatin interaction assay, TF binding assay |
| E_00881 | chr8:128765000~128767000 | Bone Marrow | K562 | chronic myeloid leukemia | Chromatin interaction assay, Functional perturbation assay |
| E_00882 | chr8:128765000~128767000 | Colon | HCT-116 | colorectal carcinoma | Chromatin interaction assay, Functional perturbation assay |
| E_00883 | chr15:93405000~93406000 | Heart | hiPSC-CMs | Enhancer activity assay, Functional perturbation assay | |
| E_00884 | chr3:12311574~12312573 | Embryonic Kidney | HEK293T | Enhancer activity assay, TF binding assay | |
| E_00885 | chr22:41500000~41501000 | Blood | RC-K8 | histiocytic lymphoma | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_00886 | chr5:132008000~132009000 | Peripheral blood | Primary human whole blood immune cells | Enhancer activity assay, Chromatin interaction assay | |
| E_00887 | chr5:125344507~125346243 | Kidney | Human embryonic kidney cell | Enhancer activity assay | |
| E_00888 | chr5:125995897~125996243 | Kidney | Human embryonic kidney cell | Enhancer activity assay | |
| E_00889 | chr14:61101000~61104000 | Kidney | 16-17 week human fetal nephron progenitor | Enhancer activity assay, TF binding assay, Gene expression assay | |
| E_00890 | chr14:61113500~61116500 | Kidney | 16-17 week human fetal nephron progenitor | Enhancer activity assay, TF binding assay, Gene expression assay | |
| E_00891 | chr8:128748243~128748308 | Brain | Neural stem | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay | |
| E_00892 | chr1:92946000~92958000 | Bone marrow | T cell | TF binding assay | |
| E_00893 | chr7:117075400~117076000 | Bronchus | 16HBE14o- human bronchial epithelial | Enhancer activity assay | |
| E_00894 | chr10:43572300~43572600 | Brain | Neuro-2A | Enhancer activity assay | |
| E_00895 | chr10:43569100~43569300 | Brain | Neuro-2A | Enhancer activity assay | |
| E_00896 | chr20:44639323~44641625 | Liver | HCCLM3 | hepatocellular carcinoma | Enhancer activity assay |
| E_00897 | chr17:69498800~69500700 | Testis | TM-4 | Enhancer activity assay | |
| E_00898 | chr17:2261913~2262186 | Liver | HepG2 | Enhancer activity assay | |
| E_00899 | chr17:54776294~54777215 | Palatal epithelium | GMSM-K | Enhancer activity assay | |
| E_00900 | chr1:214164500~214168500 | Embryonic Kidney | HEK293 | Enhancer activity assay | |
| E_00901 | chr10:64739850~64739980 | Bone | A673 | Ewing sarcoma | Enhancer activity assay |
| E_00902 | chr10:64698250~64698400 | Bone | A673 | Ewing sarcoma | Enhancer activity assay |
| E_00903 | chr10:64715600~64717000 | Bone | A673 | Ewing sarcoma | Enhancer activity assay |
| E_00904 | chr6:1614904~1616335 | Embryo | Mouse embryo (E11.5) | Enhancer activity assay | |
| E_00905 | chr16:55499100~55501100 | Urinary bladder | 5637 | bladder carcinoma | Enhancer activity assay |
| E_00906 | chr10:23508149~23508510 | Pancreas | hESC-derived progenitors | TF binding assay | |
| E_00907 | chr8:140450000~140452000 | Brain | Primary brain | Chromatin interaction assay | |
| E_00908 | chr8:128311200~128667652 | Brain | HD-MB03 | medulloblastoma | Enhancer activity assay |
| E_00909 | chr2:29411893~30163716 | Brain | Primary tumor tissue | medulloblastoma | Enhancer activity assay |
| E_00910 | chr3:147013502~147063502 | Brain | Primary tumor tissue | medulloblastoma | Enhancer activity assay |
| E_00911 | chr17:42059156~42059522 | Liver | HepG2 cells | hepatocellular carcinoma | Enhancer activity assay, TF binding assay |
| E_00912 | chr9:133205353~133205796 | Stomach | KATO III cells | gastric adenocarcinoma | Enhancer activity assay, TF binding assay |
| E_00913 | chr12:114701207~114704691 | Heart | Primary cardiomyocytes | Enhancer activity assay | |
| E_00914 | chr3:128124000~128125500 | Bone Marrow | HSPCs | Enhancer activity assay | |
| E_00915 | chr14:92450000~92451800 | Bone | A673 Ewing sarcoma | Ewing sarcoma | Functional perturbation assay |
| E_00916 | chr6:35686811~35686856 | Lung | A549 | lung adenocarcinoma | Enhancer activity assay, Functional perturbation assay |
| E_00917 | chr6:35686811~35686856 | Prostate | VCaP | prostate cancer | Enhancer activity assay, Functional perturbation assay |
| E_00918 | chr6:35686811~35686856 | Kidney | COS1 | Enhancer activity assay, Functional perturbation assay | |
| E_00919 | chr6:35697997~35698211 | Lung | A549 | lung adenocarcinoma | Enhancer activity assay, Functional perturbation assay |
| E_00920 | chr6:35697997~35698211 | Prostate | VCaP | prostate cancer | Enhancer activity assay, Functional perturbation assay |
| E_00921 | chr6:35697997~35698211 | Kidney | COS1 | Enhancer activity assay, Functional perturbation assay | |
| E_00922 | chr8:128423748~128424352 | Breast | MCF-7 | breast carcinoma | Enhancer activity assay, Chromatin interaction assay, TF binding assay |
| E_00923 | chr8:128482486~128483650 | Colon | LS174T | colorectal carcinoma | Enhancer activity assay, Chromatin interaction assay, TF binding assay |
| E_00924 | chrX:30317939~30318739 | Embryonic Kidney | HEK293 | Enhancer activity assay | |
| E_00925 | chr13:43111372~43112072 | Bone | MG-63 | osteosarcoma | TF binding assay |
| E_00926 | chr11:111250000~111350000 | Lymph node | GCB-DLBCL cell lines (OCI-LY1) | diffuse large B-cell lymphoma | Enhancer activity assay, Functional perturbation assay |
| E_00927 | chr11:111285000~111287000 | Lymph node | GCB-DLBCL cell lines (OCI-LY1) | diffuse large B-cell lymphoma | Enhancer activity assay, Functional perturbation assay |
| E_00928 | chr17:38026822~38029614 | Blood | Activated U-937 cells | histiocytic lymphoma | Enhancer activity assay |
| E_00929 | chr14:57230000~57232400 | Retina | Enhancer activity assay, TF binding assay | ||
| E_00930 | chr19:44910240~44910647 | Brain | HMC3 microglia cells | Enhancer activity assay, TF binding assay | |
| E_00931 | chrX:135625877~135641072 | Peripheral Blood | PBMCs | Chromatin interaction assay | |
| E_00932 | chrX:135656769~135660247 | Peripheral Blood | PBMCs | Chromatin interaction assay | |
| E_00933 | chrX:135846959~135851769 | Peripheral Blood | PBMCs | Chromatin interaction assay | |
| E_00934 | chrX:135959959~135963959 | Peripheral Blood | PBMCs | Chromatin interaction assay | |
| E_00935 | chrX:135990759~135994160 | Peripheral Blood | PBMCs | Chromatin interaction assay | |
| E_00936 | chr6:396135~396636 | Skin | Human melanoma cells | skin melanoma | Enhancer activity assay |
| E_00937 | chr1:83941100~83941260 | Cartilage | Human chondrosarcoma cell | chondrosarcoma | Enhancer activity assay |
| E_00938 | chr12:48355000~48355154 | Cartilage | Human chondrosarcoma cell | chondrosarcoma | Enhancer activity assay |
| E_00939 | chr1:207411000~207424000 | Blood | SKW | Enhancer activity assay | |
| E_00940 | chr11:5280741~5280786 | Blood | K-562 | chronic myeloid leukemia | Enhancer transcriptional regulation assay, Activity validation |
| E_00941 | chr7:94331300~94333600 | Skin | Primary human dermal fibroblasts | Enhancer activity assay | |
| E_00942 | chr1:23884369~23884886 | Blood | Primary macrophages | Enhancer activity assay | |
| E_00943 | chr1:23892063~23892208 | Blood | Primary macrophages | Enhancer activity assay | |
| E_00944 | chr10:123099588~123100426 | Bone | MC3T3-E1 | Enhancer activity assay | |
| E_00945 | chr8:128747680~128753680 | Bone marrow | NOMO-1 | acute myeloid leukemia | TF binding, functional perturbation |
| E_00946 | chr3:78905346~78955823 | Breast | Primary tumor | breast carcinoma | Functional perturbation assay |
| E_00947 | chr10:3929991~3930887 | Lung | A549 human alveolar basal epithelial adenocarcinoma | lung adenocarcinoma | Enhancer activity assay |
| E_00948 | chr20:56293544~56293843 | Lung | A549 human alveolar basal epithelial adenocarcinoma | lung adenocarcinoma | Enhancer activity assay |
| E_00949 | chr17:48105016~48105270 | Lung | A549 human alveolar basal epithelial adenocarcinoma | lung adenocarcinoma | Enhancer activity assay |
| E_00950 | chr17:26076200~26076350 | Liver | Primary human hepatocyte | Enhancer activity assay | |
| E_00951 | chr2:202122994~202122996 | Breast | MCF10A | Functional perturbation assay | |
| E_00952 | chr2:202123429~202123431 | Breast | T-47D | breast carcinoma | Functional perturbation assay |
| E_00953 | chr2:202204740~202204742 | Breast | MCF10A | Functional perturbation assay | |
| E_00954 | chr11:5225000~5227000 | Breast | T-47D | breast carcinoma | TF binding assay |
| E_00955 | chr9:126753431~126803431 | Blood | CD34+ cell | Chromatin interaction assay | |
| E_00956 | chr1:165355703~165405703 | Brain | HD-MB03 | medulloblastoma | Chromatin interaction assay |
| E_00957 | chr8:140948000~140952000 | Brain | HD-MB03 | medulloblastoma | Chromatin interaction assay |
| E_00958 | chr8:140748000~140750000 | Brain | Primary neurons | Chromatin interaction assay | |
| E_00959 | chr9:16857980~16858579 | Brain | Primary neurons | Enhancer activity assay | |
| E_00960 | chr2:217920100~217921400 | Skin | G361 melanoma | skin melanoma | Enhancer activity assay |
| E_00961 | chr1:98515300~98515700 | Breast | MCF7 human breast cancer | breast carcinoma | Enhancer activity assay |
| E_00962 | chr1:98515300~98515700 | Brain | SH-SY5Y human neuroblastoma | neuroblastoma | Enhancer activity assay |
| E_00963 | chr12:2350700~2350812 | Brain | SH-SY5Y human neuroblastoma | neuroblastoma | Enhancer activity assay |
| E_00964 | chr11:47159000~47159500 | Kidney | HEK293 human embryonic kidney | Enhancer activity assay | |
| E_00965 | chr16:53808696~53808927 | Hematopoietic | OCI-M2 | acute myeloid leukemia | Enhancer activity assay |
| E_00966 | chr3:16456598~16456698 | Adrenal gland | NCI-H295R | Enhancer activity assay | |
| E_00967 | chr14:105860000~105860500 | Heart | H9c2 cardiomyoblast | Chromatin interaction assay | |
| E_00968 | chr16:164235~164590 | Lymph node | DHL-4 cells | diffuse large B-cell lymphoma | Enhancer activity assay, Functional perturbation assay |
| E_00969 | chrX:130258372~130259352 | Peripheral Blood | CD71+ erythroid cells | acute myeloid leukemia | Enhancer activity assay |
| E_00970 | chr16:55500100~55502100 | Bone Marrow | JK1 human erythroleukemia cells | acute myeloid leukemia | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_00971 | chr16:55500100~55502100 | Bladder | 5637 | bladder carcinoma | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_00972 | chr11:5224750~5226210 | Bladder | T24 | bladder carcinoma | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_00973 | chr11:5225400~5225774 | Bone Marrow | K562 | chronic myeloid leukemia | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_00974 | chr11:5224750~5226210 | Bone Marrow | K562 | chronic myeloid leukemia | Enhancer activity assay, TF binding assay |
| E_00975 | chr5:122453050~122453374 | Bone Marrow | K562 | chronic myeloid leukemia | Enhancer activity assay, TF binding assay |
| E_00976 | chr5:122453050~122453374 | Bronchus | Human bronchial smooth muscle cells (HuBrSMCs) | Enhancer activity assay, TF binding assay | |
| E_00977 | chr19:12878361~12878609 | Blood vessel | Mouse endothelial cells (ECs) | Functional perturbation assay | |
| E_00978 | chr2:69342699~69343679 | Blood | T cells | Functional perturbation assay | |
| E_00979 | chr15:81090165~81090265 | Connective Tissue | Primary human mesenchymal stromal cells | Enhancer activity assay | |
| E_00980 | chr15:81090165~81090265 | Cervix | HeLa | cervical cancer | Enhancer activity assay |
| E_00981 | chr15:81090165~81090265 | Embryo | MEF | Enhancer activity assay | |
| E_00982 | chr15:81090285~81090415 | Brain | C6 | Enhancer activity assay | |
| E_00983 | chr15:81090285~81090415 | Cervix | HeLa | cervical cancer | Enhancer activity assay |
| E_00984 | chr15:81090285~81090415 | Embryo | MEF | Enhancer activity assay | |
| E_00985 | chr10:71592600~71593600 | Brain | C6 | Functional perturbation assay | |
| E_00986 | chr6:142706180~142706230 | Brain | N2A cells | Enhancer activity assay, Functional perturbation assay | |
| E_00987 | chr6:142706180~142706230 | Bladder | 5637 | bladder carcinoma | Enhancer activity assay, Functional perturbation assay |
| E_00988 | chr6:142706180~142706230 | Bladder | SW780 | bladder carcinoma | Enhancer activity assay, Functional perturbation assay |
| E_00989 | chr6:142706180~142706230 | Umbilical vein | HUVEC | Enhancer activity assay, Functional perturbation assay | |
| E_00990 | chr2:239866844~239871938 | Bladder | SVHUC-1 | bladder carcinoma | Functional perturbation assay |
| E_00991 | chr2:239884251~239900294 | Lung | NCI-H460 | non-small cell lung carcinoma | Functional perturbation assay |
| E_00992 | chr4:76192040~76237727 | Lung | NCI-H460 | non-small cell lung carcinoma | Enhancer activity assay, Chromatin interaction assay |
| E_00993 | chr7:117125000~117126200 | Colon | Human normal colon epithelial cell | Enhancer activity assay, TF binding assay | |
| E_00994 | chr7:117099117~117100317 | Intestine | Human colorectal adenocarcinoma cell | Chromatin interaction assay | |
| E_00995 | chr12:12874700~12875275 | Colon | Caco-2 | colorectal adenocarcinoma | TF binding assay |
| E_00996 | chr12:23211482~23214744 | Blood | Lymphoblastoid cell line (LCL) | Enhancer activity assay | |
| E_00997 | chr14:61120199~61122451 | Pharyngeal Arch | Not available | Enhancer activity assay | |
| E_00998 | chr2:176760000~176800000 | Dorsal Root Ganglion | Not available | Enhancer activity assay, Functional perturbation assay | |
| E_00999 | chr2:176760000~176800000 | Limb | Not available | Enhancer activity assay, Functional perturbation assay | |
| E_01000 | chr2:176760000~176800000 | Limb | Not available | Enhancer activity assay, Functional perturbation assay | |
| E_01001 | chr2:176760000~176800000 | Limb | Not available | Enhancer activity assay, Functional perturbation assay | |
| E_01002 | chr2:176760000~176800000 | Limb | Not available | Enhancer activity assay, Functional perturbation assay | |
| E_01003 | chr2:176760000~176800000 | Limb | Not available | Enhancer activity assay, Functional perturbation assay | |
| E_01004 | chr17:69542159~69542712 | Limb | Not available | Enhancer activity assay | |
| E_01005 | chr7:94374796~94376944 | Genital tubercle | TM4 cells | Enhancer activity assay, TF binding assay | |
| E_01006 | chr3:36999364~37001216 | Lung | Human lung fibroblasts | Functional perturbation assay, Chromatin interaction assay | |
| E_01007 | chr3:36999364~37001216 | Colon | SW620 | colorectal carcinoma | Functional perturbation assay, Chromatin interaction assay |
| E_01008 | chr15:67446922~67447122 | Colon | RKO | colorectal carcinoma | Enhancer activity assay |
| E_01009 | chr15:67446922~67447122 | Thyroid | TPC-1 | thyroid carcinoma | Enhancer activity assay |
| E_01010 | chr15:67464177~67464377 | Thyroid | BCPAP | thyroid carcinoma | Enhancer activity assay |
| E_01011 | chr15:67464177~67464377 | Thyroid | TPC-1 | thyroid carcinoma | Enhancer activity assay |
| E_01012 | chr11:8254932~8255884 | Thyroid | BCPAP | thyroid carcinoma | Enhancer expression quantitative trait locus assay |
| E_01013 | chr10:94770000~94776500 | Blood | Peripheral Blood Leukocytes | Enhancer activity assay | |
| E_01014 | chr10:94770000~94776500 | Retina | Retinal Progenitor Cells | Enhancer activity assay | |
| E_01015 | chr4:124383428~124386454 | Retina | Retinal Ganglion Cells | Enhancer activity assay | |
| E_01016 | chr6:45847301~45850554 | Craniofacial Tissue | Enhancer activity assay | ||
| E_01017 | chr7:18874272~18875369 | Nose | Enhancer activity assay | ||
| E_01018 | chr7:93975962~93978880 | Pharyngeal Arch | Enhancer activity assay | ||
| E_01019 | chr7:117085017~117086217 | Pharyngeal Arch | Enhancer activity assay, TF binding assay | ||
| E_01020 | chrX:827128~827691 | Lung | Human lung adenocarcinoma cell | lung adenocarcinoma | Enhancer activity assay |
| E_01021 | chr1:152416586~152416964 | Embryonic limb bud | Mouse embryo whole mount | Enhancer activity assay | |
| E_01022 | chr14:22420000~22422000 | Skin | Primary human epidermal keratinocytes (HEKa) | Enhancer activity assay, Chromatin interaction assay | |
| E_01023 | chr14:22420000~22422000 | Thymus | T Lymphocyte Progenitors | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay | |
| E_01024 | chr14:22420000~22422000 | Blood | Leukemic B Lymphoblasts | B-cell acute lymphoblastic leukemia | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay |
| E_01025 | chr16:155136~155210 | Blood | Leukemic T Lymphoblasts | T-cell acute lymphoblastic leukemia | Functional perturbation assay |
| E_01026 | chr16:170166~170655 | Blood | CD71+ erythroid cells | Functional perturbation assay | |
| E_01027 | chr16:193013~193087 | Blood | CD71+ erythroid cells | Functional perturbation assay | |
| E_01028 | chr14:72448647~72451627 | Blood | CD71+ erythroid cells | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_01029 | chr2:106794728~106796527 | Brain | SK-N-SH | neuroblastoma | Enhancer activity assay |
| E_01030 | chr10:80919330~80952655 | Heart | Transgenic mouse embryo | Enhancer activity assay, Chromatin interaction assay | |
| E_01031 | chr10:80919330~80952655 | Lung | Primary human LUSC tumor cells | lung squamous cell carcinoma | Enhancer activity assay, Chromatin interaction assay |
| E_01032 | chr3:41308601~41310601 | Lung | Primary human LUSC tumor cells | lung squamous cell carcinoma | Enhancer activity assay, Chromatin interaction assay |
| E_01033 | chr22:46105001~46107001 | Lung | Primary human LUSC tumor cells | lung squamous cell carcinoma | Enhancer activity assay, Chromatin interaction assay |
| E_01034 | chr2:219988763~219991870 | Lung | Primary human LUSC tumor cells | lung squamous cell carcinoma | Enhancer activity assay |
| E_01035 | chr1:47680000~47681000 | Eye | Primary embryonic RPE cells | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay | |
| E_01036 | chr6:31133843~31134467 | Inner cell mass | H1 hESCs | Functional perturbation assay, Enhancer activity assay | |
| E_01037 | chr6:31234516~31234664 | Inner cell mass | H1 hESCs | Functional perturbation assay, Enhancer activity assay | |
| E_01038 | chr6:31247578~31247900 | Inner cell mass | H1 hESCs | Functional perturbation assay, Enhancer activity assay | |
| E_01039 | chr7:116474936~116475436 | Inner cell mass | H1 hESCs | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay, TF binding assay | |
| E_01040 | chr14:36356112~36635984 | Skin | COLO829 | skin melanoma | Chromatin interaction assay, Functional perturbation assay |
| E_01041 | chr16:28930687~28931032 | Prostate | LNCaP | prostate cancer | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01042 | chr1:110200000~110258000 | Blood | NALM6 | B-cell acute lymphoblastic leukemia | Enhancer activity assay, Functional perturbation assay |
| E_01043 | chr10:89875711~89876693 | Breast | T47D cells | breast carcinoma | Enhancer activity assay, Functional perturbation assay |
| E_01044 | chr8:98253530~98257713 | Skin | Melanoma cell line | skin melanoma | Chromatin interaction assay |
| E_01045 | chr8:98310330~98314427 | Blood | SP-49 | acute lymphoblastic leukemia | Chromatin interaction assay |
| E_01046 | chr8:27610000~27610500 | Blood | Rec-1 | mantle cell lymphoma | Enhancer perturbation assay |
| E_01047 | chr2:11623044~11623914 | Embryonic Kidney | HEK293 | eCLIP-seq, ChIP-seq, RNA-seq, ATAC-seq, ChIA-PET, Luciferase, FISH, IF, Xenograft | |
| E_01048 | chr6:132265000~132266500 | Breast | MCF-7 | breast carcinoma | Functional perturbation assay, TF binding assay, Enhancer activity assay |
| E_01049 | chr1:85870000~85870500 | Colon | HCT116 | colorectal carcinoma | Functional perturbation assay, TF binding assay, Enhancer activity assay |
| E_01050 | chr1:85865000~85866500 | Colon | HCT116 | colorectal carcinoma | Functional perturbation assay, TF binding assay, Enhancer activity assay |
| E_01051 | chr1:85868000~85869500 | Colon | HCT116 | colorectal carcinoma | Functional perturbation assay, TF binding assay, Enhancer activity assay |
| E_01052 | chr2:60718043~60725451 | Colon | HCT116 | colorectal carcinoma | Enhancer activity assay, Functional perturbation assay, TF binding assay |
| E_01053 | chr10:92680870~92681128 | Blood | Primary erythroblasts | Enhancer activity assay | |
| E_01054 | chr8:127737737~127738437 | Breast | MDA-MB-231 | breast carcinoma | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_01055 | chr8:127737737~127738437 | Colon | HCT116 | colorectal carcinoma | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_01056 | chr12:122510495~122510896 | Embryonic Kidney | HEK293 | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay | |
| E_01057 | chr12:122510495~122510896 | Prostate | P-90 PDX primary | prostate cancer | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay |
| E_01058 | chr19:15311000~15312500 | Prostate | P-90 PDX primary | prostate cancer | Functional perturbation assay, TF binding assay |
| E_01059 | chr19:15311000~15312500 | Lung | A549 | lung adenocarcinoma | Functional perturbation assay, TF binding assay |
| E_01060 | chr19:15311000~15312500 | Lung | H460 | lung adenocarcinoma | Functional perturbation assay, TF binding assay |
| E_01061 | chr2:46550000~46555000 | Lung | H2023 | lung adenocarcinoma | Functional perturbation assay |
| E_01062 | chr2:46523219~46568173 | Breast | MCF7L-TamR | breast carcinoma | Enhancer activity assay, Functional perturbation assay |
| E_01063 | chr9:136398000~136402000 | Breast | MCF7L-TamR | breast carcinoma | Enhancer activity assay |
| E_01064 | chr6:135525000~135525800 | Bone marrow | K562 | chronic myeloid leukemia | Enhancer activity assay, Chromatin interaction assay |
| E_01065 | chr6:135530000~135530800 | Salivary gland | ACC patient-derived xenograft cell lines (ACCX2, ACCX9, ACCX12, ACCX19, ACCX22) | salivary gland adenoid cystic carcinoma | Enhancer activity assay, Chromatin interaction assay |
| E_01066 | chr6:135485000~135485800 | Salivary gland | ACC patient-derived xenograft cell lines (ACCX2, ACCX9, ACCX12, ACCX19, ACCX22) | salivary gland adenoid cystic carcinoma | Enhancer activity assay, Chromatin interaction assay |
| E_01067 | chr6:135495000~135495800 | Salivary gland | ACC patient-derived xenograft cell lines (ACCX2, ACCX9, ACCX12, ACCX19, ACCX22) | salivary gland adenoid cystic carcinoma | Enhancer activity assay, Chromatin interaction assay |
| E_01068 | chr8:128540000~128620000 | Salivary gland | ACC patient-derived xenograft cell lines (ACCX2, ACCX9, ACCX12, ACCX19, ACCX22) | salivary gland adenoid cystic carcinoma | Chromatin interaction assay, TF binding assay |
| E_01069 | chr8:128540000~128620000 | Prostate gland | LNCaP | prostate cancer | Chromatin interaction assay, TF binding assay |
| E_01070 | chr7:116735000~116735500 | Prostate gland | C4-2B | prostate cancer | Functional perturbation assay |
| E_01071 | chr7:117342000~117345000 | Skin | COLO829 | skin melanoma | Chromatin interaction assay |
| E_01072 | chr6:86160197~86176777 | Nasal epithelium | HNECs | Functional perturbation assay | |
| E_01073 | chr17:32565534~32566496 | Skin | SK-MEL28 | skin melanoma | Functional perturbation assay, Enhancer activity assay |
| E_01074 | chr3:112045517~112046117 | Liver | Liver sinusoidal endothelial cell | Enhancer activity assay | |
| E_01075 | chr3:48598405~48598558 | Umbilical vein | HUVEC | Enhancer activity assay | |
| E_01076 | chr9:101878420~101879420 | Muscle | TE-671 | rhabdomyosarcoma | Chromatin interaction assay, Enhancer-target gene assignment assay |
| E_01077 | chr21:42880000~42880500 | Brain | HD-MB03 | medulloblastoma | Chromatin interaction assay |
| E_01078 | chr11:111153185~111154290 | Breast | MCF-7 | breast carcinoma | Enhancer activity assay |
| E_01079 | chr1:47729000~47731000 | Colon | SW480 | colorectal carcinoma | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_01080 | chr17:3466973~3468374 | Blood | K562 | chronic myeloid leukemia | Functional perturbation assay, Enhancer activity assay |
| E_01081 | chr4:15581130~15619993 | Embryonic Kidney | HEK293 | Enhancer activity assay, Chromatin interaction assay, TF binding assay, Functional perturbation assay | |
| E_01082 | chr4:15581130~15619993 | Bone Marrow | SEM | B-cell acute lymphoblastic leukemia | Enhancer activity assay, Chromatin interaction assay, TF binding assay, Functional perturbation assay |
| E_01083 | chr4:15581130~15619993 | Bone Marrow | RS4 | B-cell acute lymphoblastic leukemia | Enhancer activity assay, Chromatin interaction assay, TF binding assay, Functional perturbation assay |
| E_01084 | chr4:15581130~15619993 | Bone Marrow | 11 | B-cell acute lymphoblastic leukemia | Enhancer activity assay, Chromatin interaction assay, TF binding assay, Functional perturbation assay |
| E_01085 | chr2:16370000~16380000 | Bone Marrow | Primary MLL-AF4 ALL patient blasts | B-cell acute lymphoblastic leukemia | Enhancer activity assay, TF binding assay, Chromatin interaction assay |
| E_01086 | chr2:16370000~16380000 | Adrenal gland | Kelly | neuroblastoma | Enhancer activity assay, TF binding assay, Chromatin interaction assay |
| E_01087 | chr2:29400000~29449999 | Adrenal gland | NGP | neuroblastoma | Enhancer activity assay, TF binding assay, Chromatin interaction assay |
| E_01088 | chr2:12600000~12649999 | Adrenal gland | IMR-5/75 | neuroblastoma | Enhancer activity assay, TF binding assay, Chromatin interaction assay |
| E_01089 | chr5:122452000~122454500 | Adrenal gland | CHP-212 | neuroblastoma | Enhancer activity assay, TF binding assay |
| E_01090 | chr8:128410475~128411974 | Bronchus | Human bronchial smooth muscle cells (HuBrSMCs) | Chromatin interaction assay, Enhancer activity assay | |
| E_01091 | chr17:44026548~44026648 | Prostate gland | LNCaP | prostate cancer | Enhancer activity assay, TF binding assay |
| E_01092 | chr20:3508597~3508795 | Brain | Neural progenitor | Enhancer activity assay, TF binding assay | |
| E_01093 | chr7:114541370~114542201 | Blood | K-562 | chronic myeloid leukemia | Enhancer activity assay |
| E_01094 | chr8:128747000~128748000 | Embryonic Kidney | HEK293 | Enhancer activity assay, TF binding assay | |
| E_01095 | chr2:222846900~222847900 | Endometrium | AN3CA | endometrial adenocarcinoma | Transcription factor binding assay |
| E_01096 | chr6:160101620~160102231 | Skin | A375 melanoma | skin melanoma | Enhancer activity assay |
| E_01097 | chr16:53808493~53808714 | Prostate | PC-3 | prostate cancer | Enhancer activity assay |
| E_01098 | chr13:42551634~42553034 | Hypothalamus | N38 | Enhancer activity assay | |
| E_01099 | chr5:132002000~132008000 | Bone | MG63 | osteosarcoma | Enhancer activity assay |
| E_01100 | chr11:82630000~82650000 | Blood | Jurkat T Cells | T-cell acute lymphoblastic leukemia | Chromatin interaction assay |
| E_01101 | chr1:214148800~214149632 | Forebrain | Human neural progenitor cells (NPCs) | Enhancer activity assay | |
| E_01102 | chr8:128748315~128750245 | Dermis | Primary Dermal Lymphatic Endothelial Cells (hLECs) | Enhancer activity assay | |
| E_01103 | chr11:69470000~69470500 | Lymph node | Raji | Burkitt lymphoma | Chromatin interaction assay |
| E_01104 | chr8:128754000~128755000 | Breast | MDA-MB-231 cells | breast carcinoma | Enhancer activity assay, Chromatin interaction assay, TF binding assay, Functional perturbation assay |
| E_01105 | chr8:128754000~128755000 | Colon | HCT116 | colorectal carcinoma | Enhancer activity assay, Chromatin interaction assay, TF binding assay, Functional perturbation assay |
| E_01106 | chr17:31255800~31256300 | Embryonic Kidney | HEK293 | TF binding assay, Functional perturbation assay | |
| E_01107 | chr6:35566219~35566402 | Pancreas | PANC1 | pancreatic ductal adenocarcinoma | Enhancer activity assay, Functional perturbation assay |
| E_01108 | chr6:35566219~35566402 | Lung | A549 | lung adenocarcinoma | Enhancer activity assay, Functional perturbation assay |
| E_01109 | chr6:35566219~35566402 | Prostate | VCaP | prostate cancer | Enhancer activity assay, Functional perturbation assay |
| E_01110 | chrX:30241062~30242228 | Kidney | COS1 | Enhancer activity assay, TF binding assay, Chromatin interaction assay | |
| E_01111 | chr17:26071355~26071455 | Embryonic Kidney | HEK293 | Enhancer activity assay | |
| E_01112 | chr6:35505138~35511492 | Lung | A549 | lung adenocarcinoma | Enhancer activity assay |
| E_01113 | chr6:35616283~35622638 | Lung | A549 cell line | lung adenocarcinoma | Enhancer activity assay |
| E_01114 | chr6:35636622~35642872 | Lung | A549 cell line | lung adenocarcinoma | Enhancer activity assay |
| E_01115 | chr3:181425707~181426096 | Lung | A549 cell line | lung adenocarcinoma | Enhancer activity assay |
| E_01116 | chr3:181425707~181426096 | Breast | MCF7 | breast carcinoma | Enhancer activity assay |
| E_01117 | chr11:5246500~5247000 | Breast | T47D | breast carcinoma | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay |
| E_01118 | chr8:81274400~81275960 | Blood | K562 erythroleukemia cells | chronic myeloid leukemia | Enhancer activity assay |
| E_01119 | chr12:114463712~114464080 | Blood | GM12878 | Enhancer activity assay | |
| E_01120 | chr8:128220000~128250000 | Heart | Primary cardiomyocytes | Chromatin interaction assay, Gene expression assay | |
| E_01121 | chr8:128220000~128250000 | Blood | LCL-29092 | Chromatin interaction assay, Gene expression assay | |
| E_01122 | chr4:111552482~111553989 | Blood | LCL-32370 | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_01123 | chr4:111552482~111553989 | Embryo | Zebrafish embryonic cells | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_01124 | chr4:111552482~111553989 | Heart | HL-1 | atrial fibrillation | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01125 | chr4:111552482~111553989 | Heart | WA07 hESC-CM | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_01126 | chr4:111553098~111553222 | Cervix | HeLa | cervical cancer | Enhancer activity assay, TF binding assay, Functional perturbation assay, eRNA assay |
| E_01127 | chr4:111553098~111553222 | Heart | HL-1 | atrial fibrillation | Enhancer activity assay, TF binding assay, Functional perturbation assay, eRNA assay |
| E_01128 | chr4:111553098~111553222 | Heart | WA07 hESC-CM | Enhancer activity assay, TF binding assay, Functional perturbation assay, eRNA assay | |
| E_01129 | chr10:51546800~51547317 | Cervix | HeLa | cervical cancer | Enhancer activity assay, Chromatin interaction assay, TF binding assay |
| E_01130 | chr10:51546800~51547317 | Prostate | LNCaP | prostate cancer | Enhancer activity assay, Chromatin interaction assay, TF binding assay |
| E_01131 | chr10:51546800~51547317 | Prostate | DU-145 | prostate cancer | Enhancer activity assay, Chromatin interaction assay, TF binding assay |
| E_01132 | chr10:51546800~51547317 | Prostate | BPH-1 | Enhancer activity assay, Chromatin interaction assay, TF binding assay | |
| E_01133 | chr8:11446898~11447336 | Prostate | RWPE-1 | Enhancer activity assay, Functional perturbation assay | |
| E_01134 | chr8:11446898~11447336 | Esophagus | OE19 | esophageal adenocarcinoma | Enhancer activity assay, Functional perturbation assay |
| E_01135 | chr8:128520000~128551676 | Stomach | OE33 | esophageal adenocarcinoma | Chromatin interaction assay, TF binding assay, Gene expression assay |
| E_01136 | chr8:128520000~128551676 | Prostate | LNCaP | prostate cancer | Chromatin interaction assay, TF binding assay, Gene expression assay |
| E_01137 | chr8:128520000~128551676 | Prostate | DU-145 | prostate cancer | Chromatin interaction assay, TF binding assay, Gene expression assay |
| E_01138 | chr8:128520000~128551676 | Prostate | BPH-1 | Chromatin interaction assay, TF binding assay, Gene expression assay | |
| E_01139 | chr2:85750614~85811383 | Prostate | RWPE-1 | Chromatin interaction assay, TF binding assay, Gene expression assay | |
| E_01140 | chr2:85750614~85811383 | Prostate | DU-145 | prostate cancer | Chromatin interaction assay, TF binding assay, Gene expression assay |
| E_01141 | chr2:85750614~85811383 | Prostate | BPH-1 | Chromatin interaction assay, TF binding assay, Gene expression assay | |
| E_01142 | chr2:85750614~85811383 | Prostate | RWPE-1 | Chromatin interaction assay, TF binding assay, Gene expression assay | |
| E_01143 | chr2:85750614~85811383 | Blood | LCL-29092 | Chromatin interaction assay, TF binding assay, Gene expression assay | |
| E_01144 | chr2:85750614~85811383 | Blood | LCL-32370 | Chromatin interaction assay, TF binding assay, Gene expression assay | |
| E_01145 | chr1:204518514~204561889 | Prostate | LNCaP | prostate cancer | Chromatin interaction assay, TF binding assay, Gene expression assay |
| E_01146 | chr1:204518514~204561889 | Prostate | DU-145 | prostate cancer | Chromatin interaction assay, TF binding assay, Gene expression assay |
| E_01147 | chr1:204518514~204561889 | Prostate | BPH-1 | Chromatin interaction assay, TF binding assay, Gene expression assay | |
| E_01148 | chr1:204518514~204561889 | Prostate | RWPE-1 | Chromatin interaction assay, TF binding assay, Gene expression assay | |
| E_01149 | chr21:36179867~36180107 | Breast | Human Mammary Epithelial Cells (HMEC) | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_01150 | chr21:36179867~36180107 | Breast | MDA-MB-231 | breast carcinoma | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01151 | chr21:36179867~36180107 | Breast | BT549 | breast carcinoma | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01152 | chr21:36179867~36180107 | Breast | SUM149 | breast carcinoma | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01153 | chr21:36179867~36180107 | Breast | SUM159 | breast carcinoma | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01154 | chr21:36179867~36180107 | Breast | HCC1395 | breast carcinoma | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01155 | chr1:1092486~1093650 | Breast | MDA-MB-231 cells | breast carcinoma | Enhancer activity assay |
| E_01156 | chr2:20850000~20880000 | Prostate | LNCaP | prostate cancer | Chromatin interaction assay, Gene expression assay |
| E_01157 | chr2:20850000~20880000 | Prostate | DU-145 | prostate cancer | Chromatin interaction assay, Gene expression assay |
| E_01158 | chr2:20850000~20880000 | Prostate | BPH-1 | Chromatin interaction assay, Gene expression assay | |
| E_01159 | chr2:20850000~20880000 | Prostate | RWPE-1 | Chromatin interaction assay, Gene expression assay | |
| E_01160 | chr2:20850000~20880000 | Blood | LCL-29092 | Chromatin interaction assay, Gene expression assay | |
| E_01161 | chr2:20850000~20880000 | Blood | LCL-32370 | Chromatin interaction assay, Gene expression assay | |
| E_01162 | chr6:122800000~122850000 | Prostate | LNCaP | prostate cancer | Chromatin interaction assay, Gene expression assay |
| E_01163 | chr6:122800000~122850000 | Prostate | DU-145 | prostate cancer | Chromatin interaction assay, Gene expression assay |
| E_01164 | chr6:122800000~122850000 | Prostate | BPH-1 | Chromatin interaction assay, Gene expression assay | |
| E_01165 | chr6:122800000~122850000 | Prostate | RWPE-1 | Chromatin interaction assay, Gene expression assay | |
| E_01166 | chr17:38065200~38065700 | Blood | Primary CD4+ T cells | asthma | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_01167 | chr17:38065200~38065700 | Lymphoid tissue | CD8+ T cells | asthma | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_01168 | chr17:38065200~38065700 | Blood | B cells | asthma | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_01169 | chr17:38065200~38065700 | Blood | NK cells | asthma | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_01170 | chr17:38065200~38065700 | Blood | HUT-78 | asthma | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_01171 | chr17:38022100~38022900 | Blood | Primary CD4+ T cells | asthma | Chromatin interaction assay, Enhancer activity assay, Gene expression assay |
| E_01172 | chr17:38022100~38022900 | Lymphoid tissue | HUT-78 | asthma | Chromatin interaction assay, Enhancer activity assay, Gene expression assay |
| E_01173 | chr2:191800000~191801000 | Skin | Melanoma cells | skin melanoma | Enhancer activity assay, TF binding assay |
| E_01174 | chr9:22117000~22118500 | Lung | IMR-90 cells | Enhancer activity assay, Chromatin interaction assay | |
| E_01175 | chr12:68544280~68544520 | Cervix | HeLa cells | cervical cancer | Enhancer activity assay |
| E_01176 | chr6:161085524~161086263 | Liver | HepG2 cells | hepatocellular carcinoma | Enhancer activity assay |
| E_01177 | chr6:161092630~161095030 | Liver | HepG2 cells | hepatocellular carcinoma | Enhancer activity assay |
| E_01178 | chr5:17483518~17484083 | Heart | HEK293 cells | ventricular septal defect | Enhancer activity assay |
| E_01179 | chr12:68546200~68546440 | Blood | Primary T cells | Enhancer activity assay | |
| E_01180 | chr6:135418600~135418700 | Bone marrow | Primary human hematopoietic progenitor cells | acute myeloid leukemia | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01181 | chr6:135418600~135418700 | Bone marrow | KG-1a | acute myeloid leukemia | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01182 | chr6:135418600~135418700 | Bone marrow | Kasumi-1 | acute myeloid leukemia | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01183 | chr6:135418600~135418700 | Bone marrow | MV4-11 | acute myeloid leukemia | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01184 | chr4:15450000~15579703 | Bone marrow | SEM | B-cell acute lymphoblastic leukemia | Enhancer activity assay, Chromatin interaction assay, TF binding assay, Functional perturbation assay |
| E_01185 | chr4:15450000~15579703 | Bone marrow | RS4 | B-cell acute lymphoblastic leukemia | Enhancer activity assay, Chromatin interaction assay, TF binding assay, Functional perturbation assay |
| E_01186 | chr4:15450000~15579703 | Bone marrow | 11 | B-cell acute lymphoblastic leukemia | Enhancer activity assay, Chromatin interaction assay, TF binding assay, Functional perturbation assay |
| E_01187 | chr4:15450000~15579703 | Bone marrow | Primary MLL-AF4 ALL patient blasts | B-cell acute lymphoblastic leukemia | Enhancer activity assay, Chromatin interaction assay, TF binding assay, Functional perturbation assay |
| E_01188 | chr4:15450000~15579703 | Bone marrow | THP-1 | acute monocytic leukemia | Enhancer activity assay, Chromatin interaction assay, TF binding assay, Functional perturbation assay |
| E_01189 | chr4:15450000~15579703 | Bone marrow | RCH-ACV | B-cell acute lymphoblastic leukemia | Enhancer activity assay, Chromatin interaction assay, TF binding assay, Functional perturbation assay |
| E_01190 | chr4:15450000~15579703 | Bone marrow | ML-2 | acute myeloid leukemia | Enhancer activity assay, Chromatin interaction assay, TF binding assay, Functional perturbation assay |
| E_01191 | chr4:15450000~15579703 | Bone marrow | CD34+ hematopoietic stem/progenitor cells | Enhancer activity assay, Chromatin interaction assay, TF binding assay, Functional perturbation assay | |
| E_01192 | chr12:9916938~9918379 | Blood | Jurkat T cells | Enhancer activity assay, Functional perturbation assay, TF binding assay | |
| E_01193 | chr12:9916938~9918379 | Lymph node | C1R B cells | Enhancer activity assay, Functional perturbation assay, TF binding assay | |
| E_01194 | chr6:36640690~36643070 | Skin | BJ foreskin fibroblasts | Enhancer activity assay, Genetic screen | |
| E_01195 | chr2:29880537~29880842 | Skeletal muscle | RH4 | alveolar rhabdomyosarcoma | Enhancer activity assay, Super-enhancer profiling |
| E_01196 | chr2:29880537~29880842 | Skeletal muscle | SCMC | alveolar rhabdomyosarcoma | Enhancer activity assay, Super-enhancer profiling |
| E_01197 | chr2:29880537~29880842 | Skeletal muscle | RH4 tumor cells | alveolar rhabdomyosarcoma | Enhancer activity assay, Super-enhancer profiling |
| E_01198 | chr17:37900000~37900500 | Breast | SKBR3 breast cancer cell line | breast adenocarcinoma | Enhancer functional assay, TF binding assay |
| E_01199 | chr7:105856018~105860658 | Lung | H460 | lung adenocarcinoma | Enhancer activity assay, Functional perturbation assay, TF binding assay |
| E_01200 | chr7:105856018~105860658 | Brain | U87-MG | glioblastoma | Enhancer activity assay, Functional perturbation assay, TF binding assay |
| E_01201 | chr7:105856018~105860658 | Colon | HCT116 | colorectal carcinoma | Enhancer activity assay, Functional perturbation assay, TF binding assay |
| E_01202 | chr8:129278315~129283315 | Lymph node | TRExBCBL1-RTA cells | primary effusion lymphoma | Enhancer activity assay, Functional perturbation assay, Chromatin interaction assay |
| E_01203 | chr8:129234315~129239315 | Lymph node | TRExBCBL1-RTA cells | primary effusion lymphoma | Enhancer activity assay, Functional perturbation assay, Chromatin interaction assay |
| E_01204 | chr8:129254315~129259315 | Lymph node | TRExBCBL1-RTA cells | primary effusion lymphoma | Enhancer activity assay, Functional perturbation assay, Chromatin interaction assay |
| E_01205 | chr13:40800660~40848941 | Skeletal muscle | RH4 | alveolar rhabdomyosarcoma | Enhancer activity assay, Functional perturbation assay, Chromatin interaction assay, TF binding assay |
| E_01206 | chr13:40800660~40848941 | Skeletal muscle | RH30 rhabdomyosarcoma cell lines | alveolar rhabdomyosarcoma | Enhancer activity assay, Functional perturbation assay, Chromatin interaction assay, TF binding assay |
| E_01207 | chr6:30754822~30755196 | Inner cell mass | H1 human embryonic stem cells | Functional perturbation assay, Genetic screen | |
| E_01208 | chr6:30904342~30904788 | Inner cell mass | H1 human embryonic stem cells | Functional perturbation assay, Genetic screen | |
| E_01209 | chr6:31234516~31234664 | Inner cell mass | H1 human embryonic stem cells | Functional perturbation assay, Genetic screen | |
| E_01210 | chr11:5279732~5280272 | Bone marrow | K562 | chronic myeloid leukemia | Functional perturbation assay, Enhancer activity assay |
| E_01211 | chr11:5279732~5280272 | Blood | primary erythroblasts | Functional perturbation assay, Enhancer activity assay | |
| E_01212 | chr21:42660000~42661000 | Breast | MCF-7 breast cancer cell line | breast adenocarcinoma | Functional perturbation assay, Chromatin interaction assay |
| E_01213 | chr21:42660000~42661000 | Breast | MCF-7 breast cancer cell line | breast adenocarcinoma | Functional perturbation assay, Chromatin interaction assay |
| E_01214 | chr21:42660000~42661000 | Breast | MCF-7 breast cancer cell line | breast adenocarcinoma | Functional perturbation assay, Chromatin interaction assay |
| E_01215 | chr2:10860000~10861000 | Breast | MCF-7 breast cancer cell line | breast adenocarcinoma | Functional perturbation assay |
| E_01216 | chr17:3466973~3468374 | Embryonic Kidney | HEK293 cell line | Enhancer activity assay, Functional perturbation assay | |
| E_01217 | chr6:36631690~36640853 | Skin | BJ foreskin fibroblasts | Enhancer activity assay | |
| E_01218 | chr5:172131000~172132000 | Bone | U2OS | osteosarcoma | Enhancer activity assay, Chromatin interaction assay |
| E_01219 | chr5:172131000~172132000 | Lung | A549 cell lines | lung adenocarcinoma | Enhancer activity assay, Chromatin interaction assay |
| E_01220 | chr9:21968000~21973000 | Lung | IMR-90 fetal lung fibroblasts | Functional perturbation assay, Chromatin interaction assay | |
| E_01221 | chr9:21973000~21978000 | Lung | IMR-90 fetal lung fibroblasts | Functional perturbation assay, Chromatin interaction assay | |
| E_01222 | chr9:21978000~21983000 | Lung | IMR-90 fetal lung fibroblasts | Functional perturbation assay, Chromatin interaction assay | |
| E_01223 | chr9:21983000~21988000 | Lung | IMR-90 fetal lung fibroblasts | Functional perturbation assay, Chromatin interaction assay | |
| E_01224 | chr6:36633000~36637000 | Skin | BJ-RASG12V transformed fibroblast cell line | transformed fibroblast | Genetic perturbation screen |
| E_01225 | chr16:84000000~84001000 | Skin | BJ foreskin fibroblasts | oncogene-induced cellular senescence | Functional perturbation assay, Senescence assay |
| E_01226 | chr3:181428000~181429000 | Inner cell mass | H9 human embryonic stem cells | Enhancer activity assay | |
| E_01227 | chr17:3466258~3466820 | Embryonic Kidney | HEK293 cell line | Enhancer activity assay | |
| E_01228 | chr17:3466258~3466820 | Embryonic Kidney | HEK293 cell line | Enhancer activity assay | |
| E_01229 | chr17:3466258~3466820 | Embryonic Kidney | HEK293 cell line | Enhancer activity assay | |
| E_01230 | chr17:45414208~45414987 | Breast | DCIS.COM | ductal carcinoma in situ of breast | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01231 | chr17:45414208~45414987 | Breast | SUM225 | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_01232 | chr17:45414208~45414987 | Breast | HMEC | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_01233 | chr17:45436112~45436891 | Breast | DCIS.COM | ductal carcinoma in situ of breast | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01234 | chr17:45436112~45436891 | Breast | SUM225 | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_01235 | chr17:45436112~45436891 | Breast | HMEC | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_01236 | chr14:62180000~62180066 | Kidney | COS-7 cell line | Enhancer activity assay | |
| E_01237 | chr7:113688009~113688782 | Embryonic Kidney | HEK293 | Enhancer activity assay | |
| E_01238 | chr7:113688009~113688782 | Brain | SK-N-MC cell lines | Enhancer activity assay | |
| E_01239 | chr7:114056845~114058646 | Embryonic Kidney | HEK293 cell line | Enhancer activity assay | |
| E_01240 | chr11:5241525~5251525 | Bone marrow | Primary erythroblasts | Enhancer activity assay, Chromatin interaction assay | |
| E_01241 | chr6:31777438~31777648 | Lung | H1299 | non-small cell lung carcinoma | Enhancer activity assay |
| E_01242 | chr11:70030000~70079999 | Small intestine | Primary GIST tumour cells (SDH-deficient GIST) | gastrointestinal stromal tumor | Chromatin interaction assay, Enhancer activity assay |
| E_01243 | chr11:70030000~70079999 | Small intestine | quadruple WT GIST | gastrointestinal stromal tumor | Chromatin interaction assay, Enhancer activity assay |
| E_01244 | chr11:70030000~70079999 | Small intestine | KIT mutant GIST) | gastrointestinal stromal tumor | Chromatin interaction assay, Enhancer activity assay |
| E_01245 | chr14:106032312~106033352 | Blood | Burkitt lymphoma cell line | Burkitt lymphoma | Functional perturbation assay |
| E_01246 | chr11:75928700~75928930 | Lung | H889 | small cell lung carcinoma | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01247 | chr10:43552395~43553394 | Adrenal gland | Neuroblastoma cell | neuroblastoma | Enhancer activity assay, TF binding assay |
| E_01248 | chr2:11643000~11644000 | Breast | MCF7 | breast carcinoma | Enhancer activity assay, chromatin interaction assay |
| E_01249 | chr1:20173000~20175000 | Inner cell mass | H1 human embryonic stem | Enhancer activity assay | |
| E_01250 | chr1:129180000~129181000 | Blood | T-ALL | T-cell acute lymphoblastic leukemia | Enhancer activity assay, TF binding assay |
| E_01251 | chr14:21993966~21995169 | Brain | hESC-derived NPCs | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_01252 | chr2:218305944~218306443 | Breast | MDA-MB-231 | breast carcinoma | Enhancer activity assay |
| E_01253 | chr8:130180000~130181000 | Blood | Jurkat | T-cell acute lymphoblastic leukemia | Enhancer activity assay, functional perturbation assay |
| E_01254 | chr8:130180000~130181000 | Blood | CCRF-CEM | T-cell acute lymphoblastic leukemia | Enhancer activity assay, functional perturbation assay |
| E_01255 | chr6:138215000~138215653 | Spleen | Splenic B cells | Enhancer activity assay, functional perturbation assay | |
| E_01256 | chr11:132250000~132251000 | Endometrium | Ishikawa | Functional perturbation assay | |
| E_01257 | chr1:16000000~16001000 | Endometrium | Ishikawa | Functional perturbation assay | |
| E_01258 | chr16:29018500~29021500 | Bone marrow | HL-60 | acute myeloid leukemia | Functional perturbation assay |
| E_01259 | chr16:29018500~29021500 | Bone marrow | Myeloid tissue | Functional perturbation assay | |
| E_01260 | chr5:149400000~149401000 | Bone marrow | HL-60 | acute myeloid leukemia | Functional perturbation assay |
| E_01261 | chr5:149400000~149401000 | Bone marrow | Myeloid tissue | Functional perturbation assay | |
| E_01262 | chr8:67740000~67741000 | Liver | Primary Human Hepatocellular Carcinoma Cells | hepatocellular carcinoma | Enhancer activity assay, TF binding assay |
| E_01263 | chr8:67740000~67741000 | Liver | Mouse Arid1a Knockout Hepatocytes | Enhancer activity assay, TF binding assay | |
| E_01264 | chr9:11250200~11251200 | Gonadal Tissue | hESC | Enhancer activity assay, TF binding assay | |
| E_01265 | chr9:11250200~11251200 | Gonadal Tissue | hPGCLC | Enhancer activity assay, TF binding assay | |
| E_01266 | chr5:134729406~134737909 | Limb Bud | Human forelimb progenitor cells | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay | |
| E_01267 | chr5:134729406~134737909 | Embryo | Mouse embryonic limb (E11.5) | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay | |
| E_01268 | chr4:145678450~145679450 | Breast | MCF10A-Er-Src | breast carcinoma | TF binding assay, Enhancer activity assay |
| E_01269 | chr4:145678450~145679450 | Breast | HMEC | TF binding assay, Enhancer activity assay | |
| E_01270 | chr4:145678450~145679450 | Breast | vHMEC | TF binding assay, Enhancer activity assay | |
| E_01271 | chr4:145678450~145679450 | Breast | breast myoepithelial | TF binding assay, Enhancer activity assay | |
| E_01272 | chr4:145682300~145683300 | Breast | MCF10A-Er-Src | breast carcinoma | TF binding assay, Enhancer activity assay |
| E_01273 | chr4:145682300~145683300 | Breast | HMEC | TF binding assay, Enhancer activity assay | |
| E_01274 | chr4:145682300~145683300 | Breast | vHMEC | TF binding assay, Enhancer activity assay | |
| E_01275 | chr4:145682300~145683300 | Breast | breast myoepithelial | TF binding assay, Enhancer activity assay | |
| E_01276 | chr14:98602411~98675204 | Blood | HPB-ALL cells | T-cell acute lymphoblastic leukemia | Chromatin interaction assay, Functional perturbation assay |
| E_01277 | chr14:98602411~98675204 | Blood | Primary Human T-ALL Cells | T-cell acute lymphoblastic leukemia | Chromatin interaction assay, Functional perturbation assay |
| E_01278 | chr2:60495216~60495315 | Bone marrow | CD34+ hematopoietic stem cells | Functional perturbation assay | |
| E_01279 | chr11:5226889~5226999 | Bone marrow | CD34+ hematopoietic stem cells | Functional perturbation assay | |
| E_01280 | chr9:128335472~128336978 | Brain | U251 Glioma Cell Line | glioblastoma | Enhancer activity assay, TF binding assay |
| E_01281 | chr9:128335472~128336978 | Blood | Human Lymphoblastic Cell Lines | Enhancer activity assay, TF binding assay | |
| E_01282 | chr9:128335472~128336978 | Brain | Primary Glioma Tissue | glioblastoma | Enhancer activity assay, TF binding assay |
| E_01283 | chr12:105795404~105795904 | Skin | Human melanoma cell | skin melanoma | Enhancer activity assay, TF binding assay |
| E_01284 | chrX:66110000~66116000 | Prostate | Prostate cancer epithelial cells | prostate cancer | Enhancer activity assay, TF binding assay |
| E_01285 | chrX:66110000~66116000 | Prostate | PDX cells | prostate cancer | Enhancer activity assay, TF binding assay |
| E_01286 | chr17:38670000~38770000 | Breast | MDA-MB-231 | breast carcinoma | Chromatin interaction assay |
| E_01287 | chr2:239866844~239871938 | Lung | NCI-H460 | non-small cell lung carcinoma | Functional perturbation assay |
| E_01288 | chr18:60983148~60983597 | Blood | Jurkat | T-cell acute lymphoblastic leukemia | Chromatin interaction, expression validation |
| E_01289 | chr18:60790200~60790400 | Blood | Jurkat | T-cell acute lymphoblastic leukemia | Chromatin interaction, expression validation |
| E_01290 | chr18:64156800~64157000 | Blood | Jurkat | T-cell acute lymphoblastic leukemia | Chromatin interaction, repression validation |
| E_01291 | chr20:46120155~46120433 | Articular cartilage | SW1353 | chondrosarcoma | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01292 | chr4:103350000~103351000 | Heart | AC16 | TF binding assay | |
| E_01293 | chr8:128753000~128754000 | Endometrium | MFE-296 | endometrial adenocarcinoma | Enhancer activity assay |
| E_01294 | chr8:128173203~128174158 | Prostate | LNCaP | prostate cancer | Enhancer activity assay, Chromatin interaction assay, TF binding assay |
| E_01295 | chr8:128805000~128807000 | Colon | COLO 320DM cells | colorectal carcinoma | Enhancer activity assay, Functional perturbation assay |
| E_01296 | chr20:31595392~31597085 | Colon | HCT116 | colorectal carcinoma | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_01297 | chr10:52430000~52490000 | Pancreas | PANC-1 | pancreatic ductal adenocarcinoma | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_01298 | chr10:52430000~52490000 | Pancreas | HPAC | pancreatic ductal adenocarcinoma | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_01299 | chr10:52430000~52490000 | Pancreas | AsPC-1 | pancreatic ductal adenocarcinoma | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_01300 | chr6:135323137~135323537 | Blood | K562 | chronic myeloid leukemia | Enhancer activity assay, Functional perturbation assay, Chromatin interaction assay |
| E_01301 | chr17:41792666~41793322 | Esophagus | OE19 | esophageal adenocarcinoma | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_01302 | chr17:41792666~41793322 | Esophagus | CP-A | esophageal adenocarcinoma | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_01303 | chr17:41792666~41793322 | Esophagus | OE19 | esophageal adenocarcinoma | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_01304 | chr17:41792666~41793322 | Esophagus | CP-A | esophageal adenocarcinoma | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_01305 | chr17:79804321~79805871 | Colon | HT29 | colorectal carcinoma | Enhancer activity assay, Functional perturbation assay |
| E_01306 | chr8:128804981~128806980 | Colon | COLO320-DM | colorectal carcinoma | Enhancer activity assay, Functional perturbation assay |
| E_01307 | chr8:128747000~128748000 | Blood | K562 | chronic myeloid leukemia | Enhancer activity assay, Functional perturbation assay |
| E_01308 | chr20:63680288~63681605 | Brain | U251 cells | glioblastoma | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_01309 | chr20:63680288~63681605 | Brain | LN229 cells | glioblastoma | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_01310 | chr20:63680288~63681605 | Brain | U87 cells | glioblastoma | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_01311 | chr20:50027744~50030383 | Breast | MDA-MB-231 | breast carcinoma | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_01312 | chr20:50027744~50030383 | Breast | MCF10A | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay | |
| E_01313 | chr20:50027744~50030383 | Lung | A549 | lung adenocarcinoma | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_01314 | chr4:145218235~145219235 | Lung | Human bronchial epithelial cells | Enhancer activity assay, TF binding assay, Functional perturbation assay, Chromatin interaction assay | |
| E_01315 | chr17:59785798~59787315 | Skin | A375 | skin melanoma | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_01316 | chr15:54022001~54022500 | Pancreas | MIA PaCa-2 | pancreatic ductal adenocarcinoma | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_01317 | chr7:27200782~27261018 | Bone marrow | THP-6 | acute monocytic leukemia | Enhancer activity assay, TF binding assay, Functional perturbation assay, Chromatin interaction assay |
| E_01318 | chr21:43745000~43747000 | Breast | MCF7 | breast carcinoma | Enhancer activity assay, Functional perturbation assay, TF binding assay, Chromatin interaction assay |
| E_01319 | chr5:1320000~1322000 | Embryonic Kidney | HEK293 | Enhancer activity assay, Functional perturbation assay, TF binding assay, Chromatin interaction assay | |
| E_01320 | chr3:46453226~46459225 | Prostate | LNCaP | prostate cancer | Functional perturbation assay, Enhancer activity assay, Chromatin interaction assay, TF binding assay |
| E_01321 | chr3:46453226~46459225 | Prostate | 22Rv1 | prostate cancer | Functional perturbation assay, Enhancer activity assay, Chromatin interaction assay, TF binding assay |
| E_01322 | chr3:46453226~46459225 | Prostate | Human prostate epithelial cell | Functional perturbation assay, Enhancer activity assay, Chromatin interaction assay, TF binding assay | |
| E_01323 | chr11:69419632~69420080 | Kidney | 786-O | renal cell carcinoma | Enhancer activity assay, Functional perturbation assay |
| E_01324 | chr18:26013138~26015138 | Embryonic Kidney | HEK293T cells | Fusion oncoprotein enhancer hijacking study, Chromatin interaction assay | |
| E_01325 | chr6:135321297~135321697 | Blood | K562 | chronic myeloid leukemia | Enhancer activity assay, Functional perturbation assay |
| E_01326 | chrX:114038200~114039000 | Inner cell mass | H1 hESC | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay | |
| E_01327 | chrX:114038200~114039000 | Inner cell mass | H9 hESC | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay | |
| E_01328 | chr8:118183060~118185060 | Pancreatic islet | EndoC-??H3 | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_01329 | chr8:118183060~118185060 | Pancreatic islet | Human Pancreatic Islets | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_01330 | chr8:118250000~118252000 | Pancreatic islet | EndoC-??H3 | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_01331 | chr8:118250000~118252000 | Pancreatic islet | Human Pancreatic Islets | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_01332 | chr3:169000000~169001000 | Umbilical vein | HUVEC | Enhancer activity assay, Chromatin interaction assay | |
| E_01333 | chr20:48682144~48683144 | Colon | SW480 | colorectal carcinoma | Enhancer activity assay, Functional perturbation assay |
| E_01334 | chr12:121799763~121803094 | Liver | SK-Hep-1 | hepatocellular carcinoma | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01335 | chr12:121799763~121803094 | Liver | HepG2 | hepatocellular carcinoma | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01336 | chr12:121799763~121803094 | Liver | Huh7 | hepatocellular carcinoma | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01337 | chr12:121799763~121803094 | Liver | SNU387 | hepatocellular carcinoma | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01338 | chr12:121803095~121805690 | Liver | SK-Hep-1 | hepatocellular carcinoma | Enhancer activity assay, Functional perturbation assay |
| E_01339 | chr12:121803095~121805690 | Liver | HepG2 | hepatocellular carcinoma | Enhancer activity assay, Functional perturbation assay |
| E_01340 | chr12:121803095~121805690 | Liver | Huh7 | hepatocellular carcinoma | Enhancer activity assay, Functional perturbation assay |
| E_01341 | chr12:121803095~121805690 | Liver | SNU387 | hepatocellular carcinoma | Enhancer activity assay, Functional perturbation assay |
| E_01342 | chr3:186239308~186239606 | Brain | Neural progenitor cells | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay | |
| E_01343 | chr3:186239308~186239606 | Brain | Cortical organoids | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay | |
| E_01344 | chr3:186239308~186239606 | Brain | Neural progenitor cells | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay | |
| E_01345 | chr3:186239308~186239606 | Brain | Cortical organoids | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay | |
| E_01346 | chr10:35949493~35950111 | Brain | Radial glial cells | Enhancer activity assay | |
| E_01347 | chr20:49345311~49346146 | Heart | Cardiomyocytes | Enhancer activity assay | |
| E_01348 | chr10:46073046~46074046 | Prostate | LNCaP cells | prostate cancer | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_01349 | chr10:46073046~46074046 | Prostate | C4-2 cells | prostate cancer | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_01350 | chr10:46073046~46074046 | Prostate | DU145 cells | prostate cancer | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_01351 | chr17:41245000~41246000 | Bone marrow | KASUMI-1 cells | acute myeloid leukemia | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay, TF binding assay |
| E_01352 | chr17:41245000~41246000 | Bone marrow | KG1a cells | acute myeloid leukemia | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay, TF binding assay |
| E_01353 | chr17:41245000~41246000 | Bone marrow | HL-60 cells | acute myeloid leukemia | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay, TF binding assay |
| E_01354 | chr17:41245000~41246000 | Bone marrow | NB4 cells | acute myeloid leukemia | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay, TF binding assay |
| E_01355 | chr17:41268000~41269000 | Bone marrow | KASUMI-1 cells | acute myeloid leukemia | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay, TF binding assay |
| E_01356 | chr17:41268000~41269000 | Bone marrow | KG1a cells | acute myeloid leukemia | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay, TF binding assay |
| E_01357 | chr17:41268000~41269000 | Bone marrow | HL-60 cells | acute myeloid leukemia | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay, TF binding assay |
| E_01358 | chr17:41268000~41269000 | Bone marrow | NB4 cells | acute myeloid leukemia | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay, TF binding assay |
| E_01359 | chr5:74684243~74687892 | Breast | MDA-MB-231 | breast carcinoma | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01360 | chr5:74684243~74687892 | Breast | Breast cancer cell | breast carcinoma | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01361 | chr5:74684243~74687892 | Breast | Breast cancer drug-resistant cell | breast carcinoma | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01362 | chr17:48298123~48299123 | Thyroid | Thyroid carcinoma cell | thyroid carcinoma | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_01363 | chr21:40149729~40317726 | Colon | SW480 | colorectal carcinoma | Enhancer activity assay, Chromatin interaction assay, TF binding assay, Functional perturbation assay |
| E_01364 | chr21:40149729~40317726 | Colon | HCT116 | colorectal carcinoma | Enhancer activity assay, Chromatin interaction assay, TF binding assay, Functional perturbation assay |
| E_01365 | chr21:40149729~40317726 | Colon | Colon epithelial cell | Enhancer activity assay, Chromatin interaction assay, TF binding assay, Functional perturbation assay | |
| E_01366 | chr21:40149729~40317726 | Colon | Colon organoid cells | Enhancer activity assay, Chromatin interaction assay, TF binding assay, Functional perturbation assay | |
| E_01367 | chr6:135220000~135225000 | Stomach | MKN45 | gastric adenocarcinoma | Chromatin interaction assay, Functional perturbation assay, TF binding assay |
| E_01368 | chrX:153492724~153500546 | Thyroid | Thyroid carcinoma cell | thyroid carcinoma | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_01369 | chr15:53455006~53455051 | Pancreas | Progenitor cells | Enhancer activity assay, Functional perturbation assay | |
| E_01370 | chr21:43745000~43747000 | Breast | MCF-7 | breast carcinoma | Enhancer activity assay, Functional perturbation assay, TF binding assay, Chromatin interaction assay |
| E_01371 | chr20:31595392~31597085 | Colon | HCT116 | colorectal carcinoma | Enhancer functional validation, TF binding assay, Chromatin loop analysis, Functional perturbation assay |
| E_01372 | chr20:31595392~31597085 | Colon | LoVo | colorectal carcinoma | Enhancer functional validation, TF binding assay, Chromatin loop analysis, Functional perturbation assay |
| E_01373 | chr16:46972034~46973080 | Bone marrow | Kasumi-1 | acute myeloid leukemia | Enhancer activity assay, Functional perturbation assay |
| E_01374 | chr10:61960755~61962481 | Blood | Nalm6 | B-cell acute lymphoblastic leukemia | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01375 | chr17:47970000~47975000 | Adrenal gland | SK-N-BE(2) | neuroblastoma | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_01376 | chr17:47940000~48020000 | Adrenal gland | SK-N-BE(2) | neuroblastoma | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_01377 | chr9:120869524~120870219 | Brain | Neocortical progenitors | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay | |
| E_01378 | chr2:178806313~178806949 | Heart | Cardiomyocytes | Enhancer activity assay, Functional perturbation assay | |
| E_01379 | chr10:52442551~52444237 | Pancreas | PANC-1 | pancreatic ductal adenocarcinoma | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01380 | chr10:52442551~52444237 | Pancreas | HPAC | pancreatic ductal adenocarcinoma | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01381 | chr10:52442551~52444237 | Pancreas | AsPC-1 | pancreatic ductal adenocarcinoma | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01382 | chr10:52485607~52487433 | Pancreas | PANC-1 | pancreatic ductal adenocarcinoma | Enhancer activity assay, Functional perturbation assay |
| E_01383 | chr10:52485607~52487433 | Pancreas | HPAC | pancreatic ductal adenocarcinoma | Enhancer activity assay, Functional perturbation assay |
| E_01384 | chr7:87574094~87575396 | Bone Marrow | Primary AML blasts | acute myeloid leukemia | Functional perturbation assay, TF binding assay, Enhancer activity assay, Chromatin interaction assay |
| E_01385 | chr13:26191020~26272468 | Liver | Huh7 | hepatocellular carcinoma | Enhancer activity assay, Functional perturbation assay, TF binding assay |
| E_01386 | chr6:396104~396604 | Skin | Human melanoma cell | skin melanoma | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01387 | chr5:54325645~54326045 | Blood | K562 | chronic myeloid leukemia | Enhancer activity assay, Functional perturbation assay |
| E_01388 | chr19:29844909~29845562 | Esophagus | OE19 | esophageal adenocarcinoma | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01389 | chr19:29844909~29845562 | Esophagus | CP-A | esophageal adenocarcinoma | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01390 | chr8:127668529~127669329 | Breast | MCF7 | breast carcinoma | Enhancer activity assay, Functional perturbation assay |
| E_01391 | chr1:116544766~116545360 | Blood | Nalm6 | B-cell acute lymphoblastic leukemia | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01392 | chr1:116544766~116545360 | Blood | 697 | B-cell acute lymphoblastic leukemia | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01393 | chr4:88008000~88010000 | Liver | HepG2 cells | hepatocellular carcinoma | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01394 | chr4:88008000~88010000 | Liver | Huh-7 cells | hepatocellular carcinoma | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01395 | chr4:88008000~88010000 | Liver | H22 cells | hepatocellular carcinoma | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01396 | chr4:88008000~88010000 | Liver | Hepa1-6 cells | hepatocellular carcinoma | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01397 | chr9:5450500~5452500 | Liver | HepG2 cells | hepatocellular carcinoma | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01398 | chr9:5450500~5452500 | Liver | Huh-7 cells | hepatocellular carcinoma | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01399 | chr9:5450500~5452500 | Liver | H22 cells | hepatocellular carcinoma | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01400 | chr9:5450500~5452500 | Liver | Hepa1-6 cells | hepatocellular carcinoma | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01401 | chr2:188184700~188185000 | Artery | Endothelial cells | Enhancer activity assay, Functional perturbation assay | |
| E_01402 | chr3:134200000~134500000 | Artery | Human Coronary Artery Smooth Muscle Cells (HCASMC) | Functional validation, Chromatin interaction | |
| E_01403 | chr14:23379863~23380961 | Heart | Human iPSC-derived cardiomyocytes | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay | |
| E_01404 | chr11:69419632~69420080 | Bone | OS-LM1 | osteosarcoma | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01405 | chr6:32553535~32609681 | Blood | Human Burkitt lymphoma cell | Burkitt lymphoma | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay, TF binding assay |
| E_01406 | chr10:5419501~5420500 | Breast | MCF7 Breast Cancer | breast carcinoma | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay |
| E_01407 | chr1:154150000~154150500 | Heart | hPSC-CMs | Enhancer activity assay, TF binding assay | |
| E_01408 | chr1:154150500~154151000 | Heart | hPSC-CMs | Enhancer activity assay, TF binding assay | |
| E_01409 | chr1:154151000~154151500 | Heart | hPSC-CMs | Enhancer activity assay, TF binding assay | |
| E_01410 | chr9:132901234~132902345 | Blood | K562 | chronic myeloid leukemia | Functional perturbation assay, Enhancer activity assay |
| E_01411 | chr12:10123456~10124567 | Blood | K562 | chronic myeloid leukemia | Functional perturbation assay, Enhancer activity assay |
| E_01412 | chr2:75000000~75020000 | Colon | MC38 | colorectal carcinoma | Chromatin interaction assay, TF binding assay, Functional perturbation assay |
| E_01413 | chr1:58780000~58785000 | Lung | Primary human lung fibroblasts | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_01414 | chr15:54023501~54024000 | Pancreas | MIA PaCa-2 | pancreatic ductal adenocarcinoma | TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_01415 | chr10:52472214~52473981 | Pancreas | PANC-1 | pancreatic ductal adenocarcinoma | Enhancer activity assay |
| E_01416 | chr10:52472214~52473981 | Pancreas | HPAC | pancreatic ductal adenocarcinoma | Enhancer activity assay |
| E_01417 | chr10:52472214~52473981 | Pancreas | AsPC-1 | pancreatic ductal adenocarcinoma | Enhancer activity assay |
| E_01418 | chr10:52488538~52489405 | Pancreas | PANC-1 | pancreatic ductal adenocarcinoma | Enhancer activity assay, Insulator activity assay, TF binding assay, Functional perturbation assay |
| E_01419 | chr10:52488538~52489405 | Pancreas | HPAC | pancreatic ductal adenocarcinoma | Enhancer activity assay, Insulator activity assay, TF binding assay, Functional perturbation assay |
| E_01420 | chr10:52488538~52489405 | Pancreas | AsPC-1 | pancreatic ductal adenocarcinoma | Enhancer activity assay, Insulator activity assay, TF binding assay, Functional perturbation assay |
| E_01421 | chr11:65200000~65240000 | Breast | MDA-MB-231 | breast carcinoma | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01422 | chr11:65200000~65240000 | Breast | BT549 | breast carcinoma | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01423 | chr11:65200000~65240000 | Breast | MDA-MB-468 | breast carcinoma | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01424 | chr11:65200000~65240000 | Breast | HCC1806 | breast carcinoma | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01425 | chr4:8691119~8700974 | Craniofacial Tissue | hCNCC | Enhancer activity assay, Functional perturbation assay | |
| E_01426 | chr16:51624689~51625572 | Embryonic Limb Bud | Limb bud mesenchymal cells | Enhancer activity assay, Functional perturbation assay | |
| E_01427 | chr16:51624689~51625572 | Limb Bud | Zone of polarizing activity cells | Enhancer activity assay, Functional perturbation assay | |
| E_01428 | chr14:75664000~75664749 | Prostate | LNCaP | prostate cancer | Functional perturbation assay |
| E_01429 | chr11:33941648~33942048 | Blood | K562 | chronic myeloid leukemia | Enhancer activity assay, Functional perturbation assay |
| E_01430 | chr11:33944788~33945188 | Blood | K562 | chronic myeloid leukemia | Enhancer activity assay, Functional perturbation assay |
| E_01431 | chr12:54304291~54304691 | Blood | K562 | chronic myeloid leukemia | Enhancer activity assay, Functional perturbation assay |
| E_01432 | chr7:22755717~22757217 | Tumor microenvironment | M2 macrophage | prostate cancer | Enhancer activity assay, Functional perturbation assay |
| E_01433 | chr21:38376000~38377000 | Bone Marrow | Acute Myeloid Leukemia Cells | acute myeloid leukemia | Functional validation, TF binding |
| E_01434 | chr21:38376000~38377000 | Bone Marrow | HNT-34 | acute myeloid leukemia | Functional validation, TF binding |
| E_01435 | chr19:45409200~45410200 | Breast | MCF7 | breast carcinoma | Functional perturbation assay |
| E_01436 | chr6:32543534~32553534 | Lymphoid tissue | Functional perturbation assay, Chromatin interaction assay, Enhancer activity assay | ||
| E_01437 | chr6:32570000~32573500 | Lymphoid tissue | Functional perturbation assay, Chromatin interaction assay, Enhancer activity assay | ||
| E_01438 | chr12:56075734~56076734 | Lung | BEAS-2B cells | lung adenocarcinoma | Enhancer activity assay, TF binding assay, Functional perturbation assay, Chromatin interaction assay |
| E_01439 | chr12:56075734~56076734 | Lung | HASM cells | Enhancer activity assay, TF binding assay, Functional perturbation assay, Chromatin interaction assay | |
| E_01440 | chr12:56545000~56555000 | Blood | Erythroid cells | Enhancer activity assay | |
| E_01441 | chr12:56270000~56280000 | Blood | Erythroid cells | Enhancer activity assay | |
| E_01442 | chr2:239200000~239250000 | Lung | SPC-A1/DTX cells | lung adenocarcinoma | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01443 | chr2:239200000~239250000 | Lung | H1299/DTX cells | non-small cell lung carcinoma | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01444 | chr12:12769300~12769800 | Aorta | HAECs | Enhancer activity assay, Functional perturbation assay | |
| E_01445 | chr9:139390200~139390700 | Aorta | HAECs | Enhancer activity assay, Functional perturbation assay | |
| E_01446 | chr5:129345600~129346600 | Artery | Primary human VSMCs | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_01447 | chr6:135581000~135583000 | Stomach | MKN45 | gastric adenocarcinoma | Enhancer activity assay, Functional perturbation assay, Chromatin interaction assay |
| E_01448 | chr6:32543534~32553534 | Lymphoid tissue | Not available | Functional perturbation assay, Chromatin interaction assay, Enhancer activity assay | |
| E_01449 | chr6:32570000~32573500 | Lymphoid tissue | Not available | Functional perturbation assay, Chromatin interaction assay, Enhancer activity assay | |
| E_01450 | chrX:49250000~49251200 | Peripheral blood | Primary CD4+ Treg cells | Enhancer activity assay, TF binding assay | |
| E_01451 | chr5:1320000~1322000 | Embryonic Kidney | 293T | Enhancer activity assay, Functional perturbation assay, TF binding assay, Chromatin interaction assay | |
| E_01452 | chr16:11075000~11075280 | Lymph node | Namalwa (B-lymphocyte) | Burkitt lymphoma | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01453 | chrX:48641136~48641797 | Blood | K562 | chronic myeloid leukemia | Functional perturbation assay, Enhancer activity assay |
| E_01454 | chrX:48658755~48659455 | Blood | K562 | chronic myeloid leukemia | Functional perturbation assay, Enhancer activity assay |
| E_01455 | chr11:61815000~61817000 | Blood | K562 | chronic myeloid leukemia | Functional perturbation assay, Enhancer activity assay |
| E_01456 | chr11:61820000~61822000 | Blood | K562 | chronic myeloid leukemia | Functional perturbation assay, Enhancer activity assay |
| E_01457 | chr7:108960000~108961000 | Breast | MDA-MB-231 | breast carcinoma | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_01458 | chr11:1985000~2005000 | Liver | Huh-7 | hepatocellular carcinoma | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_01459 | chr12:6933000~6941000 | Pancreas | MIA PaCa-2 | pancreatic ductal adenocarcinoma | Enhancer activity assay, Functional perturbation assay, TF binding assay |
| E_01460 | chr8:128556059~128557653 | Liver | HepG2 | hepatocellular carcinoma | Enhancer activity assay, Functional perturbation assay |
| E_01461 | chr6:36679000~36688000 | Colon | HCT-116 | colorectal carcinoma | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01462 | chr9:22004000~22010000 | Colon | HCT-116 | colorectal carcinoma | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01463 | chr15:89400200~89400500 | Brain | Neural Progenitor Cells (NPCs) | Functional perturbation assay, Enhancer activity assay | |
| E_01464 | chr15:89400200~89400500 | Brain | Neural Progenitor Cells (NPCs) | Functional perturbation assay, Enhancer activity assay | |
| E_01465 | chr8:127750000~127752000 | Breast | MCF7 | breast carcinoma | Enhancer activity assay, Functional perturbation assay, Chromatin interaction assay |
| E_01466 | chr9:37100000~37102000 | Embryonic Kidney | HEK293 | Enhancer activity assay, Functional perturbation assay, Chromatin interaction assay | |
| E_01467 | chr3:136050468~136050668 | Embryonic Kidney | HEK293 | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay | |
| E_01468 | chr1:150509075~150512075 | Blood | UoCB6 | acute myeloid leukemia | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01469 | chr1:150509075~150512075 | Lung | Alveolar type I cells | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_01470 | chr1:150509075~150512075 | Lung | Alveolar type II cells | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_01471 | chr1:150509075~150512075 | Blood | Human AML cell | acute myeloid leukemia | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01472 | chr1:9081898~9084898 | Blood | UoCB6 | acute myeloid leukemia | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01473 | chr1:9081898~9084898 | Lung | Alveolar type I cells | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_01474 | chr1:9081898~9084898 | Lung | Alveolar type II cells | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_01475 | chr1:9081898~9084898 | Blood | Human AML cell | acute myeloid leukemia | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01476 | chr12:94191892~94194892 | Blood | UoCB6 | acute myeloid leukemia | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01477 | chr12:94191892~94194892 | Lung | Alveolar type I cells | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_01478 | chr12:94191892~94194892 | Lung | Alveolar type II cells | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_01479 | chr12:94191892~94194892 | Blood | Human AML cell | acute myeloid leukemia | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01480 | chr12:99975069~99978069 | Blood | UoCB6 | acute myeloid leukemia | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01481 | chr12:99975069~99978069 | Lung | Alveolar type I cells | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_01482 | chr12:99975069~99978069 | Lung | Alveolar type II cells | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_01483 | chr12:99975069~99978069 | Blood | Human AML cell | acute myeloid leukemia | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01484 | chr14:52051517~52054517 | Blood | UoCB6 | acute myeloid leukemia | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01485 | chr14:52051517~52054517 | Lung | Alveolar type I cells | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_01486 | chr14:52051517~52054517 | Lung | Alveolar type II cells | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_01487 | chr14:52051517~52054517 | Blood | Human AML cell | acute myeloid leukemia | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01488 | chr6:136564545~136567545 | Blood | UoCB6 | acute myeloid leukemia | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01489 | chr6:136564545~136567545 | Lung | Alveolar type I cells | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_01490 | chr6:136564545~136567545 | Lung | Alveolar type II cells | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_01491 | chr6:136564545~136567545 | Blood | Human AML cell | acute myeloid leukemia | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01492 | chrX:49260470~49261090 | Blood | CD4+ T cells | Functional perturbation assay, Enhancer activity assay | |
| E_01493 | chrX:49260470~49261090 | Blood | Regulatory T cells | Functional perturbation assay, Enhancer activity assay | |
| E_01494 | chrX:49260470~49261090 | Blood | Conventional T cells | Functional perturbation assay, Enhancer activity assay | |
| E_01495 | chrX:49264210~49265210 | Blood | CD4+ T cells | Functional perturbation assay, Enhancer activity assay | |
| E_01496 | chrX:49264210~49265210 | Blood | Regulatory T cells | Functional perturbation assay, Enhancer activity assay | |
| E_01497 | chrX:49264210~49265210 | Blood | Conventional T cells | Functional perturbation assay, Enhancer activity assay | |
| E_01498 | chrX:49265618~49268300 | Blood | CD4+ T cells | Functional perturbation assay, Enhancer activity assay | |
| E_01499 | chrX:49265618~49268300 | Blood | Regulatory T cells | Functional perturbation assay, Enhancer activity assay | |
| E_01500 | chrX:49265618~49268300 | Blood | Conventional T cells | Functional perturbation assay, Enhancer activity assay | |
| E_01501 | chrX:49268807~49270673 | Blood | CD4+ T cells | Functional perturbation assay, Enhancer activity assay | |
| E_01502 | chrX:49268807~49270673 | Blood | Regulatory T cells | Functional perturbation assay, Enhancer activity assay | |
| E_01503 | chrX:49268807~49270673 | Blood | Conventional T cells | Functional perturbation assay, Enhancer activity assay | |
| E_01504 | chrX:49273000~49274000 | Blood | CD4+ T cells | Functional perturbation assay, Enhancer activity assay | |
| E_01505 | chrX:49273000~49274000 | Blood | Regulatory T cells | Functional perturbation assay, Enhancer activity assay | |
| E_01506 | chrX:49273000~49274000 | Blood | Conventional T cells | Functional perturbation assay, Enhancer activity assay | |
| E_01507 | chrX:49276500~49278500 | Blood | CD4+ T cells | Functional perturbation assay, Enhancer activity assay | |
| E_01508 | chrX:49276500~49278500 | Blood | Regulatory T cells | Functional perturbation assay, Enhancer activity assay | |
| E_01509 | chrX:49276500~49278500 | Blood | Conventional T cells | Functional perturbation assay, Enhancer activity assay | |
| E_01510 | chr1:58751000~58752500 | Pancreas | PANC-1 | pancreatic ductal adenocarcinoma | TF binding assay, Functional perturbation assay |
| E_01511 | chr1:58751000~58752500 | Pancreas | AsPC-1 | pancreatic ductal adenocarcinoma | TF binding assay, Functional perturbation assay |
| E_01512 | chr1:58751000~58752500 | Pancreas | primary PDAC cells | pancreatic ductal adenocarcinoma | TF binding assay, Functional perturbation assay |
| E_01513 | chr10:17275000~17276500 | Pancreas | AsPC-1 | pancreatic ductal adenocarcinoma | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01514 | chr10:17275000~17276500 | Pancreas | primary PDAC cells | pancreatic ductal adenocarcinoma | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01515 | chr7:95608432~95609655 | Skeletal muscle | Human Skeletal Myotubes | Enhancer activity assay, Chromatin interaction assay | |
| E_01516 | chr4:73725619~73726851 | Skeletal muscle | Human Skeletal Myotubes | Enhancer activity assay, Chromatin interaction assay | |
| E_01517 | chr6:45296454~45506241 | Pancreas | PANC-1 | pancreatic ductal adenocarcinoma | Enhancer activity assay, Functional perturbation assay, TF binding assay |
| E_01518 | chr6:45296454~45506241 | Pancreas | Pancreatic adenocarcinoma cell | pancreatic ductal adenocarcinoma | Enhancer activity assay, Functional perturbation assay, TF binding assay |
| E_01519 | chr9:21016991~21017491 | Blood | Primary monocyte-derived macrophages | Enhancer activity assay, TF binding assay | |
| E_01520 | chr7:128740000~128741500 | Breast | MCF7 cells | breast carcinoma | Enhancer activity assay |
| E_01521 | chr21:36759535~36828803 | Bone marrow | Adipose-Derived Mesenchymal Stem Cells-01 | Functional perturbation assay, Chromatin interaction assay | |
| E_01522 | chr18:70411815~70460159 | Bone marrow | Kasumi-1 | acute myeloid leukemia | Chromatin interaction assay, Functional perturbation assay |
| E_01523 | chr17:47950000~47955000 | Adrenal gland | SK-N-BE(2) | neuroblastoma | Enhancer activity assay, TF binding assay, Chromatin interaction assay |
| E_01524 | chr17:47985000~47990000 | Adrenal gland | SK-N-BE(2) | neuroblastoma | Enhancer activity assay, TF binding assay, Chromatin interaction assay |
| E_01525 | chr6:43210000~43211000 | Brain | iPSC-derived excitatory neurons | Functional perturbation assay, Enhancer activity assay | |
| E_01526 | chr3:108045000~108135000 | Lung | Primary human lung fibroblasts | TF binding assay, Functional perturbation assay | |
| E_01527 | chr1:158000000~158500000 | Blood | Jurkat | T-cell acute lymphoblastic leukemia | Enhancer activity assay, Chromatin interaction assay, TF binding assay, Functional perturbation assay |
| E_01528 | chr14:37278706~37279509 | Prostate | LNCaP | prostate cancer | Functional perturbation assay, Chromatin interaction assay |
| E_01529 | chr14:37246515~37246652 | Prostate | LNCaP | prostate cancer | Functional perturbation assay, Chromatin interaction assay |
| E_01530 | chr9:36980000~37150820 | Lymph node | SUDHL10 | diffuse large B-cell lymphoma | Chromatin interaction assay, Functional perturbation assay |
| E_01531 | chr10:3773382~3787964 | Thyroid | TPC1 | thyroid carcinoma | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay |
| E_01532 | chr10:3773382~3787964 | Thyroid | MDA-T41 | thyroid carcinoma | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay |
| E_01533 | chr10:52443227~52444237 | Pancreas | PANC-1 | pancreatic ductal adenocarcinoma | Enhancer activity assay, TF binding assay |
| E_01534 | chr10:52443227~52444237 | Pancreas | HPAC | pancreatic ductal adenocarcinoma | Enhancer activity assay, TF binding assay |
| E_01535 | chr10:52443227~52444237 | Pancreas | AsPC-1 | pancreatic ductal adenocarcinoma | Enhancer activity assay, TF binding assay |
| E_01536 | chr7:54978916~55304142 | Breast | BT549 (TNBC) | breast carcinoma | Chromatin interaction assay, Functional perturbation assay |
| E_01537 | chr6:45407433~45444666 | Thyroid | TPC1 | thyroid carcinoma | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay |
| E_01538 | chr6:45407433~45444666 | Thyroid | MDA-T41 | thyroid carcinoma | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay |
| E_01539 | chr1:158000000~158500000 | Blood | Jurkat | T-cell acute lymphoblastic leukemia | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_01540 | chr1:158000000~158500000 | Lymphoid tissue | CUTLL1 | T-cell acute lymphoblastic leukemia | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_01541 | chr1:158000000~158500000 | Blood | Primary T-ALL patient | T-cell acute lymphoblastic leukemia | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_01542 | chr1:158000000~158500000 | Blood | Normal CD4+ T | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay | |
| E_01543 | chr2:15000000~16800000 | Pons | DIPG cell line | diffuse intrinsic pontine glioma | Chromatin interaction assay, Enhancer activity assay |
| E_01544 | chr21:38989433~38991200 | Embryonic Limb Bud | Limb bud mesenchymal cells | Enhancer activity assay, Functional perturbation assay | |
| E_01545 | chr21:38989433~38991200 | Limb Bud | Zone of polarizing activity cells | Enhancer activity assay, Functional perturbation assay | |
| E_01546 | chr7:55016139~55018139 | Cervix | CaSki cell | cervical cancer | Enhancer functional perturbation, Chromatin interaction assay |
| E_01547 | chr13:73607397~74169928 | Breast | HCC1806 | breast carcinoma | Functional perturbation assay, Enhancer activity assay, TF binding assay |
| E_01548 | chr13:73607397~74169928 | Breast | HCC1937 | breast carcinoma | Functional perturbation assay, Enhancer activity assay, TF binding assay |
| E_01549 | chr2:79272263~79272447 | Colon | LIM1215 | colorectal carcinoma | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01550 | chr2:79272263~79272447 | Colon | HT-29 | colorectal carcinoma | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01551 | chr2:79272263~79272447 | Colon | SW480 | colorectal carcinoma | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01552 | chr2:79272263~79272447 | Colon | COLO 205 | colorectal carcinoma | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01553 | chr2:79272263~79272447 | Colon | FHC | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_01554 | chr20:43657287~43657942 | Esophagus | OE19 | esophageal adenocarcinoma | Enhancer activity assay, Functional perturbation assay |
| E_01555 | chr20:43657287~43657942 | Esophagus | CP-A | esophageal adenocarcinoma | Enhancer activity assay, Functional perturbation assay |
| E_01556 | chr12:122502280~122506427 | Bone | PC3 | prostate cancer | Enhancer activity assay, Chromatin interaction assay, TF binding assay |
| E_01557 | chr12:122502280~122506427 | Bone | C4-2B | prostate cancer | Enhancer activity assay, Chromatin interaction assay, TF binding assay |
| E_01558 | chr12:122502280~122506427 | Bone | P-90 | prostate cancer | Enhancer activity assay, Chromatin interaction assay, TF binding assay |
| E_01559 | chr13:150570000~150600000 | Adrenal gland | SK-N-BE(2) cells | neuroblastoma | Functional perturbation assay |
| E_01560 | chr3:70900000~70903000 | Umbilical vein | HUVECs | Enhancer activity assay, Functional perturbation assay | |
| E_01561 | chr3:70904000~70907000 | Umbilical vein | HUVECs | Enhancer activity assay, Functional perturbation assay | |
| E_01562 | chr3:70908000~70911000 | Umbilical vein | HUVECs | Enhancer activity assay, Functional perturbation assay | |
| E_01563 | chr20:49345710~49345732 | Heart | AC16 cardiomyocytes | Enhancer activity assay | |
| E_01564 | chr20:21548504~21587972 | Bone | A673 cells | Ewing sarcoma | Enhancer activity assay, Functional perturbation assay |
| E_01565 | chr11:10200000~10205000 | Breast | MCF-7 cells | breast carcinoma | Super-enhancer activity assay, Functional perturbation assay |
| E_01566 | chr2:113127450~113127690 | Blood | BLaER cells | Enhancer activity assay, Functional perturbation assay | |
| E_01567 | chr1:213425381~213425881 | Lung | BEAS-2B cells | Enhancer activity assay, Functional perturbation assay | |
| E_01568 | chr5:58919038~58919746 | Brain | U251 glioma cells | glioblastoma | Enhancer activity assay, Functional perturbation assay |
| E_01569 | chr5:58919038~58919746 | Embryonic Kidney | HEK293T cells | Enhancer activity assay, Functional perturbation assay | |
| E_01570 | chr3:15768491~15768703 | Blood | Multiple myeloma cells | multiple myeloma | Enhancer activity assay |
| E_01571 | chr3:15768491~15768703 | Blood | Multiple myeloma cells | multiple myeloma | Enhancer activity assay |
| E_01572 | chr3:15768491~15768703 | Blood | Multiple myeloma cells | multiple myeloma | Enhancer activity assay |
| E_01573 | chr3:15768491~15768703 | Blood | Multiple myeloma cells | multiple myeloma | Enhancer activity assay |
| E_01574 | chr17:40250000~40251000 | Esophagus | MNNG-M cells | esophageal squamous cell carcinoma | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01575 | chr17:40250000~40251000 | Esophagus | Het-1A cells | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_01576 | chr17:40250000~40251000 | Esophagus | KYSE-150 cells | esophageal squamous cell carcinoma | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01577 | chr17:40252000~40253000 | Esophagus | MNNG-M cells | esophageal squamous cell carcinoma | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01578 | chr17:40252000~40253000 | Esophagus | Het-1A cells | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_01579 | chr17:40252000~40253000 | Esophagus | KYSE-150 cells | esophageal squamous cell carcinoma | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01580 | chr11:76586431~76600121 | Colon | Primary Treg cells | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay | |
| E_01581 | chr16:51623658~51623898 | Embryonic Limb Bud | Limb bud mesenchymal cells | TF binding assay, Enhancer activity assay, Functional perturbation assay | |
| E_01582 | chr16:51623658~51623898 | Limb Bud | Zone of polarizing activity cells | TF binding assay, Enhancer activity assay, Functional perturbation assay | |
| E_01583 | chr16:51623899~51624805 | Embryonic Limb Bud | Limb bud mesenchymal cells | Enhancer activity assay, Functional perturbation assay | |
| E_01584 | chr16:51623899~51624805 | Limb Bud | Zone of polarizing activity cells | Enhancer activity assay, Functional perturbation assay | |
| E_01585 | chr6:31350000~31355000 | Lung | Human Pulmonary Artery Endothelial Cells | Functional perturbation assay, TF binding assay | |
| E_01586 | chr4:111397892~111402926 | Embryonic Kidney | HEK293 | Enhancer activity assay, Functional perturbation assay, TF binding assay | |
| E_01587 | chr4:111397892~111402926 | Sclera | Human embryonic scleral cells | Enhancer activity assay, Functional perturbation assay, TF binding assay | |
| E_01588 | chr15:78750919~78751419 | Artery | Human Coronary Artery Smooth Muscle Cells (HCASMC) | TF binding, Chromatin interaction | |
| E_01589 | chr21:32900000~33260000 | Pons | Human diffuse intrinsic pontine glioma cell | diffuse intrinsic pontine glioma | Chromatin interaction assay, Enhancer activity assay, Functional perturbation assay |
| E_01590 | chrX:66800000~67800000 | Prostate | Human prostate carcinoma cell | prostate cancer | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_01591 | chr2:60722150~60722350 | Bone Marrow | CD34+ hematopoietic stem/progenitor cells | Enhancer activity assay, Functional perturbation assay, TF binding assay | |
| E_01592 | chr1:97306000~97307500 | Brain | iPSC-derived excitatory neurons | Enhancer activity assay, TF binding assay | |
| E_01593 | chr5:1230131~1231631 | Brain | iPSC-derived excitatory neurons | Enhancer activity assay, TF binding assay | |
| E_01594 | chr6:156951500~156952500 | Brain | iPSC-derived excitatory neurons | Enhancer activity assay, TF binding assay | |
| E_01595 | chr7:5409000~5410500 | Brain | iPSC-derived excitatory neurons | Enhancer activity assay, TF binding assay | |
| E_01596 | chr9:75995000~75996500 | Brain | iPSC-derived excitatory neurons | Enhancer activity assay, TF binding assay | |
| E_01597 | chr4:76816143~76816143 | Blood | Primary CD14+ monocytes | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay | |
| E_01598 | chr14:24527672~24527672 | Blood | Primary CD14+ monocytes | Chromatin interaction assay, TF binding assay | |
| E_01599 | chr15:39598843~39598843 | Blood | Primary CD14+ monocytes | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay | |
| E_01600 | chr15:39607442~39607442 | Blood | Primary CD14+ monocytes | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay | |
| E_01601 | chr8:127330655~127330840 | Brain | D458 | medulloblastoma | Enhancer activity assay, Functional perturbation assay, Chromatin interaction assay |
| E_01602 | chr8:127330840~127330927 | Brain | D458 | medulloblastoma | Enhancer activity assay, Functional perturbation assay, Chromatin interaction assay |
| E_01603 | chr8:127330927~127331000 | Brain | D458 | medulloblastoma | Enhancer activity assay, Functional perturbation assay, Chromatin interaction assay |
| E_01604 | chr7:54960823~54970827 | Nasopharynx | S18 | nasopharyngeal carcinoma | Enhancer activity assay, Functional perturbation assay |
| E_01605 | chr2:44294900~44295100 | Adrenal gland | KELLY | neuroblastoma | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01606 | chr4:13816600~13816900 | Adrenal gland | KELLY | neuroblastoma | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01607 | chr22:24114000~24116000 | Prostate | SM1 (mCRPC cell line) | prostate cancer | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01608 | chr8:128556457~128556814 | Liver | Huh7 | hepatocellular carcinoma | Functional perturbation assay |
| E_01609 | chr17:64082103~64082506 | Ovary | OVCAR5 | ovarian carcinoma | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01610 | chr22:30195717~30197444 | Lung | A-549 | lung adenocarcinoma | Enhancer activity assay, TF binding assay |
| E_01611 | chr15:89000000~89002500 | Blood | Primary monocytes | Enhancer activity assay, Chromatin interaction assay | |
| E_01612 | chr10:52443566~52444237 | Pancreas | PANC-1 | pancreatic ductal adenocarcinoma | Enhancer activity assay |
| E_01613 | chr10:52443566~52444237 | Pancreas | HPAC | pancreatic ductal adenocarcinoma | Enhancer activity assay |
| E_01614 | chr10:52443566~52444237 | Pancreas | AsPC-1 | pancreatic ductal adenocarcinoma | Enhancer activity assay |
| E_01615 | chr1:13820000~13840000 | Breast | BT549 (TNBC) | breast carcinoma | TF binding assay, Gene expression correlation |
| E_01616 | chr5:171390000~171400000 | Breast | MDA-MB-231 | breast carcinoma | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01617 | chr1:58765000~58766500 | Pancreas | PANC-1 | pancreatic ductal adenocarcinoma | TF binding assay, Functional perturbation assay |
| E_01618 | chr1:58765000~58766500 | Pancreas | AsPC-1 | pancreatic ductal adenocarcinoma | TF binding assay, Functional perturbation assay |
| E_01619 | chr1:58765000~58766500 | Pancreas | primary PDAC cells | pancreatic ductal adenocarcinoma | TF binding assay, Functional perturbation assay |
| E_01620 | chr1:58770000~58771500 | Pancreas | PANC-1 | pancreatic ductal adenocarcinoma | TF binding assay, Functional perturbation assay |
| E_01621 | chr1:58770000~58771500 | Pancreas | AsPC-1 | pancreatic ductal adenocarcinoma | TF binding assay, Functional perturbation assay |
| E_01622 | chr1:58770000~58771500 | Pancreas | primary PDAC cells | pancreatic ductal adenocarcinoma | TF binding assay, Functional perturbation assay |
| E_01623 | chr17:31254200~31255700 | Pancreas | PANC-1 | pancreatic ductal adenocarcinoma | TF binding assay, Functional perturbation assay |
| E_01624 | chr17:31254200~31255700 | Pancreas | AsPC-1 | pancreatic ductal adenocarcinoma | TF binding assay, Functional perturbation assay |
| E_01625 | chr17:31254200~31255700 | Pancreas | primary PDAC cells | pancreatic ductal adenocarcinoma | TF binding assay, Functional perturbation assay |
| E_01626 | chr17:31255800~31256300 | Pancreas | PANC-1 | pancreatic ductal adenocarcinoma | TF binding assay, Functional perturbation assay |
| E_01627 | chr17:31255800~31256300 | Pancreas | AsPC-1 | pancreatic ductal adenocarcinoma | TF binding assay, Functional perturbation assay |
| E_01628 | chr17:31255800~31256300 | Pancreas | primary PDAC cells | pancreatic ductal adenocarcinoma | TF binding assay, Functional perturbation assay |
| E_01629 | chr2:28389994~28391994 | Cervix | Cervical-derived cell line 20861 | cervical cancer | Enhancer functional characterization, Chromatin interaction assay |
| E_01630 | chr16:86507790~86509790 | Gastrointestinal tract | Gastrointestinal stromal tumor cells | gastrointestinal stromal tumor | Super-enhancer regulatory network analysis, Chromatin interaction assay |
| E_01631 | chr12:57092763~57094763 | Blood | Monocyte-derived macrophages | Enhancer cistrome analysis, Chromatin interaction assay | |
| E_01632 | chr5:1294000~1297400 | Liver | HCC cells | hepatocellular carcinoma | Enhancer activity assay, TF binding assay |
| E_01633 | chr11:102245603~102246344 | Nasopharynx | 5-8F | nasopharyngeal carcinoma | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01634 | chr11:102245603~102246344 | Nasopharynx | HNE1 | nasopharyngeal carcinoma | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01635 | chr2:16000000~16002000 | Lung | H446 cells | small cell lung carcinoma | Super-enhancer activity assay |
| E_01636 | chr8:127247000~127248000 | Pancreas | MIAPaCa-2 cells | pancreatic ductal adenocarcinoma | Enhancer activity assay, Functional perturbation assay |
| E_01637 | chr8:127247000~127248000 | Pancreas | AsPC-1 cells | pancreatic ductal adenocarcinoma | Enhancer activity assay, Functional perturbation assay |
| E_01638 | chr1:100690100~100690600 | Aorta | HAECs | Enhancer activity assay | |
| E_01639 | chr3:128191800~128192300 | Bone Marrow | Hematopoietic stem/progenitor cells | Enhancer activity assay, Functional perturbation assay | |
| E_01640 | chr11:5225000~5226000 | Embryonic Kidney | HEK293 | Functional perturbation assay | |
| E_01641 | chr11:5225000~5226000 | Cervix | HeLa | cervical cancer | Functional perturbation assay |
| E_01642 | chr11:5225000~5226000 | Blood | K562 | chronic myeloid leukemia | Functional perturbation assay |
| E_01643 | chr11:5225000~5226000 | Bone | SaOS-2 | osteosarcoma | Functional perturbation assay |
| E_01644 | chrX:49238000~49239000 | Blood | Primary CD4+ Treg cells | Enhancer activity assay, TF binding assay | |
| E_01645 | chr2:11000000~11002000 | Pancreas | CFPAC1 | pancreatic ductal adenocarcinoma | Enhancer activity assay |
| E_01646 | chr12:51000000~51001000 | Skeletal muscle | Myoblast cells | Enhancer activity assay | |
| E_01647 | chr1:204379236~204380236 | Bone Marrow | NCI-H929 cells | multiple myeloma | Super enhancer activity assay, Functional perturbation assay |
| E_01648 | chr8:128740000~128750000 | Blood | K562 | chronic myeloid leukemia | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_01649 | chr9:37100000~37102000 | Embryonic Kidney | 293T | Enhancer activity assay, Functional perturbation assay, Chromatin interaction assay | |
| E_01650 | chr8:127750000~127752000 | Breast | MCF-7 | breast carcinoma | Enhancer activity assay, Functional perturbation assay, Chromatin interaction assay |
| E_01651 | chr15:56000000~58000000 | Pons | Human diffuse intrinsic pontine glioma cell | diffuse intrinsic pontine glioma | Chromatin interaction assay, Enhancer activity assay, Copy number variation analysis |
| E_01652 | chr18:59350000~59950000 | Pons | Human glioblastoma cell | glioblastoma | Chromatin interaction assay, Enhancer activity assay |
| E_01653 | chr6:146700000~146701000 | Breast | Human breast adenocarcinoma cell | breast carcinoma | Enhancer activity assay |
| E_01654 | chr6:146775000~146776000 | Breast | Human breast adenocarcinoma cell | breast carcinoma | Enhancer activity assay |
| E_01655 | chr20:31599000~31602000 | Colon | HCT116 | colorectal carcinoma | Putative enhancer screening |
| E_01656 | chr20:31599000~31602000 | Colon | LoVo | colorectal carcinoma | Putative enhancer screening |
| E_01657 | chr8:126800000~126900000 | Kidney | MRT patient-derived organoids (P103) | malignant rhabdoid tumor | Chromatin interaction assay, Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01658 | chr8:128840000~128890000 | Kidney | MRT patient-derived organoids (P103) | malignant rhabdoid tumor | Chromatin interaction assay, Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01659 | chr8:129440000~129740000 | Kidney | MRT patient-derived organoids (P60) | malignant rhabdoid tumor | Chromatin interaction assay, Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01660 | chr12:102818723~103538731 | Prostate | LuCaP93 PDX | prostate cancer | Chromatin interaction assay, Functional perturbation assay |
| E_01661 | chr20:54119731~54198946 | Breast | MCF7 (ER+) | breast carcinoma | TF binding assay, Functional perturbation assay |
| E_01662 | chr1:39000000~39645000 | Nasopharynx | CNE-2 | nasopharyngeal carcinoma | Enhancer activity assay, Functional perturbation assay |
| E_01663 | chr1:207851706~207940358 | Liver | Huh7 | hepatocellular carcinoma | Enhancer activity assay, Functional perturbation assay |
| E_01664 | chr17:50132536~50229638 | Liver | Huh7 | hepatocellular carcinoma | Enhancer activity assay, Functional perturbation assay |
| E_01665 | chr4:121743874~121852009 | Liver | Huh7 | hepatocellular carcinoma | Enhancer activity assay, Functional perturbation assay |
| E_01666 | chr5:1230131~1337133 | Liver | Huh7 | hepatocellular carcinoma | Enhancer activity assay, Functional perturbation assay |
| E_01667 | chr8:10368745~10368945 | Embryonic Kidney | HEK293 | Enhancer activity assay, Chromatin interaction assay | |
| E_01668 | chr6:162856700~162856970 | Brain | iPSC-derived excitatory neurons | Enhancer activity assay, TF binding assay | |
| E_01669 | chr7:100772345~100778921 | Endometrium | 12Z human endometriosis epithelial cells | endometriosis | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01670 | chr1:152019738~152021345 | Liver | Huh7 cells | hepatocellular carcinoma | Enhancer activity assay |
| E_01671 | chr2:233764355~233764676 | Liver | Primary hepatocytes | Enhancer activity assay | |
| E_01672 | chrX:49245000~49246500 | Blood | Primary CD4+ Treg cells | Enhancer activity assay, TF binding assay | |
| E_01673 | chr13:110388102~110388602 | Artery | Human Coronary Artery Smooth Muscle Cells (HCASMC) | TF binding, Genetic association | |
| E_01674 | chr3:171555500~171556000 | Artery | HCASMC | Chromatin interaction assay, Functional perturbation assay | |
| E_01675 | chr13:80276300~80276570 | Brain | iPSC-derived excitatory neurons | Enhancer activity assay, TF binding assay | |
| E_01676 | chr5:88396400~88396670 | Brain | iPSC-derived excitatory neurons | Enhancer activity assay, TF binding assay | |
| E_01677 | chr1:52662800~52663070 | Brain | iPSC-derived excitatory neurons | Enhancer activity assay, TF binding assay | |
| E_01678 | chr6:97306500~97306770 | Brain | iPSC-derived excitatory neurons | Enhancer activity assay, TF binding assay | |
| E_01679 | chr16:86219312~86219780 | Lung | IMR-90 | Enhancer activity assay, TF binding assay | |
| E_01680 | chr1:28883749~28884318 | Bone Marrow | K562 | chronic myeloid leukemia | Functional perturbation assay |
| E_01681 | chr5:151674321~151709808 | Thyroid | TPC1 | thyroid carcinoma | Enhancer activity assay, TF binding assay, Chromatin interaction assay |
| E_01682 | chr5:151674321~151709808 | Thyroid | MDA-T41 | thyroid carcinoma | Enhancer activity assay, TF binding assay, Chromatin interaction assay |
| E_01683 | chr1:218337520~218379240 | Thyroid | TPC1 | thyroid carcinoma | Enhancer activity assay, TF binding assay, Chromatin interaction assay |
| E_01684 | chr1:218337520~218379240 | Thyroid | MDA-T41 | thyroid carcinoma | Enhancer activity assay, TF binding assay, Chromatin interaction assay |
| E_01685 | chr8:48579000~48587000 | Embryonic craniofacial tissue | Multiple craniofacial cell types | Enhancer activity assay | |
| E_01686 | chr16:54926631~54929466 | Blood | T-ALL cells | T-cell acute lymphoblastic leukemia | Chromatin conformation capture, Histone modification ChIP-sequencing |
| E_01687 | chr16:86741301~86741644 | Blood vessel | Vascular smooth muscle cells | Enhancer activity assay | |
| E_01688 | chr2:46315253~46315668 | Blood vessel | Endothelial cells | Enhancer activity assay | |
| E_01689 | chr2:46315303~46315474 | Blood vessel | Endothelial cells | Enhancer activity assay | |
| E_01690 | chr2:46315425~46315596 | Blood vessel | Endothelial cells | Enhancer activity assay | |
| E_01691 | chr2:46315547~46315719 | Blood vessel | Endothelial cells | Enhancer activity assay | |
| E_01692 | chr19:11090422~11091028 | Liver | HuH7 cells | hepatocellular carcinoma | Functional perturbation assay |
| E_01693 | chrX:49247000~49247500 | Blood | CD4+ T cells | Enhancer activity assay, Functional perturbation assay | |
| E_01694 | chr8:128041672~128043891 | Bone Marrow | CD34+ cells | Functional perturbation assay | |
| E_01695 | chr11:17710000~17711000 | Embryonic Kidney | HEK293 | Functional perturbation assay | |
| E_01696 | chr11:17710000~17711000 | Cervix | HeLa | cervical cancer | Functional perturbation assay |
| E_01697 | chr11:17710000~17711000 | Blood | K562 | chronic myeloid leukemia | Functional perturbation assay |
| E_01698 | chr12:121567800~121568100 | Brain | Pvalb GABAergic neurons | Enhancer activity assay | |
| E_01699 | chr6:31130000~31131000 | Embryonic Kidney | HEK293 | Functional perturbation assay | |
| E_01700 | chr6:31130000~31131000 | Cervix | HeLa | cervical cancer | Functional perturbation assay |
| E_01701 | chr6:31130000~31131000 | Blood | K562 | chronic myeloid leukemia | Functional perturbation assay |
| E_01702 | chr6:31356000~31361000 | Lung | Human Pulmonary Artery Endothelial Cells | TF binding assay, Enhancer activity assay | |
| E_01703 | chr1:7995001~8260000 | Colon | Human colorectal carcinoma cell | colorectal carcinoma | Chromatin interaction assay, Functional perturbation assay |
| E_01704 | chr12:65260000~66115000 | Colon | Human colorectal carcinoma cell | colorectal carcinoma | Chromatin interaction assay, Functional perturbation assay |
| E_01705 | chr17:40880001~41560000 | Colon | Human colorectal carcinoma cell | colorectal carcinoma | Chromatin interaction assay, Functional perturbation assay |
| E_01706 | chr2:181380000~182280000 | Colon | Human colorectal carcinoma cell | colorectal carcinoma | Chromatin interaction assay, Functional perturbation assay |
| E_01707 | chr2:60722750~60722850 | Bone Marrow | CD34+ hematopoietic stem/progenitor cells | Functional perturbation assay, Enhancer activity assay | |
| E_01708 | chr8:126650000~129950000 | Colon | Human colorectal carcinoma cell | colorectal carcinoma | Chromatin interaction assay, Functional perturbation assay |
| E_01709 | chr9:21096000~22491000 | Colon | Human colorectal carcinoma cell | colorectal carcinoma | Chromatin interaction assay, Functional perturbation assay |
| E_01710 | chr1:97306120~97306390 | Brain | iPSC-derived excitatory neurons | Enhancer activity assay, TF binding assay | |
| E_01711 | chr5:1230260~1230530 | Brain | iPSC-derived excitatory neurons | Enhancer activity assay, TF binding assay | |
| E_01712 | chr6:156951620~156951890 | Brain | iPSC-derived excitatory neurons | Enhancer activity assay, TF binding assay | |
| E_01713 | chr7:5409150~5409420 | Brain | iPSC-derived excitatory neurons | Enhancer activity assay, TF binding assay | |
| E_01714 | chr9:75995180~75995450 | Brain | iPSC-derived excitatory neurons | Enhancer activity assay, TF binding assay | |
| E_01715 | chr4:76817412~76817412 | Blood | Primary CD14+ monocytes | Enhancer activity assay, Chromatin interaction assay | |
| E_01716 | chr7:1210755~1210755 | Blood | Primary CD14+ monocytes | Enhancer activity assay, Chromatin interaction assay | |
| E_01717 | chr7:1210898~1210898 | Blood | Primary CD14+ monocytes | Enhancer activity assay, Chromatin interaction assay | |
| E_01718 | chr7:1211978~1211978 | Blood | Primary CD14+ monocytes | Enhancer activity assay, Chromatin interaction assay | |
| E_01719 | chr7:1212211~1212211 | Blood | Primary CD14+ monocytes | Enhancer activity assay, Chromatin interaction assay | |
| E_01720 | chr7:26135404~26135404 | Blood | Primary CD14+ monocytes | Enhancer activity assay, Chromatin interaction assay | |
| E_01721 | chr10:129882640~129882640 | Blood | Primary CD14+ monocytes | Enhancer activity assay, Chromatin interaction assay | |
| E_01722 | chr10:30092300~30092300 | Blood | Primary CD14+ monocytes | Enhancer activity assay, Chromatin interaction assay | |
| E_01723 | chr14:90560777~90560777 | Blood | Primary CD14+ monocytes | Enhancer activity assay, Chromatin interaction assay | |
| E_01724 | chr15:39602380~39602380 | Blood | Primary CD14+ monocytes | Enhancer activity assay, Chromatin interaction assay | |
| E_01725 | chr15:39606026~39606026 | Blood | Primary CD14+ monocytes | Enhancer activity assay, Chromatin interaction assay | |
| E_01726 | chr15:39606089~39606089 | Blood | Primary CD14+ monocytes | Enhancer activity assay, Chromatin interaction assay | |
| E_01727 | chr15:39607630~39607630 | Blood | Primary CD14+ monocytes | Enhancer activity assay, Chromatin interaction assay | |
| E_01728 | chr15:39607665~39607665 | Blood | Primary CD14+ monocytes | Enhancer activity assay, Chromatin interaction assay | |
| E_01729 | chr19:54551115~54551115 | Blood | Primary CD14+ monocytes | Enhancer activity assay, Chromatin interaction assay | |
| E_01730 | chr7:117504671~117505671 | Embryonic Kidney | HEK293T | Functional perturbation assay | |
| E_01731 | chr7:117504671~117505671 | Lung | UNCCF3T (??F508/??F508 HBE) | Functional perturbation assay | |
| E_01732 | chr7:117523000~117524000 | Colon | HT29 | colorectal carcinoma | Functional perturbation assay |
| E_01733 | chr5:172650000~172651200 | Blood | Monocyte-derived macrophage (hMDM) | TF binding assay, Enhancer activity assay | |
| E_01734 | chr9:5451500~5451650 | Lung | NSCLC cell lines | non-small cell lung carcinoma | Enhancer activity assay, TF binding assay |
| E_01735 | chr7:27089386~27207428 | Prostate | LuNE | prostate cancer | Enhancer activity assay, Functional perturbation assay |
| E_01736 | chr3:157437977~157438893 | Skin | Met4 cSCC cells | cutaneous squamous cell carcinoma | Chromatin interaction assay, Functional perturbation assay |
| E_01737 | chr8:48581000~48583000 | Embryonic craniofacial tissue | Human embryonic craniofacial cells | Enhancer activity assay | |
| E_01738 | chr8:98367000~98369000 | Embryonic craniofacial tissue | Human embryonic craniofacial cells | Enhancer activity assay | |
| E_01739 | chr8:98367000~98370806 | Embryonic craniofacial tissue | Maxillary and nasal process cells | Enhancer activity assay | |
| E_01740 | chr16:86194740~86195815 | Lung | IMR90 (fetal lung fibroblasts) | Functional perturbation assay, TF binding assay | |
| E_01741 | chr7:156816030~156828070 | Blood | Lymphoblastoid | -- | |
| E_01742 | chr7:156785000~156786000 | Blood | Patient lymphoblastoid | Chromatin interaction assay, TF binding assay | |
| E_01743 | chr16:51623658~51623900 | Embryonic Limb Bud | Limb bud mesenchymal cells | Enhancer activity assay, Functional perturbation assay | |
| E_01744 | chr4:155713878~155714284 | Blood vessel | Endothelial cells | Reporter assay, TF binding, Functional validation | |
| E_01745 | chr17:61449600~61451600 | Lung | Lung fibroblasts | Super-enhancer functional study, Chromatin interaction assay | |
| E_01746 | chr16:67559907~67561907 | Blood | K562 cells | chronic myeloid leukemia | Enhancer chain 3D regulation study, Chromatin interaction assay |
| E_01747 | chr11:2126750~2128050 | Brain | Primary cortical neurons (NeuN+) | Chromatin interaction assay | |
| E_01748 | chr2:226125612~226127012 | Adipose tissue | Human Preadipocyte | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay | |
| E_01749 | chr10:128906630~128909942 | Brain | Primary tumor tissue | glioblastoma | Enhancer activity assay, Functional perturbation assay |
| E_01750 | chr19:11090550~11090678 | Liver | HuH7 cells | hepatocellular carcinoma | Enhancer activity assay |
| E_01751 | chr1:234567000~234577000 | Liver | Macrophages | Enhancer activity assay | |
| E_01752 | chr2:233768020~233768954 | Liver | HepaRG cells | hepatocellular carcinoma | Enhancer activity assay |
| E_01753 | chr11:76772927~76773266 | Liver | Hepatocytes | Super-enhancer activity assay | |
| E_01754 | chrY:2792658~2792907 | Testis | hiPSC-derived Sertoli-like cells | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_01755 | chrY:2792658~2792907 | Embryonic Kidney | HEK293 | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_01756 | chrX:49255000~49256300 | Blood | Primary CD4+ Treg cells | TF binding assay, Enhancer activity assay | |
| E_01757 | chr1:59169569~59170069 | Artery | Human Coronary Artery Smooth Muscle Cells (HCASMC) | TF binding, Genetic association | |
| E_01758 | chr2:6072150~6072450 | Bone Marrow | CD34+ hematopoietic stem/progenitor cells | Functional perturbation assay, Enhancer activity assay | |
| E_01759 | chr16:86194740~86195815 | Lung | IMR-90 | Functional perturbation assay, TF binding assay | |
| E_01760 | chr19:40464709~40464990 | Blood | K-562 | chronic myeloid leukemia | Enhancer identification, Transcriptional regulation assay |
| E_01761 | chr1:244970941~244971645 | Blood | K-562 | chronic myeloid leukemia | Enhancer identification, Transcriptional regulation assay |
| E_01762 | chr21:46325282~46325509 | Blood | K-562 | chronic myeloid leukemia | Enhancer identification, Transcriptional regulation assay |
| E_01763 | chr19:48872999~48873182 | Blood | K-562 | chronic myeloid leukemia | Enhancer identification, Transcriptional regulation assay |
| E_01764 | chr19:46786236~46786920 | Blood | K-562 | chronic myeloid leukemia | Enhancer identification, Transcriptional regulation assay |
| E_01765 | chr1:42958018~42958389 | Blood | K-562 | chronic myeloid leukemia | Enhancer identification, Transcriptional regulation assay |
| E_01766 | chr17:51121344~51122474 | Blood | K-562 | chronic myeloid leukemia | Enhancer identification, Transcriptional regulation assay |
| E_01767 | chr19:43754969~43756655 | Blood | K-562 | chronic myeloid leukemia | Enhancer identification, Transcriptional regulation assay |
| E_01768 | chr17:74875718~74876890 | Blood | K-562 | chronic myeloid leukemia | Enhancer identification, Transcriptional regulation assay |
| E_01769 | chr6:28895115~28896348 | Lymph node | Namalwa (B-lymphocyte) | Burkitt lymphoma | Enhancer identification, Transcriptional regulation assay |
| E_01770 | chr16:11075050~11075232 | Heart | iPSC-Cardiac Fibroblast | Functional perturbation assay | |
| E_01771 | chr17:43574477~43663426 | Heart | iPSC-CM | Enhancer activity assay | |
| E_01772 | chr9:137494462~137494862 | Endometrium | T-HESC (immortalized human endometrial stromal cells) | CRISPR interference (CRISPRi) | |
| E_01773 | chr4:173516002~173519662 | Meninges | Patient-derived meningioma primary cells | meningioma | Enhancer activity assay, Functional perturbation assay |
| E_01774 | chr2:218000000~218700000 | Breast | Breast Adipose Fibroblasts (BAFs) | Enhancer activity assay, Chromatin interaction assay | |
| E_01775 | chr15:51242508~51243030 | Heart | Atrial/ventricular cardiomyocytes | Enhancer activity assay, TF binding assay | |
| E_01776 | chr7:150955147~150956502 | Blood | Primary monocytes | Enhancer activity assay, Functional perturbation assay | |
| E_01777 | chr14:24058261~24058761 | Brain | U373MG | glioblastoma | Chromatin interaction assay, TF binding assay |
| E_01778 | chr7:5509938~5510616 | Brain | T98G | glioblastoma | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01779 | chr7:5509938~5510616 | Brain | primary glioblastoma cells (PT#3) | glioblastoma | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01780 | chr7:5509938~5510616 | Brain | glioma stem-like cells (GSCs) | glioblastoma | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01781 | chr7:5509938~5510616 | Blood | Human monocyte-derived macrophages | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_01782 | chr7:109460000~109460600 | Blood | HUDEP-2 cells | -- | |
| E_01783 | chr6:135178878~135180878 | Bone | Osteosarcoma cells | osteosarcoma | Enhancer functional validation, Chromatin interaction assay |
| E_01784 | chr5:69232027~69234027 | Bone marrow | Leukemia cell lines | chronic myeloid leukemia | Super-enhancer targeting therapy study, Chromatin interaction assay |
| E_01785 | chr2:60447611~60449611 | Lung | Lung carcinoma cells | lung carcinoma | Enhancer CRISPR perturbation study, Chromatin interaction assay |
| E_01786 | chr20:22578327~22580327 | Blood | B lymphocytes | LncRNA tumor suppressor study, Chromatin interaction assay | |
| E_01787 | chr16:67559749~67561749 | Breast | Breast carcinoma cells | breast carcinoma | CTCF 3D genome regulation study, Chromatin interaction assay |
| E_01788 | chr14:37586693~37588693 | Inner cell mass | Embryonic stem cells | Endocrine resistance enhancer reprogramming study, Chromatin interaction assay | |
| E_01789 | chrX:113613674~113615674 | Bronchus | Primary airway cells | Endogenous retroviral enhancer study, Chromatin interaction assay | |
| E_01790 | chr5:143200112~143200889 | Liver | HepaRG cells | hepatocellular carcinoma | Enhancer activity assay |
| E_01791 | chr2:233759112~233759498 | Liver | Hepatocytes | Enhancer activity assay | |
| E_01792 | chr20:54103941~54104461 | Liver | Hepatocytes | Super-enhancer activity assay | |
| E_01793 | chr20:54107388~54107945 | Brain | DBTRG-05MG cells | glioblastoma | Super-enhancer activity assay |
| E_01794 | chr17:42409879~42412035 | Pancreas | PANC-1 | pancreatic ductal adenocarcinoma | Enhancer activity assay |
| E_01795 | chr17:20128500~20157500 | Pancreas | PANC-1 | pancreatic ductal adenocarcinoma | TF binding assay, Enhancer activity assay |
| E_01796 | chr4:103422500~103651500 | Pancreas | PANC-1 | pancreatic ductal adenocarcinoma | TF binding assay, Enhancer activity assay |
| E_01797 | chr4:75314500~75378500 | Pancreas | PANC-1 | pancreatic ductal adenocarcinoma | TF binding assay, Enhancer activity assay |
| E_01798 | chr7:55019000~55092000 | Hypothalamus | Primary rat hypothalamic cells | TF binding assay, Enhancer activity assay | |
| E_01799 | chr11:27725730~27726223 | Brainstem | Cranial motor neurons | Enhancer activity assay | |
| E_01800 | chr11:72308500~72309000 | Brainstem | Cranial motor neurons | Enhancer activity assay, Chromatin interaction assay | |
| E_01801 | chr22:27493955~27497536 | Pancreas | BxPC-3 | pancreatic ductal adenocarcinoma | Enhancer activity assay, Chromatin interaction assay |
| E_01802 | chr12:6955000~6975000 | Liver | HepG2 | hepatocellular carcinoma | Enhancer activity assay, TF binding assay |
| E_01803 | chr19:18373265~18374622 | Skin | Human hypertrophic scar fibroblasts (HSFs) | Enhancer activity assay | |
| E_01804 | chr18:48949564~48951076 | Liver | HuH7 cells | hepatocellular carcinoma | Enhancer activity assay, TF binding assay |
| E_01805 | chr19:11090150~11090715 | Tongue | SCC25 | tongue squamous cell carcinoma | Enhancer activity assay |
| E_01806 | chr3:185824281~185824602 | Tongue | CAL27 | tongue squamous cell carcinoma | Enhancer activity assay, TF binding assay |
| E_01807 | chr3:185824281~185824602 | Bone Marrow | CD34+ hematopoietic stem/progenitor cells | Enhancer activity assay, TF binding assay | |
| E_01808 | chr11:5225440~5225500 | Bone Marrow | CD34+ hematopoietic stem/progenitor cells | Functional perturbation assay, Enhancer activity assay | |
| E_01809 | chr11:5227000~5227060 | Brain | Primary tumor tissue | glioblastoma | Functional perturbation assay, Enhancer activity assay |
| E_01810 | chr10:128568604~128569741 | Brain | Primary tumor tissue | glioblastoma | Enhancer activity assay |
| E_01811 | chr10:129033193~129034911 | Brain | Primary tumor tissue | glioblastoma | Enhancer activity assay |
| E_01812 | chr10:129605804~129607046 | Liver | Hepatocyte | Enhancer activity assay | |
| E_01813 | chr11:76773651~76774249 | Notochord | Embryonic notochord | CL:0000182 | |
| E_01814 | chr18:7076043~7076166 | Heart | Ventricular cardiomyocytes | Enhancer activity assay | |
| E_01815 | chr12:110931149~110931877 | Heart | Ventricular cardiomyocytes | Enhancer activity assay | |
| E_01816 | chr12:110928658~110929096 | Heart | Ventricular cardiomyocytes | Enhancer activity assay | |
| E_01817 | chr12:110907461~110909456 | Breast | MCF-7 | breast carcinoma | Enhancer activity assay |
| E_01818 | chr21:42879000~42881000 | Breast | T47D | breast carcinoma | Functional perturbation assay, Enhancer activity assay, Chromatin interaction assay |
| E_01819 | chr21:42879000~42881000 | Breast | MCF-7 | breast carcinoma | Functional perturbation assay, Enhancer activity assay, Chromatin interaction assay |
| E_01820 | chr6:39090000~39092000 | Breast | T47D | breast carcinoma | Functional perturbation assay, Enhancer activity assay, Chromatin interaction assay |
| E_01821 | chr6:39090000~39092000 | Breast | MCF-7 | breast carcinoma | Functional perturbation assay, Enhancer activity assay, Chromatin interaction assay |
| E_01822 | chr11:61600000~61602000 | Breast | T47D | breast carcinoma | Functional perturbation assay, Enhancer activity assay, Chromatin interaction assay |
| E_01823 | chr11:61600000~61602000 | Breast | MCF-7 | breast carcinoma | Functional perturbation assay, Enhancer activity assay, Chromatin interaction assay |
| E_01824 | chr11:101800000~101802000 | Breast | T47D | breast carcinoma | Functional perturbation assay, Enhancer activity assay, Chromatin interaction assay |
| E_01825 | chr11:101800000~101802000 | Lung | BEAS-2B human bronchial epithelial cells | Functional perturbation assay, Enhancer activity assay, Chromatin interaction assay | |
| E_01826 | chr4:144579000~144586000 | Bone marrow | Kasumi-1 | acute myeloid leukemia | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_01827 | chr15:40931917~40933388 | Blood | Jurkat | T-cell acute lymphoblastic leukemia | Enhancer activity assay, Functional perturbation assay |
| E_01828 | chr6:135323327~135323580 | Liver | HepG2 | hepatocellular carcinoma | Enhancer activity assay, Functional perturbation assay |
| E_01829 | chr16:81157582~81157701 | Blood | Jurkat cells | T-cell acute lymphoblastic leukemia | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01830 | chr6:53260000~53270000 | Heart | hPSC-CMs | Super-enhancer activity assay, Functional perturbation assay | |
| E_01831 | chr1:154149500~154150000 | Blood | Raji | Burkitt lymphoma | Enhancer activity assay, TF binding assay |
| E_01832 | chr1:116506181~116506381 | Blood | THP-1 | acute monocytic leukemia | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_01833 | chr1:116506181~116506381 | Bronchus | HBEC3-KT | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay | |
| E_01834 | chr17:39611085~39689899 | Bronchus | HSAEC1-KT | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay | |
| E_01835 | chr17:39611085~39689899 | Liver | HepG2 | hepatocellular carcinoma | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay |
| E_01836 | chr1:178551259~178551689 | Bone marrow | Adipose-Derived Mesenchymal Stem Cells-01 | Enhancer activity assay, Functional perturbation assay | |
| E_01837 | chr21:36282225~36337655 | Bone marrow | Kasumi-1 | acute myeloid leukemia | Functional perturbation assay, Chromatin interaction assay |
| E_01838 | chr2:212609118~212811039 | Cervix | SiHa | cervical cancer | Chromatin interaction assay, Functional perturbation assay |
| E_01839 | chr1:155100545~155103815 | Thyroid | TPC1 | thyroid carcinoma | Enhancer activity assay, Functional perturbation assay, Chromatin interaction assay |
| E_01840 | chr7:13905623~13926156 | Thyroid | MDA-T41 | thyroid carcinoma | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay |
| E_01841 | chr7:13905623~13926156 | Blood | Multiple myeloma cells | multiple myeloma | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay |
| E_01842 | chr3:15768491~15768703 | Bone Marrow | CD34+ HSPCs | Enhancer activity assay | |
| E_01843 | chr2:60499980~60500080 | Heart | hPSC-CMs | Functional perturbation assay | |
| E_01844 | chr1:236783700~236783957 | Blood | Primary monocytes | Enhancer activity assay | |
| E_01845 | chr15:39315234~39315720 | Brain | U251TR glioblastoma cells | glioblastoma | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay |
| E_01846 | chr22:43901526~43904612 | Blood | K562 | chronic myeloid leukemia | Super-enhancer activity assay, Functional perturbation assay |
| E_01847 | chr8:128747000~128748000 | Colon | HCT116 | colorectal carcinoma | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_01848 | chr20:31606000~31608500 | Colon | LoVo | colorectal carcinoma | Putative enhancer screening |
| E_01849 | chr20:31606000~31608500 | Heart | Cardiac Myeloid | Putative enhancer screening | |
| E_01850 | chr2:113580000~113585000 | Bone | U2OS osteosarcoma | osteosarcoma | Enhancer activity assay |
| E_01851 | chr17:66452427~66453982 | Embryonic Kidney | HEK293 | Enhancer activity assay, TF binding assay | |
| E_01852 | chr4:111399594~111399691 | Liver | HepG2 | hepatocellular carcinoma | TF binding assay, Functional perturbation assay |
| E_01853 | chr19:18373265~18374622 | Adrenal gland | SK-N-BE(2) | neuroblastoma | Enhancer activity assay |
| E_01854 | chr17:48005000~48010000 | Prostate | LuCaP PDX | prostate cancer | Enhancer activity assay, TF binding assay |
| E_01855 | chr20:20025052~20648767 | Prostate | LNCaP | prostate cancer | Chromatin interaction assay |
| E_01856 | chr17:48704466~48768465 | Prostate | LNCaP | prostate cancer | Enhancer activity assay, Functional perturbation assay |
| E_01857 | chr3:128453265~128528579 | Prostate | LNCaP | prostate cancer | Enhancer activity assay, Functional perturbation assay |
| E_01858 | chr17:48529049~48630008 | Brain | Human neural progenitor cells (hNPCs) | Enhancer activity assay, Functional perturbation assay | |
| E_01859 | chr3:41119924~41122071 | Inner cell mass | HUES8 human embryonic stem cell line | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay | |
| E_01860 | chr3:27728339~27729090 | Inner cell mass | HUES8 human embryonic stem cell line | CRISPR interference-based functional screen | |
| E_01861 | chr8:54300591~54300987 | Inner cell mass | HUES8 human embryonic stem cell line | CRISPR interference-based functional screen | |
| E_01862 | chr18:22026154~22027330 | Inner cell mass | HUES8 human embryonic stem cell line | CRISPR interference-based functional screen | |
| E_01863 | chr8:54454106~54455036 | Inner cell mass | HUES8 human embryonic stem cell line | CRISPR interference-based functional screen | |
| E_01864 | chr8:54301978~54302426 | Inner cell mass | HUES8 human embryonic stem cell line | CRISPR interference-based functional screen | |
| E_01865 | chr3:27713390~27715985 | Inner cell mass | HUES8 human embryonic stem cell line | CRISPR interference-based functional screen | |
| E_01866 | chr1:226210507~226211585 | Inner cell mass | HUES8 human embryonic stem cell line | CRISPR interference-based functional screen | |
| E_01867 | chr1:226215164~226215656 | Inner cell mass | HUES8 human embryonic stem cell line | CRISPR interference-based functional screen | |
| E_01868 | chr18:22194123~22194455 | Inner cell mass | HUES8 human embryonic stem cell line | CRISPR interference-based functional screen | |
| E_01869 | chr8:54259816~54260322 | Inner cell mass | HUES8 human embryonic stem cell line | CRISPR interference-based functional screen | |
| E_01870 | chr18:21933810~21935298 | Inner cell mass | HUES8 human embryonic stem cell line | CRISPR interference-based functional screen | |
| E_01871 | chr8:54224560~54225711 | Inner cell mass | HUES8 human embryonic stem cell line | CRISPR interference-based functional screen | |
| E_01872 | chr3:27712007~27712923 | Inner cell mass | HUES8 human embryonic stem cell line | CRISPR interference-based functional screen | |
| E_01873 | chr3:27730029~27730667 | Inner cell mass | HUES8 human embryonic stem cell line | CRISPR interference-based functional screen | |
| E_01874 | chr8:54273053~54273554 | Inner cell mass | HUES8 human embryonic stem cell line | CRISPR interference-based functional screen | |
| E_01875 | chr1:226228164~226228831 | Inner cell mass | HUES8 human embryonic stem cell line | CRISPR interference-based functional screen | |
| E_01876 | chr18:47853130~47853488 | Inner cell mass | HUES8 human embryonic stem cell line | CRISPR interference-based functional screen | |
| E_01877 | chr8:54443606~54444178 | Inner cell mass | HUES8 human embryonic stem cell line | CRISPR interference-based functional screen | |
| E_01878 | chr1:226203745~226204150 | Inner cell mass | HUES8 human embryonic stem cell line | CRISPR interference-based functional screen | |
| E_01879 | chr18:47918050~47918585 | Inner cell mass | HUES8 human embryonic stem cell line | CRISPR interference-based functional screen | |
| E_01880 | chr18:22101727~22102198 | Inner cell mass | HUES8 human embryonic stem cell line | CRISPR interference-based functional screen | |
| E_01881 | chr18:47901736~47902193 | Inner cell mass | HUES8 human embryonic stem cell line | CRISPR interference-based functional screen | |
| E_01882 | chr18:22020271~22020802 | Inner cell mass | HUES8 human embryonic stem cell line | CRISPR interference-based functional screen | |
| E_01883 | chr1:226197015~226197408 | Inner cell mass | HUES8 human embryonic stem cell line | CRISPR interference-based functional screen | |
| E_01884 | chr8:54228206~54228505 | Inner cell mass | HUES8 human embryonic stem cell line | CRISPR interference-based functional screen | |
| E_01885 | chr12:7970611~7971032 | Inner cell mass | HUES8 human embryonic stem cell line | CRISPR interference-based functional screen | |
| E_01886 | chr18:22032376~22032818 | Inner cell mass | HUES8 human embryonic stem cell line | CRISPR interference-based functional screen | |
| E_01887 | chr12:7439885~7440355 | Prostate | LNCaP prostate cancer cell line | prostate adenocarcinoma | CRISPR interference-based functional screen |
| E_01888 | chr8:127661390~127661641 | Skin | Human neonatal foreskin fibroblasts | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay | |
| E_01889 | chr17:44542500~44543500 | Skin | Human neonatal foreskin fibroblasts | CRISPR interference-based functional screen | |
| E_01890 | chr22:36656500~36657500 | Skin | Human neonatal foreskin fibroblasts | CRISPR interference-based functional screen | |
| E_01891 | chr15:40809500~40810500 | Inner cell mass | H9 human embryonic stem cells | CRISPR interference-based functional screen | |
| E_01892 | chr1:43094500~43095500 | Inner cell mass | HUES8 human embryonic stem cell line | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay | |
| E_01893 | chr8:54268115~54268740 | Cerebellum | D283 cells | medulloblastoma | CRISPR interference-based functional screen |
| E_01894 | chr14:56793806~56795906 | Blood | Lymphoblastoid | Super-enhancer activity assay, Functional perturbation assay | |
| E_01895 | chr7:156790916~156792095 | Cervix | HeLa cells | cervical cancer | -- |
| E_01896 | chr9:21074270~21076270 | Prostate | LuNE | prostate cancer | Antiviral immune enhancer activation study, Chromatin interaction assay |
| E_01897 | chr8:127675276~128081453 | Prostate | LuNE | prostate cancer | Enhancer activity assay, Functional perturbation assay |
| E_01898 | chr9:14296620~14326255 | Skin | Human Kaposi sarcoma cell line | Kaposi sarcoma | Enhancer activity assay, Functional perturbation assay |
| E_01899 | chrX:67541571~67543571 | Skin | Human Kaposi sarcoma cell line | Kaposi sarcoma | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01900 | chr21:34785412~34787412 | Colon | LS180 colon carcinoma cell line | colorectal carcinoma | Enhancer activity assay, Chromatin interaction assay |
| E_01901 | chr20:52173000~52174500 | Colon | LS180 colon carcinoma cell line | colorectal carcinoma | Enhancer activity assay, TF binding assay, Chromatin interaction assay |
| E_01902 | chr20:52157000~52158500 | Skin | Kaposi sarcoma cell line | Kaposi sarcoma | Enhancer activity assay, TF binding assay, Chromatin interaction assay |
| E_01903 | chr8:143015000~143025000 | Lung | A549 cell line | lung adenocarcinoma | Enhancer activity assay, TF binding assay |
| E_01904 | chr3:133743162~133745162 | Blood | Jurkat cell line | T-cell acute lymphoblastic leukemia | Enhancer activity assay, TF binding assay |
| E_01905 | chr16:15600300~15601300 | Prostate | VCaP | prostate cancer | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_01906 | chr6:35687716~35687816 | Prostate | LNCaP cell lines | prostate cancer | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01907 | chr6:35687716~35687816 | Prostate | VCaP | prostate cancer | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01908 | chr6:35717716~35717816 | Prostate | LNCaP cell lines | prostate cancer | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01909 | chr6:35717716~35717816 | Prostate | VCaP | prostate cancer | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01910 | chr6:35747716~35747816 | Prostate | LNCaP cell lines | prostate cancer | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01911 | chr6:35747716~35747816 | Prostate | VCaP | prostate cancer | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01912 | chr6:35757716~35757816 | Prostate | LNCaP cell lines | prostate cancer | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01913 | chr6:35757716~35757816 | Lung | SCLC cell line | small cell lung carcinoma | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01914 | chr11:120233455~120235455 | Blood | Jurkat human CD4+ T leukemia cell line | T-cell acute lymphoblastic leukemia | Enhancer activity assay, TF binding assay |
| E_01915 | chr13:39700000~39750000 | Colon | HCT116 cell line | colorectal carcinoma | Enhancer activity assay |
| E_01916 | chr11:101421506~101422130 | Umbilical vein | HUVEC cell line | Enhancer activity assay | |
| E_01917 | chr12:4808272~4809572 | Umbilical vein | HUVEC cell line | Chromatin interaction assay, Enhancer activity assay | |
| E_01918 | chr12:4818572~4820072 | Brain | SK-N-MC cell line | neuroepithelioma | Chromatin interaction assay, Enhancer activity assay |
| E_01919 | chr3:181708868~181710868 | Kidney | COS-7 cell line | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_01920 | chr17:72118256~72120256 | Bone | LM8-C3H cell line | osteosarcoma | Enhancer activity assay, TF binding assay |
| E_01921 | chr4:108044908~108046908 | Breast | MCF-7 cells | breast carcinoma | Enhancer activity assay, Functional perturbation assay |
| E_01922 | chr1:117752000~117754000 | Breast | MCF-7 cells | breast carcinoma | Enhancer activity assay |
| E_01923 | chr1:179369000~179374000 | Prostate | LNCaP | prostate cancer | Enhancer activity assay |
| E_01924 | chr8:128600697~128601159 | Cervix | HeLa | cervical cancer | Enhancer activity assay, TF binding assay |
| E_01925 | chr5:131784596~131785596 | Cervix | HeLa | cervical cancer | Reporter gene assay |
| E_01926 | chr5:131790596~131791596 | Cervix | HeLa | cervical cancer | Reporter gene assay |
| E_01927 | chr7:115940408~115941408 | Cervix | HeLa | cervical cancer | Reporter gene assay |
| E_01928 | chr9:129175952~129176952 | Blood | Reporter gene assay | ||
| E_01929 | chr13:42080367~42080909 | Bone | U-2 OS cell | Enhancer activity assay, TF binding assay | |
| E_01930 | chr11:45846943~45846959 | Breast | MCF-7 cells | breast carcinoma | Enhancer activity assay |
| E_01931 | chr1:117752500~117753100 | Lung | HFL1 cells | Enhancer activity assay | |
| E_01932 | chr9:133601400~133601900 | Skin | BJ fibroblasts | Enhancer activity assay | |
| E_01933 | chr6:36633472~36634972 | Cervix | HeLa | cervical cancer | Functional perturbation assay |
| E_01934 | chr5:131784000~131784700 | Cervix | HeLa | cervical cancer | Enhancer activity assay |
| E_01935 | chr5:131790800~131791300 | Cervix | HeLa | cervical cancer | Enhancer activity assay |
| E_01936 | chr7:115940600~115941200 | Cervix | HeLa | cervical cancer | Enhancer activity assay |
| E_01937 | chr9:129176100~129176800 | Cervix | HeLa | cervical cancer | Enhancer activity assay |
| E_01938 | chr21:34091200~34091900 | Bone marrow | FDCP-mix | Enhancer activity assay | |
| E_01939 | chr11:5246250~5246637 | Bone marrow | K562 | chronic myeloid leukemia | Enhancer activity assay |
| E_01940 | chr11:5246250~5246637 | Esophagus | KYSE-30 | esophageal squamous cell carcinoma | Enhancer activity assay |
| E_01941 | chr12:52644741~52645375 | Bone Marrow | Primary Erythroblasts | Enhancer activity assay | |
| E_01942 | chr16:110000~115000 | Bone Marrow | K562 | chronic myeloid leukemia | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01943 | chr16:110000~115000 | Bone Marrow | Primary Erythroblasts | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_01944 | chr16:118000~123000 | Bone Marrow | K562 | chronic myeloid leukemia | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01945 | chr16:118000~123000 | Bone Marrow | Primary Erythroblasts | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_01946 | chr16:125000~130000 | Bone Marrow | K562 | chronic myeloid leukemia | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01947 | chr16:125000~130000 | Bone Marrow | Primary Erythroblasts | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_01948 | chr16:148000~153000 | Bone Marrow | K562 | chronic myeloid leukemia | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01949 | chr16:148000~153000 | Blood | PEER | T-cell acute lymphoblastic leukemia | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01950 | chr14:98670000~98720000 | Connective tissue | Pluripotent stem cell | Enhancer activity assay | |
| E_01951 | chr2:209421458~209423458 | Embryonic cardiac tissue | 10T1/2 cells | Enhancer activity assay, Chromatin interaction assay | |
| E_01952 | chr5:44421506~44422602 | Forebrain | COS-1 | holoprosencephaly | Enhancer activity assay |
| E_01953 | chr7:155754267~155755366 | Forebrain | Primary embryonic cells | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_01954 | chr7:155754267~155755366 | Inner cell mass | Embryonic stem cell | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_01955 | chr17:30249928~30278499 | Embryonic cardiac tissue | 10T1/2 cells | Enhancer activity assay, Chromatin interaction assay | |
| E_01956 | chr5:44421506~44422602 | Blood | PEER | T-cell acute lymphoblastic leukemia | Enhancer activity assay |
| E_01957 | chr14:97720000~97780000 | Blood | DND-41 | T-cell acute lymphoblastic leukemia | Enhancer activity assay, Functional perturbation assay |
| E_01958 | chr14:97720000~97780000 | Blood | CCRF-CEM | T-cell acute lymphoblastic leukemia | Enhancer activity assay, Functional perturbation assay |
| E_01959 | chr14:97720000~97780000 | Blood | HPB-ALL | T-cell acute lymphoblastic leukemia | Enhancer activity assay, Functional perturbation assay |
| E_01960 | chr14:97720000~97780000 | Blood | PEER | T-cell acute lymphoblastic leukemia | Enhancer activity assay, Functional perturbation assay |
| E_01961 | chr14:97720000~97780000 | Blood | DND-41 | T-cell acute lymphoblastic leukemia | Enhancer activity assay, Functional perturbation assay |
| E_01962 | chr14:97720000~97780000 | Blood | CCRF-CEM | T-cell acute lymphoblastic leukemia | Enhancer activity assay, Functional perturbation assay |
| E_01963 | chr14:97720000~97780000 | Blood | HPB-ALL | T-cell acute lymphoblastic leukemia | Enhancer activity assay, Functional perturbation assay |
| E_01964 | chr14:97720000~97780000 | Blood | PEER | T-cell acute lymphoblastic leukemia | Enhancer activity assay, Functional perturbation assay |
| E_01965 | chr14:98500000~98710000 | Blood | DND-41 | T-cell acute lymphoblastic leukemia | Enhancer activity assay, Functional perturbation assay |
| E_01966 | chr14:98500000~98710000 | Blood | CCRF-CEM | T-cell acute lymphoblastic leukemia | Enhancer activity assay, Functional perturbation assay |
| E_01967 | chr14:98500000~98710000 | Blood | HPB-ALL | T-cell acute lymphoblastic leukemia | Enhancer activity assay, Functional perturbation assay |
| E_01968 | chr14:98500000~98710000 | Prostate | 22Rv1 cells | prostate cancer | Enhancer activity assay, Functional perturbation assay |
| E_01969 | chr12:115092472~115096258 | Connective tissue | Pluripotent stem cell | Chromatin interaction assay, Enhancer activity assay, Functional perturbation assay | |
| E_01970 | chr17:42310596~42312596 | Bone marrow | G1E cell | Enhancer activity assay | |
| E_01971 | chr16:49740654~49742654 | Testis | Sustentacular cell | testicular cancer | Enhancer activity assay, Chromatin interaction assay |
| E_01972 | chr2:105072843~105076843 | Bone marrow | Mononuclear phagocyte | Enhancer activity assay | |
| E_01973 | chr19:61151074~61161722 | Prostate | Enhancer activity assay, TF binding assay | ||
| E_01974 | chrX:67541320~67543320 | Brain | Neural cell | schizophrenia | Enhancer evolution assay |
| E_01975 | chr3:180986412~180988412 | Pancreas | CD8+ T cell | type 1 diabetes mellitus | Enhancer activity assay |
| E_01976 | chr14:92920852~92922852 | Cervix | HeLa cell | cervical cancer | Enhancer activity assay |
| E_01977 | chr12:48826675~48828675 | Cervix | HeLa cell | cervical cancer | Enhancer activity assay |
| E_01978 | chr12:48826675~48828675 | Blood vessel | Endothelial stalk cell | Enhancer activity assay | |
| E_01979 | chr6:88202011~88204330 | Liver | Hepatocyte | Enhancer activity assay, TF binding assay | |
| E_01980 | chr3:133743395~133745395 | Esophagus | Oesophageal squamous cell | esophageal carcinoma | Enhancer activity assay |
| E_01981 | chr2:43219398~43221398 | Lung | BEAS-2B cells | Enhancer activity assay | |
| E_01982 | chr5:142404236~142405236 | Blood | Jurkat E6.1 | Enhancer activity assay, TF binding assay, Chromatin interaction assay | |
| E_01983 | chr14:22553100~22553200 | Blood | primary human CD3+ T cells | Functional perturbation assay | |
| E_01984 | chr14:22553100~22553200 | Blood | Monocyte-derived macrophage (hMDM) | Functional perturbation assay | |
| E_01985 | chr1:109800000~109801100 | Heart | hPSC-CMs | TF binding assay, Enhancer activity assay | |
| E_01986 | chr1:236783100~236784400 | Bone Marrow | CD34+ HSPCs | Functional perturbation assay | |
| E_01987 | chr2:60722225~60722425 | Lung | NSCLC cell lines | non-small cell lung carcinoma | Functional perturbation assay, Enhancer activity assay |
| E_01988 | chr2:241851500~241851650 | Embryonic Limb Bud | Limb bud mesenchymal cells | Enhancer activity assay, TF binding assay | |
| E_01989 | chr5:29314497~29315844 | Limb Bud | Zone of polarizing activity cells | TF binding assay, Enhancer activity assay, Functional perturbation assay | |
| E_01990 | chr5:29314497~29315844 | Bone Marrow | 32D Cells | TF binding assay, Enhancer activity assay, Functional perturbation assay | |
| E_01991 | chr14:54705845~54707084 | Bone Marrow | Primary Mouse Bone Marrow Cells | TF binding assay, Chromatin interaction assay, Functional perturbation assay, Enhancer activity assay | |
| E_01992 | chr14:54705845~54707084 | Brain | Neural progenitor cells (NPCs) | TF binding assay, Chromatin interaction assay, Functional perturbation assay, Enhancer activity assay | |
| E_01993 | chr9:120869524~120870219 | Brown adipose tissue | Brown adipocytes (SVF) | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay | |
| E_01994 | chr8:83274000~83275000 | Brown adipose tissue | Brown adipocytes (SVF) | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay | |
| E_01995 | chr8:83277000~83278000 | Brain | Neural progenitor cells (NPCs) | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay | |
| E_01996 | chr9:120869062~120871341 | Embryo | Mouse Embryonic Stem Cells (ESCs) | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay | |
| E_01997 | chr4:139771035~139771985 | Bone marrow | Mouse hematopoietic stem cells (HSCs) | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay | |
| E_01998 | chr10:20942490~21160984 | Bone Marrow | Primary CD19+ pro-B cells | Enhancer activity assay, TF binding assay, Functional perturbation assay, Chromatin interaction assay | |
| E_01999 | chr12:114182511~114183025 | Spleen | Abl-transformed pro-B cells | Functional perturbation assay, Enhancer activity assay, Chromatin interaction assay, TF binding assay | |
| E_02000 | chr12:114182511~114183025 | Spleen | Rag1-/- pro-B cells | Functional perturbation assay, Enhancer activity assay, Chromatin interaction assay, TF binding assay | |
| E_02001 | chr12:114182511~114183025 | Spleen | Rag2-/- pro-B cells | Functional perturbation assay, Enhancer activity assay, Chromatin interaction assay, TF binding assay | |
| E_02002 | chr12:114182511~114183025 | Embryo | Mouse ESCs | Functional perturbation assay, Enhancer activity assay, Chromatin interaction assay, TF binding assay | |
| E_02003 | chr12:96450000~96452000 | Embryo | Epiblast-like cells | Enhancer activity assay, Functional perturbation assay | |
| E_02004 | chr12:96450000~96452000 | Embryo | Primordial germ cell-like cells | Enhancer activity assay, Functional perturbation assay | |
| E_02005 | chr12:96450000~96452000 | Embryo | Mouse ESCs | Enhancer activity assay, Functional perturbation assay | |
| E_02006 | chr13:24180000~24182000 | Embryo | Epiblast-like cells | Enhancer activity assay, Functional perturbation assay | |
| E_02007 | chr13:24180000~24182000 | Embryo | Primordial germ cell-like cells | Enhancer activity assay, Functional perturbation assay | |
| E_02008 | chr13:24180000~24182000 | Embryo | Mouse ESCs | Enhancer activity assay, Functional perturbation assay | |
| E_02009 | chr4:102450000~102452000 | Embryo | Epiblast-like cells | Enhancer activity assay, Functional perturbation assay | |
| E_02010 | chr4:102450000~102452000 | Embryo | Primordial germ cell-like cells | Enhancer activity assay, Functional perturbation assay | |
| E_02011 | chr4:102450000~102452000 | Embryo | Mouse ESCs | Enhancer activity assay, Functional perturbation assay | |
| E_02012 | chr4:102455000~102457000 | Embryo | Epiblast-like cells | Enhancer activity assay, Functional perturbation assay | |
| E_02013 | chr4:102455000~102457000 | Embryo | Primordial germ cell-like cells | Enhancer activity assay, Functional perturbation assay | |
| E_02014 | chr4:102455000~102457000 | Embryo | Mouse ESCs | Enhancer activity assay, Functional perturbation assay | |
| E_02015 | chr4:102460000~102462000 | Embryo | Epiblast-like cells | Enhancer activity assay, Functional perturbation assay | |
| E_02016 | chr4:102460000~102462000 | Embryo | Primordial germ cell-like cells | Enhancer activity assay, Functional perturbation assay | |
| E_02017 | chr4:102460000~102462000 | Brain | Neuro2a | neuroblastoma | Enhancer activity assay, Functional perturbation assay |
| E_02018 | chr10:80245000~80246500 | Embryo | Mouse Embryonic Stem Cells (mESCs; E14TG2a; J1) | Functional perturbation assay, Enhancer activity assay | |
| E_02019 | chr1:63185000~63188000 | Embryo | Mouse Embryonic Stem Cells (mESCs; E14TG2a; J1) | Enhancer activity assay, Chromatin interaction assay, TF binding assay | |
| E_02020 | chr1:63185000~63188000 | Blood | Dendritic cells | Enhancer activity assay, Chromatin interaction assay, TF binding assay | |
| E_02021 | chr8:121495097~121496097 | Blood | Myeloid progenitors | Enhancer activity assay, Functional perturbation assay, Chromatin interaction assay | |
| E_02022 | chr8:121495097~121496097 | Blood | Dendritic cells | Enhancer activity assay, Functional perturbation assay, Chromatin interaction assay | |
| E_02023 | chr8:121504097~121505097 | Blood | Myeloid progenitors | Enhancer activity assay, Functional perturbation assay, Chromatin interaction assay | |
| E_02024 | chr8:121504097~121505097 | Blood | Dendritic cells | Enhancer activity assay, Functional perturbation assay, Chromatin interaction assay | |
| E_02025 | chr8:121519097~121520097 | Blood | Myeloid progenitors | Enhancer activity assay, Functional perturbation assay, Chromatin interaction assay | |
| E_02026 | chr8:121519097~121520097 | Artery | Primary mouse VSMCs | Enhancer activity assay, Functional perturbation assay, Chromatin interaction assay | |
| E_02027 | chr10:87654200~87655200 | Artery | A7r5 cells | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_02028 | chr10:87654200~87655200 | Artery | Primary mouse VSMCs | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_02029 | chr10:87657800~87658800 | Artery | A7r5 cells | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_02030 | chr10:87657800~87658800 | Craniofacial Tissue | Primary cranial neural crest cells | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_02031 | chr6:50789172~50828639 | Pharyngeal Arch | Cranial neural crest cells | Chromatin interaction assay, Functional perturbation assay, Enhancer activity assay, TF binding assay | |
| E_02032 | chr6:50913170~51087888 | Adipose Tissue | Mouse preadipocyte cell | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay | |
| E_02033 | chr6:115412685~115412777 | Pharyngeal Arch | Second pharyngeal arch CNCCs | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_02034 | chr6:50789172~50828639 | Pharyngeal Arch | Cranial neural crest cells | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay | |
| E_02035 | chr6:50789172~50828639 | Craniofacial Tissue | Primary cranial neural crest cells | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay | |
| E_02036 | chr6:50913170~51087888 | Pharyngeal Arch | Cranial neural crest cells | Chromatin interaction assay, Functional perturbation assay, Enhancer activity assay, TF binding assay | |
| E_02037 | chr6:50789172~50828639 | Craniofacial Tissue | Primary cranial neural crest cells | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay | |
| E_02038 | chr6:50913170~51087888 | Pharyngeal Arch | Second pharyngeal arch CNCCs | Chromatin interaction assay, Functional perturbation assay, Enhancer activity assay, TF binding assay | |
| E_02039 | chr6:50913170~51087888 | Pharyngeal Arch | Cranial neural crest cells | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay | |
| E_02040 | chr6:50913170~51087888 | Pituitary gland | L??T2 | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay | |
| E_02041 | chr7:45416017~45418912 | Pituitary gland | ??T3-1 | Enhancer activity assay, Functional perturbation assay, Chromatin interaction assay, TF binding assay | |
| E_02042 | chr7:45416017~45418912 | Pituitary gland | primary pituitary gonadotrope cells | Enhancer activity assay, Functional perturbation assay, Chromatin interaction assay, TF binding assay | |
| E_02043 | chr7:45416017~45418912 | Embryo | Embryonic Stem Cells (mESCs) | Enhancer activity assay, Functional perturbation assay, Chromatin interaction assay, TF binding assay | |
| E_02044 | chr5:118432886~118452483 | Extraembryonic Ectoderm | Trophoblast Stem Cell | Functional perturbation assay, Chromatin interaction assay | |
| E_02045 | chr14:53397365~53398765 | Spleen | Bone Marrow-Derived Macrophages | Enhancer activity assay, TF binding assay | |
| E_02046 | chr16:10433585~10433748 | Spleen | Bone Marrow-Derived Macrophages | Functional perturbation assay | |
| E_02047 | chr16:10480585~10480785 | Embryo | Mouse Embryonic Stem Cells (mESCs; 129xCast F1; v6.5) | Functional perturbation assay | |
| E_02048 | chr7:3198900~3202780 | Embryo | Mouse Embryonic Stem Cells (mESCs; 129xCast F1; v6.5) | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_02049 | chr7:3198900~3202780 | Embryo | Epiblast-like Cells (EpiLCs) | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_02050 | chr1:63240000~63243000 | Embryo | Differentiated mESCs | Enhancer activity assay, Chromatin interaction assay, TF binding assay, Functional perturbation assay | |
| E_02051 | chr1:63240000~63243000 | Bone Marrow | Hematopoietic Stem Cells | Enhancer activity assay, Chromatin interaction assay, TF binding assay, Functional perturbation assay | |
| E_02052 | chr6:88093745~88094001 | Bone Marrow | Primary Mouse Bone Marrow Cells | Functional perturbation assay, TF binding assay, Chromatin interaction assay | |
| E_02053 | chr6:88093745~88094001 | Embryo | Mouse embryonic stem cells | Functional perturbation assay, TF binding assay, Chromatin interaction assay | |
| E_02054 | chr7:104405000~104415000 | Embryo | Mouse embryonic stem cells | Chromatin interaction assay, Functional perturbation assay, TF binding assay | |
| E_02055 | chr6:113000000~113001000 | Blood | RAW264.7 | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay | |
| E_02056 | chr18:60781333~60781702 | Embryo | Mouse embryonic stem cells | Enhancer activity assay, Functional perturbation assay, TF binding assay | |
| E_02057 | chr18:60781333~60781702 | Blood | RAW264.7 | Enhancer activity assay, Functional perturbation assay, TF binding assay | |
| E_02058 | chr18:60811244~60811580 | Brain | Mouse primary macrophages | Functional perturbation assay, Enhancer activity assay, TF binding assay | |
| E_02059 | chr18:60811244~60811580 | Skin | Langerhans cells | Functional perturbation assay, Enhancer activity assay, TF binding assay | |
| E_02060 | chr18:60811244~60811580 | Embryo | Mouse embryonic stem cells | Functional perturbation assay, Enhancer activity assay, TF binding assay | |
| E_02061 | chr18:60811244~60811580 | Blood | RAW264.7 | Functional perturbation assay, Enhancer activity assay, TF binding assay | |
| E_02062 | chr18:60917264~60917600 | Embryo | Mouse embryonic stem cells | Functional perturbation assay, Enhancer activity assay, TF binding assay | |
| E_02063 | chr18:60917264~60917600 | Skin | Langerhans cells | Functional perturbation assay, Enhancer activity assay, TF binding assay | |
| E_02064 | chr18:60917264~60917600 | Spleen | CD4+ Th1 cells | Functional perturbation assay, Enhancer activity assay, TF binding assay | |
| E_02065 | chr10:118373265~118377265 | Spleen | CD4+ Th1 cells | Chromatin interaction assay, Functional perturbation assay | |
| E_02066 | chr10:118393265~118397265 | Spleen | CD4+ Th1 cells | Chromatin interaction assay, Functional perturbation assay | |
| E_02067 | chr10:118405265~118409265 | Spleen | CD4+ Th1 cells | Chromatin interaction assay, Functional perturbation assay | |
| E_02068 | chr10:118421265~118425265 | Spleen | CD4+ Th1 cells | Chromatin interaction assay, Functional perturbation assay | |
| E_02069 | chr10:118445265~118449265 | Spleen | CD4+ Th1 cells | Chromatin interaction assay, Functional perturbation assay | |
| E_02070 | chr10:118456265~118460265 | Embryo | Mouse ESCs | Chromatin interaction assay, Functional perturbation assay | |
| E_02071 | chr3:34619000~34632000 | Embryo | Mouse ESCs | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay, TF binding assay | |
| E_02072 | chr1:39441747~39444739 | Heart | Embryonic cardiomyocyte | Enhancer capture Hi-C assay, In vivo functional validation | |
| E_02073 | chr12:114462800~114464200 | Spleen | mature B | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay | |
| E_02074 | chr12:114465285~114467786 | Spleen | mature B | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay | |
| E_02075 | chr12:114479200~114480600 | Spleen | mature B | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay | |
| E_02076 | chr12:114481431~114482631 | Spleen | mature B | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay | |
| E_02077 | chr12:114461575~114496377 | Spleen | mature B | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay | |
| E_02078 | chr7:134136598~134137038 | Bone marrow | 32Dcl3 | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_02079 | chr7:134136598~134137038 | Bone marrow | primary bone marrow | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_02080 | chr17:35600000~35630000 | Embryo | mouse ESCs | Enhancer activity assay, Functional perturbation assay | |
| E_02081 | chr4:102500000~102540000 | Embryo | mouse ESCs | Enhancer activity assay, Functional perturbation assay | |
| E_02082 | chr8:71200000~71240000 | Embryo | mouse ESCs | Enhancer activity assay, Functional perturbation assay | |
| E_02083 | chr10:12800000~12840000 | Embryo | mouse ESCs | Enhancer activity assay, Functional perturbation assay | |
| E_02084 | chr8:45600000~45640000 | Embryo | mouse ESCs | Enhancer activity assay, Functional perturbation assay | |
| E_02085 | chr1:180887014~180889994 | Embryo | Mouse embryonic stem | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay | |
| E_02086 | chr1:180924460~180925486 | Embryo | Mouse embryonic stem | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay | |
| E_02087 | chr3:103180000~103230000 | Adipose tissue | C3H10T1/2, primary adipocytes | Regulatory element functional validation, 3D chromatin architecture analysis, epigenomic profiling | |
| E_02088 | chr3:103470000~103520000 | Adipose tissue | C3H10T1/2, primary adipocytes | Regulatory element functional validation, 3D chromatin architecture analysis, epigenomic profiling | |
| E_02089 | chr17:80721358~80818896 | Embryo | Mouse Embryonic Stem Cells (v6.5) | Enhancer activity assay, Functional perturbation assay | |
| E_02090 | chr15:61958143~62188886 | Embryo | mESC | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay | |
| E_02091 | chr5:75699926~75706926 | Bone Marrow | Primary Mast cells | Functional perturbation assay, Enhancer activity assay | |
| E_02092 | chr5:75825926~75832926 | Skin | Primary Melanocytes | Functional perturbation assay, Enhancer activity assay | |
| E_02093 | chr5:75699926~75706926 | Skin | Primary Melanocytes (Kit ??30k) | Chromatin interaction assay, Functional perturbation assay | |
| E_02094 | chr5:75825926~75832926 | Skin | Primary Melanocytes (Kit ??30k) | Chromatin interaction assay, Functional perturbation assay | |
| E_02095 | chr11:112200000~112204700 | Embryonic gonad | Embryonic gonad cells (E11.5) | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_02096 | chr12:8570500~8571000 | Cerebral cortex | Primary mouse cortical neurons | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay | |
| E_02097 | chr15:8079500~8080000 | Cerebral cortex | Primary mouse cortical neurons | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay | |
| E_02098 | chr17:63643401~63643706 | Kidney | MDCK | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_02099 | chr17:63643401~63643706 | Kidney | IMCD3 | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_02100 | chrX:7566060~7568152 | Blood | CD4+ T cells | Functional perturbation assay, Enhancer activity assay | |
| E_02101 | chrX:7566060~7568152 | Blood | Regulatory T cells | Functional perturbation assay, Enhancer activity assay | |
| E_02102 | chrX:7566060~7568152 | Blood | Conventional T cells | Functional perturbation assay, Enhancer activity assay | |
| E_02103 | chrX:7570463~7571424 | Blood | CD4+ T cells | Functional perturbation assay, Enhancer activity assay | |
| E_02104 | chrX:7570463~7571424 | Blood | Regulatory T cells | Functional perturbation assay, Enhancer activity assay | |
| E_02105 | chrX:7570463~7571424 | Blood | Conventional T cells | Functional perturbation assay, Enhancer activity assay | |
| E_02106 | chrX:7573447~7575334 | Blood | CD4+ T cells | Functional perturbation assay, Enhancer activity assay | |
| E_02107 | chrX:7573447~7575334 | Blood | Regulatory T cells | Functional perturbation assay, Enhancer activity assay | |
| E_02108 | chrX:7573447~7575334 | Blood | Conventional T cells | Functional perturbation assay, Enhancer activity assay | |
| E_02109 | chrX:7579185~7580141 | Blood | CD4+ T cells | Functional perturbation assay, Enhancer activity assay | |
| E_02110 | chrX:7579185~7580141 | Blood | Regulatory T cells | Functional perturbation assay, Enhancer activity assay | |
| E_02111 | chrX:7579185~7580141 | Blood | Conventional T cells | Functional perturbation assay, Enhancer activity assay | |
| E_02112 | chrX:7583853~7584485 | Blood | CD4+ T cells | Functional perturbation assay, Enhancer activity assay | |
| E_02113 | chrX:7583853~7584485 | Blood | Regulatory T cells | Functional perturbation assay, Enhancer activity assay | |
| E_02114 | chrX:7583853~7584485 | Blood | Conventional T cells | Functional perturbation assay, Enhancer activity assay | |
| E_02115 | chr18:24570000~24570200 | Embryo | ESCs | Functional perturbation assay | |
| E_02116 | chr8:109142000~109142200 | Embryo | ESCs | Functional perturbation assay | |
| E_02117 | chr8:109150000~109150200 | Embryo | ESCs | Functional perturbation assay | |
| E_02118 | chr8:123455000~123472000 | Kidney | Pkd1-null tubule epithelial cells (PN) | polycystic kidney disease | Functional perturbation assay, Enhancer activity assay |
| E_02119 | chr8:123455000~123472000 | Kidney | Pkd1-heterozygous control tubule epithelial cells (PH) | Functional perturbation assay, Enhancer activity assay | |
| E_02120 | chr8:123455000~123472000 | Kidney | mouse primary renal tubular epithelial cells | Functional perturbation assay, Enhancer activity assay | |
| E_02121 | chr10:72890000~72895600 | Retina | Retinal Progenitor Cells | Functional perturbation assay, Enhancer activity assay | |
| E_02122 | chr10:72890000~72895600 | Retina | Retinal Ganglion Cells | Functional perturbation assay, Enhancer activity assay | |
| E_02123 | chr5:150830909~150831422 | Heart | Primary embryonic cardiomyocytes | Enhancer activity assay, TF binding assay, Functional perturbation assay, Chromatin interaction assay | |
| E_02124 | chr5:150830909~150831422 | Heart | hiPSC-CMs | Enhancer activity assay, TF binding assay, Functional perturbation assay, Chromatin interaction assay | |
| E_02125 | chr14:78376100~78379511 | Bone | Primary osteoblasts | Functional perturbation assay, Enhancer activity assay, TF binding assay | |
| E_02126 | chr14:78376100~78379511 | Bone | Periodontal ligament cells | Functional perturbation assay, Enhancer activity assay, TF binding assay | |
| E_02127 | chr14:78376100~78379511 | Bone | Osteogenic cells | Functional perturbation assay, Enhancer activity assay, TF binding assay | |
| E_02128 | chr14:78376100~78379511 | Bone | Primary calvarial osteoblasts | Functional perturbation assay, Enhancer activity assay, TF binding assay | |
| E_02129 | chr6:113009800~113010300 | Embryo | Mouse embryonic stem cells (E14TG2a) | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_02130 | chr4:135009700~135010200 | Embryo | Mouse embryonic stem cells | Enhancer activity assay, TF binding assay, Functional perturbation assay, Epigenetic modification assay | |
| E_02131 | chr4:135009700~135010200 | Embryo | EpiLCs | Enhancer activity assay, TF binding assay, Functional perturbation assay, Epigenetic modification assay | |
| E_02132 | chr4:135009700~135010200 | Embryo | PGCLCs | Enhancer activity assay, TF binding assay, Functional perturbation assay, Epigenetic modification assay | |
| E_02133 | chr1:9648563~9650544 | Embryo | Enhancer capture Hi-C assay, In vivo functional validation | ||
| E_02134 | chr15:103026344~103028143 | Heart | Sinoatrial Node Pacemaker | Enhancer activity assay, Functional perturbation assay | |
| E_02135 | chr1:179953600~179954900 | Heart | Mouse primary cardiomyocytes | Enhancer activity assay, TF binding assay | |
| E_02136 | chr7:142599494~142601493 | Skeletal muscle | Skeletal muscle myocytes | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay | |
| E_02137 | chr12:32821032~32827114 | Skin | Bone Marrow-Derived Macrophages (BMMs) | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_02138 | chr1:190181703~190182534 | Lymphatic vasculature | Lymphatic endothelial cells (LECs) | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay | |
| E_02139 | chr1:136650000~136700000 | Embryo | Mouse Embryonic Stem Cells (mESCs) | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay | |
| E_02140 | chr12:32821032~32827113 | Bone marrow | Bone marrow-derived macrophages (BMMs) | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_02141 | chr12:32821787~32821864 | Blood | RAW 264.7 | Enhancer activity assay, TF binding assay | |
| E_02142 | chr2:14492567~14492959 | Pancreas | Pancreatic Multipotent Progenitor Cells (MPCs) | Functional perturbation assay, Enhancer activity assay | |
| E_02143 | chrX:7570674~7571274 | Thymus | CD4+Foxp3+ Regulatory T Cells (Treg) | Functional perturbation assay, TF binding assay, Enhancer activity assay | |
| E_02144 | chr16:95745432~95912361 | Heart | Outflow tract cardiac muscle cells | Functional perturbation assay, Enhancer activity assay | |
| E_02145 | chr16:95847911~95849564 | Embryonic Limb Bud | Limb bud mesenchymal cells | Enhancer activity assay, Functional perturbation assay | |
| E_02146 | chr16:95847911~95849564 | Limb Bud | Zone of polarizing activity cells | Enhancer activity assay, Functional perturbation assay | |
| E_02147 | chr2:60785660~60787563 | Embryonic Limb Bud | Limb bud mesenchymal cells | Enhancer activity assay, Functional perturbation assay | |
| E_02148 | chr4:154707415~154711162 | Embryonic Limb Bud | Limb bud mesenchymal cells | Enhancer activity assay, Functional perturbation assay | |
| E_02149 | chr7:35860000~35860514 | Bone Marrow | Mouse myeloid progenitor cell | acute myeloid leukemia | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_02150 | chr7:35860000~35860514 | Bone Marrow | MUTZ-3 | acute myeloid leukemia | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_02151 | chr7:35860000~35860514 | Bone Marrow | Primary murine myeloid progenitor cells | acute myeloid leukemia | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_02152 | chr11:33524486~33543505 | Embryo | Embryonic Stem Cells (mESCs) | Functional perturbation assay | |
| E_02153 | chr4:123618309~123637993 | Embryo | Embryonic Stem Cells (mESCs) | Functional perturbation assay | |
| E_02154 | chr9:48814346~48815095 | Thymus | NKT thymocyte and ILCP | Functional perturbation assay | |
| E_02155 | chr9:48814346~48815095 | Thymus | NKT thymocyte and ILCP | Functional perturbation assay | |
| E_02156 | chr16:21480000~21482000 | Embryo | mouse gastrula | Enhancer activity assay, Functional perturbation assay | |
| E_02157 | chr16:21480000~21482000 | Embryo | mouse embryo E11.5 | Enhancer activity assay, Functional perturbation assay | |
| E_02158 | chr1:133345000~133350000 | Kidney | Juxtaglomerular cell | Functional perturbation assay | |
| E_02159 | chr10:127850000~127852000 | Mammary Gland | Mammary epithelial cells | Functional perturbation assay | |
| E_02160 | chr11:97938123~97980122 | Skeletal muscle | Myofibers | Chromatin interaction assay, Functional perturbation assay, Enhancer activity assay | |
| E_02161 | chr11:97938123~97980122 | Skeletal muscle | Myofibers | Chromatin interaction assay, Functional perturbation assay, Enhancer activity assay | |
| E_02162 | chr11:97938123~97980122 | Skeletal muscle | Myofibers | Chromatin interaction assay, Functional perturbation assay, Enhancer activity assay | |
| E_02163 | chr11:97938123~97980122 | Skeletal muscle | Myofibers | Chromatin interaction assay, Functional perturbation assay, Enhancer activity assay | |
| E_02164 | chr11:97938123~97980122 | Skeletal muscle | Myofibers | Chromatin interaction assay, Functional perturbation assay, Enhancer activity assay | |
| E_02165 | chr16:17266000~17266100 | Adipose tissue | 3T3-L1 adipocytes | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay | |
| E_02166 | chr16:17253000~17253100 | Adipose tissue | 3T3-L1 adipocytes | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay | |
| E_02167 | chr12:111517811~111518523 | Bone Marrow | Erythroblasts | Functional perturbation assay, Chromatin interaction assay, TF binding assay | |
| E_02168 | chr12:111517811~111518523 | Fetal Liver | MEL Cells | Functional perturbation assay, Chromatin interaction assay, TF binding assay | |
| E_02169 | chr6:145855899~145856116 | Blood | RAW 264.7 macrophage cells | Enhancer activity assay | |
| E_02170 | chr11:101234567~101235689 | Bone marrow | Myeloid cells | Functional perturbation assay | |
| E_02171 | chr8:89454508~89455383 | Embryonic Limb Bud | Limb bud mesenchymal cells | Enhancer activity assay, Functional perturbation assay | |
| E_02172 | chr8:89454508~89455383 | Limb Bud | Zone of polarizing activity cells | Enhancer activity assay, Functional perturbation assay | |
| E_02173 | chr7:142855000~142857000 | Embryo | Mouse embryonic stem cells (mESCs) | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay | |
| E_02174 | chr11:98480000~98510000 | Mammary Gland | Mammary alveolar epithelial cells | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_02175 | chr19:12600000~12650000 | Mammary Gland | Mammary alveolar epithelial cells | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_02176 | chr5:86800000~87200000 | Mammary Gland | Mammary alveolar epithelial cells | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_02177 | chr5:86800000~87200000 | Mammary Gland | Mammary alveolar epithelial cells | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_02178 | chr16:93024000~93024500 | Bone Marrow | Mouse hematopoietic progenitor cell | Functional perturbation assay | |
| E_02179 | chr16:93142000~93142471 | Bone Marrow | Mouse hematopoietic progenitor cell | Enhancer activity assay, Chromatin interaction assay | |
| E_02180 | chr16:93224000~93224529 | Bone Marrow | Mouse hematopoietic progenitor cell | Enhancer activity assay, Chromatin interaction assay | |
| E_02181 | chr16:93310000~93310579 | Bone Marrow | Mouse hematopoietic progenitor cell | Enhancer activity assay, Chromatin interaction assay | |
| E_02182 | chr5:28395077~28395877 | Embryonic Limb Bud | Embryonic limb bud mesenchymal cells | Enhancer activity assay, TF binding assay | |
| E_02183 | chrX:103345000~103346000 | Embryo | Mouse embryonic stem cells | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_02184 | chrX:103365000~103366000 | Embryo | Mouse embryonic stem cells | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_02185 | chr2:169760000~169760653 | Pancreas | Pancreatic islet cells | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_02186 | chr14:53210000~53210600 | Thymus | Double-negative thymocytes | Functional perturbation assay | |
| E_02187 | chr6:122663482~122708482 | Bone marrow | primary bone marrow-derived pre-B | Time-resolved multi-omic profiling of cell reprogramming | |
| E_02188 | chr9:112500000~112502800 | Cartilage | Mouse Mesenchymal Progenitor | Enhancer activity assay | |
| E_02189 | chr2:11621753~11635500 | Thymus | DN thymocytes | Regulatory element functional validation, 3D chromatin interaction mapping | |
| E_02190 | chr2:11656369~11660078 | Spleen | CD8+ T | Regulatory element functional validation, 3D chromatin interaction mapping | |
| E_02191 | chr1:152006173~152012078 | Lung | BMDM | Enhancer activity assay, Functional perturbation assay | |
| E_02192 | chr8:57331591~57335031 | Uterus | Uterine stromal cells | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_02193 | chr15:61990505~62014068 | Embryo | mESC (naive pluripotency) | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_02194 | chr15:62078497~62099928 | Embryo | EpiLC (formative pluripotency) | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_02195 | chr10:21241829~21242175 | Fetal liver | Erythroid progenitor | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay | |
| E_02196 | chr11:112217279~112217835 | Gonad | Embryonic gonadal cells | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_02197 | chr8:19275272~19275342 | Embryo | MEF | Enhancer activity assay, TF binding assay | |
| E_02198 | chr6:14570800~14570870 | Embryo | MEF | Enhancer activity assay, TF binding assay | |
| E_02199 | chr8:32199690~32200290 | Mammary gland | Met1 | breast cancer | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_02200 | chr11:10077283~10077800 | Mammary Gland | Primary Mouse Mammary Epithelial | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_02201 | chr11:10070908~10071400 | Mammary Gland | Primary Mouse Mammary Epithelial | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_02202 | chr11:10070908~10082508 | Mammary Gland | Primary Mouse Mammary Epithelial | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_02203 | chr11:96750000~96755000 | Bone marrow | Bone Marrow Derived Macrophages (BMDM) | Enhancer activity assay, TF binding assay | |
| E_02204 | chr11:103459000~103463000 | Mammary gland | Mammary epithelial cell | Enhancer activity assay, TF binding assay | |
| E_02205 | chr6:128542796~128543720 | Kidney | Conventional dendritic cells | Functional genomics assay, Epigenomic profiling assay, Genome editing assay, In vivo functional assay | |
| E_02206 | chr2:74925621~74939634 | Limb | Chromatin interaction assay, Functional perturbation assay | ||
| E_02207 | chr2:75081283~75094718 | Limb | Chromatin interaction assay, Functional perturbation assay | ||
| E_02208 | chr2:75128401~75162753 | Limb | Chromatin interaction assay, Functional perturbation assay | ||
| E_02209 | chr2:75194928~75211234 | Limb | Chromatin interaction assay, Functional perturbation assay | ||
| E_02210 | chr2:75420048~75444960 | Limb | Chromatin interaction assay, Functional perturbation assay | ||
| E_02211 | chr4:28176897~28177065 | Skeletal Muscle | Primary myoblasts | Enhancer activity assay, Functional perturbation assay | |
| E_02212 | chr4:28176897~28177065 | Skeletal Muscle | Satellite cells | Enhancer activity assay, Functional perturbation assay | |
| E_02213 | chr19:3441054~3441445 | Brain | SH-SY5Y | neuroblastoma | Enhancer activity assay, Epigenetic modulation assay, Functional perturbation assay |
| E_02214 | chr19:3441054~3441445 | Hypothalamus | Primary hypothalamic neurons | Enhancer activity assay, Epigenetic modulation assay, Functional perturbation assay | |
| E_02215 | chr19:3441054~3441445 | Amygdala | Primary amygdala neurons | Enhancer activity assay, Epigenetic modulation assay, Functional perturbation assay | |
| E_02216 | chr7:136083275~136084434 | Forebrain | Mouse Embryonic Brain Cells | Functional Perturbation Assay, Chromatin Interaction Assay | |
| E_02217 | chr6:113041000~113041700 | Cerebral Cortex | Mouse embryo fibroblast cell | Enhancer activity assay,Functional perturbation assay | |
| E_02218 | chr16:92332000~92333000 | Bone Marrow | Mouse hematopoietic progenitor cell | Enhancer activity assay, Chromatin interaction assay | |
| E_02219 | chr16:92414000~92415000 | Bone Marrow | Mouse hematopoietic progenitor cell | Enhancer activity assay, Chromatin interaction assay | |
| E_02220 | chr13:53802995~53810985 | Forebrain | Mouse neuroblastoma cell | Enhancer activity assay, TF binding assay | |
| E_02221 | chr6:122498000~122499500 | Spleen | mature B | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay | |
| E_02222 | chr6:122502000~122503500 | Spleen | mature B | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay | |
| E_02223 | chr6:122506000~122507500 | Spleen | mature B | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay | |
| E_02224 | chr6:122510000~122511500 | Spleen | mature B | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay | |
| E_02225 | chr15:61825000~62125000 | Spleen | mature B | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay | |
| E_02226 | chr11:45582000~45582499 | Thymus | double-negative thymocyte | Enhancer activity assay, Chromatin interaction assay, TF binding assay | |
| E_02227 | chr11:45582000~45582499 | Thymus | double-positive thymocyte | Enhancer activity assay, Chromatin interaction assay, TF binding assay | |
| E_02228 | chr11:45582000~45582499 | Thymus | naive CD4-positive T cell | Enhancer activity assay, Chromatin interaction assay, TF binding assay | |
| E_02229 | chr11:45582000~45582499 | Thymus | Th1 | Enhancer activity assay, Chromatin interaction assay, TF binding assay | |
| E_02230 | chr11:45586000~45586499 | Thymus | double-negative thymocyte | Enhancer activity assay, Chromatin interaction assay, TF binding assay | |
| E_02231 | chr11:45586000~45586499 | Thymus | double-positive thymocyte | Enhancer activity assay, Chromatin interaction assay, TF binding assay | |
| E_02232 | chr11:45586000~45586499 | Thymus | naive CD4-positive T cell | Enhancer activity assay, Chromatin interaction assay, TF binding assay | |
| E_02233 | chr11:45586000~45586499 | Thymus | Th1 | Enhancer activity assay, Chromatin interaction assay, TF binding assay | |
| E_02234 | chr11:45590000~45590499 | Thymus | double-negative thymocyte | Enhancer activity assay, Chromatin interaction assay, TF binding assay | |
| E_02235 | chr11:45590000~45590499 | Thymus | double-positive thymocyte | Enhancer activity assay, Chromatin interaction assay, TF binding assay | |
| E_02236 | chr11:45590000~45590499 | Thymus | naive CD4-positive T cell | Enhancer activity assay, Chromatin interaction assay, TF binding assay | |
| E_02237 | chr11:45590000~45590499 | Thymus | Th1 | Enhancer activity assay, Chromatin interaction assay, TF binding assay | |
| E_02238 | chr11:45594000~45594499 | Thymus | double-negative thymocyte | Enhancer activity assay, Chromatin interaction assay, TF binding assay | |
| E_02239 | chr11:45594000~45594499 | Thymus | double-positive thymocyte | Enhancer activity assay, Chromatin interaction assay, TF binding assay | |
| E_02240 | chr11:45594000~45594499 | Thymus | naive CD4-positive T cell | Enhancer activity assay, Chromatin interaction assay, TF binding assay | |
| E_02241 | chr11:45594000~45594499 | Thymus | Th1 | Enhancer activity assay, Chromatin interaction assay, TF binding assay | |
| E_02242 | chr11:45598000~45598499 | Thymus | double-negative thymocyte | Enhancer activity assay, Chromatin interaction assay, TF binding assay | |
| E_02243 | chr11:45598000~45598499 | Thymus | double-positive thymocyte | Enhancer activity assay, Chromatin interaction assay, TF binding assay | |
| E_02244 | chr11:45598000~45598499 | Thymus | naive CD4-positive T cell | Enhancer activity assay, Chromatin interaction assay, TF binding assay | |
| E_02245 | chr11:45598000~45598499 | Thymus | Th1 | Enhancer activity assay, Chromatin interaction assay, TF binding assay | |
| E_02246 | chr11:45602000~45602499 | Thymus | double-negative thymocyte | Enhancer activity assay, Chromatin interaction assay, TF binding assay | |
| E_02247 | chr11:45602000~45602499 | Thymus | double-positive thymocyte | Enhancer activity assay, Chromatin interaction assay, TF binding assay | |
| E_02248 | chr11:45602000~45602499 | Thymus | naive CD4-positive T cell | Enhancer activity assay, Chromatin interaction assay, TF binding assay | |
| E_02249 | chr11:45602000~45602499 | Thymus | Th1 | Enhancer activity assay, Chromatin interaction assay, TF binding assay | |
| E_02250 | chr11:45606000~45606499 | Thymus | double-negative thymocyte | Enhancer activity assay, Chromatin interaction assay, TF binding assay | |
| E_02251 | chr11:45606000~45606499 | Thymus | double-positive thymocyte | Enhancer activity assay, Chromatin interaction assay, TF binding assay | |
| E_02252 | chr11:45606000~45606499 | Thymus | naive CD4-positive T cell | Enhancer activity assay, Chromatin interaction assay, TF binding assay | |
| E_02253 | chr11:45606000~45606499 | Thymus | Th1 | Enhancer activity assay, Chromatin interaction assay, TF binding assay | |
| E_02254 | chr11:45610000~45610499 | Thymus | double-negative thymocyte | Enhancer activity assay, Chromatin interaction assay, TF binding assay | |
| E_02255 | chr11:45610000~45610499 | Thymus | double-positive thymocyte | Enhancer activity assay, Chromatin interaction assay, TF binding assay | |
| E_02256 | chr11:45610000~45610499 | Thymus | naive CD4-positive T cell | Enhancer activity assay, Chromatin interaction assay, TF binding assay | |
| E_02257 | chr11:45610000~45610499 | Thymus | Th1 | Enhancer activity assay, Chromatin interaction assay, TF binding assay | |
| E_02258 | chr11:45614000~45614499 | Thymus | double-negative thymocyte | Enhancer activity assay, Chromatin interaction assay, TF binding assay | |
| E_02259 | chr11:45614000~45614499 | Thymus | double-positive thymocyte | Enhancer activity assay, Chromatin interaction assay, TF binding assay | |
| E_02260 | chr11:45614000~45614499 | Thymus | naive CD4-positive T cell | Enhancer activity assay, Chromatin interaction assay, TF binding assay | |
| E_02261 | chr11:45614000~45614499 | Thymus | Th1 | Enhancer activity assay, Chromatin interaction assay, TF binding assay | |
| E_02262 | chr11:45618000~45618499 | Thymus | double-negative thymocyte | Enhancer activity assay, Chromatin interaction assay, TF binding assay | |
| E_02263 | chr11:45618000~45618499 | Thymus | double-positive thymocyte | Enhancer activity assay, Chromatin interaction assay, TF binding assay | |
| E_02264 | chr11:45618000~45618499 | Thymus | naive CD4-positive T cell | Enhancer activity assay, Chromatin interaction assay, TF binding assay | |
| E_02265 | chr11:45618000~45618499 | Thymus | Th1 | Enhancer activity assay, Chromatin interaction assay, TF binding assay | |
| E_02266 | chr11:45622000~45622499 | Thymus | double-negative thymocyte | Enhancer activity assay, Chromatin interaction assay, TF binding assay | |
| E_02267 | chr11:45622000~45622499 | Thymus | double-positive thymocyte | Enhancer activity assay, Chromatin interaction assay, TF binding assay | |
| E_02268 | chr11:45622000~45622499 | Thymus | naive CD4-positive T cell | Enhancer activity assay, Chromatin interaction assay, TF binding assay | |
| E_02269 | chr11:45622000~45622499 | Thymus | Th1 | Enhancer activity assay, Chromatin interaction assay, TF binding assay | |
| E_02270 | chr10:61645000~61646000 | Embryo | Mouse Embryonic Stem | Enhancer activity assay, TF binding assay, Chromatin interaction assay | |
| E_02271 | chr14:54950000~54951000 | Embryo | Mouse Embryonic Stem | Enhancer activity assay, TF binding assay, Chromatin interaction assay | |
| E_02272 | chr2:146950000~146951000 | Embryo | Mouse Embryonic Stem | Enhancer activity assay, TF binding assay, Chromatin interaction assay | |
| E_02273 | chr6:84520000~84524600 | Pituitary gland | alphaT3-1 | Enhancer activity assay, Chromatin interaction assay | |
| E_02274 | chr2:129318595~129323595 | Heart | Macrophage | Enhancer activity assay | |
| E_02275 | chr12:117170000~117198000 | Spleen | CH12F3-2A | Regulatory element functional validation, super-enhancer activation analysis | |
| E_02276 | chr7:94261534~94261892 | Intervertebral disc | Annulus fibrosus | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_02277 | chr15:71595~72481 | Cartilage | Primary chondrocytes | Enhancer activity assay, TF binding assay | |
| E_02278 | chr6:100282437~100393986 | Embryo | Mouse Embryonic Stem Cells (v6.5) | Enhancer activity assay | |
| E_02279 | chr3:34546571~34552571 | Embryo | Mouse Embryonic Stem Cells (v6.5) | Enhancer activity assay | |
| E_02280 | chr15:1~1000 | Embryo | MEF | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_02281 | chr4:49550000~49600000 | Cerebellum | Mouse Cerebellar Granule Neurons | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay | |
| E_02282 | chr13:28260000~29080000 | Cerebellum | Mouse Cerebellar Granule Neurons | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay | |
| E_02283 | chr4:95048663~95059853 | Cerebellum | Mouse Cerebellar Granule Neurons | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay | |
| E_02284 | chr10:117390000~117760000 | Cerebellum | Mouse Cerebellar Granule Neurons | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay | |
| E_02285 | chr19:25728596~25729301 | Cartilage | Primary chondrocytes | Enhancer activity assay | |
| E_02286 | chr4:95630001~95639906 | Cerebellum | Cerebellar granule neurons | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay | |
| E_02287 | chr15:79849001~79850000 | Aorta | Cardiac endothelial cells (MCECs) | TF binding assay, Enhancer activity assay | |
| E_02288 | chr5:29314591~29316266 | Limb bud | Embryonic limb mesenchyme | Enhancer activity assay, TF binding assay, Chromatin interaction assay | |
| E_02289 | chr4:156021490~156022916 | Immune System | Primary mouse regulatory T cells | Functional perturbation assay | |
| E_02290 | chr2:44123800~44124118 | Inner Ear | mESC differentiated hair cell | Enhancer activity assay, Functional perturbation assay | |
| E_02291 | chr2:9895741~9898314 | Lens | Lens epithelial cells | Enhancer activity assay | |
| E_02292 | chr2:9897700~9898314 | Lens | Lens epithelial cells | Enhancer activity assay | |
| E_02293 | chr2:9895741~9896397 | Lens | Lens epithelial cells | Enhancer activity assay | |
| E_02294 | chr2:9881939~9882773 | Lens | Lens epithelial cells | Enhancer activity assay | |
| E_02295 | chr1:13344600~13346900 | Kidney | JG cells | Functional perturbation assay | |
| E_02296 | chr18:60211000~60212000 | Liver | Primary hepatocytes | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_02297 | chr18:60211000~60212000 | Liver | McArdle hepatocytes | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_02298 | chr18:60211000~60212000 | Embryonic Kidney | HEK293T cells | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_02299 | chr18:60211000~60212000 | Liver | Primary hepatocytes | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_02300 | chr18:60211000~60212000 | Liver | McArdle hepatocytes | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_02301 | chr18:60211000~60212000 | Embryonic Kidney | HEK293T cells | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_02302 | chr8:124380000~124380454 | Bone Marrow | Common Dendritic Cell Progenitor (CDP) | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_02303 | chr8:124380000~124380454 | Bone Marrow | Pre-cDC1 | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_02304 | chr8:124380000~124380454 | Bone Marrow | Plasmacytoid Dendritic Cells (pDC) | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_02305 | chr14:48579937~48581029 | Retina | Primary Mouse Embryonic Retinal Explant Cells | Enhancer activity assay | |
| E_02306 | chr14:48584564~48585012 | Retina | Primary Mouse Embryonic Retinal Explant Cells | Enhancer activity assay | |
| E_02307 | chr14:48593170~48594188 | Retina | Primary Mouse Embryonic Retinal Explant Cells | Enhancer activity assay | |
| E_02308 | chr14:48606973~48608016 | Retina | Primary Mouse Embryonic Retinal Explant Cells | Enhancer activity assay | |
| E_02309 | chr14:48608144~48609697 | Retina | Primary Mouse Embryonic Retinal Explant Cells | Enhancer activity assay | |
| E_02310 | chr14:48616314~48617497 | Retina | Primary Mouse Embryonic Retinal Explant Cells | Enhancer activity assay | |
| E_02311 | chr14:48624486~48626389 | Retina | Primary Mouse Embryonic Retinal Explant Cells | Enhancer activity assay | |
| E_02312 | chr14:48662841~48663211 | Retina | Primary Mouse Embryonic Retinal Explant Cells | Enhancer activity assay | |
| E_02313 | chr16:95721049~95979933 | Heart | Cardiac endothelial cells | Functional perturbation assay | |
| E_02314 | chr16:95721049~95979933 | Heart | Aortic endothelial cells | Functional perturbation assay | |
| E_02315 | chr5:12345678~12346478 | Embryonic Craniofacial Tissue | Mouse cranial neural crest cells | Enhancer activity assay, Functional perturbation assay | |
| E_02316 | chr5:29314881~29315667 | Limb Bud | Zone of polarizing activity cells | Enhancer activity assay | |
| E_02317 | chr16:92829000~92829471 | Bone Marrow | Mouse hematopoietic progenitor cell | Enhancer activity assay, Chromatin interaction assay | |
| E_02318 | chr16:92832000~92832471 | Bone Marrow | Mouse hematopoietic progenitor cell | Enhancer activity assay, Chromatin interaction assay | |
| E_02319 | chr16:92846000~92846471 | Bone Marrow | Mouse hematopoietic progenitor cell | Enhancer activity assay, Chromatin interaction assay | |
| E_02320 | chr16:92879000~92879471 | Bone Marrow | Mouse hematopoietic progenitor cell | Enhancer activity assay, Chromatin interaction assay | |
| E_02321 | chr16:92897000~92897471 | Bone Marrow | Mouse hematopoietic progenitor cell | Enhancer activity assay, Chromatin interaction assay | |
| E_02322 | chr16:93110000~93110500 | Bone Marrow | Mouse hematopoietic progenitor cell | Enhancer activity assay | |
| E_02323 | chr16:93152000~93152471 | Bone Marrow | Mouse hematopoietic progenitor cell | Enhancer activity assay, Chromatin interaction assay | |
| E_02324 | chr14:23090994~23098987 | Forebrain | Mouse neuroblastoma cell | Enhancer activity assay, TF binding assay | |
| E_02325 | chr19:14773960~14781991 | Forebrain | Mouse neuroblastoma cell | Enhancer activity assay, TF binding assay | |
| E_02326 | chr2:115721983~115729990 | Forebrain | Mouse neuroblastoma cell | Enhancer activity assay, TF binding assay | |
| E_02327 | chr6:15366783~15417517 | Forebrain | Mouse neuroblastoma cell | Enhancer activity assay, TF binding assay | |
| E_02328 | chr6:15408978~15417000 | Forebrain | Mouse neuroblastoma cell | Enhancer activity assay, TF binding assay | |
| E_02329 | chr1:172411511~172413110 | Heart | Sinoatrial Node Pacemaker | Enhancer activity assay | |
| E_02330 | chr12:4704343~4706142 | Heart | Sinoatrial Node Pacemaker | Enhancer activity assay | |
| E_02331 | chr6:113010000~113010100 | Embryo | EpiLCs | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_02332 | chr6:113010000~113010100 | Embryo | PGCLCs | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_02333 | chr4:135010000~135010100 | Embryo | EpiLCs | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_02334 | chr4:135010000~135010100 | Embryo | PGCLCs | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_02335 | chr1:88392925~88392988 | Bone marrow | Primary pro-B | Enhancer activity assay, Chromatin interaction assay | |
| E_02336 | chr1:120286768~120286837 | Bone marrow | Primary pro-B | Enhancer activity assay, Chromatin interaction assay | |
| E_02337 | chr1:167519257~167519314 | Bone marrow | Primary pro-B | Enhancer activity assay, Chromatin interaction assay | |
| E_02338 | chr1:167572056~167572182 | Bone marrow | Primary pro-B | Enhancer activity assay, Chromatin interaction assay | |
| E_02339 | chr1:173848852~173848903 | Bone marrow | Primary pro-B | Enhancer activity assay, Chromatin interaction assay | |
| E_02340 | chr16:95636899~95636961 | Bone marrow | Primary pro-B | Enhancer activity assay, Chromatin interaction assay | |
| E_02341 | chr16:95640070~95640137 | Bone marrow | Primary pro-B | Enhancer activity assay, Chromatin interaction assay | |
| E_02342 | chr18:86761026~86761110 | Bone marrow | Primary pro-B | Enhancer activity assay, Chromatin interaction assay | |
| E_02343 | chr18:86772479~86772600 | Bone marrow | Primary pro-B | Enhancer activity assay, Chromatin interaction assay | |
| E_02344 | chr18:86773163~86773345 | Bone marrow | Primary pro-B | Enhancer activity assay, Chromatin interaction assay | |
| E_02345 | chr2:121974537~121974595 | Bone marrow | Primary pro-B | Enhancer activity assay, Chromatin interaction assay | |
| E_02346 | chr6:48626570~48626638 | Bone marrow | Primary pro-B | Enhancer activity assay, Chromatin interaction assay | |
| E_02347 | chr5:28369548~28371047 | Forebrain | Mouse Embryonic Neural Progenitor | Enhancer activity assay, Functional perturbation assay | |
| E_02348 | chr17:27040383~27042465 | Heart | Cardiac progenitor cells | Enhancer activity assay | |
| E_02349 | chr11:111805000~111805100 | Cartilage | Primary chondrocytes | Enhancer activity assay, TF binding assay | |
| E_02350 | chr11:111916000~111916100 | Cartilage | Primary chondrocytes | Enhancer activity assay | |
| E_02351 | chr11:111930000~111930100 | Cartilage | Primary chondrocytes | Enhancer activity assay, TF binding assay | |
| E_02352 | chr7:19145920~19146014 | Skeletal Muscle | C2C12 | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_02353 | chr7:19145920~19146014 | Skeletal Muscle | Primary Myocytes | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_02354 | chr14:64201000~64201728 | Hypothalamus | GnRH neurons | Enhancer activity assay, Functional perturbation assay | |
| E_02355 | chr14:64201000~64201728 | Hypothalamus | Ovarian surface epithelial cells | Enhancer activity assay, Functional perturbation assay | |
| E_02356 | chr14:64201000~64201728 | Hypothalamus | Granulosa cells | Enhancer activity assay, Functional perturbation assay | |
| E_02357 | chr2:8936092~8980864 | Lung | primary CD4+ T cell (Th2) | asthma | Functional perturbation assay, Chromatin interaction assay |
| E_02358 | chr11:55120386~55120691 | Kidney | MDCK | Enhancer activity assay, TF binding assay | |
| E_02359 | chr3:14761800~14762300 | Adipose tissue | MEF | Enhancer activity assay, TF binding assay | |
| E_02360 | chr3:14759100~14759600 | Adipose tissue | MEF | Enhancer activity assay, TF binding assay | |
| E_02361 | chr10:118409500~118410500 | Spleen | Primary Naive CD4+ T | TF binding assay, Functional perturbation assay | |
| E_02362 | chr10:118409500~118410500 | Lymph Node | In vitro Differentiated Th1 | TF binding assay, Functional perturbation assay | |
| E_02363 | chr10:23929882~23931253 | Olfactory epithelium | Olfactory sensory neuron (OSN) | Functional perturbation assay, Enhancer activity assay | |
| E_02364 | chr10:23987372~23988804 | Olfactory epithelium | Olfactory sensory neuron (OSN) | Functional perturbation assay, Enhancer activity assay | |
| E_02365 | chr3:98010000~98160000 | Heart | Atrial cardiomyocyte cell line | atrial fibrillation | Functional perturbation assay, Enhancer activity assay |
| E_02366 | chr1:135324502~135324868 | Blood vessel | Vascular smooth muscle cells | Enhancer activity assay | |
| E_02367 | chr1:193272679~193273133 | Cerebral Cortex | Oligodendrocyte precursor cells | Enhancer activity assay | |
| E_02368 | chr1:36539161~36539602 | Blood vessel | Vascular smooth muscle cells | Enhancer activity assay | |
| E_02369 | chr10:116270311~116271768 | Blood vessel | Endothelial cells | Enhancer activity assay | |
| E_02370 | chr10:24493568~24493998 | Blood vessel | Endothelial cells | Enhancer activity assay | |
| E_02371 | chr10:24824503~24825197 | Blood vessel | Endothelial cells | Enhancer activity assay | |
| E_02372 | chr11:106382395~106382923 | Blood vessel | Endothelial cells | Enhancer activity assay | |
| E_02373 | chr12:85455100~85455928 | Blood vessel | Endothelial cells | Enhancer activity assay | |
| E_02374 | chr13:60897338~60897768 | Blood vessel | Endothelial cells | Enhancer activity assay | |
| E_02375 | chr13:60936496~60937061 | Blood vessel | Endothelial cells | Enhancer activity assay | |
| E_02376 | chr13:97579897~97580928 | Blood vessel | Endothelial cells | Enhancer activity assay | |
| E_02377 | chr13:97580240~97580407 | Blood vessel | Endothelial cells | Enhancer activity assay | |
| E_02378 | chr14:50995230~50995698 | Blood vessel | Endothelial cells | Enhancer activity assay | |
| E_02379 | chr14:50995280~50995470 | Blood vessel | Endothelial cells | Enhancer activity assay | |
| E_02380 | chr14:50995418~50995609 | Blood vessel | Endothelial cells | Enhancer activity assay | |
| E_02381 | chr14:50995561~50995752 | Blood vessel | Endothelial cells | Enhancer activity assay | |
| E_02382 | chr15:72034077~72034453 | Blood vessel | Vascular smooth muscle cells | Enhancer activity assay | |
| E_02383 | chr15:75001522~75001829 | Blood vessel | Endothelial cells | Enhancer activity assay | |
| E_02384 | chr15:75001571~75001879 | Blood vessel | Endothelial cells | Enhancer activity assay | |
| E_02385 | chr15:85574338~85575028 | Cerebral Cortex | Oligodendrocyte precursor cells | Enhancer activity assay | |
| E_02386 | chr16:18703897~18705643 | Blood vessel | Endothelial cells | Enhancer activity assay | |
| E_02387 | chr16:32512896~32513882 | Blood vessel | Endothelial cells | Enhancer activity assay | |
| E_02388 | chr16:38432836~38433208 | Blood vessel | Vascular smooth muscle cells | Enhancer activity assay | |
| E_02389 | chr17:31905602~31906289 | Blood vessel | Endothelial cells | Enhancer activity assay | |
| E_02390 | chr19:34733020~34733442 | Blood vessel | Vascular smooth muscle cells | Enhancer activity assay | |
| E_02391 | chr19:38027995~38028468 | Blood vessel | Endothelial cells | Enhancer activity assay | |
| E_02392 | chr2:152155608~152156274 | Blood vessel | Endothelial cells | Enhancer activity assay | |
| E_02393 | chr2:157506804~157507303 | Blood vessel | Vascular smooth muscle cells | Enhancer activity assay | |
| E_02394 | chr2:181487538~181488198 | Blood vessel | Endothelial cells | Enhancer activity assay | |
| E_02395 | chr2:26575785~26576489 | Blood vessel | Endothelial cells | Enhancer activity assay | |
| E_02396 | chr2:57116616~57117116 | Blood vessel | Endothelial cells | Enhancer activity assay | |
| E_02397 | chr4:118489677~118490197 | Blood vessel | Endothelial cells | Enhancer activity assay | |
| E_02398 | chr4:119043893~119045511 | Blood vessel | Endothelial cells | Enhancer activity assay | |
| E_02399 | chr4:119044310~119044536 | Blood vessel | Endothelial cells | Enhancer activity assay | |
| E_02400 | chr4:47237059~47237485 | Blood vessel | Vascular smooth muscle cells | Enhancer activity assay | |
| E_02401 | chr4:55670153~55670693 | Blood vessel | Endothelial cells | Enhancer activity assay | |
| E_02402 | chr5:104397936~104398396 | Blood vessel | Vascular smooth muscle cells | Enhancer activity assay | |
| E_02403 | chr5:142905691~142906292 | Blood vessel | Endothelial cells | Enhancer activity assay | |
| E_02404 | chr6:142544854~142545576 | Blood vessel | Vascular smooth muscle cells | Enhancer activity assay | |
| E_02405 | chr6:58623144~58623738 | Blood vessel | Endothelial cells | Enhancer activity assay | |
| E_02406 | chr7:18884015~18884799 | Blood vessel | Endothelial cells | Enhancer activity assay | |
| E_02407 | chr7:46746201~46746883 | Blood vessel | Vascular smooth muscle cells | Enhancer activity assay | |
| E_02408 | chr7:99694197~99694747 | Blood vessel | Endothelial cells | Enhancer activity assay | |
| E_02409 | chr9:37400589~37400968 | Blood vessel | Endothelial cells | Enhancer activity assay | |
| E_02410 | chr9:37401768~37402146 | Blood vessel | Endothelial cells | Enhancer activity assay | |
| E_02411 | chr9:57597959~57598486 | Cerebral Cortex | Oligodendrocyte precursor cells | Enhancer activity assay | |
| E_02412 | chr7:35940000~35940455 | Bone Marrow | Primary murine myeloid progenitor cells | acute myeloid leukemia | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_02413 | chr7:35940000~35940455 | Bone Marrow | Common myeloid progenitor cells | acute myeloid leukemia | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_02414 | chr7:35940000~35940455 | Bone Marrow | Granulocyte-monocyte progenitor cells | acute myeloid leukemia | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_02415 | chr7:35940000~35940455 | Bone Marrow | LSK cells | acute myeloid leukemia | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_02416 | chr14:78469483~78470483 | Blood | Enhancer activity assay, TF binding assay, Chromatin interaction assay | ||
| E_02417 | chr11:98040000~98080000 | Bone Marrow | Neutrophils | Immunological functional assay, Functional genomics assay, Epigenomic profiling assay, Transcriptional regulation assay | |
| E_02418 | chr12:10710000~10750000 | Bone Marrow | Monocyte-dendritic cell progenitor cells | Immunological functional assay, Functional genomics assay, Epigenomic profiling assay, Transcriptional regulation assay, In vitro functional assay, In vivo functional assay | |
| E_02419 | chr13:48580000~48620000 | Bone Marrow | Monocyte-dendritic cell progenitor cells | Immunological functional assay, Functional genomics assay, Epigenomic profiling assay, Transcriptional regulation assay | |
| E_02420 | chr16:16980000~17020000 | Bone Marrow | B lymphocytes | Immunological functional assay, Functional genomics assay, Epigenomic profiling assay, Transcriptional regulation assay | |
| E_02421 | chr19:61222000~61250000 | Bone Marrow | Granulocyte-monocyte progenitor cells | Immunological functional assay, Functional genomics assay, Epigenomic profiling assay, Transcriptional regulation assay, In vitro functional assay, In vivo functional assay, Developmental biology assay | |
| E_02422 | chr2:103295000~103314000 | Bone Marrow | Monocyte-dendritic cell progenitor cells | Immunological functional assay, Functional genomics assay, Epigenomic profiling assay, Transcriptional regulation assay, In vitro functional assay, In vivo functional assay | |
| E_02423 | chr2:143822000~143865000 | Bone Marrow | Ly6C+ classical monocytes | Immunological functional assay, Functional genomics assay, Epigenomic profiling assay, Transcriptional regulation assay, In vitro functional assay, In vivo functional assay | |
| E_02424 | chr7:114280000~114320000 | Bone Marrow | Neutrophils | Immunological functional assay, Functional genomics assay, Epigenomic profiling assay, Transcriptional regulation assay | |
| E_02425 | chr8:44910000~44930000 | Bone Marrow | Ly6C+ classical monocytes | Immunological functional assay, Functional genomics assay, Epigenomic profiling assay, Transcriptional regulation assay, In vitro functional assay, In vivo functional assay | |
| E_02426 | chr1:152006173~152012078 | Lung | Bone Marrow-Derived Macrophages (BMDMs) | Enhancer activity assay, Functional perturbation assay, Chromatin interaction assay | |
| E_02427 | chr8:124371000~124371500 | Spleen | Mature cDC1 | Enhancer activity assay, TF binding assay | |
| E_02428 | chr8:124371000~124371500 | Bone Marrow | Pre-cDC1 | Enhancer activity assay, TF binding assay | |
| E_02429 | chr12:103026200~103027200 | Hypothalamus | Mouse primary neurons | Functional perturbation assay | |
| E_02430 | chr17:34210000~34250000 | Bone marrow | Monocyte-dendritic cell progenitor cells | Immunological functional assay, Functional genomics assay, Epigenomic profiling assay, Transcriptional regulation assay | |
| E_02431 | chr8:124580000~124620000 | Bone marrow | Ly6C+ classical monocytes | Immunological functional assay, Functional genomics assay, Epigenomic profiling assay, Transcriptional regulation assay, In vitro functional assay, In vivo functional assay | |
| E_02432 | chr9:124480000~124520000 | Bone marrow | Ly6C+ classical monocytes | Immunological functional assay, Functional genomics assay, Epigenomic profiling assay, Transcriptional regulation assay | |
| E_02433 | chr1:12189000~12190000 | Embryoid Body | Pluripotent cells | Enhancer activity assay | |
| E_02434 | chr1:12189000~12190000 | Embryoid Body | Parietal endoderm cells | Enhancer activity assay | |
| E_02435 | chr12:21830000~21831000 | Embryoid Body | Parietal endoderm cells | Enhancer activity assay | |
| E_02436 | chr15:65218400~65218700 | Cerebral Cortex | L5_IT glutamatergic neurons | Enhancer activity assay | |
| E_02437 | chr2:78542600~78542900 | Cerebral Cortex | L5_ET glutamatergic neurons | Enhancer activity assay | |
| E_02438 | chr4:98754300~98754600 | Cerebral Cortex | Astrocytes | Enhancer activity assay | |
| E_02439 | chr17:34520000~34525000 | Lung | Mouse Pulmonary Artery Endothelial Cells | Enhancer activity assay, Functional perturbation assay | |
| E_02440 | chr10:127950000~127955000 | Mammary Gland | Mammary alveolar epithelial cells | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_02441 | chr11:100950000~100955000 | Mammary Gland | Mammary alveolar epithelial cells | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_02442 | chr11:100950000~100955000 | Mammary Gland | Mammary alveolar epithelial cells | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_02443 | chr15:98450000~98455000 | Mammary Gland | Mammary alveolar epithelial cells | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_02444 | chr17:30950000~30955000 | Mammary Gland | Mammary alveolar epithelial cells | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_02445 | chr2:151850000~151855000 | Mammary Gland | Mammary alveolar epithelial cells | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_02446 | chr4:100450000~100455000 | Mammary Gland | Mammary alveolar epithelial cells | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_02447 | chr4:142900000~142905000 | Mammary Gland | Mammary alveolar epithelial cells | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_02448 | chr5:87140000~87145000 | Mammary Gland | Mammary alveolar epithelial cells | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_02449 | chr8:19550000~19555000 | Mammary Gland | Mammary alveolar epithelial cells | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_02450 | chr11:94321500~94321800 | Cerebral Cortex | L2-3_IT glutamatergic neurons | Enhancer activity assay | |
| E_02451 | chr12:102567800~102568100 | Cerebral Cortex | Sst_Chodl GABAergic neurons | Enhancer activity assay | |
| E_02452 | chr16:89765300~89765600 | Cerebral Cortex | GABAergic neurons | Enhancer activity assay | |
| E_02453 | chr3:145217900~145218200 | Cerebral Cortex | L6b glutamatergic neurons | Enhancer activity assay | |
| E_02454 | chr5:32156800~32157100 | Cerebral Cortex | Astrocytes | Enhancer activity assay | |
| E_02455 | chr7:128945200~128945500 | Cerebral Cortex | L2-3_IT glutamatergic neurons | Enhancer activity assay | |
| E_02456 | chr17:25313666~25315178 | Stomach | Enteroendocrine cells | Enhancer activity assay, Functional perturbation assay | |
| E_02457 | chr4:55630000~55650000 | Bone Marrow | Monocyte-dendritic cell progenitor cells | Immunological functional assay, Functional genomics assay, Epigenomic profiling assay, Transcriptional regulation assay, In vitro functional assay, In vivo functional assay | |
| E_02458 | chr17:34540000~34542000 | Embryo | Tail tip fibroblasts | Enhancer activity assay, Functional perturbation assay, TF binding assay | |
| E_02459 | chr5:141952000~141952800 | Embryo | Mouse embryonic stem cells (LF2 strain) | Enhancer activity assay, TF binding assay, Functional perturbation assay, Enhancer decommissioning assay | |
| E_02460 | chr7:122684500~122685300 | Embryo | Mouse embryonic stem cells (LF2 strain) | Enhancer activity assay, TF binding assay, Functional perturbation assay, Germline specification assay | |
| E_02461 | chr13:74521600~74522400 | Embryo | Mouse embryonic stem cells (LF2 strain) | TF binding assay, Functional perturbation assay, Enhancer decommissioning assay, Germline specification assay | |
| E_02462 | chr4:103876200~103877000 | Embryo | Mouse embryonic stem cells (LF2 strain) | Functional perturbation assay, Enhancer decommissioning assay, Germline specification assay | |
| E_02463 | chr3:127349185~127349631 | Midbrain | mDA progenitors/neurons (E12.5) | Enhancer activity assay, TF binding assay (ChIP-supported) | |
| E_02464 | chr17:35602100~35602600 | Embryo | mouse ESCs | Functional perturbation assay | |
| E_02465 | chr15:52153900~52154520 | Pancreas | ??TC-3 | Enhancer activity assay, TF binding assay | |
| E_02466 | chr15:52153900~52154520 | Pancreas | ??TC-6 | Enhancer activity assay, TF binding assay | |
| E_02467 | chr15:52153900~52154520 | Cervix | HeLa | cervical cancer | Enhancer activity assay, TF binding assay |
| E_02468 | chr8:120880096~120882495 | Lung | Embryonic lung tissue | Functional perturbation assay | |
| E_02469 | chr1:154150000~154150500 | Heart | Mouse embryonic/Adult cardiomyocytes | TF binding assay, Functional perturbation assay | |
| E_02470 | chr1:154150500~154151000 | Heart | Mouse embryonic/Adult cardiomyocytes | TF binding assay, Functional perturbation assay | |
| E_02471 | chr1:154151000~154151500 | Heart | Mouse embryonic/Adult cardiomyocytes | TF binding assay, Functional perturbation assay | |
| E_02472 | chr4:154706480~154712089 | Embryonic Limb Bud | Limb bud mesenchymal cells | Enhancer activity assay, Functional perturbation assay | |
| E_02473 | chr14:48799494~48801489 | Retina | Enhancer activity assay, TF binding assay | ||
| E_02474 | chr12:118718991~118721980 | Forebrain | Mouse embryonic GE progenitor | Enhancer activity assay, TF binding assay | |
| E_02475 | chr2:63090990~63093985 | Forebrain | Mouse embryonic GE progenitor | Enhancer activity assay, TF binding assay | |
| E_02476 | chr2:72425536~72428482 | Forebrain | Mouse embryonic GE progenitor | Enhancer activity assay, TF binding assay | |
| E_02477 | chr9:118718991~118721980 | Forebrain | Mouse embryonic GE progenitor | Enhancer activity assay, TF binding assay | |
| E_02478 | chr11:44280890~44281890 | Blood | Enhancer activity assay, TF binding assay | ||
| E_02479 | chr14:95982949~95983230 | Retina | Enhancer activity assay, TF binding assay | ||
| E_02480 | chr1:100900000~100900243 | Bone | mOS-482 | Enhancer activity assay | |
| E_02481 | chr17:34048994~34049208 | Lens | Lens epithelial cells | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay | |
| E_02482 | chr17:34048994~34049208 | Lens | Lens fiber cells | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay | |
| E_02483 | chr17:34049209~34050661 | Lens | Lens epithelial cells | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay | |
| E_02484 | chr17:34049209~34050661 | Lens | Lens fiber cells | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay | |
| E_02485 | chr17:34060350~34061356 | Lens | Lens epithelial cells | Enhancer activity assay, Chromatin interaction assay | |
| E_02486 | chr17:34060350~34061356 | Lens | Lens fiber cells | Enhancer activity assay, Chromatin interaction assay | |
| E_02487 | chr11:32160121~32161120 | Blood | mESC-derived erythroid cells | Functional perturbation assay | |
| E_02488 | chr11:32166121~32167120 | Blood | mESC-derived erythroid cells | Functional perturbation assay | |
| E_02489 | chrX:103455000~103456000 | Embryo | Mouse embryonic stem cells | Functional perturbation assay | |
| E_02490 | chrX:103455000~103456000 | Embryo | Mouse embryo cells | Functional perturbation assay | |
| E_02491 | chr16:92629000~92629500 | Bone Marrow | Mouse hematopoietic progenitor cell | Enhancer activity assay | |
| E_02492 | chr16:92632000~92632500 | Bone Marrow | Mouse hematopoietic progenitor cell | Enhancer activity assay | |
| E_02493 | chr16:92679000~92679500 | Bone Marrow | Mouse hematopoietic progenitor cell | Enhancer activity assay | |
| E_02494 | chr16:92697000~92697500 | Bone Marrow | Mouse hematopoietic progenitor cell | Enhancer activity assay | |
| E_02495 | chr16:92629000~92629500 | Bone Marrow | Mouse hematopoietic progenitor cell | Enhancer activity assay | |
| E_02496 | chr16:92632000~92632500 | Bone Marrow | Mouse hematopoietic progenitor cell | Enhancer activity assay | |
| E_02497 | chr16:92679000~92679500 | Bone Marrow | Mouse hematopoietic progenitor cell | Enhancer activity assay | |
| E_02498 | chr16:92697000~92697500 | Bone Marrow | Mouse hematopoietic progenitor cell | Enhancer activity assay | |
| E_02499 | chr1:92390990~92393985 | Forebrain | Mouse embryonic GE progenitor | Enhancer activity assay, TF binding assay | |
| E_02500 | chr12:39300010~39302995 | Forebrain | Mouse embryonic GE progenitor | Enhancer activity assay, TF binding assay | |
| E_02501 | chr12:51000995~51003991 | Forebrain | Mouse embryonic GE progenitor | Enhancer activity assay, TF binding assay | |
| E_02502 | chr12:56457933~56460958 | Forebrain | Mouse embryonic GE progenitor | Enhancer activity assay, TF binding assay | |
| E_02503 | chr16:15601990~15604980 | Forebrain | Mouse embryonic GE progenitor | Enhancer activity assay, TF binding assay | |
| E_02504 | chr18:8042971~8045972 | Forebrain | Mouse embryonic GE progenitor | Enhancer activity assay, TF binding assay | |
| E_02505 | chr2:72425536~72428482 | Forebrain | Mouse embryonic GE progenitor | Enhancer activity assay, TF binding assay | |
| E_02506 | chr4:71482992~71486006 | Forebrain | Mouse embryonic GE progenitor | Enhancer activity assay, TF binding assay | |
| E_02507 | chr8:94090990~94093985 | Forebrain | Mouse embryonic GE progenitor | Enhancer activity assay, TF binding assay | |
| E_02508 | chr15:62345678~62345743 | Brain | Neural stem | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay | |
| E_02509 | chr2:86750000~86800000 | Forebrain | Mouse embryonic day 11.5 forebrain tissue | Enhancer activity assay | |
| E_02510 | chr8:92145800~92146600 | Embryo | mESC | TF binding assay | |
| E_02511 | chr11:111750000~111750100 | Cartilage | Primary chondrocytes | Enhancer activity | |
| E_02512 | chr7:46069079~46073575 | Skeletal muscle | C2C12 myoblasts | Enhancer activity assay, TF binding assay | |
| E_02513 | chr7:46084867~46086466 | Skeletal muscle | C2C12 myoblasts | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_02514 | chr7:46001197~46005694 | Skeletal muscle | C2C12 | Enhancer activity assay, TF binding assay | |
| E_02515 | chr7:46016985~46018584 | Skeletal muscle | C2C12 | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_02516 | chr7:44970000~44970300 | Skeletal muscle | C2C12 | Enhancer activity assay | |
| E_02517 | chr6:88180000~88180500 | Bone marrow | Hematopoietic stem cells, HSPCs | Regulatory element functional validation, in vivo mouse model validation | |
| E_02518 | chr7:94290200~94290707 | Intervertebral disc | Annulus fibrosus | Enhancer activity assay, TF binding assay | |
| E_02519 | chr5:28820000~28821700 | Lung | Embryonic endodermal epithelial cells | Enhancer activity assay, Chromatin interaction assay | |
| E_02520 | chr11:96201500~96202300 | Endoderm | P19 cells | Enhancer activity assay, TF binding assay | |
| E_02521 | chr11:96200000~96202300 | Endoderm | P19 cells | Enhancer activity assay, TF binding assay, Transgenic reporter assay | |
| E_02522 | chr19:102157620~102158432 | Spinal cord | Primary oligodendrocytes | Enhancer activity assay, TF binding assay | |
| E_02523 | chr11:72560000~72561500 | Midbrain | mDA progenitors/neurons (E12.5) | TF binding assay, Functional perturbation assay | |
| E_02524 | chr5:142010000~142010300 | Embryo | mESC | TF binding assay | |
| E_02525 | chr6:124695557~124695892 | Liver | HepG2 | hepatocellular carcinoma | Enhancer activity assay, TF binding assay |
| E_02526 | chr6:124695557~124695892 | Cervix | HeLa | cervical cancer | Enhancer activity assay, TF binding assay |
| E_02527 | chr6:124695557~124695892 | Liver | NMuLi | Enhancer activity assay, TF binding assay | |
| E_02528 | chr15:52159003~52159479 | Pancreas | ??TC-3 | Enhancer activity assay | |
| E_02529 | chr15:52159003~52159479 | Pancreas | ??TC-6 | Enhancer activity assay | |
| E_02530 | chr15:52159003~52159479 | Cervix | HeLa | cervical cancer | Enhancer activity assay |
| E_02531 | chrX:7826505~7830405 | Bone marrow | K562 | chronic myeloid leukemia | Enhancer activity assay, TF binding assay |
| E_02532 | chrX:7826505~7830405 | Bone marrow | ES | Enhancer activity assay, TF binding assay | |
| E_02533 | chr3:14768~15068 | Embryo | Axial stem cells | Enhancer activity assay, Functional perturbation assay | |
| E_02534 | chr12:53052517~53052542 | Pancreatic islet | INS-1 | Enhancer activity assay | |
| E_02535 | chr12:53052517~53052542 | Pancreatic islet | HIT | Enhancer activity assay | |
| E_02536 | chr7:6720559~6721159 | Hypothalamus | Primary Hypothalamic Cells | Enhancer activity assay, Functional perturbation assay | |
| E_02537 | chr9:107683970~107684232 | Pancreas | Islet | Enhancer activity assay, TF binding assay | |
| E_02538 | chrX:4905800~4906065 | Mammary Gland | 4T1 | breast carcinoma | Enhancer activity assay, TF binding assay |
| E_02539 | chrX:4905800~4906065 | Mammary Gland | TSA | breast carcinoma | Enhancer activity assay, TF binding assay |
| E_02540 | chrX:4905800~4906065 | Mammary Gland | Primary Mammary Epithelial Cells | Enhancer activity assay, TF binding assay | |
| E_02541 | chr10:127874742~127875307 | Embryo | NIH3T3 | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_02542 | chr10:127874742~127875307 | Embryo | MEF | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_02543 | chr12:103437276~103437876 | Hypothalamus | POMC Arcuate Neuron | Enhancer activity assay | |
| E_02544 | chr3:37389739~37389753 | Thymus | Thymocytes | Enhancer activity assay, TF binding assay | |
| E_02545 | chr3:37389739~37389753 | Thymus | Splenic T cells | Enhancer activity assay, TF binding assay | |
| E_02546 | chr12:114666216~114667377 | Lymphoid tissue | X63-Ag8 | plasmacytoma | Enhancer activity assay, TF binding assay |
| E_02547 | chr10:89234500~89236669 | Liver | HepG2 | hepatocellular carcinoma | Enhancer activity assay |
| E_02548 | chr4:156021490~156022916 | Spleen | Primary mouse regulatory T cells | Functional perturbation assay, Enhancer activity assay | |
| E_02549 | chr19:29129170~29131699 | Brain | BV2 microglia | Enhancer activity assay, TF binding assay | |
| E_02550 | chr3:93993657~93995818 | Small intestine | ILC3s | Functional perturbation assay | |
| E_02551 | chr9:48605113~48605195 | Adipose tissue | 3T3-L1 preadipocytes | Enhancer activity assay, TF binding assay | |
| E_02552 | chr9:48606327~48606478 | Adipose tissue | 3T3-L1 preadipocytes | Enhancer activity assay, TF binding assay | |
| E_02553 | chr15:34751000~34754612 | Embryonic craniofacial tissue | Embryonic craniofacial cells | Enhancer activity assay | |
| E_02554 | chr2:73970064~73983434 | Limb bud | Primary limb cells | Enhancer activity assay | |
| E_02555 | chr13:98353215~98355279 | Face | iMEFs | Functional perturbation assay | |
| E_02556 | chr2:8936092~8980864 | Thymus | CD4+ T cell | Functional perturbation assay | |
| E_02557 | chr17:35500000~35501700 | Embryo | Mouse embryonic fibroblasts | Enhancer activity assay, Functional perturbation assay | |
| E_02558 | chr6:12265000~12266000 | Embryo | Epiblast stem cells | Enhancer activity assay, Functional perturbation assay | |
| E_02559 | chr8:105552148~105552347 | Embryo | Mouse embryonic fibroblasts | Enhancer activity assay, TF binding assay, Chromatin interaction assay | |
| E_02560 | chr8:123453500~123453720 | Embryo | Mouse embryonic fibroblasts | Enhancer activity assay | |
| E_02561 | chr6:97306690~97307260 | Brain | Neurons | Enhancer activity assay | |
| E_02562 | chr3:34765000~34767361 | Embryo | Mouse embryonic stem cells | Enhancer activity assay, Functional perturbation assay, Chromatin interaction assay | |
| E_02563 | chr10:74487110~74497835 | Hypothalamus | Arcuate nucleus neurons | Enhancer activity assay, Chromatin interaction assay, TF binding assay | |
| E_02564 | chr10:177510950~177511040 | Thymus | mTEC | Enhancer activity assay | |
| E_02565 | chr11:96840000~96840185 | Embryo | E9.5 embryo | Enhancer activity assay | |
| E_02566 | chr13:84638399~84640848 | Forebrain | transgenic mouse embryo | CRISPR deletion, Transgenic reporter assay | |
| E_02567 | chr13:84751727~84752626 | Forebrain | transgenic mouse embryo | CRISPR deletion, Transgenic reporter assay | |
| E_02568 | chr11:98250000~98285000 | Bone marrow | Hematopoietic stem cells | Enhancer activity assay, TF binding assay | |
| E_02569 | chr5:148601086~148601161 | Pancreas | INS-1 | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_02570 | chr5:148601086~148601161 | Pancreas | ?? cell lines | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_02571 | chr7:103826000~103826500 | Fetal liver | MEL erythroleukemia cells | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay | |
| E_02572 | chrX:4899200~4899465 | Mammary Gland | 4T1 | breast carcinoma | Enhancer activity assay, TF binding assay |
| E_02573 | chrX:4899200~4899465 | Mammary Gland | TSA | breast carcinoma | Enhancer activity assay, TF binding assay |
| E_02574 | chr7:1911568~1911832 | Bone Marrow | Pro-B cells | Enhancer activity assay, TF binding assay | |
| E_02575 | chr7:1911568~1911832 | Bone Marrow | B cells | Enhancer activity assay, TF binding assay | |
| E_02576 | chr7:1911568~1911832 | Bone Marrow | Multipotent Progenitors | Enhancer activity assay, TF binding assay | |
| E_02577 | chr12:114450000~114450225 | Spleen | CH12.LX | Enhancer activity assay, TF binding assay | |
| E_02578 | chr12:114450000~114450225 | Spleen | A20 | B-cell lymphoma | Enhancer activity assay, TF binding assay |
| E_02579 | chr12:114450000~114450225 | Spleen | Primary B Cells | Enhancer activity assay, TF binding assay | |
| E_02580 | chr9:110254800~110254851 | Testis | Round spermatids | Enhancer activity assay | |
| E_02581 | chr6:71233400~71233600 | Thymus | CD8+ T | Enhancer activity assay | |
| E_02582 | chr9:59048862~59048913 | Testis | Round spermatids | Enhancer activity assay, TF binding assay | |
| E_02583 | chr8:47323116~47325387 | Embryo | Mouse Embryonic Stem Cells (mESCs) | Enhancer activity assay, TF binding assay | |
| E_02584 | chr10:87376120~87376374 | Central nervous system | Embryonic neuroprogenitor cells | Functional perturbation assay, Enhancer activity assay | |
| E_02585 | chr9:55546300~55546600 | Embryonic craniofacial tissue | Sensory neurons | Enhancer activity assay | |
| E_02586 | chr9:55546300~55546600 | Embryonic craniofacial tissue | epithelial cells | Enhancer activity assay | |
| E_02587 | chr7:66376000~66378000 | Embryonic craniofacial tissue | Epithelial cells | Enhancer activity assay | |
| E_02588 | chr15:100452350~100452650 | Heart | Mouse outflow tract smooth muscle | TF binding assay | |
| E_02589 | chr7:150644800~150646500 | Face | iMEFs | Enhancer activity assay | |
| E_02590 | chr11:3650000~3652019 | Skeletal Muscle | Mouse myoblast cell | Enhancer activity assay | |
| E_02591 | chr13:10543000~10544508 | Skeletal Muscle | Mouse myoblast cell | Enhancer activity assay | |
| E_02592 | chr17:29065000~29066050 | Skeletal Muscle | Mouse myoblast cell | Enhancer activity assay | |
| E_02593 | chr17:29072000~29073308 | Skeletal Muscle | Mouse myoblast cell | Enhancer activity assay | |
| E_02594 | chr3:54351833~54571175 | Heart | Cardiac Fibroblast | Chromatin interaction assay | |
| E_02595 | chr13:84570044~84572517 | Neural tube | transgenic mouse embryo | CRISPR deletion, Transgenic reporter assay | |
| E_02596 | chr7:142580000~142580293 | Skeletal muscle | C3H10T1/2 | Enhancer activity assay, Functional perturbation assay | |
| E_02597 | chr7:142580000~142580293 | Skeletal muscle | Myoblasts | Enhancer activity assay, Functional perturbation assay | |
| E_02598 | chr5:115502658~115512658 | Nervous system | NS/PCs | Enhancer activity assay | |
| E_02599 | chr5:115502658~115512658 | Nervous system | ESCs | Enhancer activity assay | |
| E_02600 | chr5:115574958~115575553 | Nervous system | NS/PCs | Enhancer activity assay, TF binding assay | |
| E_02601 | chr5:115574958~115575553 | Nervous system | ESCs | Enhancer activity assay, TF binding assay | |
| E_02602 | chr18:61235500~61235837 | Blood | RAW264 | Enhancer activity assay, TF binding assay | |
| E_02603 | chr18:61235500~61235837 | Blood | 38B9 | Enhancer activity assay, TF binding assay | |
| E_02604 | chr18:61235500~61235837 | Blood | A20 | B-cell lymphoma | Enhancer activity assay, TF binding assay |
| E_02605 | chr6:122612768~122617768 | Embryo | murine embryonic stem cells (mESCs) | Enhancer activity assay, TF binding assay, Chromatin interaction assay | |
| E_02606 | chr6:122652768~122657768 | Embryo | murine embryonic stem cells (mESCs) | Enhancer activity assay, TF binding assay, Chromatin interaction assay | |
| E_02607 | chr6:122717768~122722768 | Embryo | murine embryonic stem cells (mESCs) | Enhancer activity assay, TF binding assay, Chromatin interaction assay | |
| E_02608 | chr3:34756748~34761748 | Embryo | murine embryonic stem cells (mESCs) | Enhancer activity assay, TF binding assay, Chromatin interaction assay | |
| E_02609 | chr13:116000000~116001000 | Brainstem | Cranial motor neurons | Enhancer activity assay, Chromatin interaction assay | |
| E_02610 | chr13:116002000~116003000 | Brainstem | Cranial motor neurons | Enhancer activity assay, Chromatin interaction assay | |
| E_02611 | chr13:116004000~116005000 | Brainstem | Cranial motor neurons | Enhancer activity assay, Chromatin interaction assay | |
| E_02612 | chr13:116006000~116007000 | Brainstem | Cranial motor neurons | Enhancer activity assay, Chromatin interaction assay | |
| E_02613 | chr17:31321000~31322000 | Lens | Embryonic lens vesicle | Enhancer activity assay, Chromatin interaction assay | |
| E_02614 | chr17:31322000~31323000 | Lens | Embryonic lens vesicle | Enhancer activity assay, Chromatin interaction assay | |
| E_02615 | chr5:135012000~135012856 | Forebrain | Embryonic neural progenitor | Enhancer activity assay, TF binding assay | |
| E_02616 | chr1:17147835~17150235 | Embryonic Limb Bud | Limb mesenchymal progenitors | Enhancer activity assay | |
| E_02617 | chr1:17147835~17150235 | Dermis | Dermal fibroblasts | Enhancer activity assay | |
| E_02618 | chr10:72890000~72890392 | Retina | Retinal Progenitor Cells | Enhancer activity assay | |
| E_02619 | chr10:72890000~72890392 | Retina | Retinal Ganglion Cells | Enhancer activity assay | |
| E_02620 | chr10:72894616~72895600 | Retina | Retinal Progenitor Cells | Enhancer activity assay | |
| E_02621 | chr10:72894616~72895600 | Retina | Retinal Ganglion Cells | Enhancer activity assay | |
| E_02622 | chr2:74558139~74559639 | Limb | Not available | Enhancer activity assay | |
| E_02623 | chr2:74558139~74559639 | Limb | Not available | Enhancer activity assay | |
| E_02624 | chr2:74560139~74561639 | Limb | Not available | Enhancer activity assay | |
| E_02625 | chr2:74560139~74561639 | Limb | Not available | Enhancer activity assay | |
| E_02626 | chr2:74728139~74729639 | Limb | Not available | Enhancer activity assay | |
| E_02627 | chr2:74728139~74729639 | Limb | Not available | Enhancer activity assay | |
| E_02628 | chr2:74808139~74809639 | Limb | Not available | Enhancer activity assay | |
| E_02629 | chr2:74808139~74809639 | Limb | Not available | Enhancer activity assay | |
| E_02630 | chr2:74888139~74889639 | Limb | Not available | Enhancer activity assay | |
| E_02631 | chr2:74888139~74889639 | Limb | Not available | Enhancer activity assay | |
| E_02632 | chr2:74460000~74500000 | Limb | Enhancer activity assay, Functional perturbation assay | ||
| E_02633 | chr2:74460000~74500000 | Limb | Enhancer activity assay, Functional perturbation assay | ||
| E_02634 | chr2:74460000~74500000 | Limb | Enhancer activity assay, Functional perturbation assay | ||
| E_02635 | chr2:74460000~74500000 | Limb | Enhancer activity assay, Functional perturbation assay | ||
| E_02636 | chr2:74460000~74500000 | Limb | Enhancer activity assay, Functional perturbation assay | ||
| E_02637 | chr2:74460000~74500000 | Limb | Enhancer activity assay, Functional perturbation assay | ||
| E_02638 | chr4:84506800~84506986 | Brain | Embryonic tissue | Enhancer activity assay | |
| E_02639 | chr6:6163229~6163674 | Embryo | Embryonic whole mount | Enhancer activity assay | |
| E_02640 | chr6:122563494~122564540 | Lymph node | Germinal center B cells | Enhancer activity assay, Functional perturbation assay | |
| E_02641 | chr6:122573553~122574125 | Lymph node | Germinal center B cells | Enhancer activity assay, Functional perturbation assay | |
| E_02642 | chr8:125454150~125454370 | Mammary gland | NMuMG cells | TF binding assay | |
| E_02643 | chr11:53495000~53501000 | Blood | Murine T Lymphocytes | Enhancer activity assay | |
| E_02644 | chr17:67749535~67749594 | Notochord | Embryonic notochord | Enhancer activity assay | |
| E_02645 | chr17:8396191~8396849 | Notochord | Embryonic notochord | Enhancer activity assay | |
| E_02646 | chr17:8444218~8444317 | Notochord | Embryonic notochord | Enhancer activity assay | |
| E_02647 | chr1:63189000~63192000 | Embryo | Mouse Embryonic Stem Cells (mESCs) | Enhancer activity assay, Chromatin interaction assay, TF binding assay | |
| E_02648 | chr1:63189000~63192000 | Embryo | E14TG2a | Enhancer activity assay, Chromatin interaction assay, TF binding assay | |
| E_02649 | chr1:63189000~63192000 | Embryo | J1) | Enhancer activity assay, Chromatin interaction assay, TF binding assay | |
| E_02650 | chr1:63193000~63196000 | Embryo | Mouse Embryonic Stem Cells (mESCs) | Enhancer activity assay, Chromatin interaction assay, TF binding assay | |
| E_02651 | chr1:63193000~63196000 | Embryo | E14TG2a | Enhancer activity assay, Chromatin interaction assay, TF binding assay | |
| E_02652 | chr1:63193000~63196000 | Embryo | J1) | Enhancer activity assay, Chromatin interaction assay, TF binding assay | |
| E_02653 | chr11:32115000~32145000 | Bone marrow | Erythroid progenitor | Enhancer activity assay, Functional perturbation assay, Chromatin interaction assay | |
| E_02654 | chr11:100810000~100812000 | Mammary Gland | Mammary epithelial cells | Functional perturbation assay | |
| E_02655 | chr1:40942777~40944397 | Heart | Enhancer capture Hi-C assay, In vivo functional validation | ||
| E_02656 | chr1:41143611~41146744 | Eye | Enhancer capture Hi-C assay, In vivo functional validation | ||
| E_02657 | chr1:41603697~41606058 | Forebrain | Enhancer capture Hi-C assay, In vivo functional validation | ||
| E_02658 | chr1:42365513~42367630 | Forebrain | Enhancer capture Hi-C assay, In vivo functional validation | ||
| E_02659 | chr1:42538429~42540496 | Forebrain | Enhancer capture Hi-C assay, In vivo functional validation | ||
| E_02660 | chr1:75770058~75773197 | Limb | Enhancer capture Hi-C assay, In vivo functional validation | ||
| E_02661 | chr1:86488603~86493027 | Heart | Enhancer capture Hi-C assay, In vivo functional validation | ||
| E_02662 | chr1:92718827~92721406 | Heart | Enhancer capture Hi-C assay, In vivo functional validation | ||
| E_02663 | chr1:155038871~155039989 | Heart | Enhancer capture Hi-C assay, In vivo functional validation | ||
| E_02664 | chr1:163361752~163364252 | Limb | Enhancer capture Hi-C assay, In vivo functional validation | ||
| E_02665 | chr1:169343173~169345241 | Limb | Enhancer capture Hi-C assay, In vivo functional validation | ||
| E_02666 | chr1:190655086~190655625 | Forebrain | Enhancer capture Hi-C assay, In vivo functional validation | ||
| E_02667 | chr1:190727026~190730523 | Forebrain | Enhancer capture Hi-C assay, In vivo functional validation | ||
| E_02668 | chr10:3393773~3395290 | Heart | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02669 | chr10:21082099~21084259 | Eye | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02670 | chr10:31052886~31054461 | Heart | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02671 | chr10:31228851~31230590 | Heart | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02672 | chr10:45894288~45894827 | Limb | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02673 | chr10:49983887~49986266 | Limb | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02674 | chr10:53324321~53325988 | Heart | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02675 | chr10:87324145~87327333 | Midbrain | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02676 | chr10:92555796~92557968 | Forebrain | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02677 | chr10:96707809~96707988 | Heart | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02678 | chr11:11955959~11958746 | Heart | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02679 | chr11:18915780~18919026 | Forebrain | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02680 | chr11:22077830~22079309 | Midbrain | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02681 | chr11:24096035~24096394 | Forebrain | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02682 | chr11:24330054~24333979 | Hindbrain | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02683 | chr11:24369946~24372657 | Forebrain | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02684 | chr11:25287174~25289345 | Face | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02685 | chr11:25531402~25532001 | Midbrain | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02686 | chr11:26006299~26007590 | Limb | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02687 | chr11:26120058~26122427 | Dorsal root ganglion | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02688 | chr11:44799152~44801733 | Neural tube | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02689 | chr11:45549323~45551898 | Limb | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02690 | chr11:54879406~54883911 | Heart | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02691 | chr11:59638982~59640132 | Heart | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02692 | chr11:64898966~64900764 | Face | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02693 | chr11:65209858~65211177 | Heart | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02694 | chr11:65648676~65651675 | Heart | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02695 | chr11:75048409~75050731 | Limb | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02696 | chr11:77422172~77424768 | Heart | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02697 | chr11:84495459~84496979 | Hindbrain | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02698 | chr11:84765200~84766279 | Limb | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02699 | chr11:85856960~85860695 | Midbrain | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02700 | chr11:85875857~85878048 | Limb | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02701 | chr11:85962963~85963802 | Limb | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02702 | chr11:98338371~98340241 | Midbrain | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02703 | chr11:106133614~106136287 | Heart | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02704 | chr11:111563103~111564513 | Limb | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02705 | chr11:111568057~111570396 | Pharyngeal arch | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02706 | chr11:111827949~111829442 | Limb | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02707 | chr11:114335424~114336143 | Forebrain | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02708 | chr11:5266607~5270082 | Ear | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02709 | chr12:12178866~12180524 | Heart | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02710 | chr12:12866488~12867793 | Midbrain | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02711 | chr12:34219098~34222003 | Limb | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02712 | chr12:38435899~38436969 | Hindbrain | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02713 | chr12:49944259~49946938 | Forebrain | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02714 | chr12:49973819~49974898 | Hindbrain | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02715 | chr12:50120052~50121911 | Forebrain | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02716 | chr12:52227850~52229485 | Heart | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02717 | chr12:53873637~53876199 | Heart | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02718 | chr12:55643171~55644130 | Forebrain | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02719 | chr12:56114427~56116838 | Hindbrain | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02720 | chr12:56458924~56460465 | Forebrain | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02721 | chr12:57290916~57292614 | Midbrain | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02722 | chr12:69757650~69759599 | Heart | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02723 | chr12:79795735~79797174 | Blood vessel | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02724 | chr12:85453982~85456023 | Heart | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02725 | chr12:86800395~86804134 | Neural tube | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02726 | chr14:99260419~99393893 | Embryonic tissue | Mouse Embryonic Stem Cells (E14) | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay | |
| E_02727 | chr11:96800000~96801500 | Cartilage | RCS chondrocytes | Enhancer activity assay, TF binding assay | |
| E_02728 | chr18:24562000~24562200 | Embryo | ESCs | Functional perturbation assay | |
| E_02729 | chr1:19698786~19700794 | Hindbrain | Enhancer capture Hi-C assay, In vivo functional validation | ||
| E_02730 | chr1:39945410~39950481 | Dorsal root ganglion | Enhancer capture Hi-C assay, In vivo functional validation | ||
| E_02731 | chr1:41165774~41167470 | Midbrain | Enhancer capture Hi-C assay, In vivo functional validation | ||
| E_02732 | chr1:41274809~41277330 | Hindbrain | Enhancer capture Hi-C assay, In vivo functional validation | ||
| E_02733 | chr1:41274477~41276046 | Midbrain | Enhancer capture Hi-C assay, In vivo functional validation | ||
| E_02734 | chr1:41389098~41390679 | Neural tube | Enhancer capture Hi-C assay, In vivo functional validation | ||
| E_02735 | chr1:41558620~41559699 | Dorsal root ganglion | Enhancer capture Hi-C assay, In vivo functional validation | ||
| E_02736 | chr1:41936018~41937045 | Pharyngeal arch | Enhancer capture Hi-C assay, In vivo functional validation | ||
| E_02737 | chr1:41980560~41982826 | Hindbrain | Enhancer capture Hi-C assay, In vivo functional validation | ||
| E_02738 | chr1:42242028~42244560 | Midbrain | Enhancer capture Hi-C assay, In vivo functional validation | ||
| E_02739 | chr1:42740097~42742436 | Hindbrain | Enhancer capture Hi-C assay, In vivo functional validation | ||
| E_02740 | chr1:42888276~42890025 | Neural tube | Enhancer capture Hi-C assay, In vivo functional validation | ||
| E_02741 | chr1:56287621~56287740 | Pharyngeal arch | Enhancer capture Hi-C assay, In vivo functional validation | ||
| E_02742 | chr1:59333610~59335295 | Somite | Enhancer capture Hi-C assay, In vivo functional validation | ||
| E_02743 | chr1:59340469~59342458 | Midbrain | Enhancer capture Hi-C assay, In vivo functional validation | ||
| E_02744 | chr1:61202186~61204482 | Face | Enhancer capture Hi-C assay, In vivo functional validation | ||
| E_02745 | chr1:67795652~67796989 | Neural tube | Enhancer capture Hi-C assay, In vivo functional validation | ||
| E_02746 | chr1:68045495~68048139 | Hindbrain | Enhancer capture Hi-C assay, In vivo functional validation | ||
| E_02747 | chr1:75784481~75787064 | Limb | Enhancer capture Hi-C assay, In vivo functional validation | ||
| E_02748 | chr1:75832340~75835632 | Limb | Enhancer capture Hi-C assay, In vivo functional validation | ||
| E_02749 | chr1:78058902~78059702 | Skin | Enhancer capture Hi-C assay, In vivo functional validation | ||
| E_02750 | chr1:89713239~89715218 | Limb | Enhancer capture Hi-C assay, In vivo functional validation | ||
| E_02751 | chr1:89750247~89752564 | Hindbrain | Enhancer capture Hi-C assay, In vivo functional validation | ||
| E_02752 | chr1:89847226~89849959 | Forebrain | Enhancer capture Hi-C assay, In vivo functional validation | ||
| E_02753 | chr1:90752845~90755953 | Somite | Enhancer capture Hi-C assay, In vivo functional validation | ||
| E_02754 | chr1:91962915~91965571 | Pharyngeal arch | Enhancer capture Hi-C assay, In vivo functional validation | ||
| E_02755 | chr1:92786133~92787932 | Hindbrain | Enhancer capture Hi-C assay, In vivo functional validation | ||
| E_02756 | chr1:92789742~92792954 | Limb | Enhancer capture Hi-C assay, In vivo functional validation | ||
| E_02757 | chr1:97538458~97543032 | Neural tube | Enhancer capture Hi-C assay, In vivo functional validation | ||
| E_02758 | chr1:118776992~118777951 | Hindbrain | Enhancer capture Hi-C assay, In vivo functional validation | ||
| E_02759 | chr1:120023430~120025609 | Embryo | Enhancer capture Hi-C assay, In vivo functional validation | ||
| E_02760 | chr1:132332673~132334764 | Hindbrain | Enhancer capture Hi-C assay, In vivo functional validation | ||
| E_02761 | chr1:133079543~133081905 | Neural tube | Enhancer capture Hi-C assay, In vivo functional validation | ||
| E_02762 | chr1:133491760~133493483 | Blood vessel | Enhancer capture Hi-C assay, In vivo functional validation | ||
| E_02763 | chr1:138498963~138501215 | Hindbrain | Enhancer capture Hi-C assay, In vivo functional validation | ||
| E_02764 | chr1:158265584~158268273 | Hindbrain | Enhancer capture Hi-C assay, In vivo functional validation | ||
| E_02765 | chr1:162074122~162077977 | Somite | Enhancer capture Hi-C assay, In vivo functional validation | ||
| E_02766 | chr1:162829985~162833284 | Neural tube | Enhancer capture Hi-C assay, In vivo functional validation | ||
| E_02767 | chr1:163897046~163900155 | Limb | Enhancer capture Hi-C assay, In vivo functional validation | ||
| E_02768 | chr1:166047034~166051082 | Neural tube | Enhancer capture Hi-C assay, In vivo functional validation | ||
| E_02769 | chr1:168341325~168343770 | Hindbrain | Enhancer capture Hi-C assay, In vivo functional validation | ||
| E_02770 | chr1:168356497~168358717 | Hindbrain | Enhancer capture Hi-C assay, In vivo functional validation | ||
| E_02771 | chr1:169384774~169387004 | Hindbrain | Enhancer capture Hi-C assay, In vivo functional validation | ||
| E_02772 | chr1:177151814~177152053 | Neural tube | Enhancer capture Hi-C assay, In vivo functional validation | ||
| E_02773 | chr1:179385555~179387659 | Midbrain | Enhancer capture Hi-C assay, In vivo functional validation | ||
| E_02774 | chr1:187907873~187909312 | Cranial nerve | Enhancer capture Hi-C assay, In vivo functional validation | ||
| E_02775 | chr1:189186446~189189286 | Neural tube | Enhancer capture Hi-C assay, In vivo functional validation | ||
| E_02776 | chr1:191238682~191241679 | Neural tube | Enhancer capture Hi-C assay, In vivo functional validation | ||
| E_02777 | chr1:192798078~192799697 | Somite | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02778 | chr1:193140090~193141613 | Limb | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02779 | chr10:14462982~14465275 | Limb | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02780 | chr10:17228620~17231920 | Hindbrain | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02781 | chr10:36483060~36486674 | Midbrain | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02782 | chr10:38551938~38556574 | Neural tube | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02783 | chr10:45228796~45231475 | Limb | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02784 | chr10:51257317~51258816 | Midbrain | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02785 | chr10:52741597~52745163 | Neural tube | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02786 | chr10:87292824~87294448 | Midbrain | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02787 | chr10:87445090~87449904 | Hindbrain | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02788 | chr10:87472791~87473750 | Neural tube | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02789 | chr10:91880854~91881573 | Midbrain | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02790 | chr10:120551807~120554146 | Neural tube | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02791 | chr10:120646283~120649237 | Hindbrain | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02792 | chr10:125809640~125811484 | Somite | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02793 | chr11:17448900~17451834 | Hindbrain | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02794 | chr11:18357518~18358569 | Hindbrain | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02795 | chr11:24426421~24428736 | Midbrain | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02796 | chr11:25356124~25357143 | Neural tube | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02797 | chr11:26771684~26773636 | Hindbrain | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02798 | chr11:32245096~32247223 | Heart | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02799 | chr11:33299155~33301650 | Hindbrain | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02800 | chr11:33399382~33401384 | Neural tube | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02801 | chr11:44634961~44636269 | Neural tube | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02802 | chr11:44656049~44658617 | Neural tube | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02803 | chr11:45136282~45138321 | Limb | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02804 | chr11:46201700~46203391 | Pharyngeal arch | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02805 | chr11:62983610~62986909 | Neural tube | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02806 | chr11:77905947~77908190 | Hindbrain | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02807 | chr11:81611872~81614511 | Neural tube | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02808 | chr11:86167051~86168070 | Embryo | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02809 | chr11:88274108~88276472 | Neural tube | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02810 | chr11:94159442~94162241 | Hindbrain | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02811 | chr11:94880838~94883684 | Neural tube | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02812 | chr11:96883943~96888120 | Hindbrain | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02813 | chr11:98496932~98499144 | Neural tube | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02814 | chr11:103840502~103842458 | Neural tube | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02815 | chr11:107761860~107764266 | Embryo | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02816 | chr11:109269018~109271202 | Neural tube | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02817 | chr11:112411851~112414154 | Limb | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02818 | chr11:113012998~113015716 | Limb | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02819 | chr11:113307250~113310296 | Neural tube | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02820 | chr11:113783986~113787857 | Neural tube | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02821 | chr11:120314730~120315389 | Dorsal root ganglion | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02822 | chr12:8385536~8387745 | Heart | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02823 | chr12:9338781~9340056 | Somite | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02824 | chr12:12707452~12712121 | Midbrain | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02825 | chr12:25890817~25892310 | Forebrain | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02826 | chr12:27564419~27567345 | Neural tube | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02827 | chr12:28817230~28818444 | Hindbrain | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02828 | chr12:31309806~31310405 | Dorsal root ganglion | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02829 | chr12:34198954~34201589 | Hindbrain | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02830 | chr12:34215806~34216763 | Limb | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02831 | chr12:39300476~39302395 | Forebrain | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02832 | chr12:39341105~39343483 | Hindbrain | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02833 | chr12:44402329~44404831 | Midbrain | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02834 | chr12:46020387~46022607 | Neural tube | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02835 | chr12:49991668~49994699 | Hindbrain | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02836 | chr12:56482102~56482581 | Hindbrain | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02837 | chr12:79846147~79848987 | Limb | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02838 | chr12:83072708~83074410 | Midbrain | Enhancer capture Hi-C, in vivo functional validation | ||
| E_02839 | chr4:55559000~55560500 | Embryo | Mouse JM8.N4 ESCs | Functional perturbation assay | |
| E_02840 | chr11:98346350~98346550 | Mammary Gland | Mammary epithelial cells | Functional perturbation assay | |
| E_02841 | chr4:46410632~46411247 | Bone Marrow | Erythroblasts | Functional perturbation assay, Chromatin interaction assay, TF binding assay | |
| E_02842 | chr4:46410632~46411247 | Fetal Liver | MEL Cells | Functional perturbation assay, Chromatin interaction assay, TF binding assay | |
| E_02843 | chr10:87230000~87234000 | Ear pinna | Wound-induced Fibroblast | Functional perturbation assay | |
| E_02844 | chr8:84109163~84109362 | Embryo | Mouse embryonic fibroblasts | TF binding assay, Functional perturbation assay | |
| E_02845 | chr6:6058554~6059028 | Embryo | Embryonic whole mount | Enhancer activity assay | |
| E_02846 | chr11:75210000~75210304 | Retina | Primary Retinal Cells | Enhancer activity assay | |
| E_02847 | chr11:3210000~3215000 | Bone Marrow | Primary Murine Erythroblasts | Enhancer activity assay, TF binding assay | |
| E_02848 | chr4:10329803~10537032 | Limb bud | Limb bud | Enhancer activity assay | |
| E_02849 | chr4:10329803~10537032 | Limb bud | Embryonic tissue | Enhancer activity assay | |
| E_02850 | chr15:98129939~98130247 | Cartilage | Enhancer activity assay, TF binding assay | ||
| E_02851 | chr11:10081501~10082508 | Mammary Gland | Primary Mouse Mammary Epithelial | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_02852 | chr11:97550000~97553161 | Gonad | Fetal gonadal somatic cells | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_02853 | chr11:97551000~97552292 | Gonad | Fetal gonadal somatic cells | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_02854 | chr7:67890000~67910000 | Skeletal muscle | C2C12 myoblasts | Chromatin interaction assay, Functional perturbation assay | |
| E_02855 | chr12:114664163~114667348 | Spleen | mature B | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay | |
| E_02856 | chr2:129323600~129328600 | Heart | Macrophage | atherosclerosis | Enhancer activity assay |
| E_02857 | chr11:101828402~101833529 | Heart | Cardiac Fibroblast | cardiac fibrosis | Chromatin interaction assay |
| E_02858 | chr9:90690384~90694866 | Midbrain | transgenic mouse embryo | CRISPR deletion, Transgenic reporter assay | |
| E_02859 | chr11:44112300~44112500 | Bone marrow | B | Enhancer activity assay | |
| E_02860 | chr14:54721862~54722816 | Retina | Rod photoreceptor | Enhancer activity assay | |
| E_02861 | chr3:37283342~37283854 | Lymph node | EL4 | T-cell lymphoma | Enhancer activity assay, TF binding assay |
| E_02862 | chr3:37283342~37283854 | Embryonic Kidney | 293T | Enhancer activity assay, TF binding assay | |
| E_02863 | chr3:37283342~37283854 | Blood | CD4+ T cell | Enhancer activity assay, TF binding assay | |
| E_02864 | chr6:122479265~122485265 | Skin | Dermal Fibroblast | scleroderma | Enhancer activity assay |
| E_02865 | chr6:122481665~122483665 | Skin | Dermal Fibroblast | scleroderma | Enhancer activity assay |
| E_02866 | chr17:35605300~35605800 | Embryo | mESC | Enhancer activity assay | |
| E_02867 | chr10:128065200~128076800 | Hypothalamus | Arcuate nucleus primary | Enhancer activity assay, Chromatin interaction assay, TF binding assay | |
| E_02868 | chr10:74487110~74497835 | Hypothalamus | Arcuate nucleus neurons | Enhancer activity assay, Chromatin interaction assay, TF binding assay | |
| E_02869 | chr12:103439326~103439476 | Hypothalamus | POMC Arcuate Neuron | Enhancer activity assay | |
| E_02870 | chr3:37390149~37390163 | Thymus | Thymocytes | Enhancer activity assay, TF binding assay | |
| E_02871 | chr3:37390149~37390163 | Thymus | Splenic T cells | Enhancer activity assay, TF binding assay | |
| E_02872 | chr3:37390185~37390199 | Thymus | Thymocytes | Enhancer activity assay, TF binding assay | |
| E_02873 | chr3:37390185~37390199 | Thymus | Splenic T cells | Enhancer activity assay, TF binding assay | |
| E_02874 | chr8:120880096~120882492 | Lung | Embryonic lung tissue | Functional perturbation assay | |
| E_02875 | chr11:111838889~111839334 | Cartilage | Primary Chondrocytes | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay | |
| E_02876 | chr11:111838889~111839334 | Cartilage | ATDC5 | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay | |
| E_02877 | chr11:111838889~111839334 | Cartilage | C3H10T1/2 | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay | |
| E_02878 | chr6:122698567~122721126 | Embryo | Mouse Embryonic Stem Cells (v6.5) | Enhancer activity assay | |
| E_02879 | chr15:79850614~79850824 | Heart | Mouse Cardiac Endothelial Cells (MCECs) | Enhancer activity assay, TF binding assay | |
| E_02880 | chr14:54721862~54722143 | Retina | Rod photoreceptor | Enhancer activity assay | |
| E_02881 | chr14:54722765~54722816 | Retina | Rod photoreceptor | Enhancer activity assay | |
| E_02882 | chr9:102705800~102706400 | Bone marrow | Bone marrow-derived macrophages (BMMs) | tumor microenvironment | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_02883 | chr9:102705800~102706400 | Bone marrow | RAW 264.7 cell line | tumor microenvironment | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_02884 | chr9:102705800~102706400 | Bone marrow | tumor-associated macrophages (TAMs) | tumor microenvironment | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_02885 | chr12:53054974~53055029 | Pancreatic islet | INS-1 | TF binding assay | |
| E_02886 | chr12:53054974~53055029 | Pancreatic islet | HIT | TF binding assay | |
| E_02887 | chr8:125450780~125451000 | Mammary gland | NMuMG | Enhancer activity assay | |
| E_02888 | chr15:72250000~72250650 | Brain | Embryonic Stem Cells (ESCs) | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay | |
| E_02889 | chr15:72290000~72290650 | Brain | Embryonic Stem Cells (ESCs) | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay | |
| E_02890 | chr17:45790442~45800636 | Embryo | Mouse embryonic fibroblasts (MEFs) | Enhancer activity assay, Signal-dependent regulation study | |
| E_02891 | chr11:119715961~119716245 | Brain | Neuro-2a (N2A) cells | Enhancer activity assay | |
| E_02892 | chr3:34752523~34766449 | Embryo | Mouse embryonic stem cells (129¡ÃCast F1; v6.5) | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_02893 | chr3:34752523~34766449 | Embryo | v6.5) | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_02894 | chrX:76054800~76055800 | Thymus | Primary CD4+ T cells | Functional perturbation assay, Chromatin interaction assay, TF binding assay | |
| E_02895 | chrX:76054800~76055800 | Thymus | thymocytes | Functional perturbation assay, Chromatin interaction assay, TF binding assay | |
| E_02896 | chrX:76071800~76072800 | Thymus | Primary CD4+ T cells | Functional perturbation assay, Chromatin interaction assay, TF binding assay | |
| E_02897 | chrX:76071800~76072800 | Thymus | thymocytes | Functional perturbation assay, Chromatin interaction assay, TF binding assay | |
| E_02898 | chr6:122620000~122660000 | Embryo | Mouse embryonic stem cells | Enhancer activity assay, TF binding assay | |
| E_02899 | chr3:34824938~34837938 | Embryo | Mouse embryonic stem cells | CRISPR deletion functional assay | |
| E_02900 | chr3:34824938~34837938 | Embryo | Mouse embryonic stem cells | CRISPR deletion functional assay | |
| E_02901 | chr17:86425000~86432000 | Embryo | Mouse embryonic stem cells | CRISPR knockout enhancer assay | |
| E_02902 | chr2:27480000~27480400 | Embryo | Mouse embryonic stem cells | CRISPR enhancer knockout assay | |
| E_02903 | chr12:113005000~113005100 | Lymph node | Primary resting B lymphocytes | Functional perturbation assay, Chromatin topology assay | |
| E_02904 | chr12:113010000~113010100 | Lymph node | Primary resting B lymphocytes | Functional perturbation assay, Chromatin topology assay | |
| E_02905 | chr12:113015000~113015100 | Lymph node | Primary resting B lymphocytes | Functional perturbation assay, Chromatin topology assay | |
| E_02906 | chr12:113019000~113019100 | Lymph node | Primary resting B lymphocytes | Functional perturbation assay, Chromatin topology assay | |
| E_02907 | chr6:122655000~122657500 | Embryo | Mouse embryonic stem cells | Functional perturbation assay | |
| E_02908 | chr4:118656335~118661035 | Bone marrow | Primary B cell progenitors | Enhancer activity assay, TF binding assay | |
| E_02909 | chr12:113005000~113005100 | Lymph node | Primary plasmacytoma cells | plasmacytoma | Functional perturbation assay, Tumorigenesis assay |
| E_02910 | chr12:113005000~113005100 | Lymph node | plasma cells | plasmacytoma | Functional perturbation assay, Tumorigenesis assay |
| E_02911 | chr12:113010000~113010100 | Lymph node | Primary plasmacytoma cells | plasmacytoma | Functional perturbation assay, Tumorigenesis assay |
| E_02912 | chr12:113010000~113010100 | Lymph node | plasma cells | plasmacytoma | Functional perturbation assay, Tumorigenesis assay |
| E_02913 | chr12:113015000~113015100 | Lymph node | Primary plasmacytoma cells | plasmacytoma | Functional perturbation assay, Tumorigenesis assay |
| E_02914 | chr12:113015000~113015100 | Lymph node | plasma cells | plasmacytoma | Functional perturbation assay, Tumorigenesis assay |
| E_02915 | chr12:113019000~113019100 | Lymph node | Primary plasmacytoma cells | plasmacytoma | Functional perturbation assay, Tumorigenesis assay |
| E_02916 | chr12:113019000~113019100 | Lymph node | plasma cells | plasmacytoma | Functional perturbation assay, Tumorigenesis assay |
| E_02917 | chr16:19007329~19008187 | Lymph node | 103/BCL-2 pre-B cells | Enhancer activity assay, TF binding assay | |
| E_02918 | chr6:64732005~64901125 | Spinal cord | Neurons | Enhancer activity assay, Functional perturbation assay | |
| E_02919 | chr8:115656318~115662318 | Adipose tissue | 3T3-L1 Adipocytes | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_02920 | chr1:136170803~136192554 | Skeletal muscle | C2C12 myoblast cell line | Enhancer activity assay, TF binding assay, Chromatin interaction assay | |
| E_02921 | chr10:72782000~72783500 | Brain | Primary mouse embryonic hindbrain cells | Functional perturbation assay | |
| E_02922 | chr10:72855000~72856500 | Brain | Primary mouse embryonic hindbrain cells | Functional perturbation assay | |
| E_02923 | chr1:136170800~136171203 | Skeletal muscle | Mouse myoblast/myotube cell | Enhancer activity assay, Functional perturbation assay | |
| E_02924 | chr1:136170803~136192554 | Skeletal muscle | Mouse myoblast/myotube cell | Enhancer activity assay | |
| E_02925 | chr1:136171700~136172103 | Skeletal muscle | Mouse myoblast/myotube cell | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_02926 | chr1:136177900~136178345 | Skeletal muscle | Mouse myoblast/myotube cell | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay | |
| E_02927 | chr1:136180500~136180903 | Skeletal muscle | Mouse myoblast/myotube cell | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay | |
| E_02928 | chr1:136184128~136184880 | Skeletal muscle | Mouse myoblast/myotube cell | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_02929 | chr12:85460146~85464510 | Cerebral Cortex | Primary mouse cortical neurons | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay | |
| E_02930 | chr12:85486555~85490135 | Cerebral Cortex | Primary mouse cortical neurons | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay | |
| E_02931 | chr12:85505903~85509655 | Cerebral Cortex | Primary mouse cortical neurons | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay | |
| E_02932 | chr3:94170946~94172113 | Spleen | CD4+ Th17 cells | experimental autoimmune encephalomyelitis | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_02933 | chr3:94170946~94172113 | Spleen | Naive CD4+ T cells | experimental autoimmune encephalomyelitis | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_02934 | chr12:85425800~85426300 | Brain | Cortical neurons | Enhancer activity assay, TF binding assay, Chromatin interaction assay | |
| E_02935 | chr16:25400000~25900000 | Prostate | Mouse Prostate Epithelial Organoids | prostate cancer | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_02936 | chr3:128750000~128770000 | Heart | Left Atrial Cardiomyocytes | atrial fibrillation | Functional perturbation assay, Chromatin interaction assay, Enhancer activity assay |
| E_02937 | chr9:119377827~119379749 | Heart | Mouse cardiomyocyte cell | Enhancer activity assay, Functional perturbation assay, TF binding assay | |
| E_02938 | chr9:119377827~119389749 | Heart | Cardiomyocytes | Enhancer activity assay, Functional perturbation assay, Chromatin interaction assay, TF binding assay | |
| E_02939 | chr12:85454000~85457752 | Brain | Primary mouse cortical neurons | Enhancer activity assay | |
| E_02940 | chr11:112334364~112335294 | Cartilage | Primary Mouse Chondrocytes | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_02941 | chr11:112334364~112335294 | Limb bud | HEK293 | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_02942 | chr11:112334364~112335294 | Cartilage | ATDC5 | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_02943 | chr11:112334364~112335294 | Cartilage | C3H10T1/2 | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_02944 | chr11:112482190~112483273 | Cartilage | Primary Mouse Chondrocytes | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_02945 | chr11:112482190~112483273 | Limb bud | HEK293 | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_02946 | chr11:112482190~112483273 | Cartilage | ATDC5 | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_02947 | chr11:112482190~112483273 | Cartilage | C3H10T1/2 | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_02948 | chr8:12428828~12432474 | Embryo | Mouse embryonic stem cells | Enhancer activity assay, Functional perturbation assay, Chromatin interaction assay | |
| E_02949 | chr7:103816000~103817000 | Fetal liver | MEL (mouse erythroleukemia) cell line | Chromatin interaction assay, Functional perturbation assay | |
| E_02950 | chr1:136178700~136179145 | Skeletal muscle | C2C12 myoblast cell line | Functional perturbation assay | |
| E_02951 | chr18:37169500~37170500 | Cerebral cortex | Cortical neurons | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay | |
| E_02952 | chr18:37169500~37170500 | Endometrium | HEC-1-B cells | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay | |
| E_02953 | chr18:37172000~37173000 | Cerebral cortex | Cortical neurons | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay | |
| E_02954 | chr18:37172000~37173000 | Endometrium | HEC-1-B cells | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay | |
| E_02955 | chr18:37000000~37100000 | Cerebral cortex | Cortical neurons | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay | |
| E_02956 | chr18:37000000~37100000 | Brain | Neuro-2A cells | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay | |
| E_02957 | chr3:3464735~3477735 | Embryo | Mouse embryonic stem cells | Functional perturbation assay, Chromatin interaction assay | |
| E_02958 | chr9:119378700~119379271 | Heart | Mouse cardiomyocyte cell | Enhancer activity assay, Functional perturbation assay | |
| E_02959 | chr12:85471268~85473533 | Cerebral Cortex | Primary mouse cortical neurons | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_02960 | chr11:32144500~32150000 | Fetal Liver | Erythroid cells | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay | |
| E_02961 | chr11:32145000~32145500 | Fetal Liver | Erythroid cells | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay | |
| E_02962 | chr11:32146000~32146500 | Fetal Liver | Erythroid cells | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay | |
| E_02963 | chr11:32147000~32147500 | Fetal Liver | Erythroid cells | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay | |
| E_02964 | chr11:32148000~32148500 | Fetal Liver | Erythroid cells | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay | |
| E_02965 | chr11:32149000~32149500 | Fetal Liver | Erythroid cells | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay | |
| E_02966 | chr15:97300000~97400000 | Bone marrow | RN2 AML cell line | acute myeloid leukemia | Enhancer activity assay, Chromatin interaction assay |
| E_02967 | chr3:3103577~3104077 | Skeletal muscle | C2C12 myoblast | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_02968 | chr3:3103577~3104077 | Adipose tissue | 3T3-F442A preadipocyte | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_02969 | chr1:136185800~136186245 | Skeletal muscle | C2C12 myoblast cell line | Chromatin interaction assay, TF binding assay | |
| E_02970 | chr15:63442671~63443111 | Bone Marrow | LSK Cells | acute myeloid leukemia | Functional perturbation assay |
| E_02971 | chr15:63479681~63480222 | Bone Marrow | LT-HSCs | acute myeloid leukemia | Functional perturbation assay |
| E_02972 | chr5:98680000~98682000 | Embryo | EpiLCs | Enhancer activity assay, Functional perturbation assay | |
| E_02973 | chr5:98660000~98662000 | Embryo | EpiLCs | Enhancer activity assay, Functional perturbation assay | |
| E_02974 | chr7:105711382~105713753 | Colon | Primary Treg cells | colitis | Functional perturbation assay, Enhancer activity assay, TF binding assay |
| E_02975 | chr15:103026344~103028143 | Heart | Not available | Enhancer activity assay, Functional perturbation assay | |
| E_02976 | chr17:31172998~31173656 | Bone Marrow | Bone marrow-derived macrophages | Enhancer activity assay, TF binding assay, Chromatin interaction assay | |
| E_02977 | chr17:45890060~45890829 | Bone Marrow | Bone marrow-derived macrophages | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay | |
| E_02978 | chr12:114462800~114464200 | Spleen | Primary mature B cells (activated with LPS + IL-4) | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay | |
| E_02979 | chr12:114465285~114467786 | Spleen | Primary mature B cells (activated with LPS + IL-4) | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay | |
| E_02980 | chr12:114479200~114480600 | Spleen | Primary mature B cells (activated with LPS + IL-4) | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay | |
| E_02981 | chr12:114481431~114482631 | Spleen | Primary mature B cells (activated with LPS + IL-4) | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay | |
| E_02982 | chr12:114461575~114496377 | Spleen | Primary mature B cells (activated with LPS + IL-4) | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay | |
| E_02983 | chr12:85488233~85490498 | Brain | Primary mouse cortical neurons | Enhancer activity assay | |
| E_02984 | chr15:102000000~102800000 | Prostate | Mouse Prostate Epithelial Organoids | prostate cancer | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_02985 | chr18:87758000~87762000 | Retina | Primary retinal pigment epithelium (RPE) cells | proliferative vitreoretinopathy | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_02986 | chr11:10954273~10955559 | Testis | Sertoli cells | sex reversal | Developmental biology assay, Functional genomics assay, Epigenomic profiling assay, Genome editing assay, Transcriptional regulation assay, In vivo transgenic reporter assay |
| E_02987 | chr11:32154500~32155500 | Fetal Liver | Primary erythroid cells | Enhancer activity assay, Functional perturbation assay, Chromatin interaction assay | |
| E_02988 | chr11:32156045~32157045 | Fetal Liver | Primary erythroid cells | Enhancer activity assay, Functional perturbation assay, Chromatin interaction assay | |
| E_02989 | chr11:32158500~32159500 | Fetal Liver | Primary erythroid cells | Enhancer activity assay, Functional perturbation assay, Chromatin interaction assay | |
| E_02990 | chr11:32160500~32161500 | Fetal Liver | Primary erythroid cells | Enhancer activity assay, Functional perturbation assay, Chromatin interaction assay | |
| E_02991 | chr11:32163000~32164000 | Fetal Liver | Primary erythroid cells | Enhancer activity assay, Functional perturbation assay, Chromatin interaction assay | |
| E_02992 | chr11:9746900~9747200 | Mammary gland | Primary MECs | Functional perturbation assay | |
| E_02993 | chr8:123400044~123400756 | Lung | Embryonic lung cells | pulmonary vascular disease | Chromatin interaction assay |
| E_02994 | chr8:123406634~123407310 | Lung | Embryonic lung cells | pulmonary vascular disease | Chromatin interaction assay |
| E_02995 | chr15:63489392~63491254 | Bone Marrow | CLPs | acute myeloid leukemia | Functional perturbation assay |
| E_02996 | chr18:37148500~37149500 | Cerebral cortex | Primary cortical neurons | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay | |
| E_02997 | chr18:37148500~37149500 | Endometrium | HEC-1-B cell line | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay | |
| E_02998 | chr18:37380000~37385000 | Cerebral cortex | Primary cortical neurons | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay | |
| E_02999 | chr18:37380000~37385000 | Brain | Neuro-2A cell line | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay | |
| E_03000 | chr11:10941473~10942029 | Genital ridge | Bipotential gonadal somatic cells | sex reversal | Developmental biology assay, Functional genomics assay, Epigenomic profiling assay, Genome editing assay, Transcriptional regulation assay, In vivo transgenic reporter assay, In vivo functional assay |
| E_03001 | chr11:10996600~10999794 | Testis | Sertoli cell precursors | sex reversal | Developmental biology assay, Functional genomics assay, Epigenomic profiling assay, Genome editing assay, Transcriptional regulation assay, In vivo functional assay |
| E_03002 | chr2:122450000~122450200 | Bone Marrow | Bone marrow-derived macrophages | Enhancer activity assay, Chromatin interaction assay | |
| E_03003 | chr7:6650000~6650600 | Brain | Neuro-2a cells | Enhancer activity assay | |
| E_03004 | chr16:92950000~92951000 | Fetal liver | MEL (mouse erythroleukemia) cell line | Chromatin interaction assay | |
| E_03005 | chr2:12870000~12871000 | Fetal liver | MEL (mouse erythroleukemia) cell line | Chromatin interaction assay | |
| E_03006 | chr15:63496914~63497514 | Bone Marrow | CMPs | acute myeloid leukemia | Functional perturbation assay |
| E_03007 | chr15:63510497~63510914 | Bone Marrow | MEPs | acute myeloid leukemia | Functional perturbation assay |
| E_03008 | chr15:63536261~63536739 | Bone Marrow | CLPs | acute myeloid leukemia | Functional perturbation assay |
| E_03009 | chr15:63567831~63568301 | Bone Marrow | MEPs | acute myeloid leukemia | Functional perturbation assay |
| E_03010 | chr6:127006796~127007720 | Kidney | Bone marrow-derived mesenchymal stem cells | chronic kidney disease | Functional genomics assay, Epigenomic profiling assay, Genome editing assay, Transcriptional regulation assay, In vivo functional assay |
| E_03011 | chr11:5202000~5255000 | Blood | CD4+ T cells | immune dysregulation | Chromatin interaction assay, Functional perturbation assay |
| E_03012 | chr9:119377827~119389749 | Heart | Cardiomyocytes | Enhancer activity assay | |
| E_03013 | chr1:136179654~136180057 | Skeletal muscle | Mouse myoblast cell line | Enhancer activity assay, Functional perturbation assay, TF binding assay | |
| E_03014 | chr1:136185854~136186299 | Skeletal muscle | Mouse myoblast cell line | Enhancer activity assay, Functional perturbation assay, TF binding assay | |
| E_03015 | chr1:136188454~136188857 | Skeletal muscle | Mouse myoblast cell line | Enhancer activity assay, Functional perturbation assay, TF binding assay | |
| E_03016 | chr11:97576234~97587534 | Liver | Primary mouse hepatocytes | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_03017 | chr15:4422074~4423282 | Liver | Primary mouse hepatocytes | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_03018 | chr2:171152164~171153352 | Liver | Primary mouse hepatocytes | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_03019 | chr8:56652281~56653526 | Liver | Primary mouse hepatocytes | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_03020 | chr12:85475221~85476912 | Cerebral Cortex | Primary mouse cortical neurons | Enhancer activity assay, TF binding assay | |
| E_03021 | chr17:35643073~35645472 | Embryo | Mouse embryonic fibroblasts | Enhancer activity assay, Functional perturbation assay | |
| E_03022 | chr1:189023000~189023400 | Embryo | Mouse embryonic stem cells | Enhancer activity assay, Functional perturbation assay, TF binding assay | |
| E_03023 | chr3:94169746~94173149 | Spleen | Naive CD4+ T cells | experimental autoimmune encephalomyelitis | Enhancer activity assay, TF binding assay |
| E_03024 | chr4:147122070~148025142 | Embryo | Mouse embryonic stem cells (mESCs) | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay | |
| E_03025 | chrX:7230000~7720000 | Embryo | Mouse embryonic stem cells (mESCs) | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay | |
| E_03026 | chr11:5202000~5255000 | Blood | CD4+ T cells | immune dysregulation | Chromatin interaction assay, Functional perturbation assay |
| E_03027 | chr11:78901000~78901400 | Embryo | Mouse embryonic stem cells | Enhancer activity assay, Functional perturbation assay, TF binding assay | |
| E_03028 | chr11:97234000~97234400 | Embryo | Mouse embryonic stem cells | Enhancer activity assay, Functional perturbation assay, TF binding assay | |
| E_03029 | chr13:48792000~48792400 | Embryo | Mouse embryonic stem cells | Enhancer activity assay, Functional perturbation assay, TF binding assay | |
| E_03030 | chr16:31208000~31208400 | Embryo | Mouse embryonic stem cells | Enhancer activity assay, Functional perturbation assay, Chromatin interaction assay, TF binding assay | |
| E_03031 | chr19:45678000~45678400 | Embryo | Mouse embryonic stem cells | Enhancer activity assay, Functional perturbation assay, TF binding assay | |
| E_03032 | chr2:130890000~130890400 | Embryo | Mouse embryonic stem cells | Enhancer activity assay, Functional perturbation assay, TF binding assay | |
| E_03033 | chr7:56789000~56789400 | Embryo | Mouse embryonic stem cells | Enhancer activity assay, Functional perturbation assay, TF binding assay | |
| E_03034 | chr8:34567000~34567400 | Embryo | Mouse embryonic stem cells | Enhancer activity assay, Functional perturbation assay, TF binding assay | |
| E_03035 | chr9:112345000~112345400 | Embryo | Mouse embryonic stem cells | Enhancer activity assay, Functional perturbation assay, TF binding assay | |
| E_03036 | chr9:12456000~12456400 | Embryo | Mouse embryonic stem cells | Enhancer activity assay, Functional perturbation assay, TF binding assay | |
| E_03037 | chrX:14567000~14567400 | Embryo | Mouse embryonic stem cells | Enhancer activity assay, Functional perturbation assay, TF binding assay | |
| E_03038 | chrX:98765000~98765400 | Embryo | Mouse embryonic stem cells | Enhancer activity assay, Functional perturbation assay, TF binding assay | |
| E_03039 | chr4:55621000~55621400 | Embryo | Mouse embryonic stem cells | Enhancer activity assay, Functional perturbation assay, Chromatin interaction assay, TF binding assay | |
| E_03040 | chr5:120456000~120456400 | Embryo | Mouse embryonic stem cells | Enhancer activity assay, Functional perturbation assay, Chromatin interaction assay, TF binding assay | |
| E_03041 | chr6:53214500~53214900 | Embryo | Mouse embryonic stem cells | Enhancer activity assay, Functional perturbation assay, Chromatin interaction assay, TF binding assay | |
| E_03042 | chr6:87652000~87652400 | Embryo | Mouse embryonic stem cells | Enhancer activity assay, Chromatin interaction assay, TF binding assay | |
| E_03043 | chr16:18164900~18165100 | Pharyngeal arch | NIH/3T3 cell line | Enhancer activity assay, TF binding assay | |
| E_03044 | chr2:73389900~73390100 | Pharyngeal arch | NIH/3T3 cell line | Enhancer activity assay, TF binding assay | |
| E_03045 | chr3:133140000~133200000 | Embryo | Mouse embryonic stem cells (mESC) | Functional perturbation assay | |
| E_03046 | chr3:62280000~62340000 | Embryo | Mouse embryonic stem cells (mESC) | Functional perturbation assay | |
| E_03047 | chr3:62280000~62340000 | Embryo | Mouse embryonic stem cells (mESC) | Functional perturbation assay | |
| E_03048 | chr11:101892458~101969015 | Bone | Ocy454 osteocyte cell line | Enhancer activity assay | |
| E_03049 | chr13:74520100~74520400 | Liver | HEK293 cell line | Enhancer activity assay | |
| E_03050 | chr12:79240000~79242000 | Brain | Primary cortical neurons | Enhancer activity assay, TF binding assay | |
| E_03051 | chr15:93680000~93682000 | Brain | Primary cortical neurons | Enhancer activity assay | |
| E_03052 | chr11:96748200~96748700 | Bone marrow | BMDMs | Enhancer activity assay | |
| E_03053 | chr16:24176502~24213494 | Spleen | Germinal center B cells | Chromatin interaction assay, Functional perturbation assay | |
| E_03054 | chr3:60330708~60331205 | Skeletal muscle | C2C12 myoblasts | Enhancer activity assay, Functional perturbation assay | |
| E_03055 | chr8:5325000~5325500 | Adipose tissue | C2C12 myoblast | TF binding assay, Enhancer activity assay | |
| E_03056 | chr6:127006900~127006914 | Kidney | Osteocytes | chronic kidney disease | Functional genomics assay, Transcriptional regulation assay, In Silico Motif Analysis |
| E_03057 | chr6:127007050~127007058 | Kidney | Renal tubular epithelial cells | chronic kidney disease | Functional genomics assay, Transcriptional regulation assay, In Silico Motif Analysis |
| E_03058 | chr6:127007200~127007209 | Kidney | Renal proximal tubular epithelial cells | chronic kidney disease | Functional genomics assay, Transcriptional regulation assay, In Silico Motif Analysis |
| E_03059 | chr7:149796331~149801250 | Striatum | Primary mouse cortical neurons | Functional perturbation assay | |
| E_03060 | chr7:149796331~149801250 | Frontal Cortex | striatal neurons | Functional perturbation assay | |
| E_03061 | chr11:10997900~10999300 | Testis | Sertoli cell precursors | sex reversal | Developmental biology assay, Functional genomics assay, Transcriptional regulation assay |
| E_03062 | chr8:87424785~87425735 | Blood | Mouse erythroid progenitor cells | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_03063 | chr14:77031707~77033014 | Spleen | Primary mouse CD4+ T cells | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay | |
| E_03064 | chr14:77080000~77081000 | Spleen | Primary mouse CD4+ T cells | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay | |
| E_03065 | chr6:122652547~122653538 | Embryo | Mouse embryonic stem cells | Enhancer activity assay, Functional perturbation assay | |
| E_03066 | chr9:99032500~99032700 | Heart | Neonatal rat ventricular cardiomyocytes | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_03067 | chr9:99032500~99033051 | Heart | Mouse atrial cardiomyocyte cell | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_03068 | chr1:172411511~172413110 | Heart | Not available | Enhancer activity assay | |
| E_03069 | chr12:4704343~4706142 | Heart | Not available | Enhancer activity assay | |
| E_03070 | chr17:46687021~48462216 | Embryo | Mouse embryonic stem cells | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay | |
| E_03071 | chr19:10050000~10650000 | Embryo | Mouse embryonic stem cells | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay | |
| E_03072 | chr2:122739000~122739200 | Bone Marrow | Bone marrow-derived macrophages | Enhancer activity assay | |
| E_03073 | chr4:88070000~88070500 | Bone Marrow | RAW264.7 macrophage cell line | TF binding assay, Enhancer activity assay | |
| E_03074 | chr17:33930235~37702617 | Colon | iKAP colorectal cancer cells | colorectal cancer | Chromatin interaction, Functional perturbation |
| E_03075 | chr14:5320000~5321500 | Thymus | DN/DP thymocytes | Enhancer activity assay, TF binding assay | |
| E_03076 | chr7:12705000~12706000 | Bone marrow | Plasmacytoid dendritic cells (pDC) | TF binding assay, Functional perturbation assay | |
| E_03077 | chr9:10980000~10981000 | Bone marrow | Plasmacytoid dendritic cells (pDC) | TF binding assay, Functional perturbation assay | |
| E_03078 | chr15:8725000~8726000 | Bone marrow | Plasmacytoid dendritic cells (pDC) | TF binding assay, Functional perturbation assay | |
| E_03079 | chr4:14960000~14961000 | Bone marrow | Monocyte-derived dendritic cells (moDC) | TF binding assay, Functional perturbation assay | |
| E_03080 | chr4:14962000~14963000 | Bone marrow | Monocyte-derived dendritic cells (moDC) | TF binding assay, Functional perturbation assay | |
| E_03081 | chr8:12340000~12341000 | Bone marrow | Monocyte-derived dendritic cells (moDC) | TF binding assay, Functional perturbation assay | |
| E_03082 | chr7:53630000~53635000 | Skeletal muscle | C2C12 myoblasts/myotubes | Functional perturbation assay, TF binding assay | |
| E_03083 | chr1:167519257~167519314 | Bone marrow | Primary pro-B cells | Enhancer activity assay, Chromatin interaction assay | |
| E_03084 | chr1:167572056~167572182 | Bone marrow | Primary pro-B cells | Enhancer activity assay, Chromatin interaction assay | |
| E_03085 | chr18:86761026~86761110 | Bone marrow | Primary pro-B cells | Enhancer activity assay, Chromatin interaction assay | |
| E_03086 | chr18:86772479~86772600 | Bone marrow | Primary pro-B cells | Enhancer activity assay, Chromatin interaction assay | |
| E_03087 | chr18:86773163~86773345 | Bone marrow | Primary pro-B cells | Enhancer activity assay, Chromatin interaction assay | |
| E_03088 | chr2:121974537~121974595 | Bone marrow | Primary pro-B cells | Enhancer activity assay, Chromatin interaction assay | |
| E_03089 | chr12:85484889~85486580 | Brain | Primary mouse cortical neurons | Enhancer activity assay | |
| E_03090 | chr5:145320091~145322975 | Pancreas | Pancreatic primordium | Enhancer activity assay | |
| E_03091 | chr9:121540000~121545000 | Retina | Primary retinal pigment epithelium (RPE) cells | proliferative vitreoretinopathy | Enhancer activity assay, Functional perturbation assay |
| E_03092 | chr16:92915000~92925000 | Retina | Primary retinal pigment epithelium (RPE) cells | proliferative vitreoretinopathy | Enhancer activity assay, TF binding assay |
| E_03093 | chr2:13800000~13810000 | Retina | Primary retinal pigment epithelium (RPE) cells | proliferative vitreoretinopathy | Enhancer activity assay |
| E_03094 | chr7:83943095~83943301 | Skeletal muscle | MM14 skeletal myocytes | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_03095 | chr7:83943095~83943301 | Skeletal muscle | C2C12 skeletal muscle | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_03096 | chr7:83943095~83943301 | Skeletal muscle | mouse skeletal muscle fibers | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_03097 | chr7:83945252~83945346 | Skeletal muscle | MM14 skeletal myocytes | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_03098 | chr7:83945252~83945346 | Skeletal muscle | C2C12 skeletal muscle | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_03099 | chr7:83945252~83945346 | Skeletal muscle | mouse skeletal muscle fibers | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_03100 | chr2:104914099~104915125 | Testis | Sertoli cells | Enhancer activity assay | |
| E_03101 | chr4:114450000~114451000 | Fetal liver | HPC-7 | Enhancer activity assay | |
| E_03102 | chr12:110769000~110772000 | Embryo | mESC | Functional perturbation assay | |
| E_03103 | chr11:98800000~98850000 | Colon | Colonic epithelium | Enhancer activity assay | |
| E_03104 | chr11:10999900~11000869 | Testis | Sertoli cells | sex reversal | Developmental biology assay, Functional genomics assay, Epigenomic profiling assay, Transcriptional regulation assay, In vivo transgenic reporter assay |
| E_03105 | chr14:75279839~75281592 | Blood | Enhancer activity assay, TF binding assay, Chromatin interaction assay | ||
| E_03106 | chr14:75301169~75302562 | Blood | Enhancer activity assay, TF binding assay, Chromatin interaction assay | ||
| E_03107 | chr14:75307707~75309014 | Blood | Enhancer activity assay, TF binding assay, Chromatin interaction assay | ||
| E_03108 | chr14:75355500~75356000 | Blood | Enhancer activity assay, TF binding assay, Chromatin interaction assay | ||
| E_03109 | chr9:119380000~119389749 | Left Ventricle | Cardiomyocytes | Functional perturbation assay | |
| E_03110 | chr18:68120000~68121000 | Fetal Liver | Primary erythroid cells | Enhancer activity assay, Functional perturbation assay | |
| E_03111 | chr4:140235012~140235389 | Blood | Mouse erythroblast cell | Chromatin interaction assay, Functional perturbation assay | |
| E_03112 | chr4:140385104~140385471 | Blood | Mouse erythroblast cell | Chromatin interaction assay, Functional perturbation assay | |
| E_03113 | chr5:142650068~142650435 | Blood | Mouse erythroblast cell | TF binding assay, Enhancer activity assay | |
| E_03114 | chr6:125380026~125380393 | Blood | Mouse erythroblast cell | TF binding assay, Enhancer activity assay | |
| E_03115 | chr7:27930056~27930423 | Blood | Mouse erythroblast cell | TF binding assay, Functional perturbation assay | |
| E_03116 | chr9:120150022~120150389 | Blood | Mouse erythroblast cell | Chromatin interaction assay, Functional perturbation assay | |
| E_03117 | chr6:122500000~122502000 | Thymus | Double-positive thymocytes | Functional perturbation assay | |
| E_03118 | chr11:112634637~112637797 | Testis | Sertoli cells | Enhancer activity assay, Functional perturbation assay, TF binding assay | |
| E_03119 | chr11:112635500~112636792 | Testis | Sertoli cells | Enhancer activity assay, Functional perturbation assay, TF binding assay | |
| E_03120 | chr6:124835092~124835618 | Thymus | CD4-positive, CD8-positive thymocyte | Genome-wide regulatory element profiling | |
| E_03121 | chr7:134235000~134355000 | Embryo | Mouse embryonic fibroblast | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_03122 | chr4:96790000~97810000 | Embryo | Mouse embryonic fibroblast | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_03123 | chr2:123456678~123456750 | Embryo | P19 cells | Enhancer activity assay, TF binding assay | |
| E_03124 | chr2:28950000~28970000 | Bone marrow | LSK hematopoietic stem cells | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay | |
| E_03125 | chr14:77129438~77130831 | Blood | Jurkat T cells | T-cell acute lymphoblastic leukemia | Enhancer activity assay |
| E_03126 | chr16:13020425~13021045 | Pancreatic islet | ¦ÃTC-3 | Enhancer activity assay, TF binding assay | |
| E_03127 | chr16:13020425~13021045 | Pancreatic islet | ¦ÃTC-6 | Enhancer activity assay, TF binding assay | |
| E_03128 | chr16:13020425~13021045 | Cervix | HeLa | cervical cancer | Enhancer activity assay, TF binding assay |
| E_03129 | chr3:34668260~34668560 | Embryo | Mouse embryonic stem | Enhancer activity assay, Functional perturbation assay | |
| E_03130 | chr3:34668260~34668560 | Embryo | primary embryonic tissue | Enhancer activity assay, Functional perturbation assay | |
| E_03131 | chr7:134235000~134355000 | Embryo | Mouse Embryonic Fibroblast (MEF) | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_03132 | chr15:63606018~63757541 | Colon | Colonic epithelial | Enhancer activity assay | |
| E_03133 | chr2:155134800~155135200 | Cartilage | Primary Mouse Chondrocytes | TF binding assay, Functional perturbation assay | |
| E_03134 | chr2:155134800~155135200 | Cartilage | ATDC5 Chondrogenic | TF binding assay, Functional perturbation assay | |
| E_03135 | chr6:126984000~126986000 | Kidney | Osteocytes | chronic kidney disease | Functional genomics assay, Epigenomic profiling assay, Transcriptional regulation assay |
| E_03136 | chr6:127030000~127032000 | Kidney | Osteocytes | chronic kidney disease | Functional genomics assay, Epigenomic profiling assay, Transcriptional regulation assay |
| E_03137 | chr4:114743698~114748936 | Blood vessel | Endothelial cells | Enhancer activity assay | |
| E_03138 | chr11:44203545~44203644 | Bone Marrow | Bone marrow-derived macrophages | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_03139 | chr4:114484000~114485000 | Fetal liver | HPC-7 | Enhancer activity assay | |
| E_03140 | chr19:45050000~45051000 | Fetal liver | HPC-7 | Enhancer activity assay | |
| E_03141 | chr1:134714823~134715623 | Brain | Primary mouse mesencephalic cells | Enhancer activity assay | |
| E_03142 | chr14:75355295~75355954 | Blood | Enhancer activity assay, TF binding assay | ||
| E_03143 | chr14:75355295~75357027 | Blood | Enhancer activity assay, TF binding assay | ||
| E_03144 | chr14:75355955~75357027 | Blood | Enhancer activity assay, TF binding assay | ||
| E_03145 | chr14:75363000~75363900 | Blood | Enhancer activity assay, TF binding assay | ||
| E_03146 | chr14:75371600~75372700 | Blood | Enhancer activity assay, TF binding assay | ||
| E_03147 | chr14:75408900~75410500 | Blood | Enhancer activity assay, TF binding assay | ||
| E_03148 | chr14:75415600~75416800 | Blood | Enhancer activity assay, TF binding assay | ||
| E_03149 | chr17:44838751~44840051 | Bone | Primary mouse osteoblasts | Enhancer activity assay, TF binding assay | |
| E_03150 | chr17:44839209~44839551 | Bone | Primary mouse osteoblasts | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_03151 | chr17:44839381~44839469 | Bone | Primary mouse osteoblasts | Enhancer activity assay, TF binding assay | |
| E_03152 | chr9:119385000~119387000 | Heart | Cardiomyocytes | Functional perturbation assay | |
| E_03153 | chr11:32145270~32146411 | Blood vessel | Endothelial cells | Enhancer activity assay | |
| E_03154 | chr13:28809515~28811310 | Blood vessel | Endothelial cells | Enhancer activity assay | |
| E_03155 | chr17:12982583~12985936 | Blood vessel | Endothelial cells | Enhancer activity assay | |
| E_03156 | chr3:87786601~87790798 | Blood vessel | Endothelial cells | Enhancer activity assay | |
| E_03157 | chr5:93426293~93427320 | Blood vessel | Endothelial cells | Enhancer activity assay | |
| E_03158 | chr7:116256647~116260817 | Heart | Cardiomyocytes | Enhancer activity assay | |
| E_03159 | chr8:28216799~28218903 | Blood vessel | Endothelial cells | Enhancer activity assay | |
| E_03160 | chr8:28216817~28218896 | Blood vessel | Endothelial cells | Enhancer activity assay | |
| E_03161 | chr5:137487678~137501478 | Kidney | Renal EPO-producing cells | Enhancer activity assay, Functional perturbation assay | |
| E_03162 | chr14:53200000~53202000 | Thymus | Double-negative thymocytes | Enhancer activity assay | |
| E_03163 | chr6:72100000~72102000 | Thymus | Double-negative thymocytes | Enhancer activity assay | |
| E_03164 | chr10:95800000~95800200 | Bone Marrow | Bone marrow-derived macrophages | Enhancer activity assay | |
| E_03165 | chr11:82100000~82100200 | Bone Marrow | Bone marrow-derived macrophages | TF binding assay | |
| E_03166 | chr4:5320000~5320100 | Bone Marrow | Bone marrow-derived macrophages | Enhancer activity assay | |
| E_03167 | chr5:137531500~137531600 | Liver | Hepatocytes | Enhancer activity assay, TF binding assay | |
| E_03168 | chr1:134976575~134977476 | Forebrain | Transgenic mouse embryo | Transgenic reporter assay | |
| E_03169 | chr1:140396600~140397726 | Forebrain | Transgenic mouse embryo | Transgenic reporter assay | |
| E_03170 | chr1:165828000~165828801 | Midbrain | Transgenic mouse embryo | Transgenic reporter assay | |
| E_03171 | chr1:167864800~167866051 | Forebrain | Transgenic mouse embryo | Transgenic reporter assay | |
| E_03172 | chr1:192551300~192552876 | Forebrain | Transgenic mouse embryo | Transgenic reporter assay | |
| E_03173 | chr1:41975300~41976076 | Forebrain | Transgenic mouse embryo | Transgenic reporter assay | |
| E_03174 | chr2:137073600~137074376 | Midbrain | Transgenic mouse embryo | Transgenic reporter assay | |
| E_03175 | chr3:141901125~141902126 | Midbrain | Transgenic mouse embryo | Transgenic reporter assay | |
| E_03176 | chr3:30006475~30007726 | Midbrain | Transgenic mouse embryo | Transgenic reporter assay | |
| E_03177 | chr3:34986900~34988201 | Forebrain | Transgenic mouse embryo | Transgenic reporter assay | |
| E_03178 | chr3:5224600~5225676 | Forebrain | Transgenic mouse embryo | Transgenic reporter assay | |
| E_03179 | chr3:55558975~55559751 | Limb | Transgenic mouse embryo | Transgenic reporter assay | |
| E_03180 | chr3:84741550~84742501 | Forebrain | Transgenic mouse embryo | Transgenic reporter assay | |
| E_03181 | chr4:44864575~44865251 | Limb | Transgenic mouse embryo | Transgenic reporter assay | |
| E_03182 | chr4:5888950~5890926 | Forebrain | Transgenic mouse embryo | Transgenic reporter assay | |
| E_03183 | chr4:6840325~6841401 | Forebrain | Transgenic mouse embryo | Transgenic reporter assay | |
| E_03184 | chr4:71828300~71829751 | Forebrain | Transgenic mouse embryo | Transgenic reporter assay | |
| E_03185 | chr4:97774675~97775901 | Forebrain | Transgenic mouse embryo | Transgenic reporter assay | |
| E_03186 | chr5:74828975~74829601 | Limb | Transgenic mouse embryo | Transgenic reporter assay | |
| E_03187 | chr6:144260800~144262201 | Midbrain | Transgenic mouse embryo | Transgenic reporter assay | |
| E_03188 | chr6:28346175~28347126 | Forebrain | Transgenic mouse embryo | Transgenic reporter assay | |
| E_03189 | chr6:51026850~51028001 | Forebrain | Transgenic mouse embryo | Transgenic reporter assay | |
| E_03190 | chr6:51146275~51148026 | Midbrain | Transgenic mouse embryo | Transgenic reporter assay | |
| E_03191 | chr2:9515156~9522270 | Thymus | Thymocytes (ETP/DN/DP/CD4 SP) | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_03192 | chr6:42300000~42301500 | Thymus | DN/DP thymocytes | Enhancer activity assay, TF binding assay | |
| E_03193 | chr1:165827290~165830012 | Limb bud | Limb mesenchymal cells | Enhancer activity assay, Functional perturbation assay | |
| E_03194 | chr5:115320000~115320500 | Embryo | Embryonic stem cells (ESC) | Enhancer activity assay, TF binding assay | |
| E_03195 | chr5:115345000~115345600 | Embryo | Embryonic stem cells (ESC) | Enhancer activity assay, TF binding assay | |
| E_03196 | chr5:142680000~142680600 | Embryo | Embryonic stem cells (ESC) | Enhancer activity assay | |
| E_03197 | chr4:101250000~101250600 | Embryo | Epiblast-like cells (EpiLC) | Enhancer activity assay | |
| E_03198 | chr14:77129438~77130831 | Blood | Jurkat cells | T-cell acute lymphoblastic leukemia | Enhancer activity assay |
| E_03199 | chr19:4473287~4473381 | Skeletal muscle | MM14 myocytes | Enhancer activity assay, TF binding assay | |
| E_03200 | chr19:4473287~4473381 | Skeletal muscle | C2C12 myocytes | Enhancer activity assay, TF binding assay | |
| E_03201 | chr9:19196000~19196100 | Blood | M12 B cells | B-cell lymphoma | Enhancer activity assay, TF binding assay |
| E_03202 | chr2:171850200~171850400 | Cartilage | Primary Chondrocytes | TF binding assay, Functional perturbation assay | |
| E_03203 | chr4:82235567~82235814 | Cerebellum | Cerebellar granule cells | TF binding assay, Enhancer activity assay | |
| E_03204 | chr4:81219772~81219968 | Cerebellum | Cerebellar granule cells | TF binding assay, Enhancer activity assay | |
| E_03205 | chr4:82185096~82185615 | Cerebellum | Cerebellar granule cells | TF binding assay, Enhancer activity assay | |
| E_03206 | chr4:81212120~81212422 | Cerebellum | Cerebellar granule cells | TF binding assay | |
| E_03207 | chr18:12947300~12947895 | Brain | Neural stem/progenitor | Enhancer activity assay, Functional perturbation assay | |
| E_03208 | chr18:12947300~12947895 | Brain | Mouse embryonic stem | Enhancer activity assay, Functional perturbation assay | |
| E_03209 | chr18:12880000~12880676 | Brain | Neural stem/progenitor | Enhancer activity assay, Functional perturbation assay | |
| E_03210 | chr18:12880000~12880676 | Brain | Mouse embryonic stem | Enhancer activity assay, Functional perturbation assay | |
| E_03211 | chr16:13020625~13020824 | Pancreatic islet | ¦ÃTC-3 | Enhancer activity assay, TF binding assay | |
| E_03212 | chr6:1778~2113 | Liver | HepG2 | hepatocellular carcinoma | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_03213 | chr6:1778~2113 | Liver | NMuLi | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_03214 | chr6:1778~2113 | Cervix | HeLa | cervical cancer | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_03215 | chr5:75546054~75548325 | Embryo | Mouse Embryonic Stem Cells (mESCs) | Enhancer activity assay, TF binding assay | |
| E_03216 | chr6:6770399~6771465 | Skeletal muscle | C2C12 cells | Enhancer activity assay, TF binding assay, Chromatin interaction assay | |
| E_03217 | chr17:26841565~26842075 | Heart | Cardiac progenitors | Enhancer activity assay | |
| E_03218 | chr17:26839438~26839943 | Heart | Cardiac progenitors | Enhancer activity assay | |
| E_03219 | chr7:53627200~53627771 | Skeletal muscle | C2C12 myoblasts | Enhancer activity assay, RNA-mediated regulation assay | |
| E_03220 | chr5:135080000~135100000 | Liver | Human hepatocellular carcinoma cell | hepatocellular carcinoma | Enhancer activity assay |
| E_03221 | chr1:133452484~133452725 | Kidney | Mouse juxtaglomerular cells | Enhancer activity assay, Functional perturbation assay | |
| E_03222 | chr5:135091600~135091864 | Kidney | Renal EPO-producing cells | Enhancer activity assay | |
| E_03223 | chr5:137521712~137522012 | Kidney | Renal EPO-producing cells | Enhancer activity assay, TF binding assay | |
| E_03224 | chr15:76897064~76899064 | Forebrain | Embryonic forebrain cell | Enhancer activity assay, Chromatin interaction assay | |
| E_03225 | chr5:29641240~29642424 | Limb bud | Mouse E14 ESCs | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay | |
| E_03226 | chr5:29641240~29642424 | Limb bud | E11.5 embryonic limb bud cells | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay | |
| E_03227 | chr2:105300000~105310000 | Pancreatic islet | ¦ÃTC-3 cells | Chromatin interaction assay, Enhancer activity assay | |
| E_03228 | chr2:105480000~105490000 | Pancreatic islet | ¦ÃTC-3 cells | Chromatin interaction assay, Enhancer activity assay | |
| E_03229 | chr8:62860000~62865000 | Forebrain | Mouse embryonic day 11.5 forebrain tissue | Enhancer activity assay | |
| E_03230 | chr4:117063735~117065404 | Limb bud | Limb mesenchymal cells | Enhancer activity assay, Functional perturbation assay | |
| E_03231 | chr2:25276566~25277137 | Blood | Primary CD4+ Th1 cells | Enhancer activity assay | |
| E_03232 | chr2:25277864~25279387 | Blood | Primary CD4+ Th1 cells | Enhancer activity assay | |
| E_03233 | chr2:123454700~123457000 | Embryo | Mouse embryo tissue | Enhancer activity assay | |
| E_03234 | chr15:8271300~8272300 | Cerebral cortex | Primary mouse cortical neurons | Chromatin interaction assay | |
| E_03235 | chr6:135005780~135006780 | Cerebral cortex | Primary mouse cortical neurons | Chromatin interaction assay | |
| E_03236 | chr14:77122986~77124293 | Spleen | CD4+ T cells | Enhancer activity assay, TF binding assay | |
| E_03237 | chr14:77122986~77124293 | Blood | Jurkat cells | T-cell acute lymphoblastic leukemia | Enhancer activity assay, TF binding assay |
| E_03238 | chr3:90502261~90502522 | Blood | CD4+ T cell | Enhancer activity assay | |
| E_03239 | chr11:105000000~105000100 | Lymph node | EL4 cells | T-cell lymphoma | Enhancer activity assay, TF binding assay |
| E_03240 | chr14:54000000~54000100 | Lymph node | EL4 cells | T-cell lymphoma | Enhancer activity assay, TF binding assay |
| E_03241 | chr2:74292472~74294212 | Cerebellum | Embryonic cerebellar cells | Enhancer activity assay | |
| E_03242 | chr10:128326106~128327832 | Embryo | Mouse embryonic cells (E8.5) | Enhancer activity assay, Functional perturbation assay | |
| E_03243 | chr16:13025528~13026004 | Pancreatic islet | ¦ÃTC-3 | Enhancer activity assay | |
| E_03244 | chr16:13025528~13026004 | Pancreatic islet | ¦ÃTC-6 | Enhancer activity assay | |
| E_03245 | chr6:6770399~6771465 | Skeletal muscle | C2C12 | Enhancer activity assay, TF binding assay, Chromatin interaction assay | |
| E_03246 | chr6:6770399~6771465 | Bone | MC3T3-E1 | Enhancer activity assay, TF binding assay, Chromatin interaction assay | |
| E_03247 | chr6:6770399~6771465 | Bone marrow | BM-MSC | Enhancer activity assay, TF binding assay, Chromatin interaction assay | |
| E_03248 | chr13:114453916~114454191 | Skeletal muscle | C2C12 | Enhancer activity assay, TF binding assay | |
| E_03249 | chr13:114453916~114454191 | Bone | MC3T3-E1 | Enhancer activity assay, TF binding assay | |
| E_03250 | chr17:44819323~44819541 | Skeletal muscle | C2C12 | Enhancer activity assay, TF binding assay | |
| E_03251 | chr17:44819323~44819541 | Bone | MC3T3-E1 | Enhancer activity assay, TF binding assay | |
| E_03252 | chr17:44819323~44819541 | Bone marrow | BM-MSC | Enhancer activity assay, TF binding assay | |
| E_03253 | chr3:2931~3443 | Lymph node | CD4+ T | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_03254 | chr3:2931~3443 | Lymph node | EL4 | T-cell lymphoma | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_03255 | chr3:2931~3443 | Embryonic Kidney | 293T | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_03256 | chr10:4147~4296 | Limb bud | Hypertrophic chondrocytes | Enhancer activity assay, TF binding assay | |
| E_03257 | chr10:128347441~128347590 | Limb bud | Hypertrophic chondrocytes | Enhancer activity assay, TF binding assay | |
| E_03258 | chr10:12845732~12845743 | Cartilage | Hypertrophic MCT chondrocytes | TF binding assay | |
| E_03259 | chr6:70500000~70500100 | Blood | MPC-11 cells | plasmacytoma | Chromatin interaction assay, TF binding assay |
| E_03260 | chr6:70500000~70500100 | Blood | Primary B cells | Chromatin interaction assay, TF binding assay | |
| E_03261 | chr6:70522000~70522100 | Blood | MPC-11 cells | plasmacytoma | Chromatin interaction assay, TF binding assay |
| E_03262 | chr6:70522000~70522100 | Blood | Primary B cells | Chromatin interaction assay, TF binding assay | |
| E_03263 | chr6:70546000~70546100 | Blood | MPC-11 cells | plasmacytoma | Chromatin interaction assay, TF binding assay |
| E_03264 | chr6:70546000~70546100 | Blood | Primary B cells | Chromatin interaction assay, TF binding assay | |
| E_03265 | chr9:119540800~119544032 | Heart | Cardiomyocyte | Enhancer activity assay | |
| E_03266 | chr9:119378051~119379479 | Heart | Cardiomyocyte | Enhancer activity assay | |
| E_03267 | chr11:112638000~112639300 | Testis | Sertoli cells | Enhancer activity assay | |
| E_03268 | chr5:135082600~135096400 | Kidney | Renal EPO-producing cells | Functional perturbation assay | |
| E_03269 | chr5:137512712~137526512 | Kidney | Renal EPO-producing cells | Enhancer activity assay | |
| E_03270 | chr5:137512712~137518112 | Kidney | Renal EPO-producing cells | Enhancer activity assay | |
| E_03271 | chr5:137518112~137521712 | Kidney | Renal EPO-producing cells | Enhancer activity assay | |
| E_03272 | chr5:137526512~137530112 | Kidney | Renal EPO-producing cells | Enhancer activity assay | |
| E_03273 | chr6:71252310~71308680 | Blood | Effector memory CD8+ T cells | Enhancer activity assay, TF binding assay | |
| E_03274 | chr6:71272801~71273297 | Blood | Effector memory CD8+ T cells | Enhancer activity assay, TF binding assay | |
| E_03275 | chr6:71275200~71275697 | Blood | CD8+ T cells | Enhancer activity assay, TF binding assay | |
| E_03276 | chr2:9515156~9516356 | Thymus | Thymocytes | Enhancer activity assay | |
| E_03277 | chr10:12845723~12845872 | Cartilage | Hypertrophic MCT chondrocytes | Enhancer activity assay | |
| E_03278 | chr11:3217000~3222000 | Bone Marrow | Primary Murine Erythroblasts | Enhancer activity assay, TF binding assay | |
| E_03279 | chr11:3222000~3227000 | Bone Marrow | Primary Mur | -- | |
| E_03280 | chr11:105000000~105000100 | Blood | EL4 cells | Enhancer activity assay, TF binding assay | |
| E_03281 | chr14:54000000~54000100 | Blood | EL4 cells | Enhancer activity assay, TF binding assay | |
| E_03282 | chr11:3222000~3227000 | Bone Marrow | Primary Murine Erythroblasts | Enhancer activity assay, TF binding assay | |
| E_03283 | chr11:3231000~3236000 | Bone Marrow | Primary Murine Erythroblasts | Enhancer activity assay, TF binding assay | |
| E_03284 | chr11:3235000~3240000 | Bone Marrow | Primary Murine Erythroblasts | Enhancer activity assay, TF binding assay | |
| E_03285 | chr6:70989543~70989643 | Blood | S194 plasmacytoma cells | plasmacytoma | Functional perturbation assay |
| E_03286 | chr6:70999043~70999143 | Blood | S194 plasmacytoma cells | plasmacytoma | Functional perturbation assay |
| E_03287 | chr3:34668443~34668497 | Embryo | Mouse embryonic tissue | Enhancer activity assay | |
| E_03288 | chrX:100581771~100582950 | Brain | Oligodendrocytes | Enhancer activity assay, Functional perturbation assay | |
| E_03289 | chrX:100581771~100582950 | Brain | Oligodendrocyte Precursor | Enhancer activity assay, Functional perturbation assay | |
| E_03290 | chrX:100581771~100582950 | Brain | Olfactory Ensheathing | Enhancer activity assay, Functional perturbation assay | |
| E_03291 | chrX:100581771~100582950 | Brain | Schwann | Enhancer activity assay, Functional perturbation assay | |
| E_03292 | chrX:100581771~100582950 | Brain | Neurons | Enhancer activity assay, Functional perturbation assay | |
| E_03293 | chr12:85427000~85427500 | Cerebral cortex | Cortical neurons | Enhancer activity assay, TF binding assay, Chromatin interaction assay | |
| E_03294 | chr12:85428000~85428500 | Cerebral cortex | Cortical neurons | Enhancer activity assay, TF binding assay, Chromatin interaction assay | |
| E_03295 | chr12:85429000~85429500 | Cerebral cortex | Cortical neurons | Enhancer activity assay, TF binding assay, Chromatin interaction assay | |
| E_03296 | chr12:85471518~85475098 | Brain | Primary mouse cortical neurons | Enhancer activity assay | |
| E_03297 | chr12:85499955~85504319 | Brain | Primary mouse cortical neurons | Enhancer activity assay | |
| E_03298 | chr1:136179600~136180045 | Skeletal muscle | C2C12 | Enhancer activity assay | |
| E_03299 | chr3:3109577~3110077 | Adipose tissue | C2C12 myoblast | Enhancer activity assay, TF binding assay | |
| E_03300 | chr6:115598005~115604631 | Embryo | mESC | Chromatin interaction assay, Functional perturbation assay | |
| E_03301 | chr6:115598005~115604631 | Embryo | Embryonic stem cell | Chromatin interaction assay, Functional perturbation assay | |
| E_03302 | chr5:98716000~98718000 | Embryo | mESCs | Enhancer activity assay, Functional perturbation assay, Chromatin interaction assay | |
| E_03303 | chr5:28889688~28890461 | Nervous system | Neural progenitor | Enhancer activity assay, Functional perturbation assay | |
| E_03304 | chr19:45700000~45702000 | Bone marrow | Plasmacytoid dendritic cell (pDC) | Functional perturbation assay | |
| E_03305 | chr1:136188400~136188845 | Skeletal muscle | C2C12 | Functional perturbation assay | |
| E_03306 | chr14:97485490~97486674 | Limb bud | Mouse E14 ESCs | Enhancer activity assay, Functional perturbation assay, Genome rearrangement assay | |
| E_03307 | chr14:97485490~97486674 | Limb bud | E11.5 embryonic limb bud cells | Enhancer activity assay, Functional perturbation assay, Genome rearrangement assay | |
| E_03308 | chr10:12845744~12845755 | Cartilage | Hypertrophic MCT chondrocytes | TF binding assay | |
| E_03309 | chr11:75210600~75210904 | Retina | Primary Retinal Cells | TF binding assay | |
| E_03310 | chr14:52100000~52101066 | Skeletal muscle | C2C12 | Enhancer activity assay | |
| E_03311 | chr13:11003340~11003615 | Skeletal muscle | C2C12 | Enhancer activity assay | |
| E_03312 | chr17:45201170~45201388 | Skeletal muscle | C2C12 | Enhancer activity assay | |
| E_03313 | chrX:10068000~10071900 | Heart | ES cells | Enhancer activity assay | |
| E_03314 | chr3:90505451~90505963 | Blood | CD4+ T cell | Enhancer activity assay | |
| E_03315 | chr5:147228000~147228250 | Pancreatic islet | INS-1 | Enhancer activity assay | |
| E_03316 | chr5:147228000~147228250 | Pancreatic islet | HIT | Enhancer activity assay | |
| E_03317 | chr5:147228000~147228250 | Liver | HepG2 | hepatocellular carcinoma | Enhancer activity assay |
| E_03318 | chr18:60725000~60725403 | Bone marrow | 38B9 | Enhancer activity assay | |
| E_03319 | chr18:60725000~60725403 | Bone marrow | A20 | B-cell lymphoma | Enhancer activity assay |
| E_03320 | chr18:60725000~60725403 | Bone marrow | Pro-B Cells | Enhancer activity assay | |
| E_03321 | chr9:19188000~19188100 | Blood | M12 B cells | B-cell lymphoma | Enhancer activity assay, TF binding assay |
| E_03322 | chr16:24132522~24174993 | Spleen | Germinal center B cells | Chromatin interaction assay, Functional perturbation assay | |
| E_03323 | chr8:83360000~83360500 | Adipose tissue | C2C12 myoblast | TF binding assay, Enhancer activity assay | |
| E_03324 | chr11:44203400~44203700 | Bone marrow | BMDM | Enhancer activity assay, TF binding assay | |
| E_03325 | chr15:98750000~98750480 | Cartilage | SW1353 chondrosarcoma cells | chondrosarcoma | Enhancer activity assay, TF binding assay |
| E_03326 | chr5:145326114~145328962 | Pancreas | Fetal pancreatic | TF binding assay | |
| E_03327 | chr14:77150408~77152161 | Blood | Jurkat cells | T-cell acute lymphoblastic leukemia | Enhancer activity assay |
| E_03328 | chr11:44203545~44203644 | Bone marrow | BMDM | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_03329 | chr11:44203545~44203644 | Bone marrow | PDM | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_03330 | chr11:44203545~44203644 | Bone marrow | RAW264.7 | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_03331 | chr19:4472130~4472336 | Skeletal muscle | MM14 myocytes | Enhancer activity assay, TF binding assay | |
| E_03332 | chr19:4472130~4472336 | Skeletal muscle | C2C12 myocytes | Enhancer activity assay, TF binding assay | |
| E_03333 | chr14:99739099~99739310 | Embryo | Mouse E14 embryonic stem cells | Functional perturbation assay, Chromatin topology assay | |
| E_03334 | chr13:74952000~74953000 | Embryo | E14 mouse embryonic stem cells | Functional perturbation assay, TF binding assay | |
| E_03335 | chr6:122656000~122657000 | Embryo | Mouse embryonic fibroblasts | Enhancer reporter assay | |
| E_03336 | chr6:122656000~122657000 | Embryo | embryonic stem cells | Enhancer reporter assay | |
| E_03337 | chr6:72190000~72200000 | Liver | Primary hepatocytes | Chromatin interaction assay, Circadian regulation assay | |
| E_03338 | chr10:24200250~24202250 | Blood vessel | Endothelial cells | Transgenic reporter assay, Developmental regulation assay | |
| E_03339 | chr10:24165250~24167250 | Cartilage | Chondrocytes | Transgenic reporter assay, Developmental regulation assay | |
| E_03340 | chr10:24102250~24104250 | Connective tissue | Fibroblasts | Transgenic reporter assay, Developmental regulation assay | |
| E_03341 | chr10:24071250~24073250 | Bone | Osteoblasts | Transgenic reporter assay, Developmental regulation assay | |
| E_03342 | chr5:28718122~28719021 | Limb bud | Mouse embryonic stem cells | Functional perturbation assay, Chromatin interaction assay | |
| E_03343 | chr5:29155811~29156811 | Limb bud | Mouse embryonic stem cells | Functional perturbation assay, Chromatin interaction assay | |
| E_03344 | chr5:29465811~29466811 | Limb bud | Mouse embryonic stem cells | Functional perturbation assay, Chromatin interaction assay | |
| E_03345 | chr16:20740332~20744432 | Kidney | COS7 | Enhancer activity assay, TF binding assay, Functional perturbation assay | |
| E_03346 | chr3:3122577~3123077 | Adipose tissue | C2C12 myoblast | Enhancer activity assay, TF binding assay | |
| E_03347 | chr3:3125577~3126077 | Adipose tissue | C2C12 myoblast | Enhancer activity assay, TF binding assay | |
| E_03348 | chr3:3139577~3140077 | Adipose tissue | C2C12 myoblast | Enhancer activity assay, TF binding assay | |
| E_03349 | chr3:3159577~3160077 | Adipose tissue | C2C12 myoblast | Enhancer activity assay, TF binding assay | |
| E_03350 | chr3:3180577~3181077 | Adipose tissue | C2C12 myoblast | Enhancer activity assay, Functional perturbation assay | |
| E_03351 | chr7:46550546~46551046 | Skeletal muscle | C2C12 myoblast | TF binding assay, Enhancer activity assay | |
| E_03352 | chr7:46556546~46557046 | Skeletal muscle | C2C12 myoblast | TF binding assay, Enhancer activity assay | |
| E_03353 | chr7:46565546~46566046 | Skeletal muscle | C2C12 myoblast | TF binding assay, Enhancer activity assay, Functional perturbation assay | |
| E_03354 | chr7:46568546~46569046 | Skeletal muscle | C2C12 myoblast | TF binding assay, Enhancer activity assay | |
| E_03355 | chr7:46587546~46588046 | Skeletal muscle | C2C12 myoblast | Enhancer activity assay, Functional perturbation assay | |
| E_03356 | chr7:46594146~46594646 | Skeletal muscle | C2C12 myoblast | TF binding assay, Enhancer activity assay | |
| E_03357 | chr7:46595846~46596346 | Skeletal muscle | C2C12 myoblast | TF binding assay, Enhancer activity assay | |
| E_03358 | chr7:35120000~35120500 | Adipose tissue | C2C12 myoblast | TF binding assay, Enhancer activity assay | |
| E_03359 | chr14:62018722~62019450 | Hypothalamus | GnRH neuron | Functional perturbation assay | |
| E_03360 | chr7:53626726~53628851 | Skeletal muscle | C2C12 myoblasts | Enhancer activity assay, Functional perturbation assay | |
| E_03361 | chr17:35643473~35645472 | Embryo | Embryonic stem cells (ESCs) | Enhancer activity assay, Chromatin interaction assay, TF binding assay, Functional perturbation assay | |
| E_03362 | chr1:120286768~120286837 | Bone marrow | Primary pro-B cells | Enhancer activity assay, Chromatin interaction assay | |
| E_03363 | chr11:96880000~96920000 | Bone marrow | Non-classical monocytes | Immunological functional assay, Functional genomics assay, Epigenomic profiling assay, Transcriptional regulation assay | |
| E_03364 | chr2:13192908~13194140 | Bone marrow | BMMC | mastocytosis | Luciferase-based enhancer assay |
| E_03365 | chr2:13192908~13194140 | Bone marrow | Mast cells | mastocytosis | Luciferase-based enhancer assay |
| E_03366 | chr2:150860120~150860367 | Brain | Primary Mouse Tissues | Enhancer activity assay, Functional perturbation assay | |
| E_03367 | chr2:150860120~150860367 | Cervix | HeLa Cells | cervical cancer | Enhancer activity assay, Functional perturbation assay |
| E_03368 | chr2:150860120~150860367 | Brain | Primary Mouse Tissues | Enhancer activity assay, Functional perturbation assay | |
| E_03369 | chr2:150860120~150860367 | Cervix | HeLa Cells | cervical cancer | Enhancer activity assay, Functional perturbation assay |
| E_03370 | chr12:31875800~31876373 | Spleen | CD4+ T cells | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay | |
| E_03371 | chr13:69400000~69410000 | Limb bud | Mouse embryonic fibroblasts (MEFs) | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay | |
| E_03372 | chr13:69400000~69410000 | Limb bud | E11.5 mouse forelimb/hindlimb buds | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay | |
| E_03373 | chr19:3441054~3441445 | Hypothalamus | Galaninergic Neuron | Enhancer activity assay, Functional perturbation assay | |
| E_03374 | chr10:87141000~87142000 | Hypothalamus | Primary neurons | Functional perturbation assay | |
| E_03375 | chr16:19026931~19027772 | Bone marrow | pro-B cell | Enhancer activity assay, Functional perturbation assay | |
| E_03376 | chr16:19026931~19027772 | Bone marrow | B cell | Enhancer activity assay, Functional perturbation assay | |
| E_03377 | chr16:19007329~19008187 | Bone marrow | pro-B cell | Enhancer activity assay, Functional perturbation assay | |
| E_03378 | chr16:19007329~19008187 | Bone marrow | B cell | Enhancer activity assay, Functional perturbation assay | |
| E_03379 | chr12:103024800~103025800 | Hypothalamus | Mouse primary neurons | Functional perturbation assay | |
| E_03380 | chr16:5510000~5550000 | Bone marrow | B lymphocytes | Immunological functional assay, Functional genomics assay, Epigenomic profiling assay, Transcriptional regulation assay | |
| E_03381 | chr3:34757100~34758037 | Embryo | Mouse embryonic stem cells | Enhancer activity assay | |
| E_03382 | chr3:34757100~34758037 | Embryoid body | Pluripotent cells from 21-day mouse embryoid bodies | Enhancer activity assay | |
| E_03383 | chr3:34761100~34762000 | Embryo | Mouse embryonic stem cells | Enhancer activity assay | |
| E_03384 | chr3:34761100~34762000 | Embryoid body | Pluripotent cells from 21-day mouse embryoid bodies | Enhancer activity assay | |
| E_03385 | chr4:8201000~8202000 | Embryoid body | Parietal endoderm cells | Enhancer activity assay | |
| E_03386 | chr15:61978434~61986531 | Bone marrow | RN2 | acute myeloid leukemia | Enhancer activity assay, TF binding assay |
| E_03387 | chr13:101200000~101201200 | Blood | Bone marrow-derived macrophage (mBMDM) | TF binding assay, Enhancer activity assay | |
| E_03388 | chr8:72500000~72501100 | Blood | Bone marrow-derived macrophage (mBMDM) | TF binding assay, Enhancer activity assay | |
| E_03389 | chr1:154149500~154150000 | Heart | Mouse embryonic/Adult cardiomyocytes | TF binding assay, Functional perturbation assay | |
| E_03390 | chr3:66550000~66650000 | Limb bud | Limb mesenchymal cells | Enhancer activity assay, Functional perturbation assay, Chromatin interaction assay | |
| E_03391 | chr3:66850000~66950000 | Limb bud | Limb mesenchymal cells | Enhancer activity assay, Functional perturbation assay, Chromatin interaction assay | |
| E_03392 | chr14:78613540~78616951 | Bone | Primary osteoblasts | Functional perturbation assay, Enhancer activity assay, TF binding assay | |
| E_03393 | chr14:78613540~78616951 | Bone | Periodontal ligament cells | Functional perturbation assay, Enhancer activity assay, TF binding assay | |
| E_03394 | chr14:78613540~78616951 | Bone | Osteogenic cells | Functional perturbation assay, Enhancer activity assay, TF binding assay | |
| E_03395 | chr14:78613540~78616951 | Bone | Primary calvarial osteoblasts | Functional perturbation assay, Enhancer activity assay, TF binding assay | |
| E_03396 | chr3:66750000~66850000 | Limb bud | Limb mesenchymal cells | Enhancer activity assay, Chromatin interaction assay | |
| E_03397 | chr6:60769316~60772093 | Brain | Primary midbrain dopaminergic neurons | Functional perturbation assay | |
| E_03398 | chr2:109689202~109690258 | Amygdala | Mouse amygdala tissue | Functional perturbation assay, Enhancer activity assay | |
| E_03399 | chr14:75391059~75392159 | Bone marrow | ST2 | Enhancer activity assay | |
| E_03400 | chr14:75331459~75332459 | Bone marrow | ST2 | Enhancer activity assay | |
| E_03401 | chr2L:1000000~1000300 | Embryo | S2 cell | None | Enhancer activity assay |
| E_03402 | chr2L:1001000~1001300 | Embryo | S2 cell | None | Enhancer activity assay |
| E_03403 | chr3R:7795000~7796400 | Embryo | embryonic cell | None | Enhancer activity assay; TF binding assay; Functional perturbation assay |
| E_03404 | chr3R:7795000~7796400 | Embryo | embryonic cell | None | Enhancer activity assay; TF binding assay; Functional perturbation assay |
| E_03405 | chr2R:10788877~10789168 | Embryo | embryonic epithelial cell | None | Enhancer activity assay; TF binding assay; Functional perturbation assay |
| E_03406 | chr3L:8670850~8671350 | Brain | Kenyon cell | None | Enhancer activity assay |
| E_03407 | chr2R:5208000~5208523 | Embryo | nc14 embryo | None | Enhancer activity assay; Functional perturbation assay |
| E_03408 | chr2R:9974054~9974699 | Embryo | blastoderm cell | None | Enhancer activity assay; Chromatin interaction assay; Functional perturbation assay |
| E_03409 | chr2R:9975013~9975699 | Embryo | blastoderm cell | None | Enhancer activity assay; Chromatin interaction assay; Functional perturbation assay |
| E_03410 | chr2R:9984101~9984849 | Embryo | blastoderm cell | None | Enhancer activity assay; Chromatin interaction assay; Functional perturbation assay |
| E_03411 | chr2R:9985221~9985886 | Embryo | blastoderm cell | None | Enhancer activity assay; Chromatin interaction assay; Functional perturbation assay |
| E_03412 | chr3:4669900~4670243 | Embryo | blastoderm embryo | None | Enhancer activity assay |
| E_03413 | chr3R:26880000~26880523 | Embryo | embryo | None | Enhancer activity assay; Functional perturbation assay |
| E_03414 | chrX:18719542~18720191 | Embryo | blastoderm embryo | None | Enhancer activity assay; TF binding assay |
| E_03415 | chrX:18741042~18741691 | Embryo | blastoderm embryo | None | Enhancer activity assay; TF binding assay |
| E_03416 | chrX:15547650~15548150 | Brain | Kenyon cell | None | Enhancer activity assay |
| E_03417 | chrX:4010500~4011000 | Brain | Kenyon cell | None | Enhancer activity assay |
| E_03418 | chrX:9786300~9786800 | Brain | Kenyon cell | None | Enhancer activity assay |
| E_03419 | chr2:5221179~5221678 | Cranial neural crest | neural crest cell | None | Enhancer activity assay; TF binding assay; Functional perturbation assay |
| E_03420 | chr2:5218800~5221678 | Cranial neural crest | neural crest cell | None | Enhancer activity assay; TF binding assay; Chromatin interaction assay |
| E_03421 | chr2:5218800~5219499 | Cranial neural crest | neural crest cell | None | Enhancer activity assay; Functional perturbation assay |
| E_03422 | chr14:6760805~6761115 | Spinal cord | ependymo-radial glial cell | None | Enhancer activity assay |
| E_03423 | chr9:31332828~31334322 | Brain | neuron | None | Enhancer activity assay |
| E_03424 | chr8:44088636~44090085 | Brain | neuron | None | Enhancer activity assay |
| E_03425 | chr5:49025012~49026815 | Heart | cardiomyocyte | None | Enhancer activity assay |
| E_03426 | chr7:7439474~7441474 | Heart | cardiomyocyte | None | Enhancer activity assay |
| E_03427 | chr23:5735883~5736938 | Heart | cardiomyocyte | None | Enhancer activity assay |
| E_03428 | chr7:18138313~18139545 | Heart | cardiomyocyte | None | Enhancer activity assay |
| E_03429 | chr1:47366207~47368074 | Heart | cardiomyocyte | None | Enhancer activity assay |
| E_03430 | chr8:2567791~2569300 | Heart | cardiomyocyte | None | Enhancer activity assay |
| E_03431 | chr25:17938108~17939563 | Kidney | embryonic kidney cell | None | Enhancer activity assay |
| E_03432 | chr5:61665365~61667095 | Kidney | embryonic kidney cell | None | Enhancer activity assay |
| E_03433 | chr25:17939264~17940252 | Kidney | embryonic kidney cell | None | Enhancer activity assay |
| E_03434 | chr6:43661350~43663650 | Brain | neuron | None | Enhancer activity assay |
| E_03435 | chr1:19433791~19434807 | Skeletal muscle | embryonic myocyte | None | Enhancer activity assay |
| E_03436 | chr1:7624913~7626890 | Skeletal muscle | embryonic myocyte | None | Enhancer activity assay |
| E_03437 | chr6:99012350~99015100 | Skeletal muscle | embryonic myocyte | None | Enhancer activity assay |
| E_03438 | chr2:716946~717020 | Embryo | embryonic cell | None | Functional perturbation assay |
| E_03439 | chr20:26689284~26689441 | Embryo | embryonic cell | None | Functional perturbation assay |
| E_03440 | chr2:684320~684414 | Embryo | embryonic cell | None | Functional perturbation assay |
| E_03441 | chr2:577491~577557 | Embryo | embryonic cell | None | Functional perturbation assay |
| E_03442 | chr2:535659~535798 | Embryo | embryonic cell | None | Functional perturbation assay |
| E_03443 | chr14:6760805~6761115 | Spinal cord | ependymo-radial glial cell | None | Enhancer activity assay |
| E_03444 | chr7:20447000~20447290 | Retina | embryonic cell | None | Enhancer activity assay |
| E_03445 | chr2:38181326~38182075 | Heart | cardiac endothelial cell | None | Regulatory element functional validation; chromatin accessibility analysis |
| E_03446 | chrX:534837~535834 | brain | NA | NA | in vivo reporter assay |
| E_03447 | chrX:534837~535834 | brain | NA | NA | in vivo reporter assay |
| E_03448 | chrX:534837~535834 | brain | NA | NA | in vivo reporter assay |
| E_03449 | chrX:534837~535834 | brain | NA | NA | in vivo reporter assay |
| E_03450 | chr3L:9193218~9194041 | brain | NA | NA | in vivo reporter assay |
| E_03451 | chr3L:9193218~9194041 | brain | NA | NA | in vivo reporter assay |
| E_03452 | chrX:18554916~18555296 | brain | NA | NA | in vivo reporter assay |
| E_03453 | chrX:18554916~18555296 | brain | NA | NA | in vivo reporter assay |
| E_03454 | chrX:18554916~18555296 | brain | NA | NA | in vivo reporter assay |
| E_03455 | chrX:18554916~18555296 | brain | NA | NA | in vivo reporter assay |
| E_03456 | chrX:18554916~18555296 | brain | NA | NA | in vivo reporter assay |
| E_03457 | chrX:18554916~18555296 | brain | NA | NA | in vivo reporter assay |
| E_03458 | chr3R:16286178~16286811 | brain | NA | NA | in vivo reporter assay |
| E_03459 | chr3R:16286178~16286811 | brain | NA | NA | in vivo reporter assay |
| E_03460 | chr3R:16286178~16286811 | brain | NA | NA | in vivo reporter assay |
| E_03461 | chr2R:16905793~16906591 | brain | NA | NA | in vivo reporter assay |
| E_03462 | chr2R:16905793~16906591 | brain | NA | NA | in vivo reporter assay |
| E_03463 | chr2R:16905793~16906591 | brain | NA | NA | in vivo reporter assay |
| E_03464 | chr2L:20040500~20041072 | brain | NA | NA | in vivo reporter assay |
| E_03465 | chr2L:20040500~20041072 | brain | NA | NA | in vivo reporter assay |
| E_03466 | chr2L:20040500~20041072 | brain | NA | NA | in vivo reporter assay |
| E_03467 | chr2L:20040500~20041072 | brain | NA | NA | in vivo reporter assay |
| E_03468 | chr2L:20040500~20041072 | brain | NA | NA | in vivo reporter assay |
| E_03469 | chr2R:19127550~19127921 | brain | NA | NA | in vivo reporter assay |
| E_03470 | chr2R:19127550~19127921 | brain | NA | NA | in vivo reporter assay |
| E_03471 | chr2R:19127550~19127921 | brain | NA | NA | in vivo reporter assay |
| E_03472 | chr10:35949193~35950411 | cerebral cortex | NA | NA | in vivo reporter assay; genome editing |
| E_03473 | chr7:117043000~117044500 | Airway epithelium | 16HBE14o- human bronchial epithelial | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay | |
| E_03474 | chr7:117043000~117044500 | Lung | Calu3 | lung adenocarcinoma | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_03475 | chr7:117052000~117053500 | Airway epithelium | 16HBE14o- human bronchial epithelial | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay | |
| E_03476 | chr7:117052000~117053500 | Lung | Calu3 | lung adenocarcinoma | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_03477 | chr10:89986509~89987396 | Skin | Melanoma cell line | skin melanoma | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay |
| E_03478 | chr15:99982353~99983277 | Skin | Melanoma cell line | skin melanoma | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay |
| E_03479 | chr1:16479332~16539780 | Cervical Epithelium | HeLa | cervical cancer | Functional perturbation assay, Enhancer activity assay |
| E_03480 | chr1:16479332~16539780 | Colon Epithelium | HCT116 | colorectal carcinoma | Functional perturbation assay, Enhancer activity assay |
| E_03481 | chr1:16479332~16539780 | Breast Epithelium | MCF7 | breast carcinoma | Functional perturbation assay, Enhancer activity assay |
| E_03482 | chr8:130550000~130551100 | Bone Marrow | Primary AML blasts | acute myeloid leukemia | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_03483 | chr8:130550000~130551100 | Peripheral Blood | K562 | acute myeloid leukemia | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_03484 | chr8:130550000~130551100 | Bone Marrow | CD34+ HSPCs | acute myeloid leukemia | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_03485 | chr8:130580000~130581100 | Peripheral Blood | K562 | acute myeloid leukemia | TF binding assay, Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay |
| E_03486 | chr8:130580000~130581100 | Bone Marrow | Primary AML blasts | acute myeloid leukemia | TF binding assay, Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay |
| E_03487 | chr8:130580000~130581100 | Bone Marrow | CD34+ HSPCs | acute myeloid leukemia | TF binding assay, Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay |
| E_03488 | chr7:128573081~128573816 | Peripheral Blood | SC monocyte-derived cells | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay | |
| E_03489 | chr7:128573081~128573816 | Peripheral Blood | Primary CD14+ monocytes | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay | |
| E_03490 | chr9:126770367~126771183 | Brain | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay | ||
| E_03491 | chr20:48900221~48901229 | Liver | Human normal liver cell | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay | |
| E_03492 | chr8:120733232~120735226 | Embryonic Kidney | HEK293 | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay | |
| E_03493 | chr2:65633710~65634058 | Embryonic Kidney | HEK293T | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay | |
| E_03494 | chr2:65609946~65610996 | Embryonic Kidney | HEK293T | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay | |
| E_03495 | chr2:65608668~65609150 | Embryonic Kidney | HEK293T | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay | |
| E_03496 | chr2:65609946~65610996 | Embryonic Kidney | HEK293T | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay | |
| E_03497 | chr1:47680000~47681000 | Blood | Jurkat cells | T-cell acute lymphoblastic leukemia | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_03498 | chr9:89630000~89631000 | Blood | MOLT-4 cells | T-cell acute lymphoblastic leukemia | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_03499 | chr9:89630000~89631000 | Breast | MCF7 | breast carcinoma | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_03500 | chr9:89630000~89631000 | Skin | MALME-3M | skin melanoma | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_03501 | chr9:133401000~133404500 | Breast | ZR-75-1 | breast carcinoma | Enhancer activity assay, Functional perturbation assay, Chromatin interaction assay |
| E_03502 | chr12:47732000~47733500 | Ovary | OVCAR3 | ovarian carcinoma | Enhancer activity assay, Functional perturbation assay |
| E_03503 | chr12:47732000~47733500 | Skin | SKmel147 | skin melanoma | Enhancer activity assay, Functional perturbation assay |
| E_03504 | chr12:11718965~11902194 | Skin | 501MEL | skin melanoma | Enhancer activity assay, Functional perturbation assay |
| E_03505 | chr12:11680000~11718964 | Bone Marrow | Primary ALL cells | B-cell acute lymphoblastic leukemia | Enhancer activity assay, Functional perturbation assay |
| E_03506 | chr6:30904342~30904788 | Bone Marrow | Primary ALL cells | B-cell acute lymphoblastic leukemia | Functional perturbation assay, Enhancer activity assay |
| E_03507 | chr8:120733232~120735226 | Hematopoietic | U-937 | histiocytic lymphoma | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_03508 | chr2:16619625~16621501 | Blood | Jurkat | T-cell acute lymphoblastic leukemia | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_03509 | chr2:16619625~16621501 | Blood | RPMI-8402 | T-cell acute lymphoblastic leukemia | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_03510 | chr2:16619625~16621501 | Blood | Primary T-ALL cells | T-cell acute lymphoblastic leukemia | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_03511 | chr2:65608668~65609150 | Synovial tissue | MH7A | rheumatoid arthritis | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_03512 | chr20:48900221~48901229 | Liver | Human hepatocellular carcinoma cell | hepatocellular carcinoma | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_03513 | chr20:48900221~48901229 | Liver | Huh7 | hepatocellular carcinoma | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_03514 | chr2:65609946~65610996 | Synovial tissue | MH7A | rheumatoid arthritis | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay |
| E_03515 | chr2:65609946~65610996 | Synovial tissue | MH7A | rheumatoid arthritis | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay |
| E_03516 | chr2:65633710~65634058 | Synovial tissue | MH7A | rheumatoid arthritis | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay |
| E_03517 | chr1:47644434~47659486 | Colon | HT29 | colorectal cancer | Super enhancer activity assay, Functional perturbation assay |
| E_03518 | chr19:51354200~51354400 | Prostate | LNCaP | prostate cancer | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_03519 | chr6:15109500~15110350 | Prostate | LNCaP | prostate cancer | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_03520 | chr7:45025000~45025850 | Prostate | LNCaP | prostate cancer | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_03521 | chr2:74155000~74155850 | Prostate | LNCaP | prostate cancer | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_03522 | chr21:32901686~32902140 | Breast | MCF7 | breast carcinoma | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_03523 | chr7:54932020~54934020 | Brain | G361 glioblastoma | glioblastoma | Functional perturbation assay |